---
layout: jacc
name: "Living Guideline"
position: "Section Decorations"
---
<div class="article__body reading-typography max-w_65">
    <section class="article-section article-section__abstract">
        <div class="hlFld-Abstract hasTowAbstracts">
            <div class="article-section__content">
                <h2 class="article-section__title section__title" id="d247731e327">Abstract</h2>
                <section class="article-section">
                    <div id="acsectitle0015" class="anchor-spacer"></div>
                    <h3 class="article-section__subtitle" id="sectitle0015">Aim</h3>
                    <p id="abspara0010">The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
                        the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 ACC/AHA/HFSA
                        Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure.” The 2022
                        guideline is intended to provide patient-centric recommendations for clinicians to prevent,
                        diagnose, and manage patients with heart failure.</p>
                </section>
                <section class="article-section">
                    <div id="acsectitle0020" class="anchor-spacer"></div>
                    <h3 class="article-section__subtitle" id="sectitle0020">Methods</h3>
                    <p id="abspara0015">A comprehensive literature search was conducted from May 2020 to December 2020,
                        encompassing studies, reviews, and other evidence conducted on human subjects that were
                        published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for
                        Healthcare Research and Quality, and other relevant databases. Additional relevant clinical
                        trials and research studies, published through September 2021, were also considered. This
                        guideline was harmonized with other American Heart Association/American College of Cardiology
                        guidelines published through December 2021.</p>
                </section>
                <section class="article-section">
                    <div id="acsectitle0025" class="anchor-spacer"></div>
                    <h3 class="article-section__subtitle" id="sectitle0025">Structure</h3>
                    <p id="abspara0020">Heart failure remains a leading cause of morbidity and mortality globally. The
                        2022 heart failure guideline provides recommendations based on contemporary evidence for the
                        treatment of these patients. The recommendations present an evidence-based approach to managing
                        patients with heart failure, with the intent to improve quality of care and align with patients’
                        interests. Many recommendations from the earlier heart failure guidelines have been updated with
                        new evidence, and new recommendations have been created when supported by published data. Value
                        statements are provided for certain treatments with high-quality published economic analyses.
                    </p>
                </section>
            </div>
        </div>
    </section><!--/abstract content--><!--fulltext content-->
    <section class="article-section article-section__full ">
        <div class="hlFld-Fulltext">
            <div id="acd247731e461" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e461">
                <div id="acsectitle0035" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0035">ACC/AHA Joint Committee Members</h2>
            <p id="p3675">Joshua A. Beckman, MD, MS, FAHA, FACC, <i>Chair</i></p>
            <p id="p3680">Patrick T. O’Gara, MD, MACC, FAHA,<i>Immediate Past Chair</i><a class="ref fn" href="#fn6"
                    target="_self">¶</a></p>
            <p id="p3685">Sana M. Al-Khatib, MD, MHS, FACC, FAHA<a class="ref fn" href="#fn6" target="_self">¶</a></p>
            <p id="p3690">Anastasia L. Armbruster, PharmD, FACC</p>
            <p id="p3695">Kim K. Birtcher, PharmD, MS, AACC<a class="ref fn" href="#fn6" target="_self">¶</a></p>
            <p id="p3700">Joaquin E. Cigarroa, MD, FACC<a class="ref fn" href="#fn6" target="_self">¶</a></p>
            <p id="p3705">Lisa de las Fuentes, MD, MS, FAHA</p>
            <p id="p3710">Anita Deswal, MD, MPH, FACC, FAHA</p>
            <p id="p3715">Dave L. Dixon, PharmD, FACC<a class="ref fn" href="#fn6" target="_self">¶</a></p>
            <p id="p3720">Lee A. Fleisher, MD, FACC, FAHA<a class="ref fn" href="#fn6" target="_self">¶</a></p>
            <p id="p3725">Federico Gentile, MD, FACC<a class="ref fn" href="#fn6" target="_self">¶</a></p>
            <p id="p3730">Zachary D. Goldberger, MD, FACC, FAHA<a class="ref fn" href="#fn6" target="_self">¶</a></p>
            <p id="p3735">Bulent Gorenek, MD, FACC</p>
            <p id="p3740">Norrisa Haynes, MD, MPH</p>
            <p id="p3745">Adrian F. Hernandez, MD, MHS</p>
            <p id="p3750">Mark A. Hlatky, MD, FACC, FAHA<a class="ref fn" href="#fn6" target="_self">¶</a></p>
            <p id="p3755">José A. Joglar, MD, FACC, FAHA</p>
            <p id="p3760">W. Schuyler Jones, MD, FACC</p>
            <p id="p3765">Joseph E. Marine, MD, FACC<a class="ref fn" href="#fn6" target="_self">¶</a></p>
            <p id="p3770">Daniel B. Mark, MD, MPH, FACC, FAHA</p>
            <p id="p3775">Debabrata Mukherjee, MD, FACC, FAHA</p>
            <p id="p3780">Latha P. Palaniappan, MD, MS, FACC, FAHA</p>
            <p id="p3785">Mariann R. Piano, RN, PhD, FAHA</p>
            <p id="p3790">Tanveer Rab, MD, FACC</p>
            <p id="p3795">Erica S. Spatz, MD, MS, FACC</p>
            <p id="p3800">Jacqueline E. Tamis-Holland, MD, FAHA, FACC</p>
            <p id="p3805">Duminda N. Wijeysundera, MD, PhD<a class="ref fn" href="#fn6" target="_self">¶</a></p>
            <p id="p3810">Y. Joseph Woo, MD, FACC, FAHA<fn id="fn6"></fn>
            </p>
            <p id="ntpara0180">Former Joint Committee member; current member during the writing effort.</p>
            <p></p>
            <div id="acd247731e551" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e551">
                <div id="acsectitle0040" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0040">Table of Contents</h2>
            <p id="p3815">
            </p>
            <table class="listgroup" border="0" width="95%" id="olist1035" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top"></td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p class="inline">Abstract e264</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top"></td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p class="inline">Top 10 Take-Home Messages e266</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top"></td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p class="inline">Preamble e267</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p3835">Introduction e268</p>
                            <table class="listgroup" border="0" width="95%" id="olist1040" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">1.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3840">Methodology and Evidence Review e268</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">1.2.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3845">Organization of the Writing Committee e268</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">1.3.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3850">Document Review and Approval e268</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">1.4.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3855">Scope of the Guideline e268</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">1.5.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3860">Class of Recommendation and Level of Evidence e270</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">1.6.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3865">Abbreviations e271</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p3870">Definition of HF e272</p>
                            <table class="listgroup" border="0" width="95%" id="olist1045" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">2.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3875">Stages of HF e272</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">2.2.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3880">Classification of HF by Left Ventricular Ejection Fraction
                                                (LVEF) e275</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">2.3.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3885">Diagnostic Algorithm for Classification of HF According to
                                                LVEF e277</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p3890">Epidemiology and Causes of HF e278</p>
                            <table class="listgroup" border="0" width="95%" id="olist1050" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">3.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3895">Epidemiology of HF e278</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">3.2.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3900">Cause of HF e279</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p3905">Initial and Serial Evaluation e279</p>
                            <table class="listgroup" border="0" width="95%" id="olist1055" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">4.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3910">Clinical Assessment: History and Physical Examination e279</p>
                                            <table class="listgroup" border="0" width="95%" id="olist1060"
                                                list-type="simple">
                                                <tbody>
                                                    <tr class="li1">
                                                        <td valign="top">4.1.1.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p3915">Initial Laboratory and Electrocardiographic
                                                                Testing e281</p>
                                                        </td>
                                                    </tr>
                                                </tbody>
                                            </table>
                                            <p></p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">4.2.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3920">Use of Biomarkers for Prevention, Initial Diagnosis, and Risk
                                                Stratification e282</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">4.3.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3925">Genetic Evaluation and Testing e284</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">4.4.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3930">Evaluation With Cardiac Imaging e285</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">4.5.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3935">Invasive Evaluation e288</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">4.6.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3940">Wearables and Remote Monitoring (Including Telemonitoring and
                                                Device Monitoring) e289</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">4.7.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3945">Exercise and Functional Capacity Testing e290</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">4.8.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3950">Initial and Serial Evaluation: Clinical Assessment: HF Risk
                                                Scoring e291</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p3955">Stage A (Patients at Risk for HF) e292</p>
                            <table class="listgroup" border="0" width="95%" id="olist1065" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">5.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3960">Patients at Risk for HF (Stage A: Primary Prevention) e292</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">6.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p3965">Stage B (Patients With Pre-HF) e295</p>
                            <table class="listgroup" border="0" width="95%" id="olist1070" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">6.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3970">Management of Stage B: Preventing the Syndrome of Clinical HF
                                                in Patients With Pre-HF e295</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">7.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p3975">Stage C HF e297</p>
                            <table class="listgroup" border="0" width="95%" id="olist1075" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">7.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p3980">Nonpharmacological Interventions e297</p>
                                            <table class="listgroup" border="0" width="95%" id="olist1080"
                                                list-type="simple">
                                                <tbody>
                                                    <tr class="li1">
                                                        <td valign="top">7.1.1.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p3985">Self-Care Support in HF e297</p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.1.2.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p3990">Dietary Sodium Restriction e299</p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.1.3.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p3995">Management of Stage C HF: Activity, Exercise
                                                                Prescription, and Cardiac Rehabilitation e300</p>
                                                        </td>
                                                    </tr>
                                                </tbody>
                                            </table>
                                            <p></p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">7.2.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4000">Diuretics and Decongestion Strategies in Patients With HF e301
                                            </p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">7.3.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4005">Pharmacological Treatment for HFrEF e302</p>
                                            <table class="listgroup" border="0" width="95%" id="olist1085"
                                                list-type="simple">
                                                <tbody>
                                                    <tr class="li1">
                                                        <td valign="top">7.3.1.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4010">Renin-Angiotensin System Inhibition With ACEi
                                                                or ARB or ARNi e302</p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.3.2.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4015">Beta Blockers e305</p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.3.3.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4020">Mineralocorticoid Receptor Antagonists
                                                                (MRAs) e306</p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.3.4.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4025">Sodium-Glucose Cotransporter 2 Inhibitors e307
                                                            </p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.3.5.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4030">Hydralazine and Isosorbide Dinitrate e308</p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.3.6.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4035">Other Drug Treatment e310</p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.3.7.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4040">Drugs of Unproven Value or That May Worsen
                                                                HF e311</p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.3.8.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4045">GDMT Dosing: Sequencing and Uptitration e313
                                                            </p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.3.9.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4050">Additional Medical Therapies e316</p>
                                                            <table class="listgroup" border="0" width="95%"
                                                                id="olist1090" list-type="simple">
                                                                <tbody>
                                                                    <tr class="li1">
                                                                        <td valign="top">7.3.9.1.</td>
                                                                        <td colspan="5" valign="top" class="paragraph">
                                                                            <p id="p4055">Management of Stage C HF:
                                                                                Ivabradine e316</p>
                                                                        </td>
                                                                    </tr>
                                                                    <tr class="li1">
                                                                        <td valign="top">7.3.9.2.</td>
                                                                        <td colspan="5" valign="top" class="paragraph">
                                                                            <p id="p4060">Pharmacological Treatment for
                                                                                Stage C HFrEF: Digoxin e316</p>
                                                                        </td>
                                                                    </tr>
                                                                    <tr class="li1">
                                                                        <td valign="top">7.3.9.3.</td>
                                                                        <td colspan="5" valign="top" class="paragraph">
                                                                            <p id="p4065">Pharmacological Treatment for
                                                                                Stage C HFrEF: Soluble Guanylyl Cyclase
                                                                                Stimulators e317</p>
                                                                        </td>
                                                                    </tr>
                                                                </tbody>
                                                            </table>
                                                            <p></p>
                                                        </td>
                                                    </tr>
                                                </tbody>
                                            </table>
                                            <p></p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">7.4.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4070">Device and Interventional Therapies for HFrEF e318</p>
                                            <table class="listgroup" border="0" width="95%" id="olist1095"
                                                list-type="simple">
                                                <tbody>
                                                    <tr class="li1">
                                                        <td valign="top">7.4.1.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4075">ICDs and CRTs e318</p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.4.2.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4080">Other Implantable Electrical
                                                                Interventions e322</p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.4.3.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4085">Revascularization for CAD e323</p>
                                                        </td>
                                                    </tr>
                                                </tbody>
                                            </table>
                                            <p></p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">7.5.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4090">Valvular Heart Disease e324</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">7.6.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4095">Heart Failure With Mildly Reduced EF (HFmrEF) and Improved EF
                                                (HFimpHF) e326</p>
                                            <table class="listgroup" border="0" width="95%" id="olist1100"
                                                list-type="simple">
                                                <tbody>
                                                    <tr class="li1">
                                                        <td valign="top">7.6.1.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4100">HF With Mildly Reduced Ejection Fraction e326
                                                            </p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.6.2.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4105">HF With Improved Ejection Fraction e327</p>
                                                        </td>
                                                    </tr>
                                                </tbody>
                                            </table>
                                            <p></p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">7.7.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4110">Preserved EF (HFpEF) e328</p>
                                            <table class="listgroup" border="0" width="95%" id="olist1105"
                                                list-type="simple">
                                                <tbody>
                                                    <tr class="li1">
                                                        <td valign="top">7.7.1.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4115">HF With Preserved Ejection Fraction e328</p>
                                                        </td>
                                                    </tr>
                                                </tbody>
                                            </table>
                                            <p></p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">7.8.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4120">Cardiac Amyloidosis e331</p>
                                            <table class="listgroup" border="0" width="95%" id="olist1110"
                                                list-type="simple">
                                                <tbody>
                                                    <tr class="li1">
                                                        <td valign="top">7.8.1.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4125">Diagnosis of Cardiac Amyloidosis e331</p>
                                                        </td>
                                                    </tr>
                                                    <tr class="li1">
                                                        <td valign="top">7.8.2.</td>
                                                        <td colspan="5" valign="top" class="paragraph">
                                                            <p id="p4130">Treatment of Cardiac Amyloidosis e332</p>
                                                        </td>
                                                    </tr>
                                                </tbody>
                                            </table>
                                            <p></p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">8.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4135">Stage D (Advanced) HF e334</p>
                            <table class="listgroup" border="0" width="95%" id="olist1115" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">8.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4140">Specialty Referral for Advanced HF e334</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">8.2.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4145">Nonpharmacological Management: Advanced HF e337</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">8.3.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4150">Inotropic Support e337</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">8.4.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4155">Mechanical Circulatory Support e339</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">8.5.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4160">Cardiac Transplantation e340</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">9.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4165">Patients Hospitalized With Acute Decompensated HF e341</p>
                            <table class="listgroup" border="0" width="95%" id="olist1120" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">9.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4170">Assessment of Patients Hospitalized With Decompensated HF e341
                                            </p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">9.2.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4175">Maintenance or Optimization of GDMT During
                                                Hospitalization e342</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">9.3.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4180">Diuretics in Hospitalized Patients: Decongestion Strategy e344
                                            </p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">9.4a.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4185">Parenteral Vasodilation Therapy in Patients Hospitalized With
                                                HF e345</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">9.4b.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4190">VTE Prophylaxis in Hospitalized Patients e346</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">9.5.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4195">Evaluation and Management of Cardiogenic Shock e346</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">9.6.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4200">Integration of Care: Transitions and Team-Based
                                                Approaches e349</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">10.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4205">Comorbidities in Patients With HF e351</p>
                            <table class="listgroup" border="0" width="95%" id="olist1125" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">10.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4210">Management of Comorbidities in Patients With HF e351</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">10.2.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4215">Management of AF in HF e354</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">11.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4220">Special Populations e356</p>
                            <table class="listgroup" border="0" width="95%" id="olist1130" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">11.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4225">Disparities and Vulnerable Populations e356</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">11.2.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4230">Cardio-Oncology e358</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">11.3.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4235">HF and Pregnancy e360</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">12.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4240">Quality Metrics and Reporting e363</p>
                            <table class="listgroup" border="0" width="95%" id="olist1135" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">12.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4245">Performance Measurement e363</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">13.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4250">Goals of Care e364</p>
                            <table class="listgroup" border="0" width="95%" id="olist1140" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">13.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4255">Palliative and Supportive Care, Shared Decision-Making, and
                                                End-of-Life e364</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">14.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4260">Recommendation for Patient-Reported Outcomes and Evidence Gaps and Future
                                Research Directions e367</p>
                            <table class="listgroup" border="0" width="95%" id="olist1145" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">14.1.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4265">Patient-Reported Outcomes e367</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">14.2.</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4270">Evidence Gaps and Future Research Directions e370</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top"></td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p class="inline">References e371</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top"></td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p class="inline">Appendix 1</p>
                            <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist1145">
                                <li id="u2655">
                                    <p class="inline">Author Relationships With Industry and Other Entities
                                        (Relevant) e411</p>
                                </li>
                            </ul>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top"></td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p class="inline">Appendix 2</p>
                            <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist1150">
                                <li id="u2665">
                                    <p class="inline">Reviewer Relationships With Industry and Other Entities
                                        (Comprehensive) e414</p>
                                </li>
                            </ul>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top"></td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p class="inline">Appendix 3</p>
                            <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist1155">
                                <li id="u2675">
                                    <p class="inline">Appendix for Tables 3 and 4: Suggested Thresholds for Structural
                                        Heart Disease and Evidence of Increased Filling Pressures e421</p>
                                </li>
                            </ul>
                            <p></p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acd247731e991" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e991">
                <div id="acsectitle0045" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0045">Top 10 Take-Home Messages</h2>
            <p id="p4310">
            </p>
            <table class="listgroup" border="0" width="95%" id="olist1150" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4315">Guideline-directed medical therapy (GDMT) for heart failure (HF) with reduced
                                ejection fraction (HFrEF) now includes 4 medication classes that include sodium-glucose
                                cotransporter-2 inhibitors (SGLT2i).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4320">SGLT2i have a Class of Recommendation 2a in HF with mildly reduced ejection
                                fraction (HFmrEF). Weaker recommendations (Class of Recommendation 2b) are made for
                                ARNi, ACEi, ARB, MRA, and beta blockers in this population.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4325">New recommendations for HFpEF are made for SGLT2i (Class of Recommendation
                                2a), MRAs (Class of Recommendation 2b), and ARNi (Class of Recommendation 2b). Several
                                prior recommendations have been renewed including treatment of hypertension (Class of
                                Recommendation 1), treatment of atrial fibrillation (Class of Recommendation 2a), use of
                                ARBs (Class of Recommendation 2b), and avoidance of routine use of nitrates or
                                phosphodiesterase-5 inhibitors (Class of Recommendation 3: No Benefit).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4330">Improved LVEF is used to refer to those patients with previous HFrEF who now
                                have an LVEF &gt;40%. These patients should continue their HFrEF treatment.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4335">Value statements were created for select recommendations where high-quality,
                                cost-effectiveness studies of the intervention have been published.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">6.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4340">Amyloid heart disease has new recommendations for treatment including
                                screening for serum and urine monoclonal light chains, bone scintigraphy, genetic
                                sequencing, tetramer stabilizer therapy, and anticoagulation.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">7.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4345">Evidence supporting increased filling pressures is important for the diagnosis
                                of HF if the LVEF is &gt;40%. Evidence for increased filling pressures can be obtained
                                from noninvasive (e.g., natriuretic peptide, diastolic function on imaging) or invasive
                                testing (e.g., hemodynamic measurement).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">8.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4350">Patients with advanced HF who wish to prolong survival should be referred to a
                                team specializing in HF. A HF specialty team reviews HF management, assesses suitability
                                for advanced HF therapies, and uses palliative care including palliative inotropes where
                                consistent with the patient’s goals of care.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">9.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4355">Primary prevention is important for those at risk for HF (stage A) or pre-HF
                                (stage B). Stages of HF were revised to emphasize the new terminologies of “at risk” for
                                HF for stage A and pre-HF for stage B.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">10.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4360">Recommendations are provided for select patients with HF and iron deficiency,
                                anemia, hypertension, sleep disorders, type 2 diabetes, atrial fibrillation, coronary
                                artery disease, and malignancy.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acd247731e1038" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e1038">
                <div id="acsectitle0050" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0050">Preamble</h2>
            <p id="p4365">Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have
                translated scientific evidence into clinical practice guidelines with recommendations to improve
                cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify
                evidence, provide a foundation for the delivery of quality cardiovascular care. The ACC and AHA sponsor
                the development and publication of clinical practice guidelines without commercial support, and members
                volunteer their time to the writing and review efforts. Guidelines are official policy of the ACC and
                AHA. For some guidelines, the ACC and AHA partner with other organizations.</p>
            <div id="acsec4" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec4">
                <div id="acsectitle0055" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0055">Intended Use</h3>
            <p id="p4370">Clinical practice guidelines provide recommendations applicable to patients with or at risk of
                developing cardiovascular disease (CVD). The focus is on medical practice in the United States, but
                these guidelines are relevant to patients throughout the world. Although guidelines may be used to
                inform regulatory or payer decisions, the intent is to improve quality of care and align with patients’
                interests. Guidelines are intended to define practices meeting the needs of patients in most, but not
                all, circumstances and should not replace clinical judgment.</p>
            <div id="acsec4" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec4">
                <div id="acsectitle0060" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0060">Clinical Implementation</h3>
            <p id="p4375">Management, in accordance with guideline recommendations, is effective only when followed by
                both practitioners and patients. Adherence to recommendations can be enhanced by shared decision-making
                between clinicians and patients, with patient engagement in selecting interventions on the basis of
                individual values, preferences, and associated conditions and comorbidities.</p>
            <div id="acsec4" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec4">
                <div id="acsectitle0065" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0065">Methodology and Modernization</h3>
            <p id="p4380">The ACC/AHA Joint Committee on Clinical Practice Guidelines (Joint Committee) continuously
                reviews, updates, and modifies guideline methodology on the basis of published standards from
                organizations, including the National Academy of Medicine (formerly, the Institute of Medicine) (<a
                    class="tab-link" href="#bib1" data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib2"
                    data-tab="pane-pcw-references">2</a>), and on the basis of internal reevaluation. Similarly,
                presentation and delivery of guidelines are reevaluated and modified in response to evolving
                technologies and other factors to optimally facilitate dissemination of information to health care
                professionals at the point of care.</p>
            <p id="p4385">Numerous modifications to the guidelines have been implemented to make them shorter and
                enhance “user friendliness.” Guidelines are written and presented in a modular, “knowledge chunk” format
                in which each chunk includes a table of recommendations, a brief synopsis, recommendation-specific
                supportive text and, when appropriate, flow diagrams or additional tables. Hyperlinked references are
                provided for each modular knowledge chunk to facilitate quick access and review.</p>
            <p id="p4390">In recognition of the importance of cost–value considerations, in certain guidelines, when
                appropriate and feasible, an assessment of value for a drug, device, or intervention may be performed in
                accordance with the ACC/AHA methodology (<a class="tab-link" href="#bib3"
                    data-tab="pane-pcw-references">3</a>).</p>
            <p id="p4395">To ensure that guideline recommendations remain current, new data will be reviewed on an
                ongoing basis by the writing committee and staff. Going forward, targeted sections/knowledge chunks will
                be revised dynamically after publication and timely peer review of potentially practice-changing
                science. The previous designations of “full revision” and “focused update” will be phased out. For
                additional information and policies on guideline development, readers may consult the ACC/AHA guideline
                methodology manual (<a class="tab-link" href="#bib4" data-tab="pane-pcw-references">4</a>) and other
                methodology articles (<a class="tab-link" href="#bib5" data-tab="pane-pcw-references">5-7</a>).</p>
            <div id="acsec4" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec4">
                <div id="acsectitle0070" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0070">Selection of Writing Committee Members</h3>
            <p id="p4400">The Joint Committee strives to ensure that the guideline writing committee contains requisite
                content expertise and is representative of the broader cardiovascular community by selection of experts
                across a spectrum of backgrounds, representing different geographic regions, sexes, races, ethnicities,
                intellectual perspectives/biases, and clinical practice settings. Organizations and professional
                societies with related interests and expertise are invited to participate as partners or collaborators.
            </p>
            <div id="acsec4" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec4">
                <div id="acsectitle0075" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0075">Relationships With Industry and Other Entities</h3>
            <p id="p4405">The ACC and AHA have rigorous policies and methods to ensure that documents are developed
                without bias or improper influence. The complete policy on relationships with industry and other
                entities (RWI) can be found <a target="_blank" class="references__uri"
                    href="https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">online</a>.
                <a class="ref" href="#appsec1">Appendix 1</a> of the guideline lists writing committee members’ relevant
                RWI; for the purposes of full transparency, their comprehensive disclosure information is available in a
                <a class="ref" href="#mmc1">Supplemental Appendix</a>. Comprehensive disclosure information for the
                Joint Committee is also available <a target="_blank" class="references__uri"
                    href="https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-task-forces">online</a>.
            </p>
            <div id="acsec4" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec4">
                <div id="acsectitle0080" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0080">Evidence Review and Evidence Review Committees</h3>
            <p id="p4410">In developing recommendations, the writing committee uses evidence-based methodologies that
                are based on all available data (<a class="tab-link" href="#bib4"
                    data-tab="pane-pcw-references">4</a>,<a class="tab-link" href="#bib5"
                    data-tab="pane-pcw-references">5</a>). Literature searches focus on randomized controlled trials
                (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series,
                cohort studies, systematic reviews, and expert opinion. Only key references are cited.</p>
            <p id="p4415">An independent evidence review committee is commissioned when there are ≥1 questions deemed of
                utmost clinical importance and merit formal systematic review to determine which patients are most
                likely to benefit from a drug, device, or treatment strategy, and to what degree. Criteria for
                commissioning an evidence review committee and formal systematic review include absence of a current
                authoritative systematic review, feasibility of defining the benefit and risk in a time frame consistent
                with the writing of a guideline, relevance to a substantial number of patients, and likelihood that the
                findings can be translated into actionable recommendations. Evidence review committee members may
                include methodologists, epidemiologists, clinicians, and biostatisticians. Recommendations developed by
                the writing committee on the basis of the systematic review are marked “<sup>SR</sup>.”</p>
            <div id="acsec4" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec4">
                <div id="acsectitle0085" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0085">Guideline-Directed Medical Therapy</h3>
            <p id="p4420">The term guideline-directed medical therapy (GDMT) encompasses clinical evaluation, diagnostic
                testing, and both pharmacological and procedural treatments. For these and all recommended drug
                treatment regimens, the reader should confirm dosage with product insert material and evaluate for
                contraindications and interactions. Recommendations are limited to drugs, devices, and treatments
                approved for clinical use in the United States.</p>
            <p id="p4425"><i>Joshua A. Beckman, MD, MS, FAHA, FACC</i></p>
            <p id="p4430"><i>Chair, ACC/AHA Joint Committee on Clinical Practice Guidelines</i></p>
            <div id="acd247731e1125" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e1125">
                <div id="acsectitle0090" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0090">1 Introduction</h2>
            <div id="acsec5" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec5">
                <div id="acsectitle0095" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0095">1.1 Methodology and Evidence Review</h3>
            <p id="p4435">The recommendations listed in this guideline are, whenever possible, evidence based. An
                initial extensive evidence review, which included literature derived from research involving human
                subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane
                Collaboration, the Agency for Healthcare Research and Quality, and other selected databases relevant to
                this guideline, was conducted from May 2020 to December 2020. Key search words included but were not
                limited to the following: <i>heart failure; heart failure with reduced ejection fraction; heart failure
                    with preserved ejection fraction; heart failure with mildly reduced ejection fraction; systolic
                    heart failure; heart failure rehabilitation; cardiac failure; chronic heart failure; acute
                    decompensated heart failure; cardiogenic shock; beta blockers; mineralocorticoid receptor
                    antagonists; ACE-inhibitors, angiotensin and neprilysin receptor antagonist; sacubitril valsartan;
                    angiotensin receptor antagonist; Sodium glucose co-transporter 2 or SGLT2 inhibitors; cardiac
                    amyloidosis; atrial fibrillation; congestive heart failure; guideline-directed medical therapy;
                    HFrEF; diabetes mellitus; cardiomyopathy; cardiac amyloidosis; valvular heart disease; mitral
                    regurgitation; cardiomyopathy in pregnancy; reduced ejection fraction; right heart pressure;
                    palliative care</i>.</p>
            <p id="p4440">Additional relevant studies, published through September 2021 during the guideline writing
                process, were also considered by the writing committee and added to the evidence tables when
                appropriate. This guideline was harmonized with other ACC/AHA guidelines published through December
                2021.The final evidence tables are included in the <a class="ref" href="#mmc2">Online Data
                    Supplement</a> and summarize the evidence used by the writing committee to formulate
                recommendations. References selected and published in the present document are representative and not
                all-inclusive.</p>
            <div id="acsec5" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec5">
                <div id="acsectitle0100" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0100">1.2 Organization of the Writing Committee</h3>
            <p id="p4445">The writing committee consisted of cardiologists, HF specialists, internists,
                interventionalists, an electrophysiologist, surgeons, a pharmacist, an advanced nurse practitioner, and
                2 lay/patient representatives. The writing committee included representatives from the ACC, AHA, and
                Heart Failure Society of America (HFSA). <a class="ref" href="#appsec1">Appendix 1</a> of the present
                document lists writing committee members’ relevant RWI. For the purposes of full transparency, the
                writing committee members’ comprehensive disclosure information is available in a <a class="ref"
                    href="#mmc1">Supplemental Appendix</a>.</p>
            <div id="acsec5" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec5">
                <div id="acsectitle0105" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0105">1.3 Document Review and Approval</h3>
            <p id="p4450">This document was reviewed by 2 official reviewers nominated by the AHA; 1 official reviewer
                nominated by the ACC; 2 official reviewers from the HFSA; 1 official Joint Committee on Clinical
                Practice Guidelines reviewer; and 32 individual content reviewers. Reviewers’ RWI information was
                distributed to the writing committee and is published in this document (<a class="ref"
                    href="#appsec2">Appendix 2</a>).</p>
            <p id="p4455">This document was approved for publication by the governing bodies of the ACC, AHA, and HFSA.
            </p>
            <div id="acsec5" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec5">
                <div id="acsectitle0110" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0110">1.4 Scope of the Guideline</h3>
            <p id="p4460">The purpose of the “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” (2022 HF
                guideline) is to provide an update and to consolidate the “2013 ACCF/AHA Guideline for the Management of
                Heart Failure” (<a class="tab-link" href="#bib8" data-tab="pane-pcw-references">1</a>) for adults and
                the “2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart
                Failure” (<a class="tab-link" href="#bib9" data-tab="pane-pcw-references">2</a>) into a new document.
                Related ACC/AHA guidelines include recommendations relevant to HF and, in such cases, the HF guideline
                refers to these documents. For example, the 2019 primary prevention of cardiovascular disease guideline
                (<a class="tab-link" href="#bib10" data-tab="pane-pcw-references">3</a>) includes recommendations that
                will be useful in preventing HF, and the 2021 valvular heart disease guideline (<a class="tab-link"
                    href="#bib11" data-tab="pane-pcw-references">4</a>) provides recommendations for mitral valve (MV)
                clipping in mitral regurgitation (MR).</p>
            <div id="acsec5" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec5">
                <div id="acsectitle0115" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0115">Areas of focus include:</h3>
            <p id="p4465">
            </p>
            <table class="listgroup" border="0" width="95%" id="ulist1160" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">▪</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4470">Prevention of HF.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">▪</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4475">Management strategies in stage C HF, including:</p>
                            <table class="listgroup" border="0" width="95%" id="ulist1165" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">▪</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4480">New treatment strategies in HF, including sodium-glucose
                                                cotransporter-2 inhibitors (SGLT2i) and angiotensin receptor-neprilysin
                                                inhibitors (ARNi).</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">▪</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4485">Management of HF and atrial fibrillation (AF), including
                                                ablation of AF.</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">▪</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4490">Management of HF and secondary MR, including MV transcatheter
                                                edge-to-edge repair.</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">▪</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4495">Specific management strategies, including:</p>
                            <table class="listgroup" border="0" width="95%" id="ulist1170" list-type="simple">
                                <tbody>
                                    <tr class="li1">
                                        <td valign="top">▪</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4500">Cardiac amyloidosis.</p>
                                        </td>
                                    </tr>
                                    <tr class="li1">
                                        <td valign="top">▪</td>
                                        <td colspan="5" valign="top" class="paragraph">
                                            <p id="p4505">Cardio-oncology.</p>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                            <p></p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">▪</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4510">Implantable devices.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">▪</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4515">Left ventricular assist device (LVAD) use in stage D HF.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <p id="p4520">The intended primary target audience consists of clinicians who are involved in the care of
                patients with HF. Recommendations are stated in reference to the patients and their condition. The focus
                is to provide the most up-to-date evidence to inform the clinician during shared decision-making with
                the patient. Although the present document is not intended to be a procedural-based manual of
                recommendations that outlines the best practice for HF, there are certain practices that clinicians
                might use that are associated with improved clinical outcomes.</p>
            <p id="p4525">In developing the 2022 HF guideline, the writing committee reviewed previously published
                guidelines and related statements. <a class="ref showTableEvent" data-id="tbl1" href="#tbl1">Table 1</a>
                contains a list of these guidelines and statements deemed pertinent to this writing effort and is
                intended for use as a resource, thus obviating the need to repeat existing guideline recommendations.
            </p>
            <div id="tbl1" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl1">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0010"><span class="captionLabel">Table 1</span> Associated Guidelines and
                                Statements</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Title</th>
                            <th colspan="1" rowspan="1">Organization</th>
                            <th colspan="1" rowspan="1">Publication Year (Reference)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="3" rowspan="1"><strong>Guidelines</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery
                                <table class="listgroup" border="0" width="95%" id="ulist002a0" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0045a"><i>Hillis et al., “2011 ACCF/AHA Guideline for Coronary
                                                        Artery Bypass Graft Surgery” is now replaced and retired by the
                                                        “2021 ACC/AHA/SCAI Guideline for Coronary Artery
                                                        Revascularization” (</i><a class="tab-link" href="#bib12"
                                                        data-tab="pane-pcw-references">5</a><i>)</i></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td align="center" colspan="1" rowspan="1">ACCF/AHA</td>
                            <td align="center" colspan="1" rowspan="1">2011 (<a class="tab-link" href="#bib13"
                                    data-tab="pane-pcw-references">6</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary
                                Intervention<table class="listgroup" border="0" width="95%" id="ulist0020aa"
                                    list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0045aa"><i>Levine et al., “2011 ACCF/AHA/SCAI Guideline for
                                                        Percutaneous Coronary Intervention,” is now replaced and retired
                                                        by the “2021 ACC/AHA/SCAI Guideline for Coronary Artery
                                                        Revascularization”(</i><a class="tab-link" href="#bib12"
                                                        data-tab="pane-pcw-references">5</a><i>)</i></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td align="center" colspan="1" rowspan="1">ACCF/AHA/SCAI</td>
                            <td align="center" colspan="1" rowspan="1">2011 (<a class="tab-link" href="#bib14"
                                    data-tab="pane-pcw-references">7</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2015 ACCF/AHA/SCAI Focused Update Guideline for Percutaneous
                                Coronary Intervention</td>
                            <td align="center" colspan="1" rowspan="1">ACCF/AHA/SCAI</td>
                            <td align="center" colspan="1" rowspan="1">2016 (<a class="tab-link" href="#bib15"
                                    data-tab="pane-pcw-references">8</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2020 ACC/AHA Guideline for the Management of Patients With
                                Valvular Heart Disease</td>
                            <td align="center" colspan="1" rowspan="1">ACC/AHA</td>
                            <td align="center" colspan="1" rowspan="1">2021 (<a class="tab-link" href="#bib11"
                                    data-tab="pane-pcw-references">4</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2020 AHA/ACC Guideline for the Diagnosis and Treatment of
                                Patients With Hypertrophic Cardiomyopathy</td>
                            <td align="center" colspan="1" rowspan="1">ACC/AHA</td>
                            <td align="center" colspan="1" rowspan="1">2020 (<a class="tab-link" href="#bib16"
                                    data-tab="pane-pcw-references">9</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2019 ACC/AHA Guideline on the Primary Prevention of
                                Cardiovascular Disease</td>
                            <td align="center" colspan="1" rowspan="1">ACC/AHA</td>
                            <td align="center" colspan="1" rowspan="1">2019 (<a class="tab-link" href="#bib10"
                                    data-tab="pane-pcw-references">3</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS
                                Guideline for the Management of Patients With Atrial Fibrillation</td>
                            <td align="center" colspan="1" rowspan="1">AHA/ACC/HRS</td>
                            <td align="center" colspan="1" rowspan="1">2019 (<a class="tab-link" href="#bib17"
                                    data-tab="pane-pcw-references">10</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline
                                for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in
                                Adults</td>
                            <td align="center" colspan="1" rowspan="1">ACC/AHA/AAPA/ABC/ACPM/AGS/AphA/ASH/ASPC/NMA/PCNA
                            </td>
                            <td align="center" colspan="1" rowspan="1">2018 (<a class="tab-link" href="#bib18"
                                    data-tab="pane-pcw-references">11</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline
                                for the Management of Heart Failure</td>
                            <td align="center" colspan="1" rowspan="1">ACC/AHA/HFSA</td>
                            <td align="center" colspan="1" rowspan="1">2017 (<a class="tab-link" href="#bib9"
                                    data-tab="pane-pcw-references">2</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy
                                for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart
                                Failure</td>
                            <td align="center" colspan="1" rowspan="1">ACC/AHA/HFSA</td>
                            <td align="center" colspan="1" rowspan="1">2016 (<a class="tab-link" href="#bib19"
                                    data-tab="pane-pcw-references">12</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline
                                for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease</td>
                            <td align="center" colspan="1" rowspan="1">ACC/AHA/AATS/PCNA/SCAI/STS</td>
                            <td align="center" colspan="1" rowspan="1">2014 (<a class="tab-link" href="#bib20"
                                    data-tab="pane-pcw-references">13</a>)<a class="ref table-fn" id="tbl1fnlowast"
                                    href="javascript:popRef('tbl1fnlowast')"><sup>∗</sup></a></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2013 AHA/ACC Guideline on Lifestyle Management to Reduce
                                Cardiovascular Risk</td>
                            <td align="center" colspan="1" rowspan="1">AHA/ACC</td>
                            <td align="center" colspan="1" rowspan="1">2014 (<a class="tab-link" href="#bib21"
                                    data-tab="pane-pcw-references">14</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2013 AHA/ACC/TOS Guideline for the Management of Overweight and
                                Obesity in Adults</td>
                            <td align="center" colspan="1" rowspan="1">AHA/ACC/TOS</td>
                            <td align="center" colspan="1" rowspan="1">2014 (<a class="tab-link" href="#bib22"
                                    data-tab="pane-pcw-references">15</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/AphA/ASPC/NLA/PCNA
                                Guideline on the Management of Blood Cholesterol</td>
                            <td align="center" colspan="1" rowspan="1">
                                AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/AphA/ASPC/NLA/PCNA</td>
                            <td align="center" colspan="1" rowspan="1">2019 (<a class="tab-link" href="#bib23"
                                    data-tab="pane-pcw-references">16</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to
                                Reduce Atherosclerotic Cardiovascular Risk in Adults</td>
                            <td align="center" colspan="1" rowspan="1">ACC/AHA</td>
                            <td align="center" colspan="1" rowspan="1">2014 (<a class="tab-link" href="#bib24"
                                    data-tab="pane-pcw-references">17</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
                            </td>
                            <td align="center" colspan="1" rowspan="1">ACC/AHA</td>
                            <td align="center" colspan="1" rowspan="1">2014 (<a class="tab-link" href="#bib25"
                                    data-tab="pane-pcw-references">18</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2013 ACCF/AHA Guideline for the Management of Heart Failure</td>
                            <td align="center" colspan="1" rowspan="1">ACCF/AHA</td>
                            <td align="center" colspan="1" rowspan="1">2013 (<a class="tab-link" href="#bib8"
                                    data-tab="pane-pcw-references">1</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2013 ACCF/AHA Guideline for the Management of ST-Elevation
                                Myocardial Infarction</td>
                            <td align="center" colspan="1" rowspan="1">ACCF/AHA</td>
                            <td align="center" colspan="1" rowspan="1">2013 (<a class="tab-link" href="#bib26"
                                    data-tab="pane-pcw-references">19</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for
                                Device-Based Therapy of Cardiac Rhythm Abnormalities</td>
                            <td align="center" colspan="1" rowspan="1">ACCF/AHA/HRS</td>
                            <td align="center" colspan="1" rowspan="1">2012 (<a class="tab-link" href="#bib27"
                                    data-tab="pane-pcw-references">20</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis
                                and Management of Patients With Stable Ischemic Heart Disease</td>
                            <td align="center" colspan="1" rowspan="1">ACCF/AHA/ACP/AATS/PCNA/SCAI/STS</td>
                            <td align="center" colspan="1" rowspan="1">2012 (<a class="tab-link" href="#bib28"
                                    data-tab="pane-pcw-references">21</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Effectiveness-Based Guidelines for the Prevention of
                                Cardiovascular Disease in Women—2011 Update</td>
                            <td align="center" colspan="1" rowspan="1">AHA</td>
                            <td align="center" colspan="1" rowspan="1">2011 (<a class="tab-link" href="#bib29"
                                    data-tab="pane-pcw-references">22</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">AHA/ACCF Secondary Prevention and Risk Reduction Therapy for
                                Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update</td>
                            <td align="center" colspan="1" rowspan="1">AHA/ACCF</td>
                            <td align="center" colspan="1" rowspan="1">2011 (<a class="tab-link" href="#bib30"
                                    data-tab="pane-pcw-references">23</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in
                                Asymptomatic Adults</td>
                            <td align="center" colspan="1" rowspan="1">ACCF/AHA</td>
                            <td align="center" colspan="1" rowspan="1">2010 (<a class="tab-link" href="#bib31"
                                    data-tab="pane-pcw-references">24</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Part 9: Post–Cardiac Arrest Care: 2010 American Heart
                                Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular
                                Care</td>
                            <td align="center" colspan="1" rowspan="1">AHA</td>
                            <td align="center" colspan="1" rowspan="1">2010 (<a class="tab-link" href="#bib32"
                                    data-tab="pane-pcw-references">25</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Seventh Report of the Joint National Committee on Prevention,
                                Detection, Evaluation, and Treatment of High Blood Pressure</td>
                            <td align="center" colspan="1" rowspan="1">NHLBI</td>
                            <td align="center" colspan="1" rowspan="1">2003 (<a class="tab-link" href="#bib33"
                                    data-tab="pane-pcw-references">26</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="3" rowspan="1"><strong>Statements</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Cardiac Amyloidosis: Evolving Diagnosis and Management</td>
                            <td align="center" colspan="1" rowspan="1">AHA</td>
                            <td align="center" colspan="1" rowspan="1">2020 (<a class="tab-link" href="#bib34"
                                    data-tab="pane-pcw-references">27</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Testing of Low-Risk Patients Presenting to the Emergency
                                Department With Chest Pain</td>
                            <td align="center" colspan="1" rowspan="1">AHA</td>
                            <td align="center" colspan="1" rowspan="1">2010 (<a class="tab-link" href="#bib35"
                                    data-tab="pane-pcw-references">28</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Primary Prevention of Cardiovascular Diseases in People With
                                Diabetes Mellitus</td>
                            <td align="center" colspan="1" rowspan="1">AHA/ADA</td>
                            <td align="center" colspan="1" rowspan="1">2007 (<a class="tab-link" href="#bib36"
                                    data-tab="pane-pcw-references">29</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Prevention and Control of Influenza</td>
                            <td align="center" colspan="1" rowspan="1">CDC</td>
                            <td align="center" colspan="1" rowspan="1">2005 (<a class="tab-link" href="#bib37"
                                    data-tab="pane-pcw-references">30</a>)</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0015">AATS indicates American Association for Thoracic Surgery; AACVPR,
                                American Association of Cardiovascular and Pulmonary Rehabilitation; AAPA, American
                                Association Academy of Physician Assistants; ABC, Association of Black Cardiologists;
                                ACC, American College of Cardiology; ACCF, American College of Cardiology Foundation;
                                ACPM, American College of Preventive Medicine; ADA, American Diabetes Association; AGS,
                                American Geriatrics Society; AHA, American Heart Association; AphA, American Pharmacists
                                Association; ASH, American Society of Hypertension; ASPC, American Society for
                                Preventive Cardiology; CDC, Centers for Disease Control and Prevention; ESC, European
                                Society of Cardiology; HFSA, Heart Failure Society of America; HRS, Heart Rhythm
                                Society; NHLBI, National Heart, Lung, and Blood Institute; NICE, National Institute for
                                Health and Care Excellence; NMA, National Medical Association; NLA, National Lipid
                                Association; PCNA, Preventive Cardiovascular Nurses Association; SCAI, Society for
                                Cardiovascular Angiography and Interventions; SIHD, stable ischemic heart disease; STS,
                                Society of Thoracic Surgeons; TOS, The Obesity Society; and WHF, World Heart Federation.
                            </p>
                        </fn>
                        <fn id="tbl1fnlowast">
                            <p id="ntpara0010">∗ The full SIHD guideline is from 2012 (<a class="tab-link" href="#bib28"
                                    data-tab="pane-pcw-references">21</a>). A focused update was published in 2014 (<a
                                    class="tab-link" href="#bib20" data-tab="pane-pcw-references">13</a>).</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="acsec5" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec5">
                <div id="acsectitle0120" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0120">1.5 Class of Recommendation and Level of Evidence
            </h3>
            <p id="p4530">The Class of Recommendation (COR) indicates the strength of recommendation, encompassing the
                estimated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates
                the quality of scientific evidence supporting the intervention on the basis of the type, quantity, and
                consistency of data from clinical trials and other sources (<a class="ref showTableEvent" data-id="tbl2"
                    href="#tbl2">Table 2</a>) (<a class="tab-link" href="#bib38" data-tab="pane-pcw-references">1</a>).
            </p>
            <div id="tbl2" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl2">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0020"><span class="captionLabel">Table 2</span> Applying American College of
                                Cardiology/American Heart Association Class of Recommendation and Level of Evidence to
                                Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care
                                (Updated May 2019)∗</p>
                        </strong></caption>
                    <tbody>
                        <tr>
                            <td>
                                <div class="imageTable">
                                    <figure id="tbl2" class="article__inlineFigure article__tabFigure"><img
                                            class="figure__image" src="/specs/ux3/releasedAssets/images/loader.gif"
                                            data-src="/cms/asset/5f93f2c0-e6cb-4988-9b9c-d0d68cb01c17/fx1.jpg"
                                            data-lg-src="/cms/asset/ac72226b-e64a-4356-9906-29f8b0d4334f/fx1.jpg"
                                            alt="Table 2">
                                        <figcaption class="hidden">
                                            <p id="tspara0020"><span class="captionLabel">Table 2</span> Applying
                                                American College of Cardiology/American Heart Association Class of
                                                Recommendation and Level of Evidence to Clinical Strategies,
                                                Interventions, Treatments, or Diagnostic Testing in Patient Care
                                                (Updated May 2019)∗</p>
                                        </figcaption>
                                    </figure>
                                </div>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div id="acsec5" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec5">
                <div id="acsectitle0125" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0125">1.6 Abbreviations</h3>
            <div id="undtbl1" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl1">
                <table class="table article-section__table">
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Abbreviation</th>
                            <th colspan="1" rowspan="1">Meaning/Phrase</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ACEi</td>
                            <td colspan="1" rowspan="1">angiotensin-converting enzyme inhibitors</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ACS</td>
                            <td colspan="1" rowspan="1">acute coronary syndrome</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ARNi</td>
                            <td colspan="1" rowspan="1">angiotensin receptor-neprilysin inhibitors</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ARB</td>
                            <td colspan="1" rowspan="1">angiotensin (II) receptor blockers</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">AF</td>
                            <td colspan="1" rowspan="1">atrial fibrillation</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">AL-CM</td>
                            <td colspan="1" rowspan="1">immunoglobulin light chain amyloid cardiomyopathy</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ATTR-CM</td>
                            <td colspan="1" rowspan="1">transthyretin amyloid cardiomyopathy</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ATTRv</td>
                            <td colspan="1" rowspan="1">variant transthyretin amyloidosis</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ATTRwt</td>
                            <td colspan="1" rowspan="1">wild-type transthyretin amyloidosis</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">BNP</td>
                            <td colspan="1" rowspan="1">B-type natriuretic peptide</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CABG</td>
                            <td colspan="1" rowspan="1">coronary artery bypass graft</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CAD</td>
                            <td colspan="1" rowspan="1">coronary artery disease</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CCM</td>
                            <td colspan="1" rowspan="1">cardiac contractility modulation</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CHF</td>
                            <td colspan="1" rowspan="1">congestive heart failure</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CKD</td>
                            <td colspan="1" rowspan="1">chronic kidney disease</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CMR</td>
                            <td colspan="1" rowspan="1">cardiovascular magnetic resonance</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">COVID-19</td>
                            <td colspan="1" rowspan="1">coronavirus disease 2019</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CPET</td>
                            <td colspan="1" rowspan="1">cardiopulmonary exercise test</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CRT</td>
                            <td colspan="1" rowspan="1">cardiac resynchronization therapy</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CRT-D</td>
                            <td colspan="1" rowspan="1">cardiac resynchronization therapy with defibrillation</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CRT-P</td>
                            <td colspan="1" rowspan="1">cardiac resynchronization therapy with pacemaker</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CT</td>
                            <td colspan="1" rowspan="1">computed tomography</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CVD</td>
                            <td colspan="1" rowspan="1">cardiovascular disease</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CVP</td>
                            <td colspan="1" rowspan="1">central venous pressure</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">DOAC</td>
                            <td colspan="1" rowspan="1">direct-acting oral anticoagulants</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">DPP-4</td>
                            <td colspan="1" rowspan="1">dipeptidyl peptidase-4</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ECG</td>
                            <td colspan="1" rowspan="1">electrocardiogram</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">EF</td>
                            <td colspan="1" rowspan="1">ejection fraction</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">eGFR</td>
                            <td colspan="1" rowspan="1">estimated glomerular filtration rate</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">FDA</td>
                            <td colspan="1" rowspan="1">U.S. Food and Drug Administration</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">FLC</td>
                            <td colspan="1" rowspan="1">free light chain</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">GDMT</td>
                            <td colspan="1" rowspan="1">guideline-directed medical therapy</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">HF</td>
                            <td colspan="1" rowspan="1">heart failure</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">HFimpEF</td>
                            <td colspan="1" rowspan="1">heart failure with improved ejection fraction</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">HFmrEF</td>
                            <td colspan="1" rowspan="1">heart failure with mildly reduced ejection fraction</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">HFpEF</td>
                            <td colspan="1" rowspan="1">heart failure with preserved ejection fraction</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">HFrEF</td>
                            <td colspan="1" rowspan="1">heart failure with reduced ejection fraction</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ICD</td>
                            <td colspan="1" rowspan="1">implantable cardioverter-defibrillator</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">IFE</td>
                            <td colspan="1" rowspan="1">immunofixation electrophoresis</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">LBBB</td>
                            <td colspan="1" rowspan="1">left bundle branch block</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">LV</td>
                            <td colspan="1" rowspan="1">left ventricular</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">LVAD</td>
                            <td colspan="1" rowspan="1">left ventricular assist device</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">LVEDV</td>
                            <td colspan="1" rowspan="1">left ventricular end-diastolic volume</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">LVEF</td>
                            <td colspan="1" rowspan="1">left ventricular ejection fraction</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">LVH</td>
                            <td colspan="1" rowspan="1">left ventricular hypertrophy</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">MCS</td>
                            <td colspan="1" rowspan="1">mechanical circulatory support</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">MI</td>
                            <td colspan="1" rowspan="1">myocardial infarction</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">MR</td>
                            <td colspan="1" rowspan="1">mitral regurgitation</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">MRA</td>
                            <td colspan="1" rowspan="1">mineralocorticoid receptor antagonist</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">MV</td>
                            <td colspan="1" rowspan="1">mitral valve</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">NSAID</td>
                            <td colspan="1" rowspan="1">nonsteroidal anti-inflammatory drug</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">NSVT</td>
                            <td colspan="1" rowspan="1">nonsustained ventricular tachycardia</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">NT-proBNP</td>
                            <td colspan="1" rowspan="1">N-terminal prohormone of B-type natriuretic peptide</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">NYHA</td>
                            <td colspan="1" rowspan="1">New York Heart Association</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">QALY</td>
                            <td colspan="1" rowspan="1">quality-adjusted life year</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">QOL</td>
                            <td colspan="1" rowspan="1">quality of life</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PA</td>
                            <td colspan="1" rowspan="1">pulmonary artery</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PCWP</td>
                            <td colspan="1" rowspan="1">pulmonary capillary wedge pressure</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PET</td>
                            <td colspan="1" rowspan="1">positron emission tomography</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PPAR-γ</td>
                            <td colspan="1" rowspan="1">peroxisome proliferator-activated receptor gamma</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PUFA</td>
                            <td colspan="1" rowspan="1">polyunsaturated fatty acid</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">RA</td>
                            <td colspan="1" rowspan="1">right atrial</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">RASS</td>
                            <td colspan="1" rowspan="1">renin-angiotensin-aldosterone system</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">RAASi</td>
                            <td colspan="1" rowspan="1">renin-angiotensin-aldosterone system inhibitors</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">RCT</td>
                            <td colspan="1" rowspan="1">randomized controlled trial</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">RV</td>
                            <td colspan="1" rowspan="1">right ventricular</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">SCD</td>
                            <td colspan="1" rowspan="1">sudden cardiac death</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">SGLT2i</td>
                            <td colspan="1" rowspan="1">sodium-glucose cotransporter-2 inhibitors</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">SPECT</td>
                            <td colspan="1" rowspan="1">single photon emission CT</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><sup>99m</sup>Tc-PYP</td>
                            <td colspan="1" rowspan="1">technetium pyrophosphate</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">TEER</td>
                            <td colspan="1" rowspan="1">transcatheter mitral edge-to-edge repair</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">TTE</td>
                            <td colspan="1" rowspan="1">transthoracic echocardiogram</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">VA</td>
                            <td colspan="1" rowspan="1">ventricular arrhythmia</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">VF</td>
                            <td colspan="1" rowspan="1">ventricular fibrillation</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">VHD</td>
                            <td colspan="1" rowspan="1">valvular heart disease</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">VO<sub>2</sub></td>
                            <td colspan="1" rowspan="1">oxygen consumption/oxygen uptake</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">VT</td>
                            <td colspan="1" rowspan="1">ventricular tachycardia</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div id="acd247731e2014" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e2014">
                <div id="acsectitle0130" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0130">2 Definition of HF</h2>
            <p id="p4540"><strong>HF Description</strong></p>
            <p id="p4545">HF is a complex clinical syndrome with symptoms and signs that result from any structural or
                functional impairment of ventricular filling or ejection of blood. The writing committee recognizes that
                asymptomatic stages with structural heart disease or cardiomyopathies are not covered under the above
                definition as having HF. Such asymptomatic stages are considered at-risk for HF (stage A) or pre-HF
                (stage B), as explained in <a class="ref sec" id="crosref3280" href="#sec6.1">Section 2.1</a>, “Stages
                of HF”.</p>
            <div id="acsec6" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec6">
                <div id="acsectitle0135" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0135">2.1 Stages of HF</h3>
            <p id="p4550">The ACC/AHA stages of HF (<a data-tab="pane-pcw-Figures" href="#fig1" id="fig1R"
                    class="">Figure 1</a>, <a class="ref showTableEvent" data-id="tbl3" href="#tbl3">Table 3</a>)
                emphasize the development and progression of disease (<a class="tab-link" href="#bib39"
                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib40"
                    data-tab="pane-pcw-references">2</a>), and advanced stages and progression are associated with
                reduced survival (<a class="tab-link" href="#bib41" data-tab="pane-pcw-references">3</a>). Therapeutic
                interventions in each stage aim to modify risk factors (stage A), treat risk and structural heart
                disease to prevent HF (stage B), and reduce symptoms, morbidity, and mortality (stages C and D). To
                address the evolving role of biomarkers and structural changes for recognition of patients who are at
                risk of developing HF, who are potential candidates for targeted treatment strategies for the prevention
                of HF, and to enhance the understanding and adoption of these classifications, the writing committee
                proposed the terminologies listed in <a class="ref showTableEvent" data-id="tbl3" href="#tbl3">Table
                    3</a> for the stages of HF. For thresholds of cardiac structural, functional changes, elevated
                filling pressures, and biomarker elevations, refer to <a class="ref" href="#appsec3">Appendix 3</a>.</p>
            <section class="article-section__inline-figure">
                <figure id="fig1" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/15af1548-2a57-419b-9293-5ebae9d894b5/gr1.jpg"
                        data-lg-src="/cms/asset/a5c11c22-a8e2-4852-9f57-360d19d0423d/gr1.jpg" alt="Figure 1">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/a5c11c22-a8e2-4852-9f57-360d19d0423d/gr1.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig1&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 1</span></strong>
                        <p>ACC/AHA Stages of HF</p>
                        <p>The ACC/AHA stages of HF are shown. ACC indicates American College of Cardiology; AHA,
                            American Heart Association; CVD, cardiovascular disease; GDMT, guideline-directed medical
                            therapy; and HF, heart failure.</p>
                    </figcaption>
                </figure>
            </section>
            <div id="tbl3" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl3">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0025"><span class="captionLabel">Table 3</span> Stages of HF</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Stages</th>
                            <th colspan="1" rowspan="1">Definition and Criteria</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Stage A: At Risk for HF</strong></td>
                            <td colspan="1" rowspan="1">At risk for HF but without symptoms, structural heart disease,
                                or cardiac biomarkers of stretch or injury (e.g., patients with hypertension,
                                atherosclerotic CVD, diabetes, metabolic syndrome and obesity, exposure to cardiotoxic
                                agents, genetic variant for cardiomyopathy, or positive family history of
                                cardiomyopathy).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="4"><strong>Stage B: Pre-HF</strong></td>
                            <td colspan="1" rowspan="1">No symptoms or signs of HF and evidence of 1 of the following:
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><i>Structural heart disease</i><a class="ref table-fn"
                                    id="tbl3fnlowast" href="javascript:popRef('tbl3fnlowast')"><i><sup>∗</sup></i></a>
                                <table class="listgroup" border="0" width="95%" id="ulist0020" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0020">Reduced left or right ventricular systolic function</p>
                                                <table class="listgroup" border="0" width="95%" id="ulist0025"
                                                    list-type="simple">
                                                    <tbody>
                                                        <tr class="li1">
                                                            <td valign="top">▪</td>
                                                            <td colspan="5" valign="top" class="paragraph">
                                                                <p id="p0025">Reduced ejection fraction, reduced strain
                                                                </p>
                                                            </td>
                                                        </tr>
                                                    </tbody>
                                                </table>
                                                <p></p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0030">Ventricular hypertrophy</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0035">Chamber enlargement</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0040">Wall motion abnormalities</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0045">Valvular heart disease</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><i>Evidence for increased filling pressures</i><a
                                    class="ref table-fn" id="tbl3fnlowast"
                                    href="javascript:popRef('tbl3fnlowast')"><i><sup>∗</sup></i></a>
                                <table class="listgroup" border="0" width="95%" id="ulist0030" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0050">By invasive hemodynamic measurements</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0055">By noninvasive imaging suggesting elevated filling
                                                    pressures (e.g., Doppler echocardiography)</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><i>Patients with risk factors and</i>
                                <table class="listgroup" border="0" width="95%" id="ulist0035" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0060"><i>Increased levels of BNPs</i><a class="ref table-fn"
                                                        id="tbl3fnlowast"
                                                        href="javascript:popRef('tbl3fnlowast')"><i><sup>∗</sup></i></a>
                                                    <i>or</i></p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0065"><i>Persistently elevated cardiac troponin</i></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>in the absence of competing diagnoses resulting in such biomarker elevations
                                such as acute coronary syndrome, CKD, pulmonary embolus, or myopericarditis
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Stage C: Symptomatic HF</strong></td>
                            <td colspan="1" rowspan="1">Structural heart disease with current or previous symptoms of
                                HF.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Stage D: Advanced HF</strong></td>
                            <td colspan="1" rowspan="1">Marked HF symptoms that interfere with daily life and with
                                recurrent hospitalizations despite attempts to optimize GDMT.</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0030">BNP indicates B-type natriuretic peptide; CKD, chronic kidney disease;
                                CVD, cardiovascular disease; GDMT, guideline-directed medical therapy; and HF, heart
                                failure.</p>
                        </fn>
                        <fn id="tbl3fnlowast">
                            <p id="ntpara0015">∗ For thresholds of cardiac structural, functional changes, elevated
                                filling pressures, and biomarker elevations, refer to <a class="ref"
                                    href="#appsec3">Appendix 3</a>.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p4555"><strong>New York Heart Association (NYHA) Classification</strong></p>
            <p id="p4560">The NYHA classification is used to characterize symptoms and functional capacity of patients
                with symptomatic (stage C) HF or advanced HF (stage D). It is a subjective assessment by a clinician and
                can change over time. Although reproducibility and validity can be limited (<a class="tab-link"
                    href="#bib42" data-tab="pane-pcw-references">4</a>,<a class="tab-link" href="#bib43"
                    data-tab="pane-pcw-references">5</a>), the NYHA functional classification is an independent
                predictor of mortality (<a class="tab-link" href="#bib44" data-tab="pane-pcw-references">6</a>,<a
                    class="tab-link" href="#bib45" data-tab="pane-pcw-references">7</a>), and it is widely used in
                clinical practice to determine the eligibility of patients for treatment strategies. Clinicians specify
                NYHA classification at baseline after the initial diagnosis and after treatment through the continuum of
                care of a patient with HF. Although a patient with symptomatic HF (stage C) may become asymptomatic with
                treatment (NYHA class I), that patient will still be categorized as stage C HF. Patients with stage C HF
                can be classified according to the trajectory of their symptoms (<a data-tab="pane-pcw-Figures"
                    href="#fig2" id="fig2R" class="">Figure 2</a>).</p>
            <section class="article-section__inline-figure">
                <figure id="fig2" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/297a9f4c-75db-4303-be3a-0c6680bb9989/gr2.jpg"
                        data-lg-src="/cms/asset/edafe333-1f12-491a-81cb-3e7fc6a8b7a1/gr2.jpg" alt="Figure 2">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/edafe333-1f12-491a-81cb-3e7fc6a8b7a1/gr2.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig2&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 2</span></strong>
                        <p>Trajectory of Stage C HF</p>
                        <p>The trajectory of stage C HF is displayed. Patients whose symptoms and signs of HF are
                            resolved are still stage C and should be treated accordingly. If all HF symptoms, signs, and
                            structural abnormalities resolve, the patient is considered to have HF in remission. HF
                            indicates heart failure; and LV, left ventricular. ∗Full resolution of structural and
                            functional cardiac abnormalities is uncommon.</p>
                    </figcaption>
                </figure>
            </section>
            <div id="acsec6" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec6">
                <div id="acsectitle0140" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0140">2.2 Classification of HF by Left Ventricular
                Ejection Fraction (LVEF)</h3>
            <p id="p4565">LVEF is considered important in the classification of patients with HF because of differing
                prognosis and response to treatments and because most clinical trials select patients based on ejection
                fraction (EF). RCTs with evidence of survival benefit in patients with HF have mainly enrolled patients
                with HF with an LVEF ≤35% or ≤40%, often labeled HF with reduced ejection fraction (HFrEF) (<a
                    class="tab-link" href="#bib46" data-tab="pane-pcw-references">1</a>). In this guideline, HFrEF is
                defined as LVEF ≤40% (<a class="ref showTableEvent" data-id="tbl4" href="#tbl4">Table 4</a>). HF with
                preserved EF (HFpEF) represents at least 50% of the population with HF, and its prevalence is increasing
                (<a class="tab-link" href="#bib47" data-tab="pane-pcw-references">2</a>). HFpEF has been variably
                classified as LVEF &gt;40%, &gt;45%, or ≥50%. Because some of these patients do not have entirely normal
                LVEF but also do not have major reduction in systolic function, the term preserved EF has been used. In
                this guideline, the threshold for HFpEF is an LVEF ≥50% (<a class="ref showTableEvent" data-id="tbl4"
                    href="#tbl4">Table 4</a>).</p>
            <div id="tbl4" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl4">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0035"><span class="captionLabel">Table 4</span> Classification of HF by LVEF
                            </p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Type of HF According to LVEF</th>
                            <th colspan="1" rowspan="1">Criteria</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">HFrEF (HF with reduced EF)</td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0040" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0070">LVEF ≤40%</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">HFimpEF (HF with improved EF)</td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0045" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0075">Previous LVEF ≤40% and a follow-up measurement of LVEF
                                                    &gt;40%</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">HFmrEF (HF with mildly reduced EF)</td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0050" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0080">LVEF 41%–49%</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0085">Evidence of spontaneous or provokable increased LV filling
                                                    pressures (e.g., elevated natriuretic peptide, noninvasive and
                                                    invasive hemodynamic measurement)</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">HFpEF (HF with preserved EF)</td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0055" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0090">LVEF ≥50%</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0095">Evidence of spontaneous or provokable increased LV filling
                                                    pressures (e.g., elevated natriuretic peptide, noninvasive and
                                                    invasive hemodynamic measurement)</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tlspara0010">Please see <a class="ref" href="#appsec3">Appendix 3</a> for suggested
                                thresholds for structural heart disease and evidence of increased filling pressures.</p>
                            <p id="tspara0040">HF indicates heart failure; LV, left ventricular; and LVEF, left
                                ventricular ejection fraction.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p4570">Patients with HF and an LVEF between the HFrEF and HFpEF range have been termed as “HF with
                mid-range EF” (<a class="tab-link" href="#bib48" data-tab="pane-pcw-references">3</a>,<a
                    class="tab-link" href="#bib49" data-tab="pane-pcw-references">4</a>), or “HF with mildly reduced EF”
                (<a class="tab-link" href="#bib49" data-tab="pane-pcw-references">4</a>). Because of LVEF being lower
                than normal, these patients are classified in this document as HF with mildly reduced EF (HFmrEF).
                Patients with HFmrEF are usually in a dynamic trajectory to improvement from HFrEF or to deterioration
                to HFrEF (<a data-tab="pane-pcw-Figures" href="#fig3" id="fig3R" class="">Figure 3</a>). Therefore, for
                patients whose EF falls into this mildly reduced category, 1 EF measurement at 1 time point may not be
                adequate, and the trajectory of LVEF over time and the cause is important to evaluate (<a
                    data-tab="pane-pcw-Figures" href="#fig3" id="fig3R" class="">Figure 3</a>). Furthermore, the
                diagnosis of HFmrEF and HFpEF can be challenging. Although the classic clinical signs and symptoms of
                HF, together with EF of 41% to 49% or ≥50%, respectively, are necessary for the diagnosis of the HFmrEF
                and HFpEF, the requirements for additional objective measures of cardiac dysfunction can improve the
                diagnostic specificity. The signs and symptoms of HF are frequently nonspecific and overlap with other
                clinical conditions. Elevated natriuretic peptide levels are supportive of the diagnosis, but normal
                levels do not exclude a diagnosis of HFmrEF or HFpEF. To improve the specificity of diagnosing HFmrEF
                and HFpEF, the clinical diagnosis of HF in these EF categories should be further supported by objective
                measures. Therefore, the writing committee proposes the addition of evidence of spontaneous (at rest) or
                provokable (e.g., during exercise, fluid challenge) increased LV filling pressures (e.g., elevated
                natriuretic peptide, noninvasive/invasive hemodynamic measurement) to the classifications of HFmrEF and
                HFpEF (<a class="ref showTableEvent" data-id="tbl4" href="#tbl4">Table 4</a>).</p>
            <section class="article-section__inline-figure">
                <figure id="fig3" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/3561a106-112c-45c2-90a3-a2134fb92e99/gr3.jpg"
                        data-lg-src="/cms/asset/8fc46017-2e89-4840-a398-15b115d788bf/gr3.jpg" alt="Figure 3">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/8fc46017-2e89-4840-a398-15b115d788bf/gr3.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig3&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 3</span></strong>
                        <p>Classification and Trajectories of HF Based on LVEF</p>
                        <p><strong>See</strong> <a class="ref" href="#appsec3"><strong>Appendix 3</strong></a> for
                            suggested thresholds for laboratory findings. The classification for baseline and subsequent
                            LVEF is shown. Patients with HFrEF who improve their LVEF to &gt;40% are considered to have
                            HFimpEF and should continue HFrEF treatment. HF indicates heart failure; HFimpEF, heart
                            failure with improved ejection fraction; HFmrEF, heart failure with mildly reduced ejection
                            fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with
                            reduced ejection fraction; and LVEF, left ventricular ejection fraction. ∗There is limited
                            evidence to guide treatment for patients who improve their LVEF from mildly reduced
                            (41%-49%) to ≥50%. It is unclear whether to treat these patients as HFpEF or HFmrEF.</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p4575">The “2013 ACCF/AHA Guideline for the Management of Heart Failure” (<a class="tab-link"
                    href="#bib46" data-tab="pane-pcw-references">1</a>) has used the HFpEF-improved terminology for
                those whose EF improved from a lower level to EF &gt;40% under the subgrouping of patients with HFpEF.
                Others have proposed a working definition of HF-recovered EF that included a baseline LVEF ≤40%, a ≥10%
                increase from baseline LVEF, and a second measurement of LVEF &gt;40% (<a class="tab-link" href="#bib48"
                    data-tab="pane-pcw-references">3</a>). Although associated with better outcomes, improvement in LVEF
                does not mean full myocardial recovery or normalization of LV function. In most patients, cardiac
                structural abnormalities, such as LV chamber dilatation and ventricular systolic and diastolic
                dysfunction, may persist. Furthermore, changes in LVEF might not be unidirectional; a patient may have
                improvement followed by a decrease in EF or vice versa depending on the underlying cause, duration of
                disease, adherence to the GDMT, or reexposure to cardiotoxicity (<a class="tab-link" href="#bib50"
                    data-tab="pane-pcw-references">5</a>). Therefore, the writing committee elected not to use
                “recovered EF” or HFpEF, even if subsequent LVEF was &gt;50% but, rather, “HF with improved EF”
                (HFimpEF) as a subgroup of HFrEF to characterize these patients (<a class="ref showTableEvent"
                    data-id="tbl4" href="#tbl4">Table 4</a>, <a data-tab="pane-pcw-Figures" href="#fig3" id="fig3R"
                    class="">Figure 3</a>). Importantly, EF can decrease after withdrawal of pharmacological treatment
                in many patients who had improved EF to normal range with GDMT (<a class="tab-link" href="#bib50"
                    data-tab="pane-pcw-references">5</a>). Trajectory of LVEF can be important, and a significant
                reduction in LVEF over time is a poor prognostic factor.</p>
            <div id="acsec6" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec6">
                <div id="acsectitle0145" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0145">2.3 Diagnostic Algorithm for Classification of HF
                According to LVEF</h3>
            <p id="p4585">Structural and functional alterations of the heart as the underlying cause for the clinical
                presentation support the diagnosis of HFmrEF and HFpEF (<a class="tab-link" href="#bib51"
                    data-tab="pane-pcw-references">1</a>) (<a data-tab="pane-pcw-Figures" href="#fig4" id="fig4R"
                    class="">Figure 4</a>). The criteria for diagnosis of HFmrEF and HFpEF require evidence of increased
                LV filling pressures at rest, exercise, or other provocations. The criteria can be fulfilled with
                findings of elevated levels of natriuretic peptides, echocardiographic diastolic parameters such as an
                E/e′ ≥15 or other evidence of elevated filling pressures, or invasive hemodynamic measurement at rest or
                exercise. Evidence of structural heart disease (e.g., LV structural or functional alterations) may be
                used to further support the diagnosis of HFpEF. Key structural alterations are an increase in left
                atrial size and volume (left atrial volume index) and/or an increase in LV mass (LV mass index).</p>
            <section class="article-section__inline-figure">
                <figure id="fig4" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/f53a8bf0-c139-4399-a08a-22ef60f2269e/gr4.jpg"
                        data-lg-src="/cms/asset/9aab5569-6e49-4a9a-9307-0a4c8abefd75/gr4.jpg" alt="Figure 4">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/9aab5569-6e49-4a9a-9307-0a4c8abefd75/gr4.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig4&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 4</span></strong>
                        <p>Diagnostic Algorithm for HF and EF-Based Classification</p>
                        <p>The algorithm for a diagnosis of HF and EF-based classification is shown. BNP indicates
                            B-type natriuretic peptide; ECG, electrocardiogram; EF, ejection fraction; HF, heart
                            failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure
                            with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF,
                            left ventricular ejection fraction; LV, left ventricular; and NT-proBNP, N-terminal pro-B
                            type natriuretic peptide.</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p4590">Exercise stress testing with echocardiographic evaluation of diastolic parameters can be
                helpful if the diagnosis remains uncertain (<a class="tab-link" href="#bib52"
                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib53"
                    data-tab="pane-pcw-references">3</a>). Alternatively, or in addition, invasive hemodynamics at rest
                or with exercise, with assessment of filling pressures (pulmonary capillary wedge pressure or LV end
                diastolic pressures, pulmonary artery [PA] pressures, stroke volumes, and cardiac output) can be
                performed to help further establish the diagnosis (<a class="tab-link" href="#bib54"
                    data-tab="pane-pcw-references">4</a>).</p>
            <p id="p4595">The diagnosis of HFpEF is often challenging. A clinical composite score to diagnose HFpEF, the
                H<sub>2</sub>FPEF score (<a class="tab-link" href="#bib55" data-tab="pane-pcw-references">5-7</a>),
                integrates these predictive variables: obesity, atrial fibrillation (AF), age &gt;60 years, treatment
                with ≥2 antihypertensive medications, echocardiographic E/e′ ratio &gt;9, and echocardiographic PA
                systolic pressure &gt;35 mm Hg. A weighted score based on these 6 variables was used to create the
                composite score ranging from 0 to 9. The odds of HFpEF doubled for each 1-unit score increase (odds
                ratio, 1.98; 95% CI: 1.74-2.30; <i>P</i>&lt;0.0001), with a c-statistic of 0.841. Scores &lt;2 and ≥6
                reflect low and high likelihood, respectively, for HFpEF. A score between 2 and 5 may require further
                evaluation of hemodynamics with exercise echocardiogram or cardiac catheterization to confirm or negate
                a diagnosis of HFpEF. The use of this H<sub>2</sub>FPEF score may help to facilitate discrimination of
                HFpEF from noncardiac causes of dyspnea and can assist in determination of the need for further
                diagnostic testing in the evaluation of patients with unexplained exertional dyspnea (<a
                    class="tab-link" href="#bib56" data-tab="pane-pcw-references">6</a>,<a class="tab-link"
                    href="#bib57" data-tab="pane-pcw-references">7</a>).</p>
            <p id="p4600">The European Society of Cardiology has developed a diagnostic algorithm (<a class="tab-link"
                    href="#bib58" data-tab="pane-pcw-references">8</a>). This involves a pretest that assesses for HF
                symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes, elderly, AF), and
                diagnostic laboratory tests, ECG, and echocardiography. In the absence of overt noncardiac causes of
                breathlessness, HFpEF can be suspected if there is a normal LVEF, no significant heart valve disease or
                cardiac ischemia, and at least 1 typical risk factor. The score used functional, morphological, and
                biomarker domains. The points score assigns 2 points for a major criterion or 1 point for a minor
                criterion within each domain, with a maximum of 2 points for each domain.</p>
            <div id="acd247731e2404" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e2404">
                <div id="acsectitle0150" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0150">3 Epidemiology and Causes of HF</h2>
            <div id="acsec7" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec7">
                <div id="acsectitle0155" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0155">3.1 Epidemiology of HF</h3>
            <p id="p4610"><strong>Trends in Mortality and Hospitalization for HF</strong></p>
            <p id="p4615">HF is a growing health and economic burden for the United States, in large part because of the
                aging population (<a class="tab-link" href="#bib59" data-tab="pane-pcw-references">1</a>,<a
                    class="tab-link" href="#bib60" data-tab="pane-pcw-references">2</a>). Beginning in 2012, the
                age-adjusted death rate per capita for HF increased for the first time in the United States (<a
                    class="tab-link" href="#bib61" data-tab="pane-pcw-references">3</a>). A recent U.S. evaluation found
                total deaths caused by HF have increased from 275,000 in 2009 to 310,000 in 2014 (<a class="tab-link"
                    href="#bib61" data-tab="pane-pcw-references">3</a>).</p>
            <p id="p4620">U.S. hospitalizations for HF decreased up until 2012 (<a class="tab-link" href="#bib62"
                    data-tab="pane-pcw-references">4</a>); however, from 2013 to 2017, an increase in HF
                hospitalizations was observed. In 2017, there were 1.2 million HF hospitalizations in the United States
                among 924,000 patients with HF (<a class="tab-link" href="#bib62" data-tab="pane-pcw-references">4</a>).
                This represents a 26% increase in HF hospitalizations and number of patients hospitalized with HF.</p>
            <p id="p4625">Although the absolute number of patients with HF has partly grown as a result of the
                increasing number of older adults, the incidence of HF has decreased (<a class="tab-link" href="#bib63"
                    data-tab="pane-pcw-references">5</a>). Among U.S. Medicare beneficiaries, HF incidence declined from
                36 cases per 1000 beneficiaries in 2011 to 27 cases per 1000 beneficiaries in 2014 and remained stable
                through 2016 (<a class="tab-link" href="#bib63" data-tab="pane-pcw-references">5</a>). Divergent trends
                in the incidence of HF have been observed for those with HFrEF (decreasing incidence) and HFpEF
                (increasing incidence) (<a class="tab-link" href="#bib64" data-tab="pane-pcw-references">6</a>,<a
                    class="tab-link" href="#bib65" data-tab="pane-pcw-references">7</a>). Deaths attributable to
                cardiomyopathies have been increasing globally because of, in part, increased recognition, diagnosis,
                and documentation of specific cardiomyopathies and cardiotoxicity (<a class="tab-link" href="#bib60"
                    data-tab="pane-pcw-references">2</a>).</p>
            <p id="p4630"><strong>Racial and Ethnic Disparities in Mortality and Hospitalization for HF</strong></p>
            <p id="p4635">Racial and ethnic disparities in death resulting from HF persist, with non-Hispanic Black
                patients having the highest death rate per capita (<a class="tab-link" href="#bib62"
                    data-tab="pane-pcw-references">4</a>). A report examining the U.S. population found age-adjusted
                mortality rate for HF to be 92 per 100,000 individuals for non-Hispanic Black patients, 87 per 100,000
                for non-Hispanic White patients, and 53 per 100,000 for Hispanic patients (<a class="tab-link"
                    href="#bib62" data-tab="pane-pcw-references">4</a>). Among Medicare beneficiaries, non-Hispanic
                Black beneficiaries had a slightly greater decrease in HF incidence (38 cases per 1000 to 26 cases per
                1000, <i>P</i>=0.009) than non-Hispanic White beneficiaries (36 cases per 1000 to 28 cases per 1000,
                <i>P</i>=0.003) from 2011 to 2016 (<a class="tab-link" href="#bib62"
                    data-tab="pane-pcw-references">4</a>). Among patients with established HF, non-Hispanic Black
                patients experienced a higher rate of HF hospitalization and a lower rate of death compared with
                non-Hispanic White patients with HF (<a class="tab-link" href="#bib66"
                    data-tab="pane-pcw-references">8-10</a>). Hispanic patients with HF have been found to have similar
                (<a class="tab-link" href="#bib66" data-tab="pane-pcw-references">8</a>) or higher (<a class="tab-link"
                    href="#bib68" data-tab="pane-pcw-references">10</a>) HF hospitalization rates and similar (<a
                    class="tab-link" href="#bib68" data-tab="pane-pcw-references">10</a>) or lower (<a class="tab-link"
                    href="#bib66" data-tab="pane-pcw-references">8</a>) mortality rates compared with non-Hispanic White
                patients. Asian/Pacific Islander patients with HF have had a similar rate of hospitalization as
                non-Hispanic White patients but a lower rate of death (<a class="tab-link" href="#bib66"
                    data-tab="pane-pcw-references">8</a>,<a class="tab-link" href="#bib68"
                    data-tab="pane-pcw-references">10</a>). These racial and ethnic disparities in outcome, for those
                with HF, warrant studies and health policy changes to address health inequity.</p>
            <div id="acsec7" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec7">
                <div id="acsectitle0160" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0160">3.2 Cause of HF</h3>
            <p id="p4640">In the United States, approximately 115 million people have hypertension, 100 million have
                obesity, 92 million have prediabetes, 26 million have diabetes, and 125 million have atherosclerotic CVD
                (<a class="tab-link" href="#bib69" data-tab="pane-pcw-references">1</a>). These are known risk factors
                with high relative risk and population attributable risk for development of HF. Therefore, a large
                proportion of the U.S. population can be categorized as being at-risk for HF or stage A HF. The common
                causes of HF include ischemic heart disease and myocardial infarction (MI), hypertension, and valvular
                heart disease (VHD). Other causes can include familial or genetic cardiomyopathies; amyloidosis;
                cardiotoxicity with cancer or other treatments or substance abuse such as alcohol, cocaine, or
                methamphetamine; tachycardia, right ventricular (RV) pacing or stress-induced cardiomyopathies;
                peripartum cardiomyopathy; myocarditis; autoimmune causes, sarcoidosis; iron overload, including
                hemochromatosis; and thyroid disease and other endocrine metabolic and nutritional causes (<a
                    class="ref showTableEvent" data-id="tbl5" href="#tbl5">Table 5</a>). Furthermore, with cardiac
                imaging and biomarkers, myocardial injury or cardiac maladaptive structural changes can be detected at
                earlier phases with a higher sensitivity, even in the absence of gross LV dysfunction or symptoms. With
                the coronavirus disease 2019 (COVID-19) pandemic, investigators are gaining better insights into
                infection and inflammation-related myocardial injury and myocarditis. With the increasing ability to
                detect myocardial injury and with an increasing awareness of cardiotoxicity and injury patterns
                including inflammation, pre-HF or stage B HF will likely continue to increase. Beyond classifications of
                EF and staging in HF, clinicians should seek the cause of HF because appropriate treatment may be
                determined by the cause (<a class="ref showTableEvent" data-id="tbl5" href="#tbl5">Table 5</a>).</p>
            <div id="tbl5" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl5">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0045"><span class="captionLabel">Table 5</span> Other Potential Nonischemic
                                Causes of HF</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Cause</th>
                            <th colspan="1" rowspan="1">Reference</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Chemotherapy and other cardiotoxic medications</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib92"
                                    data-tab="pane-pcw-references">23-25</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Rheumatologic or autoimmune</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib95"
                                    data-tab="pane-pcw-references">26</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Endocrine or metabolic (thyroid, acromegaly, pheochromocytoma,
                                diabetes, obesity)</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib96"
                                    data-tab="pane-pcw-references">27-31</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Familial cardiomyopathy or inherited and genetic heart disease
                            </td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib101"
                                    data-tab="pane-pcw-references">32</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Heart rhythm–related (e.g., tachycardia-mediated, PVCs, RV
                                pacing)</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib102"
                                    data-tab="pane-pcw-references">33</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Hypertension</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib103"
                                    data-tab="pane-pcw-references">34</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Infiltrative cardiac disease (e.g., amyloid, sarcoid,
                                hemochromatosis)</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib90"
                                    data-tab="pane-pcw-references">21</a>,<a class="tab-link" href="#bib104"
                                    data-tab="pane-pcw-references">35</a>,<a class="tab-link" href="#bib105"
                                    data-tab="pane-pcw-references">36</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Myocarditis (infectious, toxin or medication, immunological,
                                hypersensitivity)</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib106"
                                    data-tab="pane-pcw-references">37</a>,<a class="tab-link" href="#bib107"
                                    data-tab="pane-pcw-references">38</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Peripartum cardiomyopathy</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib108"
                                    data-tab="pane-pcw-references">39</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Stress cardiomyopathy (Takotsubo)</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib109"
                                    data-tab="pane-pcw-references">40</a>,<a class="tab-link" href="#bib110"
                                    data-tab="pane-pcw-references">41</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Substance abuse (e.g., alcohol, cocaine, methamphetamine)</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib111"
                                    data-tab="pane-pcw-references">42-44</a>)</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0050">HF indicates heart failure; PVC, premature ventricular contraction; and
                                RV, right ventricular.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="acd247731e2626" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e2626">
                <div id="acsectitle0165" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0165">4 Initial and Serial Evaluation</h2>
            <div id="acsec8" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec8">
                <div id="acsectitle0170" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0170">4.1 Clinical Assessment: History and Physical
                Examination</h3>
            <div id="undtbl2" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl2">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0375">Recommendations for Clinical Assessment: History and Physical Examination
                            </p>
                            <p id="tspara0380">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0090" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1090"><strong>In patients with HF, vital signs and evidence of
                                                        clinical congestion should be assessed at each encounter to
                                                        guide overall management, including adjustment of diuretics and
                                                        other medications</strong> (<a class="tab-link" href="#bib70"
                                                        data-tab="pane-pcw-references">1-6</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0095" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1095"><strong>In patients with symptomatic HF, clinical factors
                                                        indicating the presence of advanced HF should be sought via the
                                                        history and physical examination</strong> (<a class="tab-link"
                                                        href="#bib76"
                                                        data-tab="pane-pcw-references">7-12</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0100" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1100"><strong>In patients with cardiomyopathy, a 3-generation
                                                        family history should be obtained or updated when assessing the
                                                        cause of the cardiomyopathy to identify possible inherited
                                                        disease (</strong><a class="tab-link" href="#bib82"
                                                        data-tab="pane-pcw-references"><strong>13</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib83"
                                                        data-tab="pane-pcw-references"><strong>14</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0105" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1105"><strong>In patients presenting with HF, a thorough history
                                                        and physical examination should direct diagnostic strategies to
                                                        uncover specific causes that may warrant disease-specific
                                                        management (</strong><a class="tab-link" href="#bib84"
                                                        data-tab="pane-pcw-references"><strong>15</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib85"
                                                        data-tab="pane-pcw-references"><strong>16</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-EO</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0110" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1110"><strong>In patients presenting with HF, a thorough history
                                                        and physical examination should be obtained and performed to
                                                        identify cardiac and noncardiac disorders, lifestyle and
                                                        behavioral factors, and social determinants of health that might
                                                        cause or accelerate the development or progression of
                                                        HF.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p4650"><strong>Synopsis</strong></p>
            <p id="p4655">The history and physical examination remain a cornerstone in the assessment of patients with
                HF. The history and physical examination provide information about the cause of an underlying
                cardiomyopathy, including the possibility of an inherited cardiomyopathy as ascertained by a family
                history or a condition requiring disease-specific therapy like amyloid heart disease, as well as reasons
                why a previously stable patient developed acutely decompensated HF. A critical component of the history
                and physical examination is to assess for clinical congestion (i.e., those signs and symptoms resulting
                from elevated cardiac filling pressures). Congestion is a target for medication adjustment and is
                associated with quality of life (QOL) and prognosis. The history and physical examination also allow for
                the determination of clinical clues that suggest the patient has advanced HF, which may warrant referral
                to an advanced HF center.</p>
            <p id="p4660"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1155" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4665">Clinical congestion can be assessed by various methods, including the presence
                                of jugular venous distention (<a class="tab-link" href="#bib86"
                                    data-tab="pane-pcw-references">17</a>), orthopnea (<a class="tab-link" href="#bib87"
                                    data-tab="pane-pcw-references">18</a>), bendopnea (<a class="tab-link" href="#bib88"
                                    data-tab="pane-pcw-references">19</a>), a square-wave response to the Valsalva
                                maneuver (<a class="tab-link" href="#bib89" data-tab="pane-pcw-references">20</a>), and
                                leg edema (<a class="tab-link" href="#bib75" data-tab="pane-pcw-references">6</a>). On a
                                practical level, clinicians use extent of clinical congestion to guide titration of
                                pharmacological treatments, including doses of diuretics. Observational studies have
                                shown that clinical congestion is an important adverse risk factor in patients with HF
                                (<a class="tab-link" href="#bib70" data-tab="pane-pcw-references">1-6</a>,<a
                                    class="tab-link" href="#bib86" data-tab="pane-pcw-references">17</a>). Recently, the
                                PARADIGM-HF (The Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and
                                Mortality of Patients With Chronic Heart Failure) investigators showed that, in patients
                                with chronic HFrEF, changes in markers of clinical congestion were associated with QOL
                                as assessed by the Kansas City Cardiomyopathy Questionnaire and also provided prognostic
                                information independently even of natriuretic peptides or the MAGGIC (Meta-analysis
                                Global Group in Chronic Heart Failure) risk score (<a class="tab-link" href="#bib71"
                                    data-tab="pane-pcw-references">2</a>). These data highlight the ongoing relevance of
                                clinical congestion ascertained by the history and physical examination.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4670">Some patients with HF progress to an advanced state, a condition that can be
                                treated with specialized interventions such as mechanical circulatory support (MCS) or
                                cardiac transplantation. Such patients should be identified before they progress to a
                                state of extremis, at which point they may succumb to their illness or suffer
                                complications of an intervention as a result of their very advanced state. Several
                                “simple clinical clues” are available to identify advanced HF and should be ascertained
                                via a focused history and physical examination. The recognition that a patient has
                                advanced HF will allow for earlier referral to an advanced HF center, when appropriate,
                                as will be discussed later in this document (see <a class="ref sec" id="crosref3615"
                                    href="#sec12">Section 8</a>, “Specialty Referral for Advanced HF”).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4675">Increasingly, familial cardiomyopathy is recognized as a more accurate
                                diagnosis in some patients previously classified as having an idiopathic dilated
                                cardiomyopathy (DCM). A detailed family history may provide the first clue of a genetic
                                basis. A broad array of questions includes whether family members had a weak, enlarged,
                                or thick heart, or HF; muscular dystrophy; a pacemaker or defibrillator; were on a heart
                                transplant list; or died unexpectedly. Periodic updating of the family history in
                                patients with a cardiomyopathy of uncertain origin may lead to a diagnosis of familial
                                cardiomyopathy in the event that a relative subsequently develops a cardiomyopathy or a
                                related complication. A 3-generation family pedigree obtained by genetic health care
                                professionals improved the rate of detection of a familial process as compared with
                                routine care (<a class="tab-link" href="#bib83" data-tab="pane-pcw-references">14</a>).
                                Furthermore, a family history of cardiomyopathy, as determined by a 3-generation
                                pedigree analysis, was associated with findings of gadolinium enhancement on cardiac
                                magnetic resonance imaging (MRI) and increased major adverse cardiac events (<a
                                    class="tab-link" href="#bib82" data-tab="pane-pcw-references">13</a>). The
                                possibility of an inherited cardiomyopathy provides the impetus for cascade screening of
                                undiagnosed family members, thereby potentially avoiding preventable adverse events in
                                affected relatives by implementation of GDMT and other management that otherwise would
                                not be initiated.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4680">Certain conditions that cause HF require disease-specific therapies. For
                                example, in amyloid heart disease, whether on the basis of transthyretin (<a
                                    class="tab-link" href="#bib90" data-tab="pane-pcw-references">21</a>) or light chain
                                deposition (<a class="tab-link" href="#bib91" data-tab="pane-pcw-references">22</a>),
                                there are specific treatments that otherwise would not be used in patients with HF.
                                Hence, expeditious and accurate diagnosis of such conditions is important. Currently,
                                important delays have been reported in diagnosing amyloid heart disease (<a
                                    class="tab-link" href="#bib85" data-tab="pane-pcw-references">16</a>), perhaps not
                                unexpectedly given the wide spectrum of possible clinical presentations (<a
                                    class="tab-link" href="#bib84" data-tab="pane-pcw-references">15</a>). Similarly, HF
                                attributable to sarcoidosis, hemochromatosis, hypothyroidism, hyperthyroidism,
                                acromegaly, connective tissue disease, tachycardia-induced cardiomyopathy, or
                                high-output HF from an arteriovenous fistula, among others, requires specific
                                therapeutic approaches. Given that the differential diagnosis of HF is broad, the
                                history and physical examination can provide clues to narrow the number of causes to
                                consider and guide the diagnostic approach to identify such conditions (<a
                                    class="ref showTableEvent" data-id="tbl5" href="#tbl5">Table 5</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4685">The history and physical examination help to identify the cause of a clinical
                                deterioration. To determine the cause of a clinical deterioration, the clinician
                                assesses for concurrent illness (e.g., ongoing myocardial ischemia, pulmonary emboli, or
                                systemic infection), initiation of a medication potentially detrimental in the setting
                                of HF (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), or the possibility of
                                chronic RV pacing (e.g., a newly implanted pacemaker or medications such as amiodarone
                                that leads to bradycardia and resultant chronic RV pacing), nonadherence to a medication
                                or dietary regimen, and ongoing substance abuse. In addition, an assessment of social
                                determinants of health (e.g., housing stability, food security, available
                                transportation) should be made.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec8.1" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec8.1">
                <div id="acsectitle0175" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0175">4.1.1 Initial Laboratory and Electrocardiographic
                Testing</h4>
            <div id="undtbl3" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl3">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0385">Recommendations for Initial Laboratory and Electrocardiographic Testing
                            </p>
                            <p id="tspara0390">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0125" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1125"><strong>For patients presenting with HF, the specific
                                                        cause of HF should be explored using additional laboratory
                                                        testing for appropriate management</strong> (<a class="tab-link"
                                                        href="#bib114"
                                                        data-tab="pane-pcw-references">1-8</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-EO</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0115" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1115"><strong>For patients who are diagnosed with HF, laboratory
                                                        evaluation should include complete blood count, urinalysis,
                                                        serum electrolytes, blood urea nitrogen, serum creatinine,
                                                        glucose, lipid profile, liver function tests, iron studies, and
                                                        thyroid-stimulating hormone to optimize management.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-EO</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0120" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1120"><strong>For all patients presenting with HF, a 12-lead ECG
                                                        should be performed at the initial encounter to optimize
                                                        management.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p4700"><strong>Synopsis</strong></p>
            <p id="p4705">Laboratory evaluation with complete blood count, urinalysis, serum electrolytes (including
                sodium, potassium, calcium, and magnesium), blood urea nitrogen, serum creatinine, glucose, fasting
                lipid profile, liver function tests, iron studies (serum iron, ferritin, transferrin saturation), and
                thyroid-stimulating hormone level and electrocardiography is part of the standard diagnostic evaluation
                of a patient with HF. In addition to routine assessment, specific diagnostic testing and evaluation is
                often necessary to identify specific cause and other comorbidities in patients with HF.</p>
            <p id="p4710"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1160" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4725">Identifying the specific cause of HF is important, because conditions that
                                cause HF may require disease-specific therapies. Depending on the clinical suspicion,
                                additional diagnostic studies are usually required to diagnose specific causes (<a
                                    class="ref showTableEvent" data-id="tbl6" href="#tbl6">Table 6</a>) such as ischemic
                                cardiomyopathy, cardiac amyloidosis, sarcoidosis, hemochromatosis, infectious mechanisms
                                (e.g., HIV, COVID-19, Chagas), hypothyroidism, hyperthyroidism, acromegaly, connective
                                tissue disorders, tachycardia-induced cardiomyopathy, Takotsubo, peripartum
                                cardiomyopathy, cardiotoxicity with cancer therapies, or substance abuse would require
                                specific management in addition to or beyond GDMT (<a class="tab-link" href="#bib114"
                                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib115"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib122"
                                    data-tab="pane-pcw-references">9-15</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4715">Laboratory evaluation with complete blood count, urinalysis, serum
                                electrolytes, blood urea nitrogen, serum creatinine, glucose, fasting lipid profile,
                                liver function tests, iron studies (serum iron, ferritin, transferrin saturation), and
                                thyroid-stimulating hormone levels provides important information regarding patients’
                                comorbidities, suitability for and adverse effects of treatments, potential causes or
                                confounders of HF, severity and prognosis of HF, and is usually performed on initial
                                evaluation. Pertinent laboratory tests are repeated with changes in clinical condition
                                or treatments (e.g., to monitor renal function or electrolytes with diuretics).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4720">Electrocardiography is part of the routine evaluation of a patient with HF and
                                provides important information on rhythm, heart rate, QRS morphology and duration,
                                cause, and prognosis of HF. It is repeated when there is a clinical indication, such as
                                a suspicion for arrhythmia, ischemia or myocardial injury, conduction, or other cardiac
                                abnormalities.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="tbl6" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl6">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0055"><span class="captionLabel">Table 6</span> Selected Potential Causes of
                                Elevated Natriuretic Peptide Levels (<a class="tab-link" href="#bib178"
                                    data-tab="pane-pcw-references">50-53</a>)</p>
                        </strong></caption>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Cardiac</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> HF, including RV HF syndromes</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> ACS</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Heart muscle disease, including LVH</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> VHD</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Pericardial disease</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> AF</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Myocarditis</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Cardiac surgery</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Cardioversion</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Toxic-metabolic myocardial insults, including cancer
                                chemotherapy</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Noncardiac</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Advancing age</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Anemia</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Renal failure</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Pulmonary: Obstructive sleep apnea, severe pneumonia</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Pulmonary embolism, pulmonary arterial hypertension</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Critical illness</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Bacterial sepsis</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> Severe burns</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0060">ACS indicates acute coronary syndromes; AF, atrial fibrillation; HF,
                                heart failure; LVH, left ventricular hypertrophy; RV, right ventricular; and VHD,
                                valvular heart disease.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="acsec8" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec8">
                <div id="acsectitle0180" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0180">4.2 Use of Biomarkers for Prevention, Initial
                Diagnosis, and Risk Stratification</h3>
            <div id="undtbl4" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl4">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0395">Recommendations for Use of Biomarkers for Prevention, Initial Diagnosis,
                                and Risk Stratification</p>
                            <p id="tspara0400">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0130" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1130"><strong>In patients presenting with dyspnea, measurement
                                                        of B-type natriuretic peptide (BNP) or N-terminal prohormone of
                                                        B-type natriuretic peptide (NT-proBNP) is useful to support a
                                                        diagnosis or exclusion of HF</strong> (<a class="tab-link"
                                                        href="#bib129"
                                                        data-tab="pane-pcw-references">1-12</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0135" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1135"><strong>In patients with chronic HF, measurements of BNP
                                                        or NT-proBNP levels are recommended for risk stratification
                                                        (</strong><a class="tab-link" href="#bib139"
                                                        data-tab="pane-pcw-references"><strong>11</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib141"
                                                        data-tab="pane-pcw-references"><strong>13-29</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0140" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1140"><strong>In patients hospitalized for HF, measurement of
                                                        BNP or NT-proBNP levels at admission is recommended to establish
                                                        prognosis (</strong><a class="tab-link" href="#bib139"
                                                        data-tab="pane-pcw-references"><strong>11</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib141"
                                                        data-tab="pane-pcw-references"><strong>13-19</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0145" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1145"><strong>In patients at risk of developing HF, BNP or
                                                        NT-proBNP–based screening followed by team-based care, including
                                                        a cardiovascular specialist, can be useful to prevent the
                                                        development of LV dysfunction or new-onset HF (</strong><a
                                                        class="tab-link" href="#bib158"
                                                        data-tab="pane-pcw-references"><strong>30</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib159"
                                                        data-tab="pane-pcw-references"><strong>31</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0150" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1150"><strong>In patients hospitalized for HF, a predischarge
                                                        BNP or NT-proBNP level can be useful to inform the trajectory of
                                                        the patient and establish a postdischarge prognosis (</strong><a
                                                        class="tab-link" href="#bib142"
                                                        data-tab="pane-pcw-references"><strong>14</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib145"
                                                        data-tab="pane-pcw-references"><strong>17</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib148"
                                                        data-tab="pane-pcw-references"><strong>20-29</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p4735"><strong>Synopsis</strong></p>
            <p id="p4740">Assays for BNP and NT-proBNP are frequently used to establish the presence and severity of HF.
                In general, BNP and NT-proBNP levels are similar, and either can be used in patient care settings as
                long as their respective absolute values and cut-points are not used interchangeably (<a
                    class="tab-link" href="#bib160" data-tab="pane-pcw-references">32-34</a>). Obesity is associated
                with lower levels of BNP and NT-proBNP thereby reducing their diagnostic sensitivity (<a
                    class="tab-link" href="#bib163" data-tab="pane-pcw-references">35</a>,<a class="tab-link"
                    href="#bib164" data-tab="pane-pcw-references">36</a>). A substantial evidence base supports the use
                of natriuretic peptide biomarkers for excluding HF as a cause of symptoms in ambulatory and emergency
                department settings. Although a reduction in BNP and NT-proBNP has been associated with better outcomes,
                the evidence for treatment guidance using serial BNP or NT-proBNP measurements remains insufficient (<a
                    class="tab-link" href="#bib165" data-tab="pane-pcw-references">37-39</a>). Lastly, a widening array
                of biomarkers including markers of myocardial injury, inflammation, oxidative stress, vascular
                dysfunction, and matrix remodeling have been shown to provide incremental prognostic information over
                natriuretic peptides but remain without evidence of an incremental management benefit (<a
                    class="tab-link" href="#bib141" data-tab="pane-pcw-references">13</a>,<a class="tab-link"
                    href="#bib168" data-tab="pane-pcw-references">40-49</a>).</p>
            <p id="p4745"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1165" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4750">Measurement of BNP and NT-proBNP levels in the ambulatory setting for a
                                suspected cardiac cause of dyspnea provides incremental diagnostic value to clinical
                                judgment when the cause of dyspnea is unclear and the physical examination equivocal (<a
                                    class="tab-link" href="#bib129" data-tab="pane-pcw-references">1-9</a>). In the
                                emergency setting, BNP and NT-proBNP levels have higher sensitivity than specificity and
                                may be more useful for ruling out HF than ruling in HF. Although lower levels of BNP and
                                NT-proBNP may help exclude the presence of HF, and higher levels have high positive
                                predictive value to diagnose HF, increases in both BNP and NT-proBNP levels have been
                                reported in patients with various cardiac and noncardiac causes (<a
                                    class="ref showTableEvent" data-id="tbl6" href="#tbl6">Table 6</a>) (<a
                                    class="tab-link" href="#bib178" data-tab="pane-pcw-references">50-53</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4755">and 3. Higher levels of BNP and NT-proBNP are associated with a greater risk
                                for adverse short- and long-term outcomes in patients with HF, including all-cause and
                                cardiovascular death and major cardiovascular events (<a class="tab-link" href="#bib139"
                                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib141"
                                    data-tab="pane-pcw-references">13-19</a>). Studies have shown incremental prognostic
                                value of these biomarkers to standard approaches of CVD risk assessment (<a
                                    class="tab-link" href="#bib139" data-tab="pane-pcw-references">11</a>,<a
                                    class="tab-link" href="#bib144" data-tab="pane-pcw-references">16</a>). Not all
                                patients may need biomarker measurement for prognostication, especially if they already
                                have advanced HF with established poor prognosis or persistently elevated levels of
                                biomarkers in former settings.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4760">The STOP-HF (St Vincent’s Screening to Prevent Heart Failure) study is a large
                                single-center trial of patients at risk of HF, defined by the presence of hypertension,
                                diabetes, or known vascular disease but without established LV systolic dysfunction or
                                symptomatic HF, who were randomly assigned to screening with BNP testing or usual care
                                (<a class="tab-link" href="#bib159" data-tab="pane-pcw-references">31</a>). Participants
                                in the intervention group with BNP levels ≥50 pg/mL underwent echocardiography and
                                referral to a cardiovascular specialist (<a class="tab-link" href="#bib159"
                                    data-tab="pane-pcw-references">31</a>). All patients received coaching by a
                                specialist nurse who provided education on the importance of adherence to medication and
                                healthy lifestyle behaviors (<a class="tab-link" href="#bib159"
                                    data-tab="pane-pcw-references">31</a>). BNP-based screening reduced the composite
                                endpoint of incident asymptomatic LV dysfunction with or without newly diagnosed HF.
                                Similarly, accelerated uptitration of renin-angiotensin-aldosterone system (RAAS)
                                antagonists and beta blockers reduced cardiac events in patients with diabetes and
                                elevated NT-proBNP levels but without cardiac disease at baseline (<a class="tab-link"
                                    href="#bib158" data-tab="pane-pcw-references">30</a>). Standardized screening for HF
                                remains challenging as a result of the heterogeneity of risk factors across different
                                patient populations. Studies are needed to assess the cost-effectiveness and risks of
                                such screening, as well as its impact on QOL and mortality.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4765">Predischarge BNP and NT-proBNP levels are strong predictors of the risk of
                                death or hospital readmission for HF (<a class="tab-link" href="#bib142"
                                    data-tab="pane-pcw-references">14</a>,<a class="tab-link" href="#bib145"
                                    data-tab="pane-pcw-references">17</a>,<a class="tab-link" href="#bib148"
                                    data-tab="pane-pcw-references">20-29</a>). Although patients in whom levels of BNP
                                or NT-proBNP decreased with treatment had better outcomes than those without any changes
                                or with a biomarker rise (<a class="tab-link" href="#bib142"
                                    data-tab="pane-pcw-references">14</a>,<a class="tab-link" href="#bib151"
                                    data-tab="pane-pcw-references">23</a>,<a class="tab-link" href="#bib156"
                                    data-tab="pane-pcw-references">28</a>,<a class="tab-link" href="#bib157"
                                    data-tab="pane-pcw-references">29</a>), targeting a certain threshold, value, or
                                relative change in these biomarker levels during hospitalization has not been shown to
                                be consistently effective in improving outcomes (<a class="tab-link" href="#bib165"
                                    data-tab="pane-pcw-references">37-39</a>). Patients in which GDMT leads to a
                                reduction in BNP and NT-proBNP levels represent a population with improved long-term
                                outcomes compared with those with persistently elevated levels despite appropriate
                                treatment (<a class="tab-link" href="#bib165" data-tab="pane-pcw-references">37-39</a>).
                                BNP and NT-proBNP levels and their change could help guide discussions on prognosis as
                                well as adherence to, and optimization of, GDMT.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec8" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec8">
                <div id="acsectitle0185" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0185">4.3 Genetic Evaluation and Testing</h3>
            <div id="undtbl5" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl5">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0405">Recommendations for Genetic Evaluation and Testing</p>
                            <p id="tspara0410">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0155" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1155"><strong>In first-degree relatives of selected patients
                                                        with genetic or inherited cardiomyopathies, genetic screening
                                                        and counseling are recommended to detect cardiac disease and
                                                        prompt consideration of treatments to decrease HF progression
                                                        and sudden death (</strong><a class="tab-link" href="#bib182"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib183"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0160" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1160"><strong>In select patients with nonischemic
                                                        cardiomyopathy, referral for genetic counseling and testing is
                                                        reasonable to identify conditions that could guide treatment for
                                                        patients and family members (</strong><a class="tab-link"
                                                        href="#bib184"
                                                        data-tab="pane-pcw-references"><strong>3</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib185"
                                                        data-tab="pane-pcw-references"><strong>4</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p4780"><strong>Synopsis</strong></p>
            <p id="p4785">In patients in whom a genetic or inherited cardiomyopathy is suspected, a family history
                should be performed, including at least 3 generations and ideally diagrammed as a family tree pedigree
                (see <a class="ref sec" id="crosref3755" href="#sec8.1">Section 4.1</a>, “Clinical Assessment: History
                and Physical Examination”). Genetic variants have been implicated in 25% to 40% of patients with DCM
                with a positive family history but also in 10% to 30% of patients without a recognized family history
                (<a class="tab-link" href="#bib184" data-tab="pane-pcw-references">3</a>,<a class="tab-link"
                    href="#bib185" data-tab="pane-pcw-references">4</a>). Phenotype and family history are important for
                identifying patients in whom genetic testing is most likely to yield clinically actionable information
                (<a class="ref showTableEvent" data-id="tbl7" href="#tbl7">Table 7</a>). Presentation of DCM with
                conduction disease or ventricular arrhythmias raises concern of sarcoidosis and arrhythmogenic
                cardiomyopathy, which is of particular concern because of the risk of sudden death in patients and
                families (<a class="tab-link" href="#bib186" data-tab="pane-pcw-references">5</a>). No controlled
                studies have shown clinical benefits of genetic testing for cardiomyopathy, but genetic testing
                contributes to risk stratification and has implications for treatment, currently most often for
                decisions regarding defibrillators for primary prevention of sudden death (<a class="tab-link"
                    href="#bib186" data-tab="pane-pcw-references">5</a>) and regarding exercise limitation for
                hypertrophic cardiomyopathy and the desmosomal variants. Consultation with a trained counselor before
                and after genetic testing helps patients to understand and weigh the implications of possible results
                for their own lives and those of family members, including possible discrimination on the basis of
                genetic information. Unless shown to be free of the genetic variant(s) implicated in the proband,
                first-degree relatives of affected probands should undergo periodic screening with echocardiography and
                electrocardiography.</p>
            <div id="tbl7" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl7">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0065"><span class="captionLabel">Table 7</span> Examples of Factors Implicating
                                Possible Genetic Cardiomyopathy</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Phenotypic Category</th>
                            <th colspan="1" rowspan="1">Patient or Family Member Phenotypic Finding<a
                                    class="ref table-fn" id="tbl7fnlowast"
                                    href="javascript:popRef('tbl7fnlowast')"><sup>∗</sup></a></th>
                            <th colspan="1" rowspan="1">Ask Specifically About Family Members<a class="ref table-fn"
                                    id="tbl7fnlowast" href="javascript:popRef('tbl7fnlowast')"><sup>∗</sup></a> With
                            </th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Cardiac morphology</td>
                            <td colspan="1" rowspan="1">Marked LV hypertrophy</td>
                            <td align="center" colspan="1" rowspan="3">Any mention of cardiomyopathy, enlarged or weak
                                heart, HF.<br>Document even if attributed to other causes, such as alcohol or peripartum
                                cardiomyopathy</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1">LV noncompaction</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1">Right ventricular thinning or fatty replacement on imaging or
                                biopsy</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Findings on 12-lead ECG</td>
                            <td colspan="1" rowspan="1">Abnormal high or low voltage or conduction, and repolarization,
                                altered RV forces</td>
                            <td colspan="1" rowspan="1">Long QT or Brugada syndrome</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Dysrhythmias</td>
                            <td colspan="1" rowspan="1">Frequent NSVT or very frequent PVCs</td>
                            <td colspan="1" rowspan="2">ICD<br>Recurrent syncope<br>Sudden death attributed to “massive
                                heart attack” without known CAD<br>Unexplained fatal event such as drowning or
                                single-vehicle crash</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1">Sustained ventricular tachycardia or fibrillation</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1">Early onset AF</td>
                            <td colspan="1" rowspan="1">“Lone” AF before age 65 y</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1">Early onset conduction disease</td>
                            <td colspan="1" rowspan="1">Pacemaker before age 65 y</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Extracardiac features</td>
                            <td colspan="1" rowspan="1">Skeletal myopathy<br>Neuropathy<br>Cutaneous stigmata<br>Other
                                possible manifestations of systemic syndromes</td>
                            <td colspan="1" rowspan="1">Any known skeletal muscle disease, including mention of Duchenne
                                and Becker’s, Emory-Dreifuss limb-girdle dystrophy<br>Systemic syndromes:<table
                                    class="listgroup" border="0" width="95%" id="ulist0060" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0100">Dysmorphic features</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0105">Mental retardation</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0110">Congenital deafness</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0115">Neurofibromatosis</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0120">Renal failure with neuropathy</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0070">AF indicates atrial fibrillation; CAD, coronary artery disease; LV, left
                                ventricular; NSVT, nonsustained ventricular tachycardia; PVC, premature ventricular
                                contraction; and RV, right ventricular.</p>
                        </fn>
                        <fn id="tbl7fnlowast">
                            <p id="ntpara0020">∗ Note that genetic cause is more likely when the person is younger at
                                the onset of events. However, the cardiac morphology and peripheral manifestations of
                                hereditary amyloidosis may present in later life, unlike most other inherited
                                cardiomyopathies.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p4790"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1170" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1. and 2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4795">Inherited dilated, restrictive, and hypertrophic cardiomyopathies have been
                                identified, although 1 gene variant may cause different phenotypes in the same family.
                                The most common pathogenic variants identified are truncations in the large structural
                                protein titin, which have been implicated in DCM (<a class="tab-link" href="#bib184"
                                    data-tab="pane-pcw-references">3-5</a>) and also in peripartum or alcoholic
                                cardiomyopathies; however, variants that do not cause disease are also common.
                                Pathogenic variants in lamin A/C can be associated with conduction block and atrial
                                arrhythmias as well as ventricular arrhythmias, which may progress more rapidly than
                                symptoms of HF. Although previously linked with the phenotype of arrhythmogenic RV
                                cardiomyopathy, desmosomal protein variants are now recognized to affect the left
                                ventricle also with or without the right ventricle, and the term arrhythmogenic
                                cardiomyopathy is now preferred for the phenotype of arrhythmias combined with DCM.
                                Filamin-C mutations have been associated with skeletal myopathies and with isolated
                                cardiomyopathy with ventricular arrhythmias. The identification of pathogenic variants
                                associated with increased risk of sudden death may trigger consideration of primary
                                prevention implantable cardioverter-defibrillators (ICDs) even in patients who have LVEF
                                &gt;0.35 or &lt;3 months of guideline-recommended therapies (<a class="tab-link"
                                    href="#bib187" data-tab="pane-pcw-references">6</a>). Evidence of desmosomal cardiac
                                disease carries the additional implication of advice to avoid strenuous exercise, which
                                may accelerate ventricular remodeling (<a class="tab-link" href="#bib188"
                                    data-tab="pane-pcw-references">7</a>). Genetic confirmation of symptomatic Fabry’s
                                cardiomyopathy is an indication for replacement therapy with the enzyme agalsidase beta,
                                and migalastat was recently approved for this uncommon cardiomyopathy.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec8" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec8">
                <div id="acsectitle0190" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0190">4.4 Evaluation With Cardiac Imaging</h3>
            <div id="undtbl6" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl6">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0415">Recommendations for Evaluation With Cardiac Imaging</p>
                            <p id="tspara0420">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0165" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1165"><strong>In patients with suspected or new-onset HF, or
                                                        those presenting with acute decompensated HF, a chest x-ray
                                                        should be performed to assess heart size and pulmonary
                                                        congestion and to detect alternative cardiac, pulmonary, and
                                                        other diseases that may cause or contribute to the patient’s
                                                        symptoms (</strong><a class="tab-link" href="#bib189"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib190"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0170" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1170"><strong>In patients with suspected or newly diagnosed HF,
                                                        transthoracic echocardiography (TTE) should be performed during
                                                        initial evaluation to assess cardiac structure and
                                                        function</strong> (<a class="tab-link" href="#bib191"
                                                        data-tab="pane-pcw-references">3</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0175" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1175"><strong>In patients with HF who have had a significant
                                                        clinical change, or who have received GDMT and are being
                                                        considered for invasive procedures or device therapy, repeat
                                                        measurement of EF, degree of structural remodeling, and valvular
                                                        function are useful to inform therapeutic interventions</strong>
                                                    (<a class="tab-link" href="#bib192"
                                                        data-tab="pane-pcw-references">4-7</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0180" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1180"><strong>In patients for whom echocardiography is
                                                        inadequate, alternative imaging (e.g., cardiac magnetic
                                                        resonance [CMR], cardiac computed tomography [CT], radionuclide
                                                        imaging) is recommended for assessment of LVEF</strong> (<a
                                                        class="tab-link" href="#bib196"
                                                        data-tab="pane-pcw-references">8-15</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0185" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1185"><strong>In patients with HF or cardiomyopathy, CMR can be
                                                        useful for diagnosis or management</strong> (<a class="tab-link"
                                                        href="#bib204"
                                                        data-tab="pane-pcw-references">16-23</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0190" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">6.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1190"><strong>In patients with HF, an evaluation for possible
                                                        ischemic heart disease can be useful to identify the cause and
                                                        guide management</strong> (<a class="tab-link" href="#bib212"
                                                        data-tab="pane-pcw-references">24-27</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0195" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">7.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1195"><strong>In patients with HF and coronary artery disease
                                                        (CAD) who are candidates for coronary revascularization,
                                                        noninvasive stress imaging (stress echocardiography,
                                                        single-photon emission CT [SPECT], CMR, or positron emission
                                                        tomography [PET]) may be considered for detection of myocardial
                                                        ischemia to help guide coronary revascularization</strong> (<a
                                                        class="tab-link" href="#bib216"
                                                        data-tab="pane-pcw-references">28-32</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: No Benefit</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-EO</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0200" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">8.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1200"><strong>In patients with HF in the absence of: 1) clinical
                                                        status change, 2) treatment interventions that might have had a
                                                        significant effect on cardiac function, or 3) candidacy for
                                                        invasive procedures or device therapy, routine repeat assessment
                                                        of LV function is not indicated.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p4810"><strong>Synopsis</strong></p>
            <p id="p4815">Cardiac imaging has a key role in the initial evaluation of individuals with suspected HF and,
                when indicated, in the serial assessment of patients with HF. After a complete history and physical
                examination, a comprehensive TTE is the most useful initial diagnostic test given the vast amount of
                diagnostic and prognostic information provided. The determination of LVEF is a fundamental step to
                classify HF and to guide evidence-based pharmacological and device-based therapy. In certain situations,
                the echocardiogram is unable to accurately assess cardiac structure and/or function or more information
                is needed to determine the cause of the cardiac dysfunction. Other imaging modalities, such as CMR,
                SPECT or radionuclide ventriculography, PET, or cardiac CT or invasive coronary angiography, can provide
                additional and complementary information to cardiac ultrasound (<a class="tab-link" href="#bib199"
                    data-tab="pane-pcw-references">11</a>). In general, cardiac imaging tests, including repeat tests,
                are performed only when the results have a meaningful impact on clinical care.</p>
            <p id="p4820"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1175" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4825">The chest x-ray is a useful initial diagnostic test for the evaluation of
                                patients presenting with signs and symptoms of HF because it assesses cardiomegaly,
                                pulmonary venous congestion, and interstitial or alveolar edema and may reveal
                                alternative causes, cardiopulmonary or otherwise, of the patient’s symptoms (<a
                                    class="tab-link" href="#bib189" data-tab="pane-pcw-references">1</a>,<a
                                    class="tab-link" href="#bib190" data-tab="pane-pcw-references">2</a>). Apart from
                                congestion, other findings on chest x-ray are associated with HF only in the context of
                                clinical presentation. Importantly, cardiomegaly may be absent in acute HF and, although
                                cephalization, interstitial edema, and alveolar edema are modestly specific for HF,
                                these findings are relatively insensitive (<a class="tab-link" href="#bib190"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib221"
                                    data-tab="pane-pcw-references">33</a>). Considering the limited sensitivity and
                                specificity, the chest x-ray should not be used as the only determinant of the specific
                                cause or presence of HF.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4830">TTE provides information regarding cardiac structure and function and
                                identifies abnormalities of myocardium, heart valves, and pericardium. Echocardiography
                                reveals structural and functional information that predicts subsequent risk (<a
                                    class="tab-link" href="#bib222" data-tab="pane-pcw-references">34-40</a>).
                                Guidelines provide recommendations for quantification of cardiac structure and function,
                                including LVEF measurements, ventricular dimensions and volumes, evaluation of chamber
                                geometry, and regional wall motion (<a class="tab-link" href="#bib229"
                                    data-tab="pane-pcw-references">41</a>). RV size and function, atrial size, and all
                                valves are evaluated for anatomic and flow abnormalities. Guidelines also provide
                                recommendations for diastolic function and estimates of LV filling and left atrial
                                pressure (<a class="tab-link" href="#bib230" data-tab="pane-pcw-references">42</a>). The
                                tricuspid valve regurgitant gradient, coupled with inferior vena cava diameter and its
                                response during respiration, provides estimates of systolic PA pressure and central
                                venous pressure. Indices of myocardial deformation, such as global longitudinal strain,
                                may identify subclinical LV systolic dysfunction, which has been associated with greater
                                risk of developing HF or recurrent HF hospitalizations (<a class="tab-link"
                                    href="#bib226" data-tab="pane-pcw-references">38</a>,<a class="tab-link"
                                    href="#bib231" data-tab="pane-pcw-references">43-46</a>). Given the widespread
                                availability, lack of ionizing radiation, and wealth of provided information,
                                echocardiography is the preferred initial imaging modality for evaluation of patients
                                with suspected HF. Point-of-care cardiac ultrasound is an evolving tool for assessment
                                of cardiac function and assessment of volume status and pulmonary congestion (<a
                                    class="tab-link" href="#bib235" data-tab="pane-pcw-references">47-52</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4835">Serial echocardiograms to assess changes in EF, structural remodeling, and
                                valvular function, although not recommended routinely in stable patients, are useful in
                                various situations. In patients who have an unexplained, significant change in clinical
                                status, echocardiography can provide important information, such as worsening
                                ventricular or valvular function. A subset of patients may also have reverse remodeling,
                                improvement in LVEF, and valvular function in response to evidence-based medical,
                                revascularization, and device therapies, and repeat assessment of LVEF and remodeling is
                                appropriate in those who have received treatments that might have had a significant
                                effect on cardiac structure and function (<a class="tab-link" href="#bib192"
                                    data-tab="pane-pcw-references">4-7</a>,<a class="tab-link" href="#bib241"
                                    data-tab="pane-pcw-references">53-59</a>). Recovery of function appears more common
                                in those with LV systolic dysfunction occurring in the setting of adverse energetic
                                circumstances (e.g., chronic tachycardia or thyroid disease), dilated cardiomyopathies
                                associated with immune responses (e.g., peripartum cardiomyopathy, acute myocarditis,
                                systemic inflammatory responses), or in those who have undergone revascularization or
                                device-based therapies (<a class="tab-link" href="#bib248"
                                    data-tab="pane-pcw-references">60</a>). Reevaluation of EF (&gt;40 days after MI,
                                &gt;90 days after revascularization, &gt;90 days after GDMT) is useful to determine
                                candidacy for implantable cardioverter-defibrillator (ICD) or cardiac resynchronization
                                therapy (CRT). Finally, repeat surveillance of LV function is appropriate in patients
                                exposed to treatments that potentially damage the myocardium, such as chemotherapy.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4840">If TTE is unable to accurately evaluate cardiac structure and function,
                                additional noninvasive imaging modalities are available to clarify the initial diagnosis
                                and to provide information on cardiac structure and function. The choice between these
                                modalities depends on availability, local expertise, patient characteristics,
                                indication, and goal of limiting radiation exposure. CMR provides an accurate and highly
                                reproducible assessment of cardiac volumes, mass, and EF of the left and right
                                ventricles (<a class="tab-link" href="#bib196" data-tab="pane-pcw-references">8-10</a>).
                                CMR provides high anatomic resolution of all aspects of the heart and surrounding
                                structures and is not associated with ionizing radiation, leading to its recommended use
                                in known or suspected congenital heart diseases (<a class="tab-link" href="#bib199"
                                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib249"
                                    data-tab="pane-pcw-references">61</a>). Electrocardiographic-gated cardiac CT can
                                also accurately assess ventricular size, EF, and wall motion abnormalities, but it is
                                accompanied with ionizing radiation (<a class="tab-link" href="#bib201"
                                    data-tab="pane-pcw-references">13-15</a>). Radionuclide ventriculography is highly
                                reproducible for measurement of LVEF, although it also exposes the patient to ionizing
                                radiation (<a class="tab-link" href="#bib200" data-tab="pane-pcw-references">12</a>).
                            </p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4845">CMR provides noninvasive characterization of the myocardium that may provide
                                insights into HF cause (<a class="tab-link" href="#bib250"
                                    data-tab="pane-pcw-references">62</a>). Late-gadolinium enhancement, reflecting
                                fibrosis and damaged myocardium, can identify acute and chronic MI (<a class="tab-link"
                                    href="#bib251" data-tab="pane-pcw-references">63</a>,<a class="tab-link"
                                    href="#bib252" data-tab="pane-pcw-references">64</a>) and identify HF caused by CAD
                                (<a class="tab-link" href="#bib253" data-tab="pane-pcw-references">65</a>,<a
                                    class="tab-link" href="#bib254" data-tab="pane-pcw-references">66</a>). Patterns of
                                late-gadolinium enhancement or specific T-1 and T-2 techniques can suggest specific
                                infiltrative and inflammatory cardiomyopathies, such as myocarditis, sarcoidosis, Fabry
                                disease, Chagas disease, noncompaction, iron overload, and amyloidosis (<a
                                    class="tab-link" href="#bib204" data-tab="pane-pcw-references">16</a>,<a
                                    class="tab-link" href="#bib208" data-tab="pane-pcw-references">20</a>,<a
                                    class="tab-link" href="#bib210" data-tab="pane-pcw-references">22</a>,<a
                                    class="tab-link" href="#bib255" data-tab="pane-pcw-references">67</a>). T-1 mapping
                                techniques allow for measurement of interstitial space characteristics and extracellular
                                volume fraction and provides diagnostic and prognostic information (<a class="tab-link"
                                    href="#bib207" data-tab="pane-pcw-references">19</a>,<a class="tab-link"
                                    href="#bib209" data-tab="pane-pcw-references">21-23</a>,<a class="tab-link"
                                    href="#bib256" data-tab="pane-pcw-references">68-71</a>). The presence of delayed
                                hyperenhancement has been associated with worse outcomes and can provide risk
                                stratification (<a class="tab-link" href="#bib260"
                                    data-tab="pane-pcw-references">72-77</a>). Although registry data show that CMR
                                findings commonly impact patient care management and provide diagnostic information in
                                patients with suspected myocarditis or cardiomyopathy (<a class="tab-link"
                                    href="#bib205" data-tab="pane-pcw-references">17</a>,<a class="tab-link"
                                    href="#bib206" data-tab="pane-pcw-references">18</a>), a strategy of routine
                                screening with CMR in patients with nonischemic cardiomyopathy was not shown to yield
                                more specific HF causes than a strategy of selective CMR strategy based on
                                echocardiographic and clinical findings in a recent trial (<a class="tab-link"
                                    href="#bib266" data-tab="pane-pcw-references">78</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">6.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4850">HF is often caused by coronary atherosclerosis (<a class="tab-link"
                                    href="#bib267" data-tab="pane-pcw-references">79</a>), and evaluation for ischemic
                                heart disease can help in determining the presence of significant coronary artery
                                disease (CAD). Noninvasive stress imaging with echocardiography or nuclear scintigraphy
                                can be helpful in identifying patients likely to have obstructive CAD (<a
                                    class="tab-link" href="#bib212" data-tab="pane-pcw-references">24</a>,<a
                                    class="tab-link" href="#bib213" data-tab="pane-pcw-references">25</a>). Invasive or
                                computed tomography coronary angiography can detect and characterize extent of CAD (<a
                                    class="tab-link" href="#bib214" data-tab="pane-pcw-references">26</a>,<a
                                    class="tab-link" href="#bib215" data-tab="pane-pcw-references">27</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">7.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4855">CAD is a leading cause of HF (<a class="tab-link" href="#bib267"
                                    data-tab="pane-pcw-references">79</a>) and myocardial ischemia may contribute to new
                                or worsening HF symptoms. Noninvasive testing (i.e., stress echocardiography, SPECT,
                                CMR, or PET) may be considered for detection of myocardial ischemia to help guide
                                coronary revascularization decisions. Multiple nonrandomized, observational studies have
                                reported improved survival with revascularization in patients with viable but
                                dysfunctional myocardium (<a class="tab-link" href="#bib216"
                                    data-tab="pane-pcw-references">28</a>,<a class="tab-link" href="#bib218"
                                    data-tab="pane-pcw-references">30-32</a>). Despite these observational data, RCTs
                                have not shown that viability imaging improves guidance of revascularization to a
                                reduction of adverse cardiovascular outcomes (<a class="tab-link" href="#bib268"
                                    data-tab="pane-pcw-references">80-82</a>). A prespecified viability substudy of the
                                STICH (Surgical Treatment for Ischemic Heart Failure) trial showed that the presence of
                                myocardial viability did not determine the long-term benefit from surgical
                                revascularization in patients with ischemic cardiomyopathy (<a class="tab-link"
                                    href="#bib269" data-tab="pane-pcw-references">81</a>,<a class="tab-link"
                                    href="#bib270" data-tab="pane-pcw-references">82</a>). Of note, a relatively small
                                number of individuals enrolled in the STICH substudy did not have viability, which may
                                limit the power of the study. Although these data do not support the concept of routine
                                viability assessment before revascularization, myocardial viability is used as one of
                                the tools to inform decisions regarding revascularization in patients with high surgical
                                risk or with complex medical problems.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">8.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4860">Repeat noninvasive imaging of cardiac structure and function for routine
                                surveillance is rarely appropriate in the absence of a change in clinical status or
                                treatment interventions (<a class="tab-link" href="#bib199"
                                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib271"
                                    data-tab="pane-pcw-references">83</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec8" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec8">
                <div id="acsectitle0195" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0195">4.5 Invasive Evaluation</h3>
            <div id="undtbl7" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl7">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0425">Recommendations for Invasive Evaluation</p>
                            <p id="tspara0430">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0210" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1210"><strong>In patients with HF, endomyocardial biopsy may be
                                                        useful when a specific diagnosis is suspected that would
                                                        influence therapy (</strong><a class="tab-link" href="#bib272"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib273"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-EO</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0205" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1205"><strong>In selected patients with HF with persistent or
                                                        worsening symptoms, signs, diagnostic parameters, and in whom
                                                        hemodynamics are uncertain, invasive hemodynamic monitoring can
                                                        be useful to guide management.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: No Benefit</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0215" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1215"><strong>In patients with HF, routine use of invasive
                                                        hemodynamic monitoring is not recommended (</strong><a
                                                        class="tab-link" href="#bib274"
                                                        data-tab="pane-pcw-references"><strong>3</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib275"
                                                        data-tab="pane-pcw-references"><strong>4</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0220" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1220"><strong>For patients undergoing routine evaluation of HF,
                                                        endomyocardial biopsy should not be performed because of the
                                                        risk of complications (</strong><a class="tab-link"
                                                        href="#bib276"
                                                        data-tab="pane-pcw-references"><strong>5</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib277"
                                                        data-tab="pane-pcw-references"><strong>6</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p4870"><strong>Synopsis</strong></p>
            <p id="p4875">Invasive evaluation of patients with HF may provide important clinical information to
                determine the cause of HF and treatment options. Routine right heart catheterization does not provide
                sufficient information to guide treatment decisions (<a class="tab-link" href="#bib274"
                    data-tab="pane-pcw-references">3</a>,<a class="tab-link" href="#bib275"
                    data-tab="pane-pcw-references">4</a>). However, hemodynamic evaluation with right heart
                catheterization and monitoring in the setting of acute respiratory distress, systemic hypoperfusion
                including cardiogenic shock, or when hemodynamics are uncertain, may guide treatment decisions. Coronary
                angiography may be useful in patients who are candidates for revascularization (<a class="tab-link"
                    href="#bib278" data-tab="pane-pcw-references">7-9</a>) (see <a class="ref sec" id="crosref3985"
                    href="#sec8.4">Section 4.4</a>, “Evaluation with Cardiac Imaging,” for recommendations).
                Endomyocardial biopsy may be advantageous in patients with HF in which a histological diagnosis, such as
                amyloidosis or myocarditis, may influence treatment decisions (<a class="tab-link" href="#bib272"
                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib273"
                    data-tab="pane-pcw-references">2</a>).</p>
            <p id="p4880"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1180" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4890">Endomyocardial biopsy may be useful when seeking a specific diagnosis that
                                would influence treatment, and biopsy should thus be considered in patients with rapidly
                                progressive clinical HF or worsening ventricular dysfunction that persists despite
                                appropriate medical treatment. Endomyocardial biopsy should also be considered in
                                patients suspected of having acute cardiac rejection status after heart transplantation
                                or having myocardial infiltrative processes. A specific example is to determine
                                treatment for light chain (AL) amyloidosis or transthyretin amyloidosis (<a
                                    class="tab-link" href="#bib276" data-tab="pane-pcw-references">5</a>). Additional
                                indications for endomyocardial biopsy include patients with rapidly progressive and
                                unexplained cardiomyopathy and those in whom active myocarditis, especially giant cell
                                myocarditis, is being considered (<a class="tab-link" href="#bib272"
                                    data-tab="pane-pcw-references">1</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4885">Right-heart catherization in patients in acute HF. The ESCAPE (Evaluation
                                Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness)
                                trial found that routine use of PA catheter monitoring for patients with HF did not
                                provide benefit (<a class="tab-link" href="#bib274"
                                    data-tab="pane-pcw-references">3</a>). However, invasive hemodynamic evaluation or
                                monitoring can be useful to guide management in carefully selected patients with acute
                                HF who have persistent symptoms despite treatment. This includes patients whose fluid
                                status, perfusion, or systemic or pulmonary vascular resistance is uncertain whose
                                systolic blood pressure (SBP) remains low, or is associated with symptoms, despite
                                initial treatment; whose renal function is worsening with therapy; or who require
                                parenteral vasoactive agents.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4895">There has been no established role for routine or periodic invasive
                                hemodynamic measurements in the management of HF. Most drugs used to treat HF are
                                prescribed on the basis of their ability to improve symptoms or survival rather than
                                their effect on hemodynamic variables. The initial and target doses of these drugs are
                                generally selected on the basis of controlled trial experience rather than changes
                                produced in cardiac output or pulmonary capillary wedge pressure (<a class="tab-link"
                                    href="#bib274" data-tab="pane-pcw-references">3</a>,<a class="tab-link"
                                    href="#bib275" data-tab="pane-pcw-references">4</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4900">Patients with HF should not undergo routine endomyocardial biopsy because of
                                the risk of complications that include perforation, cardiac tamponade, and thrombus
                                formation, as well as limited diagnostic yield (<a class="tab-link" href="#bib276"
                                    data-tab="pane-pcw-references">5</a>,<a class="tab-link" href="#bib277"
                                    data-tab="pane-pcw-references">6</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec8" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec8">
                <div id="acsectitle0200" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0200">4.6 Wearables and Remote Monitoring (Including
                Telemonitoring and Device Monitoring)</h3>
            <div id="undtbl8" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl8">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0435">Recommendation for Wearables and Remote Monitoring (Including
                                Telemonitoring and Device Monitoring)</p>
                            <p id="tspara0440">Referenced studies that support the recommendation are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0225" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1225"><strong>In selected adult patients with NYHA class III HF
                                                        and history of a HF hospitalization in the past year or elevated
                                                        natriuretic peptide levels, on maximally tolerated stable doses
                                                        of GDMT with optimal device therapy, the usefulness of wireless
                                                        monitoring of PA pressure by an implanted hemodynamic monitor to
                                                        reduce the risk of subsequent HF hospitalizations is
                                                        uncertain</strong> (<a class="tab-link" href="#bib281"
                                                        data-tab="pane-pcw-references">1-4</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: Uncertain Value (B-NR)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0230" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1230"><strong>In patients with NYHA class III HF with a HF
                                                        hospitalization within the previous year, wireless monitoring of
                                                        the PA pressure by an implanted hemodynamic monitor provides
                                                        uncertain value</strong> (<a class="tab-link" href="#bib284"
                                                        data-tab="pane-pcw-references">4-7</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p4910"><strong>Synopsis</strong></p>
            <p id="p4915">HF is a chronic condition punctuated by periods of instability. Despite close longitudinal
                monitoring via in-person visits, event rates remain high, affording a potential role for remote
                monitoring strategies to improve clinical outcomes. Strategies tested in randomized trials include an
                implantable PA pressure sensor (CardioMEMS), noninvasive telemonitoring, or monitoring via existing
                implanted electronic devices (ICDs or CRT-Ds). Results from a single randomized trial (<a
                    class="tab-link" href="#bib281" data-tab="pane-pcw-references">1-3</a>), and subsequent
                observational studies (<a class="tab-link" href="#bib288" data-tab="pane-pcw-references">8-10</a>),
                support consideration of an implantable PA sensor in selected patients with HF to reduce the risk of HF
                hospitalization. In contrast, a recent trial testing a PA pressure sensor did not meet its primary
                endpoint (<a class="tab-link" href="#bib284" data-tab="pane-pcw-references">4</a>). Results from
                previous clinical trials do not support the alternative remote monitoring strategies (e.g., noninvasive
                telemonitoring or remote monitoring of physiological parameters such as patient activity, thoracic
                impedance, heart rate) for this purpose (<a class="tab-link" href="#bib291"
                    data-tab="pane-pcw-references">11-18</a>).</p>
            <p id="p4920"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1185" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4925">The CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve
                                Outcomes in NYHA Class III Heart Failure patients) trial reported a significant 28%
                                reduction of HF-related hospitalizations after 6 months in patients randomized to an
                                implanted PA pressure monitor compared with a control group (<a class="tab-link"
                                    href="#bib281" data-tab="pane-pcw-references">1</a>). Patients had to have a HF
                                hospitalization in the previous year and be on stable doses of a beta blocker and
                                angiotensin-converting enzyme inhibitor (ACEi) (or angiotensin (II) receptor blocker
                                [ARB]) if tolerated. The clinical benefit persisted after longer term follow-up and was
                                seen in both subjects with reduced (<a class="tab-link" href="#bib283"
                                    data-tab="pane-pcw-references">3</a>) and preserved (<a class="tab-link"
                                    href="#bib282" data-tab="pane-pcw-references">2</a>) LVEF. However, CHAMPION was a
                                nonblinded trial, and there was differential contact of study personnel with patients in
                                the treatment arm, raising methodological concerns about the opportunity for bias to
                                have influenced its results (<a class="tab-link" href="#bib299"
                                    data-tab="pane-pcw-references">19-21</a>). In the recent GUIDE-HF
                                (Haemodynamic-GUIDEed management of Heart Failure) study, hemodynamic-guided management
                                of patients with NYHA class II to IV heart failure did not significantly reduce the
                                composite endpoint rate of mortality and total HF events (<a class="tab-link"
                                    href="#bib284" data-tab="pane-pcw-references">4</a>). The usefulness of noninvasive
                                telemonitoring (<a class="tab-link" href="#bib291"
                                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib292"
                                    data-tab="pane-pcw-references">12</a>,<a class="tab-link" href="#bib302"
                                    data-tab="pane-pcw-references">22</a>,<a class="tab-link" href="#bib303"
                                    data-tab="pane-pcw-references">23</a>) or remote monitoring of physiological
                                parameters (<a class="tab-link" href="#bib293" data-tab="pane-pcw-references">13-18</a>)
                                (e.g., patient activity, thoracic impedance, heart rate) via implanted electrical
                                devices (ICDs or CRT-Ds) to improve clinical outcomes remains uncertain. Further study
                                of these approaches is needed before they can be recommended for routine clinical care.
                            </p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4930">Three model-based studies (<a class="tab-link" href="#bib285"
                                    data-tab="pane-pcw-references">5-7</a>) have evaluated the cost-effectiveness of
                                wireless PA pressure monitoring using data from the CHAMPION-HF (<a class="tab-link"
                                    href="#bib281" data-tab="pane-pcw-references">1</a>) study of the CardioMEMS device.
                                All 3 studies estimated CardioMEMS implantation and monitoring increased survival and
                                quality-adjusted life year (QALY) while increasing costs. Primarily based on differences
                                regarding the expected magnitude of clinical benefit, 2 analyses (<a class="tab-link"
                                    href="#bib285" data-tab="pane-pcw-references">5</a>,<a class="tab-link"
                                    href="#bib287" data-tab="pane-pcw-references">7</a>) estimated the device provided
                                high value while the third (<a class="tab-link" href="#bib286"
                                    data-tab="pane-pcw-references">6</a>) estimated intermediate value. These analyses
                                had several important differences detailed in the evidence tables, including the model
                                duration, QOL data, cost estimates, and assumptions regarding mortality. One analysis
                                (<a class="tab-link" href="#bib286" data-tab="pane-pcw-references">6</a>) found the
                                economic value of CardioMEMS implantation was highly dependent on its effect on
                                mortality and duration of treatment benefit, both of which remain unclear.
                                Cost-effectiveness studies incorporating data from GUIDE-HF (<a class="tab-link"
                                    href="#bib284" data-tab="pane-pcw-references">4</a>) have not been published.
                                Additional data regarding clinical outcomes following CardioMEMS implantation will
                                improve estimates of its economic value.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec8" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec8">
                <div id="acsectitle0205" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0205">4.7 Exercise and Functional Capacity Testing</h3>
            <div id="undtbl9" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl9">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0445">Recommendations for Exercise and Functional Capacity Testing</p>
                            <p id="tspara0450">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0235" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1235"><strong>In patients with HF, assessment and documentation
                                                        of NYHA functional classification are recommended to determine
                                                        eligibility for treatments</strong> (<a class="tab-link"
                                                        href="#bib304"
                                                        data-tab="pane-pcw-references">1-3</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0240" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1240"><strong>In selected ambulatory patients with HF,
                                                        cardiopulmonary exercise testing (CPET) is recommended to
                                                        determine appropriateness of advanced treatments (e.g., LVAD,
                                                        heart transplant)</strong> (<a class="tab-link" href="#bib307"
                                                        data-tab="pane-pcw-references">4-8</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0245" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1245"><strong>In ambulatory patients with HF, performing a CPET
                                                        or 6-minute walk test is reasonable to assess functional
                                                        capacity (</strong><a class="tab-link" href="#bib307"
                                                        data-tab="pane-pcw-references"><strong>4</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib308"
                                                        data-tab="pane-pcw-references"><strong>5</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib312"
                                                        data-tab="pane-pcw-references"><strong>9-16</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0250" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1250"><strong>In ambulatory patients with unexplained dyspnea,
                                                        CPET is reasonable to evaluate the cause of dyspnea (</strong><a
                                                        class="tab-link" href="#bib320"
                                                        data-tab="pane-pcw-references"><strong>17</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib321"
                                                        data-tab="pane-pcw-references"><strong>18</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p4940"><strong>Synopsis</strong></p>
            <p id="p4945">Functional impairment and exercise intolerance are common in HF. CPET and the 6-minute walk
                test are standardized, reliable, and reproducible tests to quantify functional capacity (<a
                    class="tab-link" href="#bib322" data-tab="pane-pcw-references">19-22</a>). The NYHA functional
                classification can be used to grade the severity of functional limitation based on patient report of
                symptoms experienced with activity (<a class="tab-link" href="#bib304"
                    data-tab="pane-pcw-references">1</a>) and is used to define candidates for certain treatments.</p>
            <p id="p4950"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1190" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4955">NYHA functional classification is an ordinal, categorical variable (I-IV) that
                                is used to document functional limitation in patients with cardiac disease, including HF
                                (<a class="tab-link" href="#bib304" data-tab="pane-pcw-references">1</a>). In HF, NYHA
                                functional class I includes patients with no limitations in physical activity resulting
                                from their HF. NYHA class II includes patients who are comfortable at rest but have
                                slight symptoms resulting from HF (dyspnea, fatigue, lightheadedness) with ordinary
                                activity. NYHA class III includes patients who are comfortable at rest but have symptoms
                                of HF with less than ordinary activity. NYHA class IV includes patients who are unable
                                to carry out any physical activity without symptoms and have symptoms at rest. NYHA
                                functional classification has been widely used in clinical practice, clinical trials,
                                and clinical practice guidelines to determine candidacy for drug and device therapy.
                                Limitations include its ability to be inconsistently assessed from 1 clinician to
                                another, resulting in poor reproducibility (<a class="tab-link" href="#bib326"
                                    data-tab="pane-pcw-references">23</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4960">Many CPET variables have been associated with prognosis in patients with HF
                                (<a class="tab-link" href="#bib307" data-tab="pane-pcw-references">4</a>,<a
                                    class="tab-link" href="#bib308" data-tab="pane-pcw-references">5</a>,<a
                                    class="tab-link" href="#bib315" data-tab="pane-pcw-references">12</a>,<a
                                    class="tab-link" href="#bib317" data-tab="pane-pcw-references">14</a>,<a
                                    class="tab-link" href="#bib319" data-tab="pane-pcw-references">16</a>,<a
                                    class="tab-link" href="#bib327" data-tab="pane-pcw-references">24</a>). Peak
                                exercise oxygen consumption/oxygen uptake (VO<sub>2</sub>) is often used to risk
                                stratify patients and make decisions about timing of advanced HF therapies, including
                                heart transplantation and LVAD. In a landmark article (<a class="tab-link"
                                    href="#bib310" data-tab="pane-pcw-references">7</a>), investigators divided patients
                                referred for heart transplantation into groups based on their peak VO<sub>2</sub> (<a
                                    class="tab-link" href="#bib310" data-tab="pane-pcw-references">7</a>). Patients with
                                peak VO<sub>2</sub> &lt;14 mL/kg/min were listed for transplant, while those with higher
                                peak VO<sub>2</sub> values were deferred for being too well. Patients with peak
                                VO<sub>2</sub> &gt;14 mL/kg/min who were deferred had 1- and 2-year survival of 94% and
                                84%, respectively, which was similar to survival after heart transplant. As such, the
                                authors proposed peak VO<sub>2</sub> ≤14 mL/kg/min as a cutoff to distinguish patients
                                who may derive survival benefit from heart transplant (<a class="tab-link"
                                    href="#bib310" data-tab="pane-pcw-references">7</a>). Patients tolerating beta
                                blockers may have improved survival with an equivalent VO<sub>2</sub> compared with
                                patients who do not tolerate beta blockers (<a class="tab-link" href="#bib328"
                                    data-tab="pane-pcw-references">25</a>,<a class="tab-link" href="#bib329"
                                    data-tab="pane-pcw-references">26</a>). For patients on beta blockers, a peak
                                VO<sub>2</sub> ≤12 mL/kg/min has been suggested as a more appropriate cutoff to consider
                                cardiac transplant listing (<a class="tab-link" href="#bib311"
                                    data-tab="pane-pcw-references">8</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4965">Objective assessment of exercise capacity with CPET can be useful in the
                                clinical management of patients with HF. Although CPET remains the gold standard measure
                                of exercise capacity, limitations to more widespread use include need for special
                                equipment and trained personnel, which leads to lack of availability at many hospitals
                                and clinics. Furthermore, it is not well tolerated by some patients. The 6-minute walk
                                test is an alternative way to measure exercise capacity that is widely available and
                                well tolerated by patients. It entails walking for 6 minutes on a measured flat course,
                                and patients are allowed to slow down or stop if needed. A systematic review of 14
                                studies found that the 6-minute walk test results correlated moderately with peak
                                VO<sub>2</sub> levels and were a reliable and valid indicator of functional capacity in
                                patients with HF who did not walk &gt;490 m (<a class="tab-link" href="#bib311"
                                    data-tab="pane-pcw-references">8</a>). Distance walked in the 6-minute walk test has
                                been associated with prognosis in HF across multiple studies (<a class="tab-link"
                                    href="#bib312" data-tab="pane-pcw-references">9-13</a>,<a class="tab-link"
                                    href="#bib318" data-tab="pane-pcw-references">15</a>,<a class="tab-link"
                                    href="#bib319" data-tab="pane-pcw-references">16</a>,<a class="tab-link"
                                    href="#bib330" data-tab="pane-pcw-references">27</a>). A cutoff of &lt;300 m roughly
                                correlates to patients with NYHA class III to IV symptoms and is associated with worse
                                3-year survival free of heart transplant (62% versus 82% for those walking ≥300 m) (<a
                                    class="tab-link" href="#bib330" data-tab="pane-pcw-references">27</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4970">Dyspnea is a complex symptom that can reflect abnormalities in a number of
                                different systems and can be influenced by psychological and environmental factors. CPET
                                involves having patients perform a treadmill (or stationary bicycle) exercise test,
                                while also performing ventilatory gas exchange measurements (<a class="tab-link"
                                    href="#bib331" data-tab="pane-pcw-references">28</a>). CPET enables the
                                comprehensive assessment of multiple physiological measures that can impact exercise
                                capacity and contribute to dyspnea. It provides analysis of gas exchange and yields
                                measures of oxygen uptake (VO<sub>2</sub>), carbon dioxide output, and ventilation.
                                These measures can be integrated with standard exercise testing variables, such as heart
                                rate, blood pressure, electrocardiographic findings, and symptoms to provide insights
                                into the physiologic mechanisms underlying a patient’s dyspnea. In particular, CPET can
                                help to distinguish respiratory versus cardiac etiologies of dyspnea. If exercise
                                capacity is diminished but cardiopulmonary responses are normal, other causes of
                                dyspnea, such as metabolic abnormalities and deconditioning, should be considered.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec8" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec8">
                <div id="acsectitle0210" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0210">4.8 Initial and Serial Evaluation: Clinical
                Assessment: HF Risk Scoring</h3>
            <div id="undtbl10" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl10">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0455">Recommendation for Initial and Serial Evaluation: Clinical Assessment: HF
                                Risk Scoring</p>
                            <p id="tspara0460">Referenced studies that support the recommendation are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0255" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1255"><strong>In ambulatory or hospitalized patients with HF,
                                                        validated multivariable risk scores can be useful to estimate
                                                        subsequent risk of mortality</strong> (<a class="tab-link"
                                                        href="#bib332"
                                                        data-tab="pane-pcw-references">1-14</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p4980"><strong>Synopsis</strong></p>
            <p id="p4985">Clinicians should routinely assess a patient’s risk for an adverse outcome to guide
                discussions on prognosis, goals of care, and treatment decisions. Several predictive models of outcomes
                of patients with HF have been developed and validated using data from clinical trials, registries, and
                population-based cohorts. The best performing models have focused on predicting short- and long-term
                mortality, whereas predictive models for hospitalization or readmission for HF have generally had poor
                or modest discrimination. Predictive models may also assess the risk of incident HF among the general
                population and should be considered in the prevention of HF. In the course of standard evaluation,
                clinicians should routinely assess the patient’s potential for adverse outcome, because accurate risk
                stratification may help guide therapeutic decision-making, including a more rapid transition to advanced
                HF therapies. Several methods objectively assess risk (<a class="ref showTableEvent" data-id="tbl8"
                    href="#tbl8">Table 8</a>), including biomarker testing, as well as various multivariable clinical
                risk scores, and some that include machine learning (<a class="tab-link" href="#bib332"
                    data-tab="pane-pcw-references">1-14</a>). These risk scores are for use in ambulatory, hospitalized
                patients, and the general population.</p>
            <div id="tbl8" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl8">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0075"><span class="captionLabel">Table 8</span> Selected Multivariable Risk
                                Scores to Predict Outcome in HF</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Risk Score</th>
                            <th colspan="1" rowspan="1">Reference/Link</th>
                            <th colspan="1" rowspan="1">Year Published</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Chronic HF</strong></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>All Patients With Chronic HF</strong></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Seattle Heart Failure Model</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib333"
                                    data-tab="pane-pcw-references">2</a>) <a target="_blank" class="references__uri"
                                    href="https://depts.washington.edu/shfm/?width=1440&amp;height=900">https://depts.washington.edu/shfm/?width=1440&amp;height=900</a>
                                (<a class="tab-link" href="#bib346" data-tab="pane-pcw-references">15</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2006</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Heart Failure Survival Score</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib332"
                                    data-tab="pane-pcw-references">1</a>)</td>
                            <td align="center" colspan="1" rowspan="1">1997</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">MAGGIC</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib334"
                                    data-tab="pane-pcw-references">3</a>) <a target="_blank" class="references__uri"
                                    href="http://www.heartfailurerisk.org/">http://www.heartfailurerisk.org/</a> (<a
                                    class="tab-link" href="#bib347" data-tab="pane-pcw-references">16</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2013</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CHARM Risk Score</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib335"
                                    data-tab="pane-pcw-references">4</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2006</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CORONA Risk Score</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib336"
                                    data-tab="pane-pcw-references">5</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2009</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Specific to Chronic HFrEF</strong></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PARADIGM-HF</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib337"
                                    data-tab="pane-pcw-references">6</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2020</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">HF-ACTION</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib338"
                                    data-tab="pane-pcw-references">7</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2012</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">GUIDE-IT</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib339"
                                    data-tab="pane-pcw-references">8</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2019</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Specific to Chronic HFpEF</strong></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">I-PRESERVE Score</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib340"
                                    data-tab="pane-pcw-references">9</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2011</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">TOPCAT</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib341"
                                    data-tab="pane-pcw-references">10</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2020</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Acutely Decompensated HF</strong></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ADHERE Classification and Regression Tree (CART) Model</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib342"
                                    data-tab="pane-pcw-references">11</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2005</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">AHA Get With The Guidelines Score</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib343"
                                    data-tab="pane-pcw-references">12</a>) <a target="_blank" class="references__uri"
                                    href="https://www.mdcalc.com/gwtg-heart-failure-risk-score">https://www.mdcalc.com/gwtg-heart-failure-risk-score</a>
                                (<a class="tab-link" href="#bib348" data-tab="pane-pcw-references">17</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2010, 2021</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">EFFECT Risk Score</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib344"
                                    data-tab="pane-pcw-references">13</a>) <a target="_blank" class="references__uri"
                                    href="http://www.ccort.ca/Research/CHFRiskModel.aspx">http://www.ccort.ca/Research/CHFRiskModel.aspx</a>
                                (<a class="tab-link" href="#bib349" data-tab="pane-pcw-references">18</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2003, 2016</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ESCAPE Risk Model and Discharge Score</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib345"
                                    data-tab="pane-pcw-references">14</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2010</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0080">ADHERE indicates Acute Decompensated Heart Failure National Registry;
                                AHA, American Heart Association; ARIC, Atherosclerosis Risk in Communities; CHARM,
                                Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity; CORONA,
                                Controlled Rosuvastatin Multinational Trial in Heart Failure; EFFECT, Enhanced Feedback
                                for Effective Cardiac Treatment; ESCAPE, Evaluation Study of Congestive Heart Failure
                                and Pulmonary Artery Catheterization Effectiveness; GUIDE-ID, Guiding Evidence-Based
                                Therapy Using Biomarker Intensified Treatment; HF, heart failure; HFpEF, heart failure
                                with preserved ejection fraction; HF-ACTION, Heart Failure: A Controlled Trial
                                Investigating Outcomes of Exercise Training MAGGIC Meta-analysis Global Group in Chronic
                                Heart Failure; I-PRESERVE, Irbesartan in Heart Failure with Preserved Ejection Fraction
                                Study; PCP-HF, Pooled Cohort Equations to Prevent HF; and TOPCAT, Treatment of Preserved
                                Cardiac Function Heart Failure with an Aldosterone Antagonist trial.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p4990"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1195" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p4995">For HF, there are several clinical models to consider that include the
                                spectrum of HF based on EF and clinical setting. For chronic HF, the Seattle Heart
                                Failure Model (<a class="tab-link" href="#bib333" data-tab="pane-pcw-references">2</a>),
                                the Heart Failure Survival score (<a class="tab-link" href="#bib332"
                                    data-tab="pane-pcw-references">1</a>), and the MAGGIC score (<a class="tab-link"
                                    href="#bib334" data-tab="pane-pcw-references">3</a>) have commonly been used to
                                provide estimates of survival. The MAGGIC predictive model may be quite useful given its
                                derivation and validation across multiple clinical trials and cohorts, including more
                                recent studies. For chronic HFrEF, there are additional models that include other
                                clinical variables, including exercise capacity (<a class="tab-link" href="#bib338"
                                    data-tab="pane-pcw-references">7</a>) and natriuretic peptide levels (<a
                                    class="tab-link" href="#bib339" data-tab="pane-pcw-references">8</a>). Likewise, for
                                chronic HFpEF there are more specific predictive models for that population derived from
                                clinical trial data (<a class="tab-link" href="#bib340"
                                    data-tab="pane-pcw-references">9</a>,<a class="tab-link" href="#bib341"
                                    data-tab="pane-pcw-references">10</a>). In acute HF, several clinical models may be
                                used to predict short-term survival (<a class="tab-link" href="#bib342"
                                    data-tab="pane-pcw-references">11-13</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acd247731e4519" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e4519">
                <div id="acsectitle0215" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0215">5 Stage A (Patients at Risk for HF)</h2>
            <div id="acsec9" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec9">
                <div id="acsectitle0220" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0220">5.1 Patients at Risk for HF (Stage A: Primary
                Prevention)</h3>
            <div id="undtbl11" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl11">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0465">Recommendations for Patients at Risk for HF (Stage A: Primary Prevention)
                            </p>
                            <p id="tspara0470">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0260" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1260"><strong>In patients with hypertension, blood pressure
                                                        should be controlled in accordance with GDMT for hypertension to
                                                        prevent symptomatic HF</strong> (<a class="tab-link"
                                                        href="#bib350"
                                                        data-tab="pane-pcw-references">1-9</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0265" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1265"><strong>In patients with type 2 diabetes and either
                                                        established CVD or at high cardiovascular risk, SGLT2i should be
                                                        used to prevent hospitalizations for HF</strong> (<a
                                                        class="tab-link" href="#bib359"
                                                        data-tab="pane-pcw-references">10-12</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0270" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1270"><strong>In the general population, healthy lifestyle
                                                        habits such as regular physical activity, maintaining normal
                                                        weight, healthy dietary patterns, and avoiding smoking are
                                                        helpful to reduce future risk of HF</strong> (<a
                                                        class="tab-link" href="#bib362"
                                                        data-tab="pane-pcw-references">13-21</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0275" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1275"><strong>For patients at risk of developing HF, natriuretic
                                                        peptide biomarker–based screening followed by team-based care,
                                                        including a cardiovascular specialist optimizing GDMT, can be
                                                        useful to prevent the development of LV dysfunction (systolic or
                                                        diastolic) or new-onset HF (</strong><a class="tab-link"
                                                        href="#bib371"
                                                        data-tab="pane-pcw-references"><strong>22</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib372"
                                                        data-tab="pane-pcw-references"><strong>23</strong></a><strong>)<i>.</i></strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0280" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1280"><strong>In the general population, validated multivariable
                                                        risk scores can be useful to estimate subsequent risk of
                                                        incident HF</strong> (<a class="tab-link" href="#bib373"
                                                        data-tab="pane-pcw-references">24-26</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5010"><strong>Synopsis</strong></p>
            <p id="p5015">Healthy lifestyle habits such as maintaining regular physical activity; normal weight, blood
                pressure, and blood glucose levels; healthy dietary patterns, and not smoking reduce primordial risk and
                have been associated with a lower lifetime risk of developing HF (<a class="tab-link" href="#bib362"
                    data-tab="pane-pcw-references">13-21</a>,<a class="tab-link" href="#bib376"
                    data-tab="pane-pcw-references">27</a>). The AHA/ACC primary prevention guidelines provide
                recommendations for diet, physical activity, and weight control, all of which have been associated with
                the risk of HF (<a class="tab-link" href="#bib377" data-tab="pane-pcw-references">28</a>). Blood
                pressure is an important risk factor for HF, and a treatment goal of &lt;130/80 mm Hg is recommended for
                those with a CVD risk of ≥10% (<a class="tab-link" href="#bib378"
                    data-tab="pane-pcw-references">29</a>,<a class="tab-link" href="#bib379"
                    data-tab="pane-pcw-references">30</a>). Multiple RCTs have found that patients with diabetes and CVD
                without HF have improved survival and reduced HF hospitalizations with SGLT2i (<a class="tab-link"
                    href="#bib380" data-tab="pane-pcw-references">31</a>). Patients at risk for HF screened with BNP or
                NT-proBNP followed by collaborative care, diagnostic evaluation, and treatment in those with elevated
                levels can reduce combined rates of LV systolic dysfunction, diastolic dysfunction, and HF (<a
                    class="tab-link" href="#bib371" data-tab="pane-pcw-references">22</a>,<a class="tab-link"
                    href="#bib372" data-tab="pane-pcw-references">23</a>). See <a data-tab="pane-pcw-Figures"
                    href="#fig5" id="fig5R" class="">Figure 5</a> for COR 1 and 2a for stage A (at risk for HF) and
                stage B (pre-HF).</p>
            <section class="article-section__inline-figure">
                <figure id="fig5" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/224689d0-38c4-4b31-a125-23015955896c/gr5.jpg"
                        data-lg-src="/cms/asset/a06a5744-d71f-495c-bffa-3efda702789b/gr5.jpg" alt="Figure 5">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/a06a5744-d71f-495c-bffa-3efda702789b/gr5.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig5&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 5</span></strong>
                        <p>Recommendations (Class 1 and 2a) for Patients at Risk of HF (Stage A) and Those With Pre-HF
                            (Stage B)</p>
                        <p><strong>Colors correspond to COR in</strong> <a class="ref showTableEvent" data-id="tbl2"
                                href="#tbl2"><strong>Table 2</strong></a><strong>.</strong> COR 1 and COR 2a for
                            patients at risk for HF (stage A) and those with pre-HF (stage B) are shown. Management
                            strategies implemented in patients at risk for HF (stage A) should be continued though stage
                            B. ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
                            blocker; BP, blood pressure; COR, Class of Recommendation; CVD, cardiovascular disease; HF,
                            heart failure; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection
                            fraction; MI, myocardial infarction; and SGLT2i, sodium glucose cotransporter 2 inhibitor.
                        </p>
                    </figcaption>
                </figure>
            </section>
            <p id="p5020"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1200" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5025">Elevated systolic and diastolic blood pressure are major risk factors for the
                                development of symptomatic HF (<a class="tab-link" href="#bib357"
                                    data-tab="pane-pcw-references">8</a>,<a class="tab-link" href="#bib358"
                                    data-tab="pane-pcw-references">9</a>,<a class="tab-link" href="#bib381"
                                    data-tab="pane-pcw-references">32</a>). Many trials have shown that hypertension
                                control reduces the risk of HF (<a class="tab-link" href="#bib350"
                                    data-tab="pane-pcw-references">1-7</a>). Although the magnitude of benefit varies
                                with the patient population, target blood pressure reduction, and HF criteria, effective
                                hypertension treatment invariably reduces HF events. In the SPRINT (Systolic Blood
                                Pressure Intervention Trial) trial, control to an SBP goal &lt;120 mm Hg decreased
                                incident HF by 38% and mortality by 23% compared with an SBP goal of &lt;140 mm Hg (<a
                                    class="tab-link" href="#bib355" data-tab="pane-pcw-references">6</a>,<a
                                    class="tab-link" href="#bib356" data-tab="pane-pcw-references">7</a>). A
                                meta-analysis showed that blood pressure control was associated with an approximately
                                40% reduction in HF events (<a class="tab-link" href="#bib354"
                                    data-tab="pane-pcw-references">5</a>). Therefore, SBP and diastolic blood pressure
                                should be controlled in accordance with published clinical practice guidelines (<a
                                    class="tab-link" href="#bib379" data-tab="pane-pcw-references">30</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5030">Multiple RCTs in patients with type 2 diabetes and at risk for, or with
                                established CVD or at high risk for CVD, have shown that SGLT2i prevent HF
                                hospitalizations compared with placebo (<a class="tab-link" href="#bib359"
                                    data-tab="pane-pcw-references">10-12</a>). The benefit for reducing HF
                                hospitalizations in these trials predominantly reflects primary prevention of
                                symptomatic HF, because only approximately 10% to 14% of participants in these trials
                                had HF at baseline. The mechanisms for the improvement in HF events have not been
                                clearly elucidated but seem to be independent of glucose lowering. Proposed mechanisms
                                include reductions in plasma volume, cardiac preload and afterload, alterations in
                                cardiac metabolism, reduced arterial stiffness, and interaction with the
                                Na<sup>+</sup>/H<sup>+</sup> exchanger (<a class="tab-link" href="#bib382"
                                    data-tab="pane-pcw-references">33</a>,<a class="tab-link" href="#bib383"
                                    data-tab="pane-pcw-references">34</a>). SGLT2i are generally well tolerated, but
                                these agents have not been evaluated in those with severe renal impairment (estimated
                                glomerular filtration rate [eGFR] &lt;25 mL/min/1.73 m<sup>2</sup>) (<a class="tab-link"
                                    href="#bib384" data-tab="pane-pcw-references">35</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5035">Greater adherence to healthy lifestyle habits such as regular physical
                                activity, avoiding obesity, maintaining normal blood pressure and blood glucose, not
                                smoking, and healthy dietary patterns have been associated with a lower lifetime risk of
                                HF and greater preservation of cardiac structure (<a class="tab-link" href="#bib362"
                                    data-tab="pane-pcw-references">13-16</a>,<a class="tab-link" href="#bib376"
                                    data-tab="pane-pcw-references">27</a>). Healthful eating patterns, particularly
                                those that are based more on consumption of foods derived from plants, such as the
                                Mediterranean, whole grain, plant-based diet and the DASH (Dietary Approaches to Stop
                                Hypertension) diet, are inversely associated with incident HF and may offer some
                                protection against HF development (<a class="tab-link" href="#bib366"
                                    data-tab="pane-pcw-references">17-21</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5040">A large-scale unblinded single-center study (STOP-HF [The St Vincent’s
                                Screening to Prevent Heart Failure]) (<a class="tab-link" href="#bib371"
                                    data-tab="pane-pcw-references">22</a>) of patients at risk of HF (identified by the
                                presence of hypertension, diabetes, or known vascular disease) but without established
                                LV systolic dysfunction or symptomatic HF at baseline found that screening with BNP
                                testing and then intervening on those with levels of ≥50 pg/mL (performing
                                echocardiography and referral to a cardiovascular specialist) reduced the composite
                                endpoint of asymptomatic LV dysfunction (systolic or diastolic) with or without newly
                                diagnosed HF (<a class="tab-link" href="#bib371" data-tab="pane-pcw-references">22</a>).
                                Similarly, in another small, single-center RCT, accelerated uptitration of RAAS
                                antagonists and beta blockers reduced cardiac events in patients with diabetes and
                                elevated NT-proBNP levels but without cardiac disease at baseline (<a class="tab-link"
                                    href="#bib372" data-tab="pane-pcw-references">23</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5045">Incident HF may be predicted from different models, including those derived
                                from diverse populations (<a class="ref showTableEvent" data-id="tbl9"
                                    href="#tbl9">Table 9</a>). The PCP-HF (Pooled Cohort equations to Prevent HF) model
                                provides race- and sex-specific 10-year risk equations from 7 community-based cohorts
                                with at least 12 years of follow-up (<a class="tab-link" href="#bib378"
                                    data-tab="pane-pcw-references">29</a>). Predictors of HF included in the race- and
                                sex-specific models were age, blood pressure (treated or untreated), fasting glucose
                                (treated or untreated), body mass index, cholesterol, smoking status, and QRS duration.
                                Models can be applied to the clinical setting of interest, with clinical trial models
                                potentially less generalizable to registry- or population-based models. In addition,
                                predictive models provide the average estimate of risk derived from a population, and
                                individual risk may vary (<a class="tab-link" href="#bib385"
                                    data-tab="pane-pcw-references">36</a>). The integration of risk scores into clinical
                                practice have shown improved outcomes. As data generation increases from electronic
                                health records and digital sources, advanced methods with machine learning are expected
                                to proliferate the development of risk prediction models. Machine learning models are
                                often not externally validated, and their performance may vary based on the population
                                and clinical setting (<a class="tab-link" href="#bib386"
                                    data-tab="pane-pcw-references">37</a>). Patient populations change over time, and
                                models may need to be recalibrated periodically.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="tbl9" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl9">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0085"><span class="captionLabel">Table 9</span> Selected Multivariable Risk
                                Scores to Predict Development of Incident HF</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Risk Score</th>
                            <th colspan="1" rowspan="1">Reference</th>
                            <th colspan="1" rowspan="1">Year Published</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Framingham Heart Failure Risk Score</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib373"
                                    data-tab="pane-pcw-references">24</a>)</td>
                            <td align="center" colspan="1" rowspan="1">1999</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Health ABC Heart Failure Score</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib374"
                                    data-tab="pane-pcw-references">25</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2008</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ARIC Risk Score</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib375"
                                    data-tab="pane-pcw-references">26</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2012</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PCP-HF</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib378"
                                    data-tab="pane-pcw-references">29</a>)</td>
                            <td align="center" colspan="1" rowspan="1">2019</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0090">ARIC indicates Atherosclerosis Risk in Communities; HF, heart failure;
                                and PCP-HF, Pooled Cohort Equations to Prevent HF.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="acd247731e4835" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e4835">
                <div id="acsectitle0225" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0225">6 Stage B (Patients With Pre-HF)</h2>
            <div id="acsec10" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec10">
                <div id="acsectitle0230" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0230">6.1 Management of Stage B: Preventing the Syndrome
                of Clinical HF in Patients With Pre-HF</h3>
            <div id="undtbl12" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl12">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0475">Recommendations for Management of Stage B: Preventing the Syndrome of
                                Clinical HF in Patients With Pre-HF</p>
                            <p id="tspara0480">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0285" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1285"><strong>In patients with LVEF ≤40%, ACEi should be used to
                                                        prevent symptomatic HF and reduce mortality</strong> (<a
                                                        class="tab-link" href="#bib387"
                                                        data-tab="pane-pcw-references">1-4</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0300" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1300"><strong>In patients with a recent or remote history of MI
                                                        or ACS, statins should be used to prevent symptomatic HF and
                                                        adverse cardiovascular events</strong> (<a class="tab-link"
                                                        href="#bib391"
                                                        data-tab="pane-pcw-references">5-9</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0290" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1290"><strong>In patients with a recent MI and LVEF ≤40% who are
                                                        intolerant to ACEi, ARB should be used to prevent symptomatic HF
                                                        and reduce mortality</strong> (<a class="tab-link"
                                                        href="#bib396"
                                                        data-tab="pane-pcw-references">10</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0295" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1295"><strong>In patients with a recent or remote history of MI
                                                        or acute coronary syndrome (ACS) and LVEF ≤40%, evidence-based
                                                        beta blockers should be used to reduce mortality</strong> (<a
                                                        class="tab-link" href="#bib397"
                                                        data-tab="pane-pcw-references">11-13</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0310" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1310"><strong>In patients who are at least 40 days post-MI with
                                                        LVEF ≤30% and NYHA class I symptoms while receiving GDMT and
                                                        have reasonable expectation of meaningful survival for &gt;1
                                                        year, an ICD is recommended for primary prevention of sudden
                                                        cardiac death (SCD) to reduce total mortality</strong> (<a
                                                        class="tab-link" href="#bib400"
                                                        data-tab="pane-pcw-references">14</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0305" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">6.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1305"><strong>In patients with LVEF ≤40%, beta blockers should
                                                        be used to prevent symptomatic HF (</strong><a class="tab-link"
                                                        href="#bib398"
                                                        data-tab="pane-pcw-references"><strong>12</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib399"
                                                        data-tab="pane-pcw-references"><strong>13</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0320" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">7.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1320"><strong>In patients with LVEF &lt;50%, thiazolidinediones
                                                        should not be used because they increase the risk of HF,
                                                        including hospitalizations</strong> (<a class="tab-link"
                                                        href="#bib401"
                                                        data-tab="pane-pcw-references">15</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0315" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">8.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1315"><strong>In patients with LVEF &lt;50%, nondihydropyridine
                                                        calcium channel blockers with negative inotropic effects may be
                                                        harmful (</strong><a class="tab-link" href="#bib402"
                                                        data-tab="pane-pcw-references"><strong>16</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib403"
                                                        data-tab="pane-pcw-references"><strong>17</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5070aa"><strong>Synopsis</strong></p>
            <p id="p5070">In general, all recommendations for patients with stage A HF also apply to those with stage B
                HF. Stage B (pre-HF) represents a phase of clinically asymptomatic structural and functional cardiac
                abnormalities that increases the risk for symptomatic HF (<a class="tab-link" href="#bib404"
                    data-tab="pane-pcw-references">18-21</a>). Identifying individuals with stage B HF provides an
                opportunity to initiate lifestyle modification and pharmacological therapy that may prevent or delay the
                transition to symptomatic HF (stage C/D). Several ACC/AHA clinical practice guidelines address
                appropriate management of patients with stage B HF (<a class="ref showTableEvent" data-id="tbl10"
                    href="#tbl10">Table 10</a>). Although multiple studies highlight the increased HF risk associated
                with asymptomatic LV systolic (<a class="tab-link" href="#bib405"
                    data-tab="pane-pcw-references">19</a>,<a class="tab-link" href="#bib406"
                    data-tab="pane-pcw-references">20</a>,<a class="tab-link" href="#bib408"
                    data-tab="pane-pcw-references">22-26</a>) and diastolic dysfunction identified by noninvasive
                imaging (<a class="tab-link" href="#bib405" data-tab="pane-pcw-references">19</a>,<a class="tab-link"
                    href="#bib412" data-tab="pane-pcw-references">26-30</a>), beneficial pharmacotherapy for
                asymptomatic LV systolic dysfunction, such as inhibitors of the renin-angiotensin system and beta
                blockers, have been predominantly observed in individuals with depressed LVEF (LVEF &lt;35%–40%) (<a
                    class="tab-link" href="#bib387" data-tab="pane-pcw-references">1-4</a>,<a class="tab-link"
                    href="#bib397" data-tab="pane-pcw-references">11-13</a>). Studies of specific treatments to alter
                the onset of HF in the setting of asymptomatic cardiac dysfunction with preserved LVEF (e.g.,
                abnormalities of myocardial deformation or diastolic dysfunction) have been limited. Several comorbid
                conditions, including diabetes, obesity, and hypertension, have been associated with asymptomatic LV
                dysfunction (<a class="tab-link" href="#bib413" data-tab="pane-pcw-references">27</a>,<a
                    class="tab-link" href="#bib414" data-tab="pane-pcw-references">28</a>,<a class="tab-link"
                    href="#bib416" data-tab="pane-pcw-references">30</a>,<a class="tab-link" href="#bib417"
                    data-tab="pane-pcw-references">31</a>) and with progression of asymptomatic LV dysfunction to
                symptomatic HF (<a class="tab-link" href="#bib413" data-tab="pane-pcw-references">27</a>). Accordingly,
                these comorbidities are controlled according to current clinical practice guidelines. The benefits of
                mineralocorticoid receptor antagonists (MRA) after MI have mostly been shown in patients with
                symptomatic HFrEF (<a class="tab-link" href="#bib418" data-tab="pane-pcw-references">32-34</a>).</p>
            <div id="tbl10" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl10">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0095"><span class="captionLabel">Table 10</span> Other ACC/AHA Clinical
                                Practice Guidelines Addressing Patients With Stage B HF</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Consideration</th>
                            <th colspan="1" rowspan="1">Reference</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Patients with an acute MI who have not developed HF symptoms
                                treated in accordance with GDMT</td>
                            <td colspan="1" rowspan="1">2013 ACCF/AHA Guideline for the Management of ST-Elevation
                                Myocardial Infarction (<a class="tab-link" href="#bib437"
                                    data-tab="pane-pcw-references">51</a>)<br>2014 AHA/ACC Guideline for the Management
                                of Patients With Non–ST-Elevation Acute Coronary Syndromes (<a class="tab-link"
                                    href="#bib438" data-tab="pane-pcw-references">52</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Coronary revascularization for patients without symptoms of HF
                                in accordance with GDMT</td>
                            <td colspan="1" rowspan="1">2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous
                                Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of
                                the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013
                                ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction (<a
                                    class="tab-link" href="#bib439" data-tab="pane-pcw-references">53</a>) (This
                                guideline has been replaced by Lawton, 2021[<a class="tab-link" href="#bib440"
                                    data-tab="pane-pcw-references">54</a>].)<br>2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused
                                Update of the Guideline for the Diagnosis and Management of Patients With Stable
                                Ischemic Heart Disease (<a class="tab-link" href="#bib441"
                                    data-tab="pane-pcw-references">55</a>)<br>2011 ACCF/AHA Guideline for Coronary
                                Artery Bypass Graft Surgery (<a class="tab-link" href="#bib442"
                                    data-tab="pane-pcw-references">56</a>) (This guideline has been replaced by Lawton,
                                2021[<a class="tab-link" href="#bib440" data-tab="pane-pcw-references">54</a>].)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Valve replacement or repair for patients with hemodynamically
                                significant valvular stenosis or regurgitation and no symptoms of HF in accordance with
                                GDMT</td>
                            <td colspan="1" rowspan="1">2020 ACC/AHA Guideline for the Management of Patients With
                                Valvular Heart Disease (<a class="tab-link" href="#bib443"
                                    data-tab="pane-pcw-references">57</a>,<a class="tab-link" href="#bib444"
                                    data-tab="pane-pcw-references">58</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Patients with congenital heart disease that may increase the
                                risk for the development of HF</td>
                            <td colspan="1" rowspan="1">2018 AHA/ACC Guideline for the Management of Adults With
                                Congenital Heart Disease (<a class="tab-link" href="#bib445"
                                    data-tab="pane-pcw-references">59</a>)</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0100">AATS indicates American Association for Thoracic Surgery; ACC, American
                                College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American
                                Heart Association; GDMT, guideline-directed medical therapy; HF, heart failure; MI,
                                myocardial infarction; PCNA, Preventive Cardiovascular Nurses Association; SCAI, Society
                                for Cardiovascular Angiography and Interventions; and STS, The Society of Thoracic
                                Surgeons.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p5075">ARNi have not been well studied in stage B HF. The PARADISE-MI (Prospective ARNi vs. ACE
                inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction)
                study (<a class="tab-link" href="#bib421" data-tab="pane-pcw-references">35</a>) will report the
                efficacy and safety of sacubitril/valsartan in patients after acute MI, with LVEF ≤40 and/or pulmonary
                congestion, plus an additional risk-enhancing factor, compared with ramipril.</p>
            <p id="p5080"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1205" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5085">ACEi have been shown to impede maladaptive remodeling after acute MI in
                                patients with reduced LVEF (<a class="tab-link" href="#bib422"
                                    data-tab="pane-pcw-references">36</a>,<a class="tab-link" href="#bib423"
                                    data-tab="pane-pcw-references">37</a>). In survivors of acute MI with asymptomatic
                                LV dysfunction (LVEF &lt;35%–40%), RCTs have shown that ACEi reduced mortality, HF
                                hospitalizations, and progression to severe HF compared with placebo (<a
                                    class="tab-link" href="#bib388" data-tab="pane-pcw-references">2</a>,<a
                                    class="tab-link" href="#bib390" data-tab="pane-pcw-references">4</a>). Similarly, in
                                those individuals with asymptomatic LV dysfunction in the SOLVD (Studies of Left
                                Ventricular Systolic Dysfunction) prevention trial, which included approximately 20%
                                without ischemic heart disease, enalapril was associated with reduced HF hospitalization
                                and mortality compared with placebo (<a class="tab-link" href="#bib387"
                                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib389"
                                    data-tab="pane-pcw-references">3</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5100">In multiple RCTs (<a class="tab-link" href="#bib428"
                                    data-tab="pane-pcw-references">42</a>), statins have been shown to prevent adverse
                                CAD events in patients with an MI, ACS, and with high cardiovascular risk. These trials
                                have also shown that statin therapy reduces the risk of incident HF (<a class="tab-link"
                                    href="#bib391" data-tab="pane-pcw-references">5-9</a>). A meta-analysis of 6 RCTs of
                                &gt;110,000 patients with an ACS showed that intensive statin therapy reduced
                                hospitalizations for HF (<a class="tab-link" href="#bib391"
                                    data-tab="pane-pcw-references">5</a>). A subsequent, larger collaborative
                                meta-analysis of up to 17 major primary and secondary prevention RCTs showed that
                                statins reduced HF hospitalization (<a class="tab-link" href="#bib428"
                                    data-tab="pane-pcw-references">42</a>). These data support the use of statins to
                                prevent symptomatic HF and cardiovascular events in patients with acute MI or ACS.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5090">Two major trials have compared ARB with ACEi after MI. The VALIANT (Valsartan
                                in Acute Myocardial Infarction) trial, which included approximately 25% of patients with
                                asymptomatic LV dysfunction, showed that the benefits of valsartan on mortality and
                                other adverse cardiovascular outcomes were comparable to captopril (<a class="tab-link"
                                    href="#bib396" data-tab="pane-pcw-references">10</a>,<a class="tab-link"
                                    href="#bib424" data-tab="pane-pcw-references">38</a>). In the OPTIMAAL (Optimal
                                Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) trial,
                                losartan did not meet the noninferiority criteria for mortality compared with captopril
                                (<a class="tab-link" href="#bib425" data-tab="pane-pcw-references">39</a>). It has been
                                hypothesized that the lower dose of losartan (50 mg daily) in the OPTIMAAL trial may
                                have contributed to the greater difference than those seen with valsartan in VALIANT (<a
                                    class="tab-link" href="#bib426" data-tab="pane-pcw-references">40</a>). No clinical
                                trials have specifically evaluated ARB in patients with asymptomatic reduced LVEF in the
                                absence of previous MI. Although ARB are alternatives for patients with ACEi-induced
                                angioedema, caution is advised because some patients have also developed angioedema with
                                ARB.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5095">Current evidence supports the use of beta blockers to improve adverse cardiac
                                remodeling and outcomes in patients with asymptomatic reduced LVEF after MI. Among
                                patients with a recent MI and reduced LVEF, carvedilol reduced maladaptive remodeling
                                (<a class="tab-link" href="#bib427" data-tab="pane-pcw-references">41</a>) and reduced
                                mortality compared with placebo (<a class="tab-link" href="#bib397"
                                    data-tab="pane-pcw-references">11</a>). Among patients with asymptomatic LV systolic
                                dysfunction in the SOLVD prevention trial (which included 80% with previous MI) and the
                                SAVE (Survival and Ventricular Enlargement) trial, secondary analyses showed that the
                                administration of beta blockers in addition to ACEi reduced mortality and
                                hospitalization (<a class="tab-link" href="#bib398"
                                    data-tab="pane-pcw-references">12</a>,<a class="tab-link" href="#bib399"
                                    data-tab="pane-pcw-references">13</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5110">The Framingham studies have shown a 60% increased risk of death in patients
                                with asymptomatic low LVEF compared with those with normal LVEF, and almost half of
                                these patients remained free of HF before their death (<a class="tab-link"
                                    href="#bib411" data-tab="pane-pcw-references">25</a>). MADIT-II (Multicenter
                                Automatic Defibrillator Implantation Trial II) showed a 31% relative risk reduction in
                                all-cause mortality in patients with post-MI with LVEF ≤30% receiving a prophylactic ICD
                                compared with standard of care (<a class="tab-link" href="#bib400"
                                    data-tab="pane-pcw-references">14</a>). These findings provided justification for
                                the broad adoption of ICDs for primary prevention of SCD in the post-MI setting with
                                reduced LVEF, even in the absence of HF symptoms.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">6.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5105">Although beta blockers have been shown to improve outcomes in patients with
                                symptomatic HFrEF and in patients with reduced LVEF after MI (<a class="tab-link"
                                    href="#bib397" data-tab="pane-pcw-references">11</a>), few data exist regarding the
                                use of beta blockers in asymptomatic patients with depressed LVEF without a history of
                                MI. There is evidence to support the role of beta blockers to prevent adverse LV
                                remodeling in asymptomatic patients with LV systolic dysfunction, including those with
                                nonischemic cause (<a class="tab-link" href="#bib429"
                                    data-tab="pane-pcw-references">43</a>). Also, in a post hoc analysis of the SOLVD
                                prevention trial, which included approximately 20% of participants with nonischemic HF
                                cause, beta blockers were associated with a reduction in the risk of death and in death
                                or hospitalization for symptomatic HF in those patients randomized to enalapril, a
                                finding that was not seen in the placebo group (<a class="tab-link" href="#bib398"
                                    data-tab="pane-pcw-references">12</a>). Given the long-term benefits of beta
                                blockers to reduce HF hospitalizations in patients with symptomatic HFrEF (<a
                                    class="tab-link" href="#bib430" data-tab="pane-pcw-references">44</a>), beta-blocker
                                therapy is recommended to prevent symptomatic HF in patients with reduced LVEF.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">7.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5120">Thiazolidinediones have been associated with fluid retention and increased
                                rates of HF in RCTs of patients with type 2 diabetes who were predominantly free of
                                symptomatic HF at baseline (<a class="tab-link" href="#bib433"
                                    data-tab="pane-pcw-references">47-49</a>). In a smaller RCT of patients with more
                                severely symptomatic HFrEF, pioglitazone was associated with increased rates of HF
                                hospitalization compared with placebo (<a class="tab-link" href="#bib436"
                                    data-tab="pane-pcw-references">50</a>). In patients with more mild symptoms (NYHA
                                class I to II) but with depressed LVEF (<a class="tab-link" href="#bib401"
                                    data-tab="pane-pcw-references">15</a>), rosiglitazone was associated with more
                                fluid-related events, including worsening edema and need for increased HF medications
                                (<a class="tab-link" href="#bib401" data-tab="pane-pcw-references">15</a>). Given the
                                evidence, thiazolidinediones should be avoided in patients with reduced LVEF.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">8.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5115">Nondihydropiridine calcium channel blockers diltiazem and verapamil are
                                myocardial depressants and generally not tolerated in HF. In previous studies of
                                patients with HF or reduced LVEF after acute MI, diltiazem was associated with increased
                                risk of HF (<a class="tab-link" href="#bib402" data-tab="pane-pcw-references">16</a>,<a
                                    class="tab-link" href="#bib403" data-tab="pane-pcw-references">17</a>), although in
                                a smaller study of patients with nonischemic cardiomyopathy, diltiazem had no impact on
                                mortality (<a class="tab-link" href="#bib431" data-tab="pane-pcw-references">45</a>).
                                Verapamil had no impact on survival or major cardiovascular events after acute MI (<a
                                    class="tab-link" href="#bib432" data-tab="pane-pcw-references">46</a>). Although not
                                specifically tested in asymptomatic patients with low LVEF, nondihydropyridine calcium
                                channel blockers may be harmful in this population because of their negative inotropic
                                effects.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acd247731e5256" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e5256">
                <div id="acsectitle0235" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0235">7 Stage C HF</h2>
            <div id="acsec11" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec11">
                <div id="acsectitle0240" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0240">7.1 Nonpharmacological Interventions</h3>
            <div id="acsec11.1" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.1">
                <div id="acsectitle0245" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0245">7.1.1 Self-Care Support in HF</h4>
            <div id="undtbl13" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl13">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0485">Recommendations for Nonpharmacological Interventions: Self-Care Support
                                in HF</p>
                            <p id="tspara0490">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0325" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1325"><strong>Patients with HF should receive care from
                                                        multidisciplinary teams to facilitate the implementation of
                                                        GDMT, address potential barriers to self-care, reduce the risk
                                                        of subsequent rehospitalization for HF, and improve
                                                        survival</strong> (<a class="tab-link" href="#bib446"
                                                        data-tab="pane-pcw-references">1-4</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0330" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1330"><strong>Patients with HF should receive specific education
                                                        and support to facilitate HF self-care in a multidisciplinary
                                                        manner (</strong><a class="tab-link" href="#bib447"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib450"
                                                        data-tab="pane-pcw-references"><strong>5-9</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0335" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1335"><strong>In patients with HF, vaccinating against
                                                        respiratory illnesses is reasonable to reduce mortality</strong>
                                                    (<a class="tab-link" href="#bib455"
                                                        data-tab="pane-pcw-references">10-16</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0340" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1340"><strong>In adults with HF, screening for depression
                                                        (</strong><a class="tab-link" href="#bib462"
                                                        data-tab="pane-pcw-references"><strong>17</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib463"
                                                        data-tab="pane-pcw-references"><strong>18</strong></a><strong>),
                                                        social isolation</strong> (<a class="tab-link" href="#bib464"
                                                        data-tab="pane-pcw-references">19-22</a>)<strong>, frailty
                                                        (</strong><a class="tab-link" href="#bib468"
                                                        data-tab="pane-pcw-references"><strong>23</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib469"
                                                        data-tab="pane-pcw-references"><strong>24</strong></a><strong>),
                                                        and low health literacy (</strong><a class="tab-link"
                                                        href="#bib470"
                                                        data-tab="pane-pcw-references"><strong>25</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib471"
                                                        data-tab="pane-pcw-references"><strong>26</strong></a><strong>)
                                                        as risk factors for poor self-care is reasonable to improve
                                                        management.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5135"><strong>Synopsis</strong></p>
            <p id="p5140">Because of the complexity of HF management and coordination of other health and social
                services required, HF care is ideally provided by multidisciplinary teams (<a class="tab-link"
                    href="#bib472" data-tab="pane-pcw-references">27-30</a>) that include cardiologists, nurses, and
                pharmacists who specialize in HF as well as dieticians, mental health clinicians, social workers,
                primary care clinicians, and additional specialists (<a class="tab-link" href="#bib476"
                    data-tab="pane-pcw-references">31-33</a>). Self-care in HF comprises treatment adherence and health
                maintenance behaviors (<a class="tab-link" href="#bib479" data-tab="pane-pcw-references">34</a>,<a
                    class="tab-link" href="#bib480" data-tab="pane-pcw-references">35</a>). Patients with HF should
                learn to take medications as prescribed, restrict sodium intake, stay physically active, and get
                vaccinations (<a class="tab-link" href="#bib481" data-tab="pane-pcw-references">36</a>,<a
                    class="tab-link" href="#bib482" data-tab="pane-pcw-references">37</a>). They also should understand
                how to monitor for signs and symptoms of worsening HF, and what to do in response to symptoms when they
                occur (<a class="tab-link" href="#bib481" data-tab="pane-pcw-references">36</a>,<a class="tab-link"
                    href="#bib482" data-tab="pane-pcw-references">37</a>). Knowledge alone is insufficient to improve
                self-care (<a class="tab-link" href="#bib483" data-tab="pane-pcw-references">38</a>). Patients with HF
                need time and support to gain skills and overcome barriers to effective self-care (<a class="tab-link"
                    href="#bib482" data-tab="pane-pcw-references">37</a>). Measures listed as Class 1 recommendations
                for patients in stages A and B are recommended where appropriate for patients in stage C. GDMT, as
                depicted in <a data-tab="pane-pcw-Figures" href="#fig6" id="fig6R" class="">Figure 6</a>, should be the
                mainstay of pharmacological therapy for HFrEF.</p>
            <section class="article-section__inline-figure">
                <figure id="fig6" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/30b69986-20b7-4285-b2bf-7287bdc656d5/gr6.jpg"
                        data-lg-src="/cms/asset/dc769637-1028-4c82-8c9b-6f19bbadeb17/gr6.jpg" alt="Figure 6">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/dc769637-1028-4c82-8c9b-6f19bbadeb17/gr6.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig6&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 6</span></strong>
                        <p>Treatment of HFrEF Stages C and D</p>
                        <p><strong>Colors correspond to COR in</strong> <a class="ref showTableEvent" data-id="tbl2"
                                href="#tbl2"><strong>Table 2</strong></a><strong>.</strong> Treatment recommendations
                            for patients with HFrEF are displayed. Step 1 medications may be started simultaneously at
                            initial (low) doses recommended for HFrEF. Alternatively, these medications may be started
                            sequentially, with sequence guided by clinical or other factors, without need to achieve
                            target dosing before initiating next medication. Medication doses should be increased to
                            target as tolerated. ACEi indicates angiotensin-converting enzyme inhibitor; ARB,
                            angiotensin receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; COR, Class of
                            Recommendation; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical
                            therapy; ICD, implantable cardioverter-defibrillator; hydral-nitrates, hydralazine and
                            isosorbide dinitrate; HFrEF, heart failure with reduced ejection fraction; LBBB, left bundle
                            branch block; MCS, mechanical circulatory support; LVEF, left ventricular ejection fraction;
                            MRA, mineralocorticoid receptor antagonist; NSR, normal sinus rhythm; NYHA, New York Heart
                            Association; and SGLT2i, sodium-glucose cotransporter 2 inhibitor. ∗Participation in
                            investigational studies is appropriate for stage C, NYHA class II and III HF.</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p5145"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1210" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5150">In a meta-analysis of 30 RCTs, multidisciplinary interventions reduced
                                hospital admission and all-cause mortality (<a class="tab-link" href="#bib446"
                                    data-tab="pane-pcw-references">1</a>). In a separate meta-analysis of 22 RCTs,
                                specialized multidisciplinary team follow-up was associated with reduced HF
                                hospitalizations and all-cause hospitalizations (<a class="tab-link" href="#bib447"
                                    data-tab="pane-pcw-references">2</a>). In a recent meta-analysis of 22 RCTs,
                                multidisciplinary interventions that included a pharmacist reduced HF hospitalizations
                                (<a class="tab-link" href="#bib448" data-tab="pane-pcw-references">3</a>). In a recent
                                Cochrane systematic review and meta-analysis of 43 RCTs, both case management (i.e.,
                                active management of complex patients by case managers working in integrated care
                                systems) and multidisciplinary interventions (i.e., coordinated multidisciplinary health
                                care interventions and communications) were shown to reduce all-cause mortality,
                                all-cause readmission, and readmission for HF (<a class="tab-link" href="#bib449"
                                    data-tab="pane-pcw-references">4</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5155">Meta-analyses of RCTs have shown that interventions focused on improving HF
                                self-care significantly reduce the risk of HF-related hospitalization (<a
                                    class="tab-link" href="#bib447" data-tab="pane-pcw-references">2</a>,<a
                                    class="tab-link" href="#bib450" data-tab="pane-pcw-references">5-8</a>), all-cause
                                hospitalization (<a class="tab-link" href="#bib447"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib453"
                                    data-tab="pane-pcw-references">8</a>,<a class="tab-link" href="#bib454"
                                    data-tab="pane-pcw-references">9</a>), and all-cause mortality (<a class="tab-link"
                                    href="#bib451" data-tab="pane-pcw-references">6</a>,<a class="tab-link"
                                    href="#bib454" data-tab="pane-pcw-references">9</a>), as well as improve QOL (<a
                                    class="tab-link" href="#bib450" data-tab="pane-pcw-references">5</a>). Interventions
                                that aim to improve self-care knowledge and skill (<a class="tab-link" href="#bib447"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib450"
                                    data-tab="pane-pcw-references">5</a>,<a class="tab-link" href="#bib453"
                                    data-tab="pane-pcw-references">8</a>), and those that focus on enhancing medication
                                adherence (<a class="tab-link" href="#bib454" data-tab="pane-pcw-references">9</a>) or
                                reinforce self-care with structured telephone support (<a class="tab-link"
                                    href="#bib451" data-tab="pane-pcw-references">6</a>,<a class="tab-link"
                                    href="#bib452" data-tab="pane-pcw-references">7</a>), are effective in patients with
                                HF. There is uncertainty whether mobile health–delivered educational interventions
                                improve self-care in patients with HF (<a class="tab-link" href="#bib484"
                                    data-tab="pane-pcw-references">39</a>). In a single RCT involving rural patients
                                with HF, an educational intervention was shown to improve knowledge and self-care (<a
                                    class="tab-link" href="#bib485" data-tab="pane-pcw-references">40</a>) but did not
                                significantly decrease the combined endpoint of cardiac death or HF hospitalization (<a
                                    class="tab-link" href="#bib486" data-tab="pane-pcw-references">41</a>). In a recent
                                pragmatic trial, a transitional care services program that included self-care education
                                improved discharge preparedness, quality of transition, and QOL but did not
                                significantly improve clinical outcomes compared with usual care (<a class="tab-link"
                                    href="#bib487" data-tab="pane-pcw-references">42</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5160">In propensity-adjusted models, influenza vaccination was associated with a
                                significant reduction in all-cause mortality among participants in PARADIGM-HF
                                (Prospective Comparison of ARNi with ACEi to Determine Impact on Global Mortality and
                                Morbidity in Heart Failure) (<a class="tab-link" href="#bib459"
                                    data-tab="pane-pcw-references">14</a>). In adjusted models, influenza vaccination
                                was associated with significant reductions in all-cause mortality and cardiovascular
                                mortality (<a class="tab-link" href="#bib457" data-tab="pane-pcw-references">12</a>) in
                                1 registry study and was associated with significant reductions in all-cause mortality
                                and the composite of all-cause mortality and cardiovascular hospitalizations in another
                                large cohort study (<a class="tab-link" href="#bib456"
                                    data-tab="pane-pcw-references">11</a>). In a self-controlled case series study of
                                patients with HF, influenza vaccination was associated with a significantly lower risk
                                of cardiovascular, respiratory, and all-cause hospitalization (<a class="tab-link"
                                    href="#bib488" data-tab="pane-pcw-references">43</a>). In a meta-analysis of 16
                                studies of patients with CVD, influenza vaccination was associated with a lower risk of
                                all-cause, cardiovascular mortality, and major adverse cardiovascular events compared
                                with control patients (<a class="tab-link" href="#bib460"
                                    data-tab="pane-pcw-references">15</a>). In the Cardiovascular Health Study,
                                pneumococcal vaccination was associated with significant reductions in incident HF,
                                all-cause mortality, and cardiovascular mortality (<a class="tab-link" href="#bib461"
                                    data-tab="pane-pcw-references">16</a>). Patients with HF are uniquely susceptible to
                                poor outcomes in the setting of SARS-CoV-2 infection (<a class="tab-link" href="#bib489"
                                    data-tab="pane-pcw-references">44-47</a>) and should be vaccinated against COVID-19
                                (<a class="tab-link" href="#bib455" data-tab="pane-pcw-references">10</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5165">Many health and social factors are associated with poor HF self-care (<a
                                    class="tab-link" href="#bib481" data-tab="pane-pcw-references">36</a>,<a
                                    class="tab-link" href="#bib482" data-tab="pane-pcw-references">37</a>) (<a
                                    class="ref showTableEvent" data-id="tbl11" href="#tbl11">Table 11</a>) but have also
                                been linked to poor clinical outcomes and fundamentally change how education and support
                                must be delivered. Depression is a risk factor for poor self-care (<a class="tab-link"
                                    href="#bib485" data-tab="pane-pcw-references">40</a>), rehospitalization (<a
                                    class="tab-link" href="#bib462" data-tab="pane-pcw-references">17</a>), and
                                all-cause mortality (<a class="tab-link" href="#bib463"
                                    data-tab="pane-pcw-references">18</a>) among patients with HF. Interventions that
                                focus on improving HF self-care have been reported to be effective among patients with
                                moderate/severe depression with reductions in hospitalization and mortality risk (<a
                                    class="tab-link" href="#bib450" data-tab="pane-pcw-references">5</a>). Nonrandomized
                                studies have provided evidence of a link between social isolation and mortality in
                                patients with HF (<a class="tab-link" href="#bib464"
                                    data-tab="pane-pcw-references">19</a>,<a class="tab-link" href="#bib465"
                                    data-tab="pane-pcw-references">20</a>). In a recent meta-analysis of 29 cohort
                                studies, frailty was associated with an increased risk of all-cause mortality and
                                hospitalization (<a class="tab-link" href="#bib468"
                                    data-tab="pane-pcw-references">23</a>). Frailty also has been shown to impair
                                self-care among elderly patients with HF (<a class="tab-link" href="#bib469"
                                    data-tab="pane-pcw-references">24</a>). A recent meta-analysis of observational
                                studies revealed social isolation to be common among adults with HF (i.e., 37%) and
                                associated with a 55% greater risk of HF-related rehospitalization (<a class="tab-link"
                                    href="#bib466" data-tab="pane-pcw-references">21</a>). Poor social support also has
                                been shown in nonrandomized studies to be associated with lower HF self-care (<a
                                    class="tab-link" href="#bib467" data-tab="pane-pcw-references">22</a>). A recent
                                meta-analysis of observational studies showed that inadequate/marginal health literacy
                                is common among adults with HF (i.e., 24%) and associated independently with the risk of
                                mortality and hospitalization (<a class="tab-link" href="#bib470"
                                    data-tab="pane-pcw-references">25</a>). Low literacy also is associated with poor HF
                                self-care, as most interventions depend on both literacy and health literacy/numeracy
                                (<a class="tab-link" href="#bib471" data-tab="pane-pcw-references">26</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="tbl11" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl11">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0105"><span class="captionLabel">Table 11</span> Potential Barriers to
                                Effective HF Self-Care and Example Interventions</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Potential Barrier</th>
                            <th colspan="1" rowspan="1">Example Screening Tools</th>
                            <th colspan="1" rowspan="1">Example Interventions</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="3" rowspan="1"><strong>Medical Barriers</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Cognitive impairment (<a class="tab-link" href="#bib493"
                                    data-tab="pane-pcw-references">48-50</a>)</td>
                            <td colspan="1" rowspan="1">Mini-Cog<br>Mini-Mental State Examination (MMSE)<br>Montreal
                                Cognitive Assessment (MoCA)</td>
                            <td colspan="1" rowspan="1">Home health aide<br>Home meal deliveries<br>Adult day
                                care<br>Geriatric psychiatry referral<br>Memory care support groups</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Depression (<a class="tab-link" href="#bib496"
                                    data-tab="pane-pcw-references">51</a>,<a class="tab-link" href="#bib497"
                                    data-tab="pane-pcw-references">52</a>)</td>
                            <td colspan="1" rowspan="1">Hamilton Depression Rating Scale (HAM-D)<br>Beck Depression
                                Inventory-II (BDI-II)<br>Patient Health Questionnaire-9 (PHQ-9)</td>
                            <td colspan="1" rowspan="1">Psychotherapy<br>Selective serotonin reuptake
                                inhibitors<br>Nurse-led support</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Substance use disorders (<a class="tab-link" href="#bib498"
                                    data-tab="pane-pcw-references">53</a>)</td>
                            <td colspan="1" rowspan="1">Tobacco, Alcohol, Prescription medication, and other Substance
                                use (TAPS)</td>
                            <td colspan="1" rowspan="1">Referral to social work services and community support
                                partners<br>Referral for addiction psychiatry consultation</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Frailty (<a class="tab-link" href="#bib499"
                                    data-tab="pane-pcw-references">54</a>)</td>
                            <td colspan="1" rowspan="1">Fried frailty phenotype</td>
                            <td colspan="1" rowspan="1">Cardiac rehabilitation<br>Registered dietitian nutritionist
                                evaluation for malnutrition</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="3" rowspan="1"><strong>Social Barriers</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Financial burden of HF treatments (<a class="tab-link"
                                    href="#bib500" data-tab="pane-pcw-references">55</a>)</td>
                            <td colspan="1" rowspan="1">COmprehensive Score for financial Toxicity–Functional Assessment
                                of Chronic Illness Therapy (COST-FACIT)</td>
                            <td colspan="1" rowspan="1">PharmD referral to review prescription assistance eligibilities
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Food insecurity (<a class="tab-link" href="#bib501"
                                    data-tab="pane-pcw-references">56</a>,<a class="tab-link" href="#bib502"
                                    data-tab="pane-pcw-references">57</a>)</td>
                            <td colspan="1" rowspan="1">Hunger Vital Sign, 2 items<br>U.S. Household Food Security
                                Survey Module, 6 items</td>
                            <td colspan="1" rowspan="1">Determine eligibility for the Supplemental Nutrition Assistance
                                Program (SNAP)<br>Connect patients with community partners such as food pantries/food
                                banks<br>Home meal deliveries<br>Registered dietitian nutritionist evaluation for
                                potential malnutrition</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Homelessness or housing insecurity (<a class="tab-link"
                                    href="#bib503" data-tab="pane-pcw-references">58-60</a>)</td>
                            <td colspan="1" rowspan="1">Homelessness Screening Clinical Reminder (HSCR)</td>
                            <td colspan="1" rowspan="1">Referral to local housing services<br>Connect patients with
                                community housing partners</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Intimate partner violence or elder abuse (<a class="tab-link"
                                    href="#bib506" data-tab="pane-pcw-references">61</a>,<a class="tab-link"
                                    href="#bib507" data-tab="pane-pcw-references">62</a>)</td>
                            <td colspan="1" rowspan="1">Humiliation, Afraid, Rape, Kick (HARK) questionnaire<br>Partner
                                Violence Screen (PVS)<br>Woman Abuse Screening Tool (WAST)</td>
                            <td colspan="1" rowspan="1">Referral to social work services and community support partners
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Limited English proficiency or other language barriers (<a
                                    class="tab-link" href="#bib508" data-tab="pane-pcw-references">63</a>)</td>
                            <td colspan="1" rowspan="1">Routinely inquire in which language the patient is most
                                comfortable conversing</td>
                            <td colspan="1" rowspan="1">Access to interpreter services covering a wide range of
                                languages, ideally in person or, alternatively, via video platform<br>Printed
                                educational materials in a range of appropriate languages</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Low health literacy (<a class="tab-link" href="#bib509"
                                    data-tab="pane-pcw-references">64</a>)</td>
                            <td colspan="1" rowspan="1">Short Assessment of Health Literacy (SAHL)<br>Rapid Estimate of
                                Adult Literacy in Medicine–Short Form (REALM-SF)<br>Brief Health Literacy Screen (BHLS),
                                3 items</td>
                            <td colspan="1" rowspan="1">Agency for Healthcare Research and Quality (AHRQ) Health
                                Literacy Universal Precautions Toolkit<br>Written education tools provided at sixth
                                grade reading level or below Graphic educational documents</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Social isolation or low social support (<a class="tab-link"
                                    href="#bib510" data-tab="pane-pcw-references">65</a>)</td>
                            <td colspan="1" rowspan="1">Patient-Reported Outcomes Measurement Information System
                                (PROMIS) Social Isolation Short Form</td>
                            <td colspan="1" rowspan="1">Determine eligibility for home care services<br>Support group
                                referral</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Transport limitations</td>
                            <td colspan="1" rowspan="1">No validated tools currently available.</td>
                            <td colspan="1" rowspan="1">Referral to social work services<br>Determine eligibility for
                                insurance or state-based transportation, or reduced-cost public
                                transportation<br>Maximize opportunities for telehealth visits and remote monitoring
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0110">HF indicates heart failure.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="acsec11.1" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.1">
                <div id="acsectitle0250" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0250">7.1.2 Dietary Sodium Restriction</h4>
            <div id="undtbl14" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl14">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0495">Recommendation for Dietary Sodium Restriction</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0345" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1345"><strong>For patients with stage C HF, avoiding excessive
                                                        sodium intake is reasonable to reduce congestive
                                                        symptoms</strong> (<a class="tab-link" href="#bib511"
                                                        data-tab="pane-pcw-references">1-6</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5180"><strong>Synopsis</strong></p>
            <p id="p5185">Restricting dietary sodium is a common nonpharmacological treatment for patients with HF
                symptomatic with congestion, but specific recommendations have been based on low-quality evidence (<a
                    class="tab-link" href="#bib517" data-tab="pane-pcw-references">7</a>). Concerns about the quality of
                data regarding clinical benefits or harm of sodium restriction in patients with HF include the lack of
                current pharmacological therapy, small samples without sufficient racial and ethnic diversity, questions
                about the correct threshold for clinical benefit, uncertainty about which subgroups benefit most from
                sodium restriction (<a class="tab-link" href="#bib517" data-tab="pane-pcw-references">7</a>,<a
                    class="tab-link" href="#bib518" data-tab="pane-pcw-references">8</a>), and serious questions about
                the validity of several RCTs in this area (<a class="tab-link" href="#bib519"
                    data-tab="pane-pcw-references">9-11</a>). However, there are promising pilot trials of sodium
                restriction in patients with HF (<a class="tab-link" href="#bib513"
                    data-tab="pane-pcw-references">3</a>,<a class="tab-link" href="#bib515"
                    data-tab="pane-pcw-references">5</a>,<a class="tab-link" href="#bib516"
                    data-tab="pane-pcw-references">6</a>). The AHA currently recommends a reduction of sodium intake to
                &lt;2300 mg/d for general cardiovascular health promotion (<a class="tab-link" href="#bib522"
                    data-tab="pane-pcw-references">12</a>); however, there are no trials to support this level of
                restriction in patients with HF (<a class="tab-link" href="#bib523"
                    data-tab="pane-pcw-references">13</a>). Sodium restriction can result in poor dietary quality with
                inadequate macronutrient and micronutrient intake (<a class="tab-link" href="#bib524"
                    data-tab="pane-pcw-references">14</a>). Nutritional inadequacies have been associated with clinical
                instability (<a class="tab-link" href="#bib525" data-tab="pane-pcw-references">15-17</a>), but routine
                supplementation of oral iron (<a class="tab-link" href="#bib528" data-tab="pane-pcw-references">18</a>),
                thiamine (<a class="tab-link" href="#bib529" data-tab="pane-pcw-references">19</a>), zinc (<a
                    class="tab-link" href="#bib530" data-tab="pane-pcw-references">20</a>), vitamin D (<a
                    class="tab-link" href="#bib531" data-tab="pane-pcw-references">21</a>), or multivitamins has not
                proven beneficial (<a class="tab-link" href="#bib532" data-tab="pane-pcw-references">22</a>). The DASH
                diet is rich in antioxidants and potassium, can achieve sodium restriction without compromising
                nutritional adequacy when accompanied by dietary counseling (<a class="tab-link" href="#bib515"
                    data-tab="pane-pcw-references">5</a>), and may be associated with reduced hospitalizations for HF
                (<a class="tab-link" href="#bib533" data-tab="pane-pcw-references">23</a>).</p>
            <p id="p5190"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1215" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5195">A registered dietitian- or nurse-coached intervention with 2 to 3 g/d sodium
                                restriction improved NYHA functional class and leg edema in patients with HFrEF (<a
                                    class="tab-link" href="#bib511" data-tab="pane-pcw-references">1</a>). In a
                                nonrandomized study (&gt;2.5 g/d versus &lt;2.5 g/d), lower dietary sodium was
                                associated with worse all-cause mortality in patients with HFrEF (<a class="tab-link"
                                    href="#bib512" data-tab="pane-pcw-references">2</a>). In small RCTs, aggressive
                                sodium restriction (0.8 g/d) during hospitalization for acute decompensated HF has not
                                reduced weight, congestion, diuretic use, rehospitalization, or all-cause mortality in
                                patients with HFrEF (<a class="tab-link" href="#bib534"
                                    data-tab="pane-pcw-references">24</a>) or in patients with HFpEF (<a
                                    class="tab-link" href="#bib535" data-tab="pane-pcw-references">25</a>). A recent
                                pilot RCT N=27) showed that providing patients with 1.5 g/d sodium meals can reduce
                                urinary sodium and improve QOL but not improve clinical outcomes (<a class="tab-link"
                                    href="#bib513" data-tab="pane-pcw-references">3</a>). Another recent pilot RCT
                                (N=38) of 1.5 versus 2.3 g/d sodium resulted in sodium intake and improvement in BNP
                                levels and QOL in the 1.5 g/d sodium intake arm (<a class="tab-link" href="#bib515"
                                    data-tab="pane-pcw-references">5</a>); the full trial is due to be completed in
                                2022. A third pilot RCT (N=66) of home-delivered 1.5 g/d meals showed favorable but
                                nonsignificant trends toward improvement in clinical status and readmission rates (<a
                                    class="tab-link" href="#bib516" data-tab="pane-pcw-references">6</a>). Moreover,
                                results from RCTs have shown that reducing dietary sodium is difficult to achieve in
                                patients with HF, even with prepared meals (<a class="tab-link" href="#bib513"
                                    data-tab="pane-pcw-references">3</a>) or home visits (<a class="tab-link"
                                    href="#bib536" data-tab="pane-pcw-references">26</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.1" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.1">
                <div id="acsectitle0255" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0255">7.1.3 Management of Stage C HF: Activity, Exercise
                Prescription, and Cardiac Rehabilitation</h4>
            <div id="undtbl15" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl15">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0500">Recommendations for Management of Stage C HF: Activity, Exercise
                                Prescription, and Cardiac Rehabilitation</p>
                            <p id="tspara0505">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0350" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1350"><strong>For patients with HF who are able to participate,
                                                        exercise training (or regular physical activity) is recommended
                                                        to improve functional status, exercise performance, and
                                                        QOL</strong> (<a class="tab-link" href="#bib537"
                                                        data-tab="pane-pcw-references">1-9</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0355" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1355"><strong>In patients with HF, a cardiac rehabilitation
                                                        program can be useful to improve functional capacity, exercise
                                                        tolerance, and health-related QOL (</strong><a class="tab-link"
                                                        href="#bib537"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib538"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib541"
                                                        data-tab="pane-pcw-references"><strong>5</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib542"
                                                        data-tab="pane-pcw-references"><strong>6</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib544"
                                                        data-tab="pane-pcw-references"><strong>8</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5205"><strong>Synopsis</strong></p>
            <p id="p5210">Exercise training in patients with HF is safe and has numerous benefits. In a major trial of
                exercise and HF, exercise training was associated with a reduction in CVD mortality or hospitalizations
                in the exercise training group after adjustment for risk factors (<a class="tab-link" href="#bib537"
                    data-tab="pane-pcw-references">1</a>). Meta-analyses show that cardiac rehabilitation improves
                functional capacity, exercise duration, and health-related QOL. A cardiac rehabilitation program for
                patients with HF usually includes a medical evaluation, education regarding the importance of medical
                adherence, dietary recommendations, psychosocial support, and an exercise training and physical activity
                counseling program. Patients with HF on optimal GDMT, who are in stable medical condition and are able
                to participate in an exercise program, are candidates for an exercise rehabilitation program (<a
                    class="tab-link" href="#bib546" data-tab="pane-pcw-references">10</a>,<a class="tab-link"
                    href="#bib547" data-tab="pane-pcw-references">11</a>).</p>
            <p id="p5215"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1220" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5220">Evidence from RCTs indicates that exercise training improves functional
                                status, exercise performance, and QOL in patients with HFrEF and HFpEF. In HF-ACTION,
                                the largest randomized trial with exercise training in patients with HF (<a
                                    class="tab-link" href="#bib537" data-tab="pane-pcw-references">1</a>), 2331 patients
                                with LVEF ≤35% (NYHA class II and III) were randomized to usual care versus supervised
                                exercise training plus usual care. There were modest reductions in all-cause mortality
                                and hospitalization rates that did not reach significance by primary analysis but, after
                                prespecified adjustment, were associated with reductions in cardiovascular mortality or
                                HF hospitalizations (<a class="tab-link" href="#bib537"
                                    data-tab="pane-pcw-references">1</a>). Many RCTs of exercise training in HF have
                                been conducted, but the statistical power of most was low (<a class="tab-link"
                                    href="#bib538" data-tab="pane-pcw-references">2-5</a>,<a class="tab-link"
                                    href="#bib545" data-tab="pane-pcw-references">9-13</a>). Meta-analyses suggest that
                                exercise training is associated with improvement in functional capacity, exercise
                                duration, health-related QOL, and reduction in HF hospitalizations in patients with
                                HFrEF as well as HFpEF (<a class="tab-link" href="#bib538"
                                    data-tab="pane-pcw-references">2-6</a>,<a class="tab-link" href="#bib544"
                                    data-tab="pane-pcw-references">8</a>,<a class="tab-link" href="#bib547"
                                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib550"
                                    data-tab="pane-pcw-references">14</a>,<a class="tab-link" href="#bib551"
                                    data-tab="pane-pcw-references">15</a>). Most studies and meta-analyses have not
                                shown significant changes in all-cause mortality (<a class="tab-link" href="#bib538"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib548"
                                    data-tab="pane-pcw-references">12</a>,<a class="tab-link" href="#bib550"
                                    data-tab="pane-pcw-references">14-22</a>), except for a few showing mortality
                                benefit with longer follow-up (<a class="tab-link" href="#bib542"
                                    data-tab="pane-pcw-references">6</a>,<a class="tab-link" href="#bib543"
                                    data-tab="pane-pcw-references">7</a>). Other benefits of exercise training include
                                improved endothelial function, blunted catecholamine spillover, increased peripheral
                                oxygen extraction, and improvement in peak oxygen consumption (<a class="tab-link"
                                    href="#bib538" data-tab="pane-pcw-references">2-5</a>,<a class="tab-link"
                                    href="#bib544" data-tab="pane-pcw-references">8</a>,<a class="tab-link"
                                    href="#bib546" data-tab="pane-pcw-references">10-12</a>,<a class="tab-link"
                                    href="#bib557" data-tab="pane-pcw-references">21</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5225">A formal cardiac rehabilitation program usually includes a medical evaluation,
                                education regarding the importance of medical adherence, dietary recommendations,
                                psychosocial support, and an exercise training and physical activity counseling program.
                                Exercise-based cardiac rehabilitation has been associated with an improvement in
                                functional capacity, exercise tolerance, the rate of overall and HF-specific
                                hospitalization, and improved QOL (<a class="tab-link" href="#bib539"
                                    data-tab="pane-pcw-references">3</a>,<a class="tab-link" href="#bib540"
                                    data-tab="pane-pcw-references">4</a>,<a class="tab-link" href="#bib542"
                                    data-tab="pane-pcw-references">6</a>,<a class="tab-link" href="#bib543"
                                    data-tab="pane-pcw-references">7</a>,<a class="tab-link" href="#bib547"
                                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib552"
                                    data-tab="pane-pcw-references">16</a>,<a class="tab-link" href="#bib553"
                                    data-tab="pane-pcw-references">17</a>). In a diverse population of older patients
                                who were hospitalized for acute decompensated HF, an early, transitional, tailored,
                                progressive rehabilitation intervention that included multiple physical-function domains
                                (strength, balance, mobility, and endurance) initiated during, or early after
                                hospitalization for HF, and continued after discharge, resulted in greater improvement
                                in physical function than usual care (<a class="tab-link" href="#bib545"
                                    data-tab="pane-pcw-references">9</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec11">
                <div id="acsectitle0260" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0260">7.2 Diuretics and Decongestion Strategies in
                Patients With HF</h3>
            <div id="undtbl16" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl16">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0510">Recommendations for Diuretics and Decongestion Strategies in Patients
                                With HF</p>
                            <p id="tspara0515">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0360" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1360"><strong>In patients with HF who have fluid retention,
                                                        diuretics are recommended to relieve congestion, improve
                                                        symptoms, and prevent worsening HF</strong> (<a class="tab-link"
                                                        href="#bib559"
                                                        data-tab="pane-pcw-references">1-5</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0365" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1365"><strong>For patients with HF and congestive symptoms,
                                                        addition of a thiazide (e.g., metolazone) to treatment with a
                                                        loop diuretic should be reserved for patients who do not respond
                                                        to moderate- or high-dose loop diuretics to minimize electrolyte
                                                        abnormalities</strong> (<a class="tab-link" href="#bib564"
                                                        data-tab="pane-pcw-references">6</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5235"><strong>Synopsis</strong></p>
            <p id="p5240">Bumetanide, furosemide, and torsemide inhibit reabsorption of sodium or chloride at the loop
                of Henle, whereas thiazide and thiazide-like diuretics act in the distal convoluting tubule and
                potassium-sparing diuretics (e.g., spironolactone) in the collecting duct (<a class="tab-link"
                    href="#bib565" data-tab="pane-pcw-references">7</a>,<a class="tab-link" href="#bib566"
                    data-tab="pane-pcw-references">8</a>). Loop diuretics are the preferred diuretic agents for use in
                most patients with HF. Thiazide diuretics such as chlorthalidone or hydrochlorothiazide may be
                considered in patients with hypertension and HF and mild fluid retention. Metolazone or chlorothiazide
                may be added to loop diuretics in patients with refractory edema unresponsive to loop diuretics alone.
                Diuretics should be prescribed to patients who have evidence of congestion or fluid retention. In any
                patient with a history of congestion, maintenance diuretics should be considered to avoid recurrent
                symptoms. The treatment goal of diuretic use is to eliminate clinical evidence of fluid retention, using
                the lowest dose possible to maintain euvolemia. With the exception of MRAs, the effects of diuretics on
                morbidity and mortality are uncertain (<a class="tab-link" href="#bib559"
                    data-tab="pane-pcw-references">1-5</a>). As such, diuretics should not be used in isolation but
                always combined with other GDMT for HF that reduces hospitalizations and prolongs survival. <a
                    class="ref showTableEvent" data-id="tbl12" href="#tbl12">Table 12</a> lists oral diuretics
                recommended for use in the treatment of chronic HF. Hyponatremia complicates HF management. If reversing
                potential causes and free water restriction do not improve hyponatremia, vasopressin antagonists may be
                helpful in the acute management of volume overload to decrease congestion while maintaining serum
                sodium.</p>
            <div id="tbl12" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl12">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0115"><span class="captionLabel">Table 12</span> Commonly Used Oral Diuretics
                                in Treatment of Congestion for Chronic HF</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Drug</th>
                            <th colspan="1" rowspan="1">Initial Daily Dose</th>
                            <th colspan="1" rowspan="1">Maximum Total Daily Dose</th>
                            <th colspan="1" rowspan="1">Duration of Action</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="4" rowspan="1"><strong>Loop diuretics</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Bumetanide</td>
                            <td align="center" colspan="1" rowspan="1">0.5–1.0 mg once or twice</td>
                            <td align="center" colspan="1" rowspan="1">10 mg</td>
                            <td align="center" colspan="1" rowspan="1">4–6 h</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Furosemide</td>
                            <td align="center" colspan="1" rowspan="1">20–40 mg once or twice</td>
                            <td align="center" colspan="1" rowspan="1">600 mg</td>
                            <td align="center" colspan="1" rowspan="1">6–8 h</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Torsemide</td>
                            <td align="center" colspan="1" rowspan="1">10–20 mg once</td>
                            <td align="center" colspan="1" rowspan="1">200 mg</td>
                            <td align="center" colspan="1" rowspan="1">12–16 h</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="4" rowspan="1"><strong>Thiazide diuretics</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Chlorthiazide</td>
                            <td align="center" colspan="1" rowspan="1">250–500 mg once or twice</td>
                            <td align="center" colspan="1" rowspan="1">1000 mg</td>
                            <td align="center" colspan="1" rowspan="1">6–12 h</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Chlorthalidone</td>
                            <td align="center" colspan="1" rowspan="1">12.5–25 mg once</td>
                            <td align="center" colspan="1" rowspan="1">100 mg</td>
                            <td align="center" colspan="1" rowspan="1">24–72 h</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Hydrochlorothiazide</td>
                            <td align="center" colspan="1" rowspan="1">25 mg once or twice</td>
                            <td align="center" colspan="1" rowspan="1">200 mg</td>
                            <td align="center" colspan="1" rowspan="1">6–12 h</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Indapamide</td>
                            <td align="center" colspan="1" rowspan="1">2.5 mg once</td>
                            <td align="center" colspan="1" rowspan="1">5 mg</td>
                            <td align="center" colspan="1" rowspan="1">36 h</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Metolazone</td>
                            <td align="center" colspan="1" rowspan="1">2.5 mg once</td>
                            <td align="center" colspan="1" rowspan="1">20 mg</td>
                            <td align="center" colspan="1" rowspan="1">12–24 h</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0120">HF indicates heart failure.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p5245"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1225" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5250">Controlled trials with diuretics showed their effects to increase urinary
                                sodium excretion, decrease physical signs of fluid retention, and improve symptoms, QOL,
                                and exercise tolerance (<a class="tab-link" href="#bib559"
                                    data-tab="pane-pcw-references">1-5</a>). Recent data from the nonrandomized
                                OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients
                                with Heart Failure) registry revealed reduced 30-day all-cause mortality and
                                hospitalization for HF with diuretic use compared with no diuretic use after hospital
                                discharge for HF (<a class="tab-link" href="#bib567"
                                    data-tab="pane-pcw-references">9</a>). The most commonly used loop diuretic for the
                                treatment of HF is furosemide, but some patients respond more favorably to other agents
                                in this category (e.g., bumetanide, torsemide), potentially because of their increased
                                oral bioavailability (<a class="tab-link" href="#bib568"
                                    data-tab="pane-pcw-references">10-12</a>). In outpatients with HF, diuretic therapy
                                is commonly initiated with low doses, and the dose is increased until urine output
                                increases and weight decreases, generally by 0.5 to 1.0 kg daily. Patients may become
                                unresponsive to high doses of diuretic drugs if they consume large amounts of dietary
                                sodium, are taking agents that can block the effects of diuretics (e.g., NSAIDs), or
                                have significant impairment of renal function or perfusion.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5255">Diuretic resistance can be overcome in several ways, including escalation of
                                loop diuretic dose, intravenous administration of diuretics (bolus or continuous
                                infusion) (<a class="tab-link" href="#bib564" data-tab="pane-pcw-references">6</a>), or
                                combination of different diuretic classes (<a class="tab-link" href="#bib571"
                                    data-tab="pane-pcw-references">13-16</a>). The use of a thiazide or thiazide-like
                                diuretic (e.g., metolazone) in combination with a loop diuretic inhibits compensatory
                                distal tubular sodium reabsorption, leading to enhanced natriuresis. However, in a
                                propensity-score matched analysis in patients with hospitalized HF, the addition of
                                metolazone to loop diuretics was found to increase the risk for hypokalemia,
                                hyponatremia, worsening renal function, and mortality, whereas use of higher doses of
                                loop diuretics was not found to adversely affect survival (<a class="tab-link"
                                    href="#bib575" data-tab="pane-pcw-references">17</a>). Although randomized data
                                comparing the 2 diuretic strategies are limited, the DOSE (Diuretic Optimization
                                Strategies Evaluation) trial lends support for the use of high-dose intravenous loop
                                diuretics (<a class="tab-link" href="#bib576" data-tab="pane-pcw-references">18</a>).
                            </p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec11">
                <div id="acsectitle0265" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0265">7.3 Pharmacological Treatment<a class="ref table-fn"
                    id="dtbl1fnlowast" href="javascript:popRef('dtbl1fnlowast')"><sup>∗</sup></a> for HFrEF</h3>
            <div id="acsec11.3" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.3">
                <div id="acsectitle0270" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0270">7.3.1 Renin-Angiotensin System Inhibition With ACEi
                or ARB or ARNi</h4>
            <div id="undtbl17" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl17">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0520">Recommendations for Renin-Angiotensin System Inhibition With ACEi or ARB
                                or ARNi</p>
                            <p id="tspara0525">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0370" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1370"><strong>In patients with HFrEF and NYHA class II to III
                                                        symptoms, the use of ARNi is recommended to reduce morbidity and
                                                        mortality</strong> (<a class="tab-link" href="#bib577"
                                                        data-tab="pane-pcw-references">1-5</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0375" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1375"><strong>In patients with previous or current symptoms of
                                                        chronic HFrEF, the use of ACEi is beneficial to reduce morbidity
                                                        and mortality when the use of ARNi is not feasible</strong> (<a
                                                        class="tab-link" href="#bib582"
                                                        data-tab="pane-pcw-references">6-13</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0380" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1380"><strong>In patients with previous or current symptoms of
                                                        chronic HFrEF who are intolerant to ACEi because of cough or
                                                        angioedema and when the use of ARNi is not feasible, the use of
                                                        ARB is recommended to reduce morbidity and mortality</strong>
                                                    (<a class="tab-link" href="#bib590"
                                                        data-tab="pane-pcw-references">14-18</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: High Value (A)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0385" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1385"><strong>In patients with previous or current symptoms of
                                                        chronic HFrEF, in whom ARNi is not feasible, treatment with an
                                                        ACEi or ARB provides high economic value</strong> (<a
                                                        class="tab-link" href="#bib595"
                                                        data-tab="pane-pcw-references">19-25</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0390" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1390"><strong>In patients with chronic symptomatic HFrEF NYHA
                                                        class II or III who tolerate an ACEi or ARB, replacement by an
                                                        ARNi is recommended to further reduce morbidity and
                                                        mortality</strong> (<a class="tab-link" href="#bib577"
                                                        data-tab="pane-pcw-references">1-5</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: High Value (A)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0395" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">6.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1395"><strong>In patients with chronic symptomatic HFrEF,
                                                        treatment with an ARNi instead of an ACEi provides high economic
                                                        value</strong> (<a class="tab-link" href="#bib602"
                                                        data-tab="pane-pcw-references">26-29</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0400" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">7.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1400"><strong>ARNi should not be administered concomitantly with
                                                        ACEi or within 36 hours of the last dose of an ACEi (</strong><a
                                                        class="tab-link" href="#bib606"
                                                        data-tab="pane-pcw-references"><strong>30</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib607"
                                                        data-tab="pane-pcw-references"><strong>31</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0405" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">8.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1405"><strong>ARNi should not be administered to patients with
                                                        any history of angioedema</strong> (<a class="tab-link"
                                                        href="#bib608"
                                                        data-tab="pane-pcw-references">32-35</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0410" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">9.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1410"><strong>ACEi should not be administered to patients with
                                                        any history of angioedema</strong> (<a class="tab-link"
                                                        href="#bib612"
                                                        data-tab="pane-pcw-references">36-39</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn id="dtbl1fnlowast">
                            <p id="ntpara0070">∗ See <a class="ref sec" id="crosref1485" href="#sec11.2">Section
                                    7.2</a>, “Diuretics and Decongestion Strategies in Patients with HF,” for diuretic
                                recommendations.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p5270"><strong>Synopsis</strong></p>
            <p id="p5275">Inhibition of the renin-angiotensin system is recommended to reduce morbidity and mortality
                for patients with HFrEF, and ARNi, ACEi, or ARB are recommended as first-line therapy (<a
                    class="tab-link" href="#bib577" data-tab="pane-pcw-references">1-18</a>). If patients have chronic
                symptomatic HFrEF with NYHA class II or III symptoms and they tolerate an ACEi or ARB, they should be
                switched to an ARNi because of improvement in morbidity and mortality (<a class="tab-link"
                    href="#bib577" data-tab="pane-pcw-references">1-5</a>). An ARNi is recommended as de novo treatment
                in hospitalized patients with acute HF before discharge given improvement in health status, reduction in
                the prognostic biomarker NT-proBNP, and improvement of LV remodeling parameters compared with ACEi/ARB.
                Although data are limited, the use of an ARNi may be efficacious as de novo treatment in patients with
                symptomatic chronic HFrEF to simplify management. ARB may be used as an alternative to ACEi in the
                setting of intolerable cough, or as alternatives to ACEi and ARNi in patients with a history of
                angioedema. If patients are switched from an ACEi to an ARNi or vice versa, there should be at least 36
                hours between ACEi and ARNi doses.</p>
            <p id="p5280"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1230" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5285">An ARNi is composed of an ARB and an inhibitor of neprilysin, an enzyme that
                                degrades natriuretic peptides, bradykinin, adrenomedullin, and other vasoactive
                                peptides. In PARADIGM-HF (Prospective Comparison of ARNi with ACEi to Determine Impact
                                on Global Mortality and Morbidity in Heart Failure), an RCT that compared the first
                                approved ARNi, sacubitril-valsartan, with enalapril in symptomatic patients with HFrEF
                                tolerating an adequate dose of either ACEi or ARB, sacubitril-valsartan significantly
                                reduced the composite endpoint of cardiovascular death or HF hospitalization by 20%
                                relative to enalapril (<a class="tab-link" href="#bib577"
                                    data-tab="pane-pcw-references">1</a>). The benefit was observed to a similar extent
                                for death and HF hospitalization and was consistent across prespecified subgroups (<a
                                    class="tab-link" href="#bib577" data-tab="pane-pcw-references">1</a>). Use of an
                                ARNi is more frequently associated with symptomatic hypotension and a comparable
                                incidence of angioedema when compared with enalapril (<a class="tab-link" href="#bib577"
                                    data-tab="pane-pcw-references">1</a>). Sacubitril-valsartan has been approved for
                                patients with symptomatic HF. HF effects and potential off-target effects may be complex
                                with inhibition of the neprilysin enzyme, which has multiple biological targets. Trial
                                data have included ACEi/ARB-naïve patients before ARNi initiation (53% in the PIONEER-HF
                                [Comparison of Sacubitril-Valsartan versus Enalapril on Effect on NT-proBNP in Patients
                                Stabilized from an Acute Heart Failure Episode] trial and 24% in the TRANSITION
                                [Comparison of Pre- and Post-discharge Initiation of Sacubitril/Valsartan Therapy in
                                HFrEF Patients After an Acute Decompensation Event] trial) and have shown similar
                                efficacy and safety in treatment-naïve patients (<a class="tab-link" href="#bib578"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib579"
                                    data-tab="pane-pcw-references">3</a>). The PIONEER-HF trial showed that ARNi reduced
                                NT-proBNP levels in patients hospitalized for acute decompensated HF without increased
                                rates of adverse events (worsening renal function, hyperkalemia, symptomatic
                                hypotension, angioedema) when compared with enalapril (<a class="tab-link"
                                    href="#bib579" data-tab="pane-pcw-references">3</a>). Additional outcome analyses
                                suggested reduction in all-cause mortality and rehospitalization for HF but were only
                                hypothesis-generating as exploratory study endpoints. In the open-label TRANSITION
                                trial, patients with HFrEF hospitalized with worsening HF were randomized to start ARNi
                                either before or after discharge (<a class="tab-link" href="#bib578"
                                    data-tab="pane-pcw-references">2</a>). Safety outcomes were similar for both arms,
                                suggesting that early initiation may simplify management (rather than initiating and
                                uptitrating ACEi first and then switching to ARNi) (<a class="tab-link" href="#bib578"
                                    data-tab="pane-pcw-references">2</a>). ARNi should be initiated de novo in patients
                                hospitalized with acute HFrEF before discharge in the absence of contraindications. ARNi
                                may be initiated de novo in patients with chronic symptomatic HFrEF to simplify
                                management, although data are limited. The PARADISE-MI (Prospective ARNi vs ACE
                                Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI)
                                trial (<a class="tab-link" href="#bib616" data-tab="pane-pcw-references">40</a>) will
                                provide information on whether sacubitril-valsartan will significantly reduce the rate
                                of cardiovascular death, HF hospitalization or outpatient HF requiring treatment in
                                patients after acute MI, with LVEF ≤40% and/or pulmonary congestion, and 1 of 8
                                additional risk-enhancing factors like AF, previous MI, diabetes, compared with the ACEi
                                ramipril; and whether the safety and tolerability of sacubitril-valsartan was comparable
                                to that of ramipril. Thus, at the present time, the efficacy of ARNi in patients with LV
                                dysfunction, and HF in the early post-MI period, remains uncertain.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5290">ACEi reduce morbidity and mortality in HFrEF. RCTs clearly establish the
                                benefits of ACE inhibition in patients with mild, moderate, or severe symptoms of HF and
                                in patients with or without CAD (<a class="tab-link" href="#bib582"
                                    data-tab="pane-pcw-references">6-11</a>). Data suggest that there are no differences
                                among available ACEi in their effects on symptoms or survival (<a class="tab-link"
                                    href="#bib588" data-tab="pane-pcw-references">12</a>). ACEi should be started at low
                                doses and titrated upward to doses shown to reduce the risk of cardiovascular events in
                                clinical trials. ACEi can produce angioedema and should be given with caution to
                                patients with low systemic blood pressures, renal insufficiency, or elevated serum
                                potassium (&gt;5.0 mEq/L). If maximal doses are not tolerated, intermediate doses should
                                be tried; abrupt withdrawal of ACE inhibition can lead to clinical deterioration and
                                should be avoided. Although the use of an ARNi in lieu of an ACEi for HFrEF has been
                                found to be superior, for those patients for whom ARNi is inappropriate, continued use
                                of an ACEi for all classes of HFrEF remains strongly advised.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5295">ARB have been shown to reduce mortality and HF hospitalizations in patients
                                with HFrEF in large RCTs (<a class="tab-link" href="#bib590"
                                    data-tab="pane-pcw-references">14-16</a>). Long-term treatment with ARB in patients
                                with HFrEF produces hemodynamic, neurohormonal, and clinical effects consistent with
                                those expected after interference with the renin-angiotensin system (<a class="tab-link"
                                    href="#bib593" data-tab="pane-pcw-references">17</a>,<a class="tab-link"
                                    href="#bib594" data-tab="pane-pcw-references">18</a>). Unlike ACEi, ARB do not
                                inhibit kininase and are associated with a much lower incidence of cough and angioedema,
                                although kininase inhibition by ACEi may produce beneficial vasodilatory effects.
                                Patients who are intolerant to ACEi because of cough or angioedema should be started on
                                an ARB. ARB should be started at low doses and titrated upward, with an attempt to use
                                doses shown to reduce the risk of cardiovascular events in clinical trials. ARB should
                                be given with caution to patients with low systemic blood pressure, renal insufficiency,
                                or elevated serum potassium (&gt;5.0 mEq/L). Although ARB are alternatives for patients
                                with ACEi-induced angioedema, caution is advised because some patients have also
                                developed angioedema with ARB. For those patients for whom an ACEi or ARNi is
                                inappropriate, use of an ARB remains advised.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5300">Several cost-effectiveness analyses consistently found that ACEi therapy
                                provides high value for patients with chronic HF. A model-based analysis, using generic
                                ACEi costs, found ACEi therapy was high value (<a class="tab-link" href="#bib595"
                                    data-tab="pane-pcw-references">19</a>). Previous analyses also found ACEi therapy
                                was high value despite previously higher ACEi costs (<a class="tab-link" href="#bib595"
                                    data-tab="pane-pcw-references">19</a>,<a class="tab-link" href="#bib597"
                                    data-tab="pane-pcw-references">21</a>,<a class="tab-link" href="#bib598"
                                    data-tab="pane-pcw-references">22</a>,<a class="tab-link" href="#bib600"
                                    data-tab="pane-pcw-references">24</a>,<a class="tab-link" href="#bib601"
                                    data-tab="pane-pcw-references">25</a>). This includes a trial-based analysis of
                                SOLVD (Studies of Left Ventricular Dysfunction) that modeled long-term outcomes (<a
                                    class="tab-link" href="#bib597" data-tab="pane-pcw-references">21</a>). Previous
                                analyses included a range of clinical scenarios including asymptomatic LV dysfunction
                                (<a class="tab-link" href="#bib600" data-tab="pane-pcw-references">24</a>) and LV
                                dysfunction after MI (<a class="tab-link" href="#bib601"
                                    data-tab="pane-pcw-references">25</a>), with ACEi therapy providing high value in
                                each. There are limited data on the cost-effectiveness of ARBs from 2 clinical trials—a
                                within-trial analysis of Val-HeFT (Valsartan Heart Failure Trial) (<a class="tab-link"
                                    href="#bib599" data-tab="pane-pcw-references">23</a>) and an analysis of the ELITE
                                (Evaluation of Losartan in the Elderly) study (<a class="tab-link" href="#bib596"
                                    data-tab="pane-pcw-references">20</a>)—which both suggested ARB therapy is high
                                value. The high value of ARB therapy is also supported by its similar efficacy as ACEi
                                therapy and the low-cost generic availability for both medication classes.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5305">Patients with chronic stable HFrEF who tolerate ACEi and ARB should be
                                switched to ARNi. In patients with mild-to-moderate HF who were able to tolerate both a
                                target dose of enalapril (10 mg twice daily) and then subsequently an ARNi
                                (sacubitril-valsartan; 200 mg twice daily, with the ARB component equivalent to
                                valsartan 160 mg), hospitalizations and mortality were significantly decreased with the
                                valsartan-sacubitril compound compared with enalapril (<a class="tab-link"
                                    href="#bib577" data-tab="pane-pcw-references">1</a>). Another RCT and meta-analysis
                                showed improvement in LV remodeling parameters with ARNi compared with enalapril (<a
                                    class="tab-link" href="#bib580" data-tab="pane-pcw-references">4</a>,<a
                                    class="tab-link" href="#bib581" data-tab="pane-pcw-references">5</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">6.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5310">Multiple model-based analyses evaluated the economic value of ARNi therapy
                                compared with ACEi therapy using the results of PARADIGM-HF (<a class="tab-link"
                                    href="#bib602" data-tab="pane-pcw-references">26-29</a>,<a class="tab-link"
                                    href="#bib617" data-tab="pane-pcw-references">41</a>). Three high-quality analyses
                                (<a class="tab-link" href="#bib602" data-tab="pane-pcw-references">26</a>,<a
                                    class="tab-link" href="#bib604" data-tab="pane-pcw-references">28</a>,<a
                                    class="tab-link" href="#bib605" data-tab="pane-pcw-references">29</a>) consistently
                                found costs per QALY &lt;$60,000, which provides high value according to the benchmarks
                                adopted for the current clinical practice guideline. These results were robust to the
                                range of sacubitril-valsartan costs currently seen in care. These results were sensitive
                                to the estimated mortality reduction and duration of treatment effectiveness. ARNi would
                                need to maintain effectiveness beyond the PARADIGM-HF study period (mean, 27 months) to
                                be considered high value (<a class="tab-link" href="#bib605"
                                    data-tab="pane-pcw-references">29</a>). If clinical benefit were limited to 27
                                months, ARNi would be intermediate value. One additional analysis, based on the
                                PIONEER-HF trial, found that inpatient initiation of ARNi was also high value compared
                                with delayed initiation postdischarge (<a class="tab-link" href="#bib603"
                                    data-tab="pane-pcw-references">27</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">7.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5315">Oral neprilysin inhibitors, used in combination with ACEi, can lead to
                                angioedema, and concomitant use is contraindicated and should be avoided. A medication
                                that represented a neprilysin inhibitor and an ACEi—omapatrilat—was studied in
                                hypertension and HF, but its development was terminated because of an unacceptable
                                incidence of angioedema (<a class="tab-link" href="#bib606"
                                    data-tab="pane-pcw-references">30</a>,<a class="tab-link" href="#bib607"
                                    data-tab="pane-pcw-references">31</a>) and associated significant morbidity. This
                                adverse effect was thought to occur because ACEi and neprilysin break down bradykinin,
                                which can directly or indirectly cause angioedema (<a class="tab-link" href="#bib607"
                                    data-tab="pane-pcw-references">31</a>,<a class="tab-link" href="#bib608"
                                    data-tab="pane-pcw-references">32</a>). An ARNi should not be administered within 36
                                hours of switching from or to an ACEi.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">8.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5320">Omapatrilat, a neprilysin inhibitor (as well as an ACEi and aminopeptidase P
                                inhibitor), was associated with a higher frequency of angioedema than that seen with
                                enalapril in an RCT of patients with HFrEF (<a class="tab-link" href="#bib606"
                                    data-tab="pane-pcw-references">30</a>). In a very large RCT of hypertensive
                                patients, omapatrilat was associated with a 3-fold increased risk of angioedema compared
                                with enalapril (<a class="tab-link" href="#bib607"
                                    data-tab="pane-pcw-references">31</a>). Black patients and patients who smoked were
                                particularly at risk. The high incidence of angioedema ultimately led to cessation of
                                the clinical development of omapatrilat (<a class="tab-link" href="#bib609"
                                    data-tab="pane-pcw-references">33</a>,<a class="tab-link" href="#bib610"
                                    data-tab="pane-pcw-references">34</a>). Because of these observations, angioedema
                                was an exclusion criterion in the first large trial assessing ARNi therapy in patients
                                with hypertension (<a class="tab-link" href="#bib611"
                                    data-tab="pane-pcw-references">35</a>) and then in the large trial that showed
                                clinical benefit of ARNi therapy in HFrEF (<a class="tab-link" href="#bib577"
                                    data-tab="pane-pcw-references">1</a>). The rates of angioedema were numerically
                                higher in patients treated with ARNi than in patients treated with ACEi in PARADIGM-HF,
                                although this difference did not reach significance (<a class="tab-link" href="#bib577"
                                    data-tab="pane-pcw-references">1</a>). ARNi therapy should not be administered in
                                patients with a history of angioedema because of the concern that it will increase the
                                risk of a recurrence of angioedema.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">9.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5325">Angioedema attributable to ACEi is thought to result from defective
                                degradation of the vasoactive peptides bradykinin, des-Arg9-BK (a metabolite of
                                bradykinin), and substance P (<a class="tab-link" href="#bib612"
                                    data-tab="pane-pcw-references">36</a>,<a class="tab-link" href="#bib613"
                                    data-tab="pane-pcw-references">37</a>). ACEi should not be administered to patients
                                with any history of angioedema, but ARB do not interfere as directly with bradykinin
                                metabolism and have been associated with low rates of angioedema (<a class="tab-link"
                                    href="#bib614" data-tab="pane-pcw-references">38</a>,<a class="tab-link"
                                    href="#bib615" data-tab="pane-pcw-references">39</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.3" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.3">
                <div id="acsectitle0275" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0275">7.3.2 Beta Blockers</h4>
            <div id="undtbl18" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl18">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0530">Recommendation for Beta Blockers</p>
                            <p id="tspara0535">Referenced studies that support the recommendation are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0415" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1415"><strong>In patients with HFrEF, with current or previous
                                                        symptoms, use of 1 of the 3 beta blockers proven to reduce
                                                        mortality (e.g., bisoprolol, carvedilol, sustained-release
                                                        metoprolol succinate) is recommended to reduce mortality and
                                                        hospitalizations</strong> (<a class="tab-link" href="#bib618"
                                                        data-tab="pane-pcw-references">1-3</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: High Value (A)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0420" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1420"><strong>In patients with HFrEF, with current or previous
                                                        symptoms, beta-blocker therapy provides high economic
                                                        value</strong> (<a class="tab-link" href="#bib621"
                                                        data-tab="pane-pcw-references">4-8</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5335"><strong>Synopsis</strong></p>
            <p id="p5340">Treatment with beta blockers reduces the risk of death and the combined risk of death or
                hospitalization in patients with HFrEF (<a class="tab-link" href="#bib618"
                    data-tab="pane-pcw-references">1-3</a>). In addition, this treatment can improve LVEF, lessen the
                symptoms of HF, and improve clinical status (<a class="tab-link" href="#bib618"
                    data-tab="pane-pcw-references">1-3</a>,<a class="tab-link" href="#bib626"
                    data-tab="pane-pcw-references">9-11</a>). Clinical trials have shown that beta blockers should be
                prescribed to all patients when HFrEF is diagnosed, including in-hospital, unless contraindicated or not
                tolerated (<a class="tab-link" href="#bib618" data-tab="pane-pcw-references">1-3</a>,<a class="tab-link"
                    href="#bib626" data-tab="pane-pcw-references">9-11</a>). These benefits of beta blockers were
                observed in patients with or without CAD, and in patients with or without diabetes, older patients, as
                well as in women and across racial and ethnic groups but not in patients with AF (<a class="tab-link"
                    href="#bib618" data-tab="pane-pcw-references">1-3</a>,<a class="tab-link" href="#bib627"
                    data-tab="pane-pcw-references">10-12</a>). Even if symptoms do not improve, long-term treatment
                should be maintained to reduce the risk of major cardiovascular events. Beta blockers should be
                initiated at low doses, and every effort should be made to achieve the target doses of the beta blockers
                shown to be effective in major clinical trials, as tolerated (<a class="tab-link" href="#bib618"
                    data-tab="pane-pcw-references">1-3</a>,<a class="tab-link" href="#bib626"
                    data-tab="pane-pcw-references">9</a>,<a class="tab-link" href="#bib627"
                    data-tab="pane-pcw-references">10</a>) (see <a class="ref sec" id="crosref5370"
                    href="#sec11.3.8">Section 7.3.8</a>, “GDMT Dosing, Sequencing and Uptitration”).</p>
            <p id="p5345"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1235" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5350">Three beta blockers have been shown to be effective in reducing the risk of
                                death in patients with HFrEF: bisoprolol, sustained-release metoprolol (succinate), and
                                carvedilol (<a class="tab-link" href="#bib618" data-tab="pane-pcw-references">1-3</a>).
                                The favorable findings with these 3 agents, however, should not be considered a
                                beta-blocker class effect in HFrEF. Other beta blockers are not included in this
                                recommendation for use (<a class="tab-link" href="#bib630"
                                    data-tab="pane-pcw-references">13-15</a>). Even when asymptomatic, or when symptoms
                                are mild or improve with other therapies, beta-blocker therapy is important and should
                                not be delayed until symptoms return or disease progression is documented (<a
                                    class="tab-link" href="#bib633" data-tab="pane-pcw-references">16</a>). Data show
                                that beta blockers can be safely initiated before hospital discharge, provided patients
                                are clinically stabilized and do not require intravenous inotropic therapy for HF (<a
                                    class="tab-link" href="#bib634" data-tab="pane-pcw-references">17</a>). If a
                                contraindication or intolerance are noted, they should be documented, and the patient
                                restarted on beta-blocker therapy in the future, so long as an absolute contraindication
                                is not present. Even if symptoms or LVEF improve, long-term treatment with beta blockers
                                and use of target doses should be maintained to reduce the risk of progression in LV
                                dysfunction or major cardiovascular events (<a class="tab-link" href="#bib635"
                                    data-tab="pane-pcw-references">18</a>,<a class="tab-link" href="#bib636"
                                    data-tab="pane-pcw-references">19</a>). Abrupt withdrawal of beta-blocker therapy
                                can lead to clinical deterioration and should be avoided unless indicated (<a
                                    class="tab-link" href="#bib635" data-tab="pane-pcw-references">18</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5355">Multiple analyses have shown the high value of beta-blocker therapy among HF
                                patients. A model-based analysis, using generic beta-blocker costs, found beta-blocker
                                therapy was high value (<a class="tab-link" href="#bib621"
                                    data-tab="pane-pcw-references">4</a>). These results were consistent with earlier
                                model-based cost-effectiveness analyses (<a class="tab-link" href="#bib622"
                                    data-tab="pane-pcw-references">5-7</a>) and a trial-based economic analysis of the
                                U.S. Carvedilol Heart Failure (CHF) Trials Program (<a class="tab-link" href="#bib625"
                                    data-tab="pane-pcw-references">8</a>). Each of these studies also found treatment
                                with a beta blocker was high value despite using previously higher beta-blocker costs.
                            </p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.3" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.3">
                <div id="acsectitle0280" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0280">7.3.3 Mineralocorticoid Receptor Antagonists (MRAs)
            </h4>
            <div id="undtbl19" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl19">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0540">Recommendations for Mineralocorticoid Receptor Antagonists (MRAs)</p>
                            <p id="tspara0545">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">1</td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0425" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1425"><strong>In patients with HFrEF and NYHA class II to IV
                                                        symptoms, an MRA (spironolactone or eplerenone) is recommended
                                                        to reduce morbidity and mortality, if eGFR is &gt;30 mL/min/1.73
                                                        m</strong><sup><strong>2</strong></sup> <strong>and serum
                                                        potassium is &lt;5.0 mEq/L. Careful monitoring of potassium,
                                                        renal function, and diuretic dosing should be performed at
                                                        initiation and closely monitored thereafter to minimize risk of
                                                        hyperkalemia and renal insufficiency</strong> (<a
                                                        class="tab-link" href="#bib637"
                                                        data-tab="pane-pcw-references">1-3</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: High Value (A)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0430" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1430"><strong>In patients with HFrEF and NYHA class II to IV
                                                        symptoms, MRA therapy provides high economic value</strong> (<a
                                                        class="tab-link" href="#bib640"
                                                        data-tab="pane-pcw-references">4-7</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0435" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1435"><strong>In patients taking MRA whose serum potassium
                                                        cannot be maintained at &lt;5.5 mEq/L, MRA should be
                                                        discontinued to avoid life-threatening hyperkalemia (</strong><a
                                                        class="tab-link" href="#bib644"
                                                        data-tab="pane-pcw-references"><strong>8</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib645"
                                                        data-tab="pane-pcw-references"><strong>9</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5365"><strong>Synopsis</strong></p>
            <p id="p5370">MRA (also known as aldosterone antagonists or anti-mineralocorticoids) show consistent
                improvements in all-cause mortality, HF hospitalizations, and SCD across a wide range of patients with
                HFrEF (<a class="tab-link" href="#bib637" data-tab="pane-pcw-references">1-3</a>). Patients at risk for
                renal dysfunction or hyperkalemia require close monitoring, and eGFR ≤30 mL/min/1.73 m<sup>2</sup> or
                serum potassium ≥5.0 mEq/L are contraindications to MRA initiation (<a class="tab-link" href="#bib646"
                    data-tab="pane-pcw-references">10</a>,<a class="tab-link" href="#bib647"
                    data-tab="pane-pcw-references">11</a>). Because of the higher selectivity of eplerenone for the
                aldosterone receptor, adverse effects such as gynecomastia and vaginal bleeding are observed less often
                in patients who take eplerenone than in those who take spironolactone.</p>
            <p id="p5375"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1240" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5380">Clinical trials taken on MRA together—RALES (Randomized Aldactone Evaluation
                                Study) (<a class="tab-link" href="#bib637" data-tab="pane-pcw-references">1</a>)
                                randomized highly symptomatic patients with LVEF ≤35%; EPHESUS (Eplerenone Post–Acute
                                Myocardial Infarction Heart Failure Efficacy and Survival Study) (<a class="tab-link"
                                    href="#bib638" data-tab="pane-pcw-references">2</a>) randomized patients post-MI
                                with LVEF ≤40%; and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and
                                Survival Study in Heart Failure) (<a class="tab-link" href="#bib639"
                                    data-tab="pane-pcw-references">3</a>) randomized patients with mild symptoms and
                                LVEF ≤30%—suggest a benefit of MRA across the spectrum of HFrEF, inclusive of a wide
                                range of etiologies and disease severities. Initiation in the ambulatory or hospital
                                setting is appropriate (<a class="tab-link" href="#bib648"
                                    data-tab="pane-pcw-references">12</a>). The starting dose of spironolactone and
                                eplerenone is 25 mg orally daily, increased to 50 mg daily orally after a month; for
                                eGFR 31 to 49 mL/min/1.73 m<sup>2</sup>, dosing should be reduced by half. Regular
                                checks of serum potassium levels and renal function should be performed according to
                                clinical status, approximately 1 week, then 4 weeks, then every 6 months after
                                initiating or intensifying MRA, with more frequent testing for clinical instability. We
                                elected to remove the 2013 recommendation “Aldosterone receptor antagonists are
                                recommended to reduce morbidity and mortality following an acute MI in patients who have
                                LVEF of 40% or less who develop symptoms of HF or who have a history of diabetes
                                mellitus, unless contraindicated” because the new recommendation covers the spectrum of
                                symptomatic patients with HF.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5385">The economic value of MRA therapy was assessed by both RCTs (RALES [<a
                                    class="tab-link" href="#bib641" data-tab="pane-pcw-references">5</a>] and EPHESUS
                                [<a class="tab-link" href="#bib642" data-tab="pane-pcw-references">6</a>,<a
                                    class="tab-link" href="#bib643" data-tab="pane-pcw-references">7</a>]) and a
                                model-based analysis (<a class="tab-link" href="#bib640"
                                    data-tab="pane-pcw-references">4</a>). The model-based analysis used generic MRA
                                costs and found therapy was high value with a cost per QALY of under $1000 (<a
                                    class="tab-link" href="#bib640" data-tab="pane-pcw-references">4</a>). The earlier
                                trial-based economic analyses of MRAs from RALES and EPHESUS also found MRA therapy was
                                high value despite using previously higher MRA costs (<a class="tab-link" href="#bib641"
                                    data-tab="pane-pcw-references">5-7</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5390">Spironolactone and eplerenone are partially excreted through the kidneys,
                                raising concerns about safety when eGFR is ≤30 mL/min/1.73 m<sup>2</sup> (<a
                                    class="tab-link" href="#bib646" data-tab="pane-pcw-references">10</a>,<a
                                    class="tab-link" href="#bib647" data-tab="pane-pcw-references">11</a>).
                                Spironolactone and eplerenone decrease renal potassium excretion, raising the risk of
                                hyperkalemia, particularly when MRA is initiated at serum potassium ≥5.0 mEq/L and
                                continued ≥5.5 mEq/L. The incidence of clinically significant hyperkalemia events was
                                &lt;1% in EPHESUS and EMPHASIS-HF, without a significant difference between eplerenone
                                and placebo (<a class="tab-link" href="#bib638" data-tab="pane-pcw-references">2</a>,<a
                                    class="tab-link" href="#bib639" data-tab="pane-pcw-references">3</a>); however, in
                                the closely monitored setting of a RCT with enrollment of younger patients with fewer
                                multiple chronic conditions than seen in the general HFrEF population, safety may be
                                overstated. Observational data have raised concerns about less favorable outcomes of MRA
                                use for HFrEF during usual care (<a class="tab-link" href="#bib644"
                                    data-tab="pane-pcw-references">8</a>,<a class="tab-link" href="#bib645"
                                    data-tab="pane-pcw-references">9</a>). Coadministration of MRA with ACEi or ARB
                                mildly increases the risk of hyperkalemia. Hyperkalemia risk was lower with ARNi in
                                patients with chronic HF in the PARADIGM-HF trial (<a class="tab-link" href="#bib649"
                                    data-tab="pane-pcw-references">13</a>) but not different in patients with HF who
                                were decompensated in the PIONEER-HF trial (<a class="tab-link" href="#bib650"
                                    data-tab="pane-pcw-references">14</a>) when compared with ACEi. Diarrhea causing
                                dehydration or loop diuretic therapy interruption, because of worsening renal function
                                or hyperkalemia, should be a consideration for temporarily holding the MRA. The
                                development of worsening renal function or hyperkalemia is often a reflection of acute
                                clinical change or progressive disease, prompting careful evaluation of the entire
                                medical regimen and other causes of hyperkalemia, in addition to holding the MRA. The
                                efficacy of the use of potassium binders (e.g., patiromer, sodium zirconium
                                cyclosilicate) to improve outcomes by facilitating continuation of MRA is uncertain (<a
                                    class="tab-link" href="#bib651" data-tab="pane-pcw-references">15</a>,<a
                                    class="tab-link" href="#bib652" data-tab="pane-pcw-references">16</a>) and is
                                addressed in <a class="ref sec" id="crosref5515" href="#sec11.3.6">Section 7.3.6</a>,
                                “Other Drug Treatment”.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.3" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.3">
                <div id="acsectitle0285" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0285">7.3.4 Sodium-Glucose Cotransporter 2 Inhibitors</h4>
            <div id="undtbl20" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl20">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0550">Recommendation for SGLT2i</p>
                            <p id="tspara0555">Referenced studies that support the recommendation are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0440" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1440"><strong>In patients with symptomatic chronic HFrEF, SGLT2i
                                                        are recommended to reduce hospitalization for HF and
                                                        cardiovascular mortality, irrespective of the presence of type 2
                                                        diabetes (</strong><a class="tab-link" href="#bib653"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib654"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: Intermediate Value (A)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0445" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1445"><strong>In patients with symptomatic chronic HFrEF, SGLT2i
                                                        therapy provides intermediate economic value (</strong><a
                                                        class="tab-link" href="#bib655"
                                                        data-tab="pane-pcw-references"><strong>3</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib656"
                                                        data-tab="pane-pcw-references"><strong>4</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5400"><strong>Synopsis</strong></p>
            <p id="p5405">Several RCTs in patients with type 2 diabetes and either established CVD or high risk for CVD
                have shown that SGLT2i prevent HF hospitalizations compared with placebo (<a class="tab-link"
                    href="#bib657" data-tab="pane-pcw-references">5-7</a>). The overall 31% reduction in HF
                hospitalizations was noted irrespective of the presence or absence of preexisting HF, although only 10%
                to 14% of participants had HF at baseline. The benefit appears independent of the glucose-lowering
                effects (<a class="tab-link" href="#bib660" data-tab="pane-pcw-references">8</a>). Therefore, several
                trials were launched to examine the efficacy of SGLT2i on outcomes in patients with HF, irrespective of
                the presence of type 2 diabetes. The DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart
                Failure) trial and EMPEROR-Reduced (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure
                With Reduced Ejection Fraction) showed the benefit of SGLT2i (dapagliflozin and empagliflozin,
                respectively) versus placebo on outcomes (median follow-up, 16–18 months) (<a class="tab-link"
                    href="#bib653" data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib654"
                    data-tab="pane-pcw-references">2</a>). Patients enrolled had symptomatic chronic HFrEF (LVEF ≤40%,
                NYHA class II to IV, and elevated natriuretic peptides) and were already on GDMT. Important exclusions
                were eGFR &lt;20 (EMPEROR-Reduced) or &lt;30 mL/min/1.73 m<sup>2</sup> (DAPA-HF), type 1 diabetes, or
                lower SBP &lt;95 to 100 mm Hg.</p>
            <p id="p5410"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1245" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5415">In the DAPA-HF and EMPEROR-Reduced trials, SGLT2i compared with placebo
                                reduced the composite of cardiovascular death or HF hospitalization by approximately 25%
                                (<a class="tab-link" href="#bib653" data-tab="pane-pcw-references">1</a>,<a
                                    class="tab-link" href="#bib654" data-tab="pane-pcw-references">2</a>,<a
                                    class="tab-link" href="#bib661" data-tab="pane-pcw-references">9</a>). The benefit
                                in reduction of HF hospitalization was greater (30%) in both trials (<a class="tab-link"
                                    href="#bib661" data-tab="pane-pcw-references">9</a>). Risk of cardiovascular death
                                was significantly lowered (18%) with dapagliflozin, as was risk of all-cause mortality
                                (17%). Although no significant cardiovascular mortality benefit was observed with
                                empagliflozin in a meta-analysis of DAPA-HF and EMPEROR-Reduced trials, SGLT2i therapy
                                was associated with a reduction in all-cause mortality and cardiovascular death (<a
                                    class="tab-link" href="#bib661" data-tab="pane-pcw-references">9</a>). The benefits
                                in both trials were seen irrespective of baseline diabetes status. Furthermore, serious
                                renal outcomes were less frequent, and the rate of decline in eGFR was slower in
                                patients treated with SGLT2i (<a class="tab-link" href="#bib653"
                                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib654"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib661"
                                    data-tab="pane-pcw-references">9</a>). In the SOLOIST-WHF (Effect of Sotagliflozin
                                on Cardiovascular Events in Patients With Type 2 Diabetes And Worsening Heart Failure)
                                trial, patients with diabetes and HF hospitalization (79%: LVEF, &lt;50%) were enrolled
                                before discharge or within 3 days of discharge. Sotagliflozin, a dual inhibitor of
                                sodium-glucose co-transporters 1 and 2, reduced the combined endpoint of cardiovascular
                                death, HF hospitalization, or urgent HF visits by 33% (<a class="tab-link"
                                    href="#bib662" data-tab="pane-pcw-references">10</a>) but has not been approved by
                                the U.S. Food and Drug Administration (FDA) as of 2021. Although SGLT2i increased risk
                                for genital infections, they were otherwise well tolerated in the trials. As the use of
                                SGLT2i is translated into clinical practice, caution is warranted for euglycemic
                                ketoacidosis, genital and soft tissue infections, and adjustment of diuretics, if
                                needed, to prevent volume depletion (<a class="tab-link" href="#bib663"
                                    data-tab="pane-pcw-references">11</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5420">Two model-based analyses evaluated the economic value of dapagliflozin therapy
                                compared with usual care based on the results of the DAPA-HF trial (<a class="tab-link"
                                    href="#bib655" data-tab="pane-pcw-references">3</a>,<a class="tab-link"
                                    href="#bib656" data-tab="pane-pcw-references">4</a>). Both analyses found costs per
                                QALY between $60,000 and $90,000, which is consistent with intermediate value according
                                to the benchmarks adopted for the current guideline. The results were most sensitive to
                                the magnitude of cardiovascular mortality reduction, with a ≥8% reduction in
                                cardiovascular mortality necessary for a cost per QALY below $150,000 in 1 study (<a
                                    class="tab-link" href="#bib655" data-tab="pane-pcw-references">3</a>). There are a
                                wide range of costs currently seen with dapagliflozin. These 2 analyses estimated a cost
                                per QALY below $50,000 with annual dapagliflozin costs of $3240 (43% reduction from main
                                analysis) and $2500 (40% reduction from main analysis), respectively (<a
                                    class="tab-link" href="#bib655" data-tab="pane-pcw-references">3</a>,<a
                                    class="tab-link" href="#bib656" data-tab="pane-pcw-references">4</a>). A smaller
                                reduction in drug cost would lead to a cost per QALY of under $60,000, the threshold for
                                high value in this guideline.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.3" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.3">
                <div id="acsectitle0290" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0290">7.3.5 Hydralazine and Isosorbide Dinitrate</h4>
            <div id="undtbl21" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl21">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0560">Recommendations for Hydralazine and Isosorbide Dinitrate</p>
                            <p id="tspara0565">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0450" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1450"><strong>For patients self-identified as African American
                                                        with NYHA class III-IV HFrEF who are receiving optimal medical
                                                        therapy, the combination of hydralazine and isosorbide dinitrate
                                                        is recommended to improve symptoms and reduce morbidity and
                                                        mortality (</strong><a class="tab-link" href="#bib664"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib665"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: High Value (B-NR)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0455" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1455"><strong>For patients self-identified as African American
                                                        with NYHA class III to IV HFrEF who are receiving optimal
                                                        medical therapy with ACEi or ARB, beta blockers, and MRA, the
                                                        combination of hydralazine and isosorbide dinitrate provides
                                                        high economic value</strong> (<a class="tab-link" href="#bib666"
                                                        data-tab="pane-pcw-references">3</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0460" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1460"><strong>In patients with current or previous symptomatic
                                                        HFrEF who cannot be given first-line agents, such as ARNi, ACEi,
                                                        or ARB, because of drug intolerance or renal insufficiency, a
                                                        combination of hydralazine and isosorbide dinitrate might be
                                                        considered to reduce morbidity and mortality (</strong><a
                                                        class="tab-link" href="#bib667"
                                                        data-tab="pane-pcw-references"><strong>4</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib668"
                                                        data-tab="pane-pcw-references"><strong>5</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5430"><strong>Synopsis</strong></p>
            <p id="p5435">Two RCTs, V-HeFT I (Vasodilator Heart Failure Trial) and A-HeFT (African-American Heart
                Failure Trial), established benefit of the combination of hydralazine-isosorbide dinitrate in
                self-identified African Americans (<a class="tab-link" href="#bib665"
                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib667"
                    data-tab="pane-pcw-references">4</a>). A-HeFT was terminated early because of evidence of remarkable
                benefit, but the result is vulnerable to a small number of events and the exigencies of early cessation
                of RCTs (<a class="tab-link" href="#bib665" data-tab="pane-pcw-references">2</a>). The benefit in both
                trials was seen only at doses achieved in those trials that are higher than doses typically used in
                clinical practice and with short-acting nitrate therapy (<a class="tab-link" href="#bib665"
                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib667"
                    data-tab="pane-pcw-references">4</a>). Uptake of this regimen has been modest as a result of the
                complexity of the medical regimen and the array of drug-related adverse effects (<a class="tab-link"
                    href="#bib668" data-tab="pane-pcw-references">5</a>). Even when prescribed, there is marked
                underusage based on very low prescription refill rates. Race-based medical therapy remains a challenging
                issue, as well, with ongoing research now focused on biological hypotheses, particularly absence of
                European ancestry, which may be associated with responsiveness to this combination. There are
                insufficient data to guide the use of hydralazine-isosorbide dinitrate with ARNi. In patients with HFrEF
                who cannot receive first-line agents such as ARNi, ACEi, or ARB, referral to a HF specialist can provide
                guidance for further management because the use of hydralazine and isosorbide dinitrate in these
                patients is uncertain.</p>
            <p id="p5440"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1250" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5445">In a large-scale trial that compared the vasodilator combination with placebo,
                                the use of hydralazine and isosorbide dinitrate reduced mortality in patients with HF
                                treated with digoxin and diuretics but not an ACEi or beta blocker (<a class="tab-link"
                                    href="#bib667" data-tab="pane-pcw-references">4</a>). However, in 2 other trials
                                that compared the vasodilator combination with an ACEi, the ACEi produced more favorable
                                effects on survival (<a class="tab-link" href="#bib669"
                                    data-tab="pane-pcw-references">6</a>,<a class="tab-link" href="#bib670"
                                    data-tab="pane-pcw-references">7</a>). A post hoc retrospective analysis of these
                                vasodilator trials showed particular efficacy of isosorbide dinitrate and hydralazine in
                                the African American cohort (<a class="tab-link" href="#bib664"
                                    data-tab="pane-pcw-references">1</a>). In a subsequent trial, which was limited to
                                patients self-identified as African American, the addition of a fixed-dose combination
                                of hydralazine and isosorbide dinitrate to standard therapy with an ACEi or ARB, a beta
                                blocker, and MRA offered significant benefit (<a class="tab-link" href="#bib665"
                                    data-tab="pane-pcw-references">2</a>). Thus, the combination of hydralazine and
                                isosorbide dinitrate is appropriate for African Americans with HFrEF who remain
                                symptomatic despite concomitant use of ACEi (or ARB), beta blockers, and MRA. There are
                                insufficient data for concomitant use with ARNi.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5450">The economic value of hydralazine and isosorbide nitrate therapy was assessed
                                by the A-HeFT trial (<a class="tab-link" href="#bib666"
                                    data-tab="pane-pcw-references">3</a>). This analysis found hydralazine and
                                isosorbide dinitrate increased survival and reduced health care costs over the
                                12.8-month trial. Extrapolating beyond the trial, the analysis found hydralazine and
                                isosorbide dinitrate remained high value over a lifetime with a cost per life-year
                                &lt;$60,000 despite conservative assumptions regarding the durability of therapy
                                effectiveness and previously higher hydralazine and isosorbide dinitrate costs.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5455">It is unclear if a benefit of hydralazine-isosorbide dinitrate (suggested in a
                                trial before the use of ACEi) (<a class="tab-link" href="#bib667"
                                    data-tab="pane-pcw-references">4</a>) exists for non–African Americans with HFrEF.
                                Despite the lack of data with the vasodilator combination in patients who are intolerant
                                of ACEi or ARB, especially those with renal insufficiency, the combined use of
                                hydralazine and isosorbide dinitrate might be considered as a therapeutic option in such
                                patients. Although the potential benefit is unknown and has not been shown in recent
                                observational datasets (<a class="tab-link" href="#bib668"
                                    data-tab="pane-pcw-references">5</a>), in V-HeFT I, the use of hydralazine and
                                isosorbide dinitrate reduced mortality in patients with HF treated with digoxin and
                                diuretics, compared with placebo (<a class="tab-link" href="#bib667"
                                    data-tab="pane-pcw-references">4</a>). If patients are unable to tolerate first-line
                                agents, such as ARNi, ACEi, or ARB, because of drug intolerance, hypotension, or renal
                                insufficiency, referral to a HF specialist can provide guidance for further management,
                                and the use of hydralazine and isosorbide dinitrate in these patients might be
                                considered.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.3" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.3">
                <div id="acsectitle0295" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0295">7.3.6 Other Drug Treatment</h4>
            <div id="undtbl22" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl22">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0570">Recommendations for Other Drug Treatment</p>
                            <p id="tspara0575">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0465" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1465"><strong>In patients with HF class II to IV symptoms,
                                                        omega-3 polyunsaturated fatty acid (PUFA) supplementation may be
                                                        reasonable to use as adjunctive therapy to reduce mortality and
                                                        cardiovascular hospitalizations</strong> (<a class="tab-link"
                                                        href="#bib671"
                                                        data-tab="pane-pcw-references">1-4</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0470" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1470"><strong>In patients with HF who experience hyperkalemia
                                                        (serum potassium level ≥5.5 mEq/L) while taking a
                                                        renin-angiotensin-aldosterone system inhibitor (RAASi), the
                                                        effectiveness of potassium binders (patiromer, sodium zirconium
                                                        cyclosilicate) to improve outcomes by facilitating continuation
                                                        of RAASi therapy is uncertain (</strong><a class="tab-link"
                                                        href="#bib675"
                                                        data-tab="pane-pcw-references"><strong>5</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib676"
                                                        data-tab="pane-pcw-references"><strong>6</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: No Benefit</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0475" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1475"><strong>In patients with chronic HFrEF without a specific
                                                        indication (e.g., venous thromboembolism [VTE], AF, a previous
                                                        thromboembolic event, or a cardioembolic source),
                                                        anticoagulation is not recommended (</strong><a class="tab-link"
                                                        href="#bib677"
                                                        data-tab="pane-pcw-references"><strong>7-9</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5470"><strong>Synopsis</strong></p>
            <p id="p5475">Trials in prevention of CVD, including HF, showed that omega-3 PUFA supplementation results in
                a 10% to 20% risk reduction in fatal and nonfatal cardiovascular events when used with other
                evidence-based therapies (<a class="tab-link" href="#bib672" data-tab="pane-pcw-references">2</a>,<a
                    class="tab-link" href="#bib673" data-tab="pane-pcw-references">3</a>,<a class="tab-link"
                    href="#bib680" data-tab="pane-pcw-references">10</a>). Hyperkalemia is common in HF and can lead to
                arrhythmias and underuse of GDMT (<a class="tab-link" href="#bib681"
                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib682"
                    data-tab="pane-pcw-references">12</a>). Two newer gastrointestinal potassium-binding
                agents—patiromer and sodium zirconium cyclosilicate—have been shown to lower potassium levels and enable
                treatment with a RAASi in patients with HF (<a class="tab-link" href="#bib675"
                    data-tab="pane-pcw-references">5</a>,<a class="tab-link" href="#bib676"
                    data-tab="pane-pcw-references">6</a>,<a class="tab-link" href="#bib683"
                    data-tab="pane-pcw-references">13</a>).</p>
            <p id="p5480"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1255" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5485">Supplementation with omega-3 PUFA has been evaluated as an adjunctive therapy
                                for CVD and HF (<a class="tab-link" href="#bib684"
                                    data-tab="pane-pcw-references">14</a>). The GISSI-HF (Effect of n-3 polyunsaturated
                                fatty acids in patients with chronic heart failure) trial showed a reduction in death
                                among post-MI patients taking 1 g of omega-3 PUFA (850–882 mg of eicosapentaenoic acid
                                [EPA] and docosahexaenoic acid [DHA] as ethyl esters in the ratio of 1:1.2) (<a
                                    class="tab-link" href="#bib680" data-tab="pane-pcw-references">10</a>). A post hoc
                                subgroup analysis revealed that this reduction in mortality and SCD was concentrated in
                                the approximately 2000 patients with reduced LVEF (<a class="tab-link" href="#bib680"
                                    data-tab="pane-pcw-references">10</a>). The GISSI-HF investigators randomized
                                symptomatic patients with HF to 1 g daily of omega-3 PUFA (850–882 mg of EPA-DHA) or
                                placebo. Death from any cause was reduced from 29% with placebo to 27% in those treated
                                with omega-3 PUFA (<a class="tab-link" href="#bib672"
                                    data-tab="pane-pcw-references">2</a>). The outcome of death or admission to hospital
                                for a cardiovascular event was also significantly reduced. The REDUCE-IT trial
                                randomized patients with established CVD or diabetes with risk factors to 2 g of
                                icosapent ethyl (a highly purified EPA) twice daily or placebo and showed a reduced risk
                                for the composite of cardiovascular death, nonfatal MI, nonfatal stroke, coronary
                                revascularization, or unstable angina (<a class="tab-link" href="#bib673"
                                    data-tab="pane-pcw-references">3</a>). In reported studies, omega-3 PUFA therapy has
                                been well tolerated. Recent studies have reported that in patients with cardiovascular
                                risk treated with omega-3 fatty acid, there may be a dose-related risk of AF (<a
                                    class="tab-link" href="#bib673" data-tab="pane-pcw-references">3</a>,<a
                                    class="tab-link" href="#bib685" data-tab="pane-pcw-references">15</a>,<a
                                    class="tab-link" href="#bib686" data-tab="pane-pcw-references">16</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5490">Hyperkalemia is common in HF as a result of the syndrome itself, comorbidities
                                (diabetes, CKD), and use of RAASi, and can increase the risk for ventricular arrhythmias
                                and mortality (<a class="tab-link" href="#bib681"
                                    data-tab="pane-pcw-references">11</a>). Hyperkalemia results in dose reductions or
                                discontinuation of RAASi, compromising their cardiorenal benefit in HF (<a
                                    class="tab-link" href="#bib682" data-tab="pane-pcw-references">12</a>). Two newer
                                gastrointestinal potassium binders—patiromer (RLY5016) and sodium zirconium
                                cyclosilicate (SZC)—remove potassium by exchanging cations (calcium for patiromer, and
                                sodium and hydrogen for SZC), leading to increased fecal excretion. Both agents have
                                been FDA approved for treatment of hyperkalemia for patients receiving RAASi. In the
                                PEARL-HF (Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder
                                in patients with chronic heart failure) trial, patiromer led to lower potassium levels,
                                less hyperkalemia, and a higher proportion of patients able to increase spironolactone
                                dose to 50 mg daily compared with placebo (<a class="tab-link" href="#bib675"
                                    data-tab="pane-pcw-references">5</a>). The HARMONIZE (Hyperkalemia Randomized
                                Intervention Multidose ZS-9 Maintenance) trial included 94 patients (out of 258 total)
                                with HF (87 of whom entered the double-blind phase) (<a class="tab-link" href="#bib676"
                                    data-tab="pane-pcw-references">6</a>,<a class="tab-link" href="#bib683"
                                    data-tab="pane-pcw-references">13</a>). The SZC groups achieved lower potassium
                                levels overall compared with placebo, and a higher proportion maintained normokalemia
                                (potassium levels, &lt;5.1 mEq/L). Whether patiromer or SZC improve clinical outcomes is
                                under investigation. Adverse effects for the newer potassium binders include
                                hypomagnesemia (for patiromer) and edema (for SZC).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5495">In several retrospective analyses, the risk of thromboembolic events was not
                                lower in patients with HF taking warfarin than in patients not treated with
                                antithrombotic drugs (<a class="tab-link" href="#bib687"
                                    data-tab="pane-pcw-references">17-19</a>). The use of warfarin was associated with a
                                reduction in major cardiovascular events and death in patients with HF in some studies
                                but not in others (<a class="tab-link" href="#bib690"
                                    data-tab="pane-pcw-references">20-22</a>). An RCT that compared the outcome of
                                patients with HFrEF assigned to aspirin, warfarin, or clopidogrel found that no therapy
                                was superior (<a class="tab-link" href="#bib677" data-tab="pane-pcw-references">7</a>).
                                Another trial that compared aspirin with warfarin in patients with reduced LVEF, sinus
                                rhythm, and no cardioembolic source showed no difference in either the primary outcome
                                of death, stroke, or intracerebral hemorrhage, and no difference in the combined outcome
                                of death, ischemic stroke, intracerebral hemorrhage, MI, or HF hospitalization (<a
                                    class="tab-link" href="#bib678" data-tab="pane-pcw-references">8</a>). There was a
                                significant increase in major bleeding with warfarin. A trial of rivaroxaban in patients
                                with HFrEF, CAD, and normal sinus rhythm showed no difference in mortality, MI, and
                                stroke compared with placebo (<a class="tab-link" href="#bib679"
                                    data-tab="pane-pcw-references">9</a>). Therefore, there is no evidence of benefit
                                for anticoagulation in HF patients without a specific indication (e.g., VTE, AF, a
                                previous thromboembolic event, or a cardioembolic source).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.3" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.3">
                <div id="acsectitle0300" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0300">7.3.7 Drugs of Unproven Value or That May Worsen HF
            </h4>
            <div id="undtbl23" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl23">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0580">Recommendations for Drugs of Unproven Value or Drugs That May Worsen HF
                            </p>
                            <p id="tspara0585">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: No Benefit</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0480" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1480"><strong>In patients with HFrEF, dihydropyridine calcium
                                                        channel-blocking drugs are not recommended treatment for HF
                                                        (</strong><a class="tab-link" href="#bib693"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib694"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: No Benefit</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0485" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1485"><strong>In patients with HFrEF, vitamins, nutritional
                                                        supplements, and hormonal therapy are not recommended other than
                                                        to correct specific deficiencies</strong> (<a class="tab-link"
                                                        href="#bib695"
                                                        data-tab="pane-pcw-references">3-9</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0490" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1490"><strong>In patients with HFrEF, nondihydropyridine calcium
                                                        channel-blocking drugs are not recommended</strong> (<a
                                                        class="tab-link" href="#bib702"
                                                        data-tab="pane-pcw-references">10-13</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0495" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1495"><strong>In patients with HFrEF, class IC antiarrhythmic
                                                        medications and dronedarone may increase the risk of
                                                        mortality</strong> (<a class="tab-link" href="#bib706"
                                                        data-tab="pane-pcw-references">14-16</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0500" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1500"><strong>In patients with HFrEF, thiazolidinediones
                                                        increase the risk of worsening HF symptoms and
                                                        hospitalizations</strong> (<a class="tab-link" href="#bib709"
                                                        data-tab="pane-pcw-references">17-21</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0510" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">6.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1510"><strong>In patients with type 2 diabetes and high
                                                        cardiovascular risk, the dipeptidyl peptidase-4 (DPP-4)
                                                        inhibitors saxagliptin and alogliptin increase the risk of HF
                                                        hospitalization and should be avoided in patients with
                                                        HF</strong> (<a class="tab-link" href="#bib714"
                                                        data-tab="pane-pcw-references">22-24</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0505" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">7.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1505"><strong>In patients with HFrEF, NSAIDs worsen HF symptoms
                                                        and should be avoided or withdrawn whenever possible</strong>
                                                    (<a class="tab-link" href="#bib717"
                                                        data-tab="pane-pcw-references">25-28</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5505"><strong>Synopsis</strong></p>
            <p id="p5510">Although there is strong evidence for benefit with selected medications for HFrEF as outlined
                in <a class="ref sec" id="crosref5805" href="#sec11.3">Section 7.3</a>, “Pharmacological Treatment for
                HF With Reduced Ejection Fraction (HFrEF)”, there remain several classes of medications that have either
                unproven value or potential for harm (<a class="ref showTableEvent" data-id="tbl13" href="#tbl13">Table
                    13</a>). These recommendations are not exhaustive but focus on the most relevant and commonly
                encountered medications in the management of patients with HFrEF: calcium channel blockers;
                antiarrhythmic agents; NSAIDs; medications for treatment of type 2 diabetes including thiazolidinediones
                and DPP-4 inhibitors; and vitamins, hormones, and nutritional supplements.</p>
            <div id="tbl13" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl13">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0125"><span class="captionLabel">Table 13</span> Selected Prescription
                                Medications That May Cause or Exacerbate HF</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="2">Drug or Therapeutic Class</th>
                            <th colspan="2" rowspan="1">Associated With HF</th>
                            <th colspan="1" rowspan="2">Magnitude of HF Induction or Precipitation</th>
                            <th colspan="1" rowspan="2">LOE for HF Induction or Precipitation</th>
                            <th colspan="1" rowspan="2">Possible Mechanism(s)</th>
                            <th colspan="1" rowspan="2">Onset</th>
                        </tr>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Causes Direct Myocardial Toxicity</th>
                            <th colspan="1" rowspan="1">Exacerbates Underlying Myocardial Dysfunction</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">COX, nonselective inhibitors (NSAIDs)</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Major</td>
                            <td align="center" colspan="1" rowspan="1">B</td>
                            <td align="center" colspan="1" rowspan="2">Prostaglandin inhibition leading to sodium and
                                water retention, increased systemic vascular resistance, and blunted response to
                                diuretics</td>
                            <td align="center" colspan="1" rowspan="2">Immediate</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">COX, selective inhibitors (COX-2 inhibitors)</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Major</td>
                            <td align="center" colspan="1" rowspan="1">B</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Thiazolidinediones</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Major</td>
                            <td align="center" colspan="1" rowspan="1">A</td>
                            <td align="center" colspan="1" rowspan="1">Possible calcium channel blockade</td>
                            <td align="center" colspan="1" rowspan="1">Intermediate</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Saxagliptin</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Major</td>
                            <td align="center" colspan="1" rowspan="1">A</td>
                            <td align="center" colspan="1" rowspan="2">Unknown</td>
                            <td align="center" colspan="1" rowspan="2">Intermediate to delayed</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Alogliptin</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Major</td>
                            <td align="center" colspan="1" rowspan="1">A</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Flecainide</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Major</td>
                            <td align="center" colspan="1" rowspan="1">A</td>
                            <td align="center" colspan="1" rowspan="1">Negative inotrope, proarrhythmic effects</td>
                            <td align="center" colspan="1" rowspan="1">Immediate to intermediate</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Disopyramide</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Major</td>
                            <td align="center" colspan="1" rowspan="1">B</td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Sotalol</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Major</td>
                            <td align="center" colspan="1" rowspan="1">A</td>
                            <td align="center" colspan="1" rowspan="1">Proarrhythmic properties, beta blockade</td>
                            <td align="center" colspan="1" rowspan="1">Immediate to intermediate</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Dronedarone</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Major</td>
                            <td align="center" colspan="1" rowspan="1">A</td>
                            <td align="center" colspan="1" rowspan="1">Negative inotrope</td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Alpha-1 blockers</strong></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Doxazosin</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Moderate</td>
                            <td align="center" colspan="1" rowspan="1">B</td>
                            <td align="center" colspan="1" rowspan="1">Beta-1-receptor stimulation with increases in
                                renin and aldosterone</td>
                            <td align="center" colspan="1" rowspan="1">Intermediate to delayed</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Diltiazem</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Major</td>
                            <td align="center" colspan="1" rowspan="1">B</td>
                            <td align="center" colspan="1" rowspan="1">Negative inotrope</td>
                            <td align="center" colspan="1" rowspan="1">Immediate to intermediate</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Verapamil</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Major</td>
                            <td align="center" colspan="1" rowspan="1">B</td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Nifedipine</td>
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">Moderate</td>
                            <td align="center" colspan="1" rowspan="1">C</td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0130">COX indicates cyclo-oxygenase; HF, heart failure; LOE, Level of Evidence;
                                and NSAID, nonsteroidal anti-inflammatory drug.</p>
                            <p id="tspara0135">Adapted from Page RL 2nd et al. (<a class="tab-link" href="#bib749"
                                    data-tab="pane-pcw-references">57</a>). Copyright 2016 American Heart Association
                                Inc.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p5515"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1260" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5520">Second-generation dihydropyridine calcium channel blockers, including
                                amlodipine and felodipine, have greater selectivity for calcium channels in vascular
                                smooth muscle cells and less myocardial depressant activity. By reducing peripheral
                                vasoconstriction and LV afterload, calcium channel blockers were thought to have a
                                potential role in the management of chronic HF. The PRAISE-1 (Prospective Randomized
                                Amlodipine Survival Evaluation-1) study showed a reduction in mortality in the subgroup
                                of patients with nonischemic cardiomyopathy who received amlodipine (<a class="tab-link"
                                    href="#bib693" data-tab="pane-pcw-references">1</a>). However, in the PRAISE-2
                                (Prospective Randomized Amlodipine Survival Evaluation 2) trial, which enrolled only
                                patients with nonischemic cardiomyopathy, no survival benefit was observed, indicating
                                the limitations of conclusions derived from subgroup analyses (<a class="tab-link"
                                    href="#bib721" data-tab="pane-pcw-references">29</a>). However, dihydropyridine
                                calcium channel blockers may be used for treatment of hypertension in patients who have
                                elevated blood pressure despite optimization of GDMT.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5525">Many nutritional supplements and hormonal therapies have been proposed for the
                                treatment of HF (<a class="tab-link" href="#bib695"
                                    data-tab="pane-pcw-references">3-9</a>,<a class="tab-link" href="#bib722"
                                    data-tab="pane-pcw-references">30</a>,<a class="tab-link" href="#bib723"
                                    data-tab="pane-pcw-references">31</a>). Ultimately, most studies are limited by
                                small sample sizes, surrogate endpoints, or nonrandomized design (<a class="tab-link"
                                    href="#bib724" data-tab="pane-pcw-references">32</a>,<a class="tab-link"
                                    href="#bib725" data-tab="pane-pcw-references">33</a>). In addition, adverse effects
                                and drug-nutraceutical interactions remain unresolved. There is a lack of evidence of
                                benefit from vitamin D (<a class="tab-link" href="#bib695"
                                    data-tab="pane-pcw-references">3-5</a>), thiamine (<a class="tab-link"
                                    href="#bib726" data-tab="pane-pcw-references">34-36</a>), carnitine (<a
                                    class="tab-link" href="#bib729" data-tab="pane-pcw-references">37</a>), and taurine
                                (<a class="tab-link" href="#bib730" data-tab="pane-pcw-references">38</a>,<a
                                    class="tab-link" href="#bib731" data-tab="pane-pcw-references">39</a>) and potential
                                harm from vitamin E (<a class="tab-link" href="#bib698"
                                    data-tab="pane-pcw-references">6</a>,<a class="tab-link" href="#bib699"
                                    data-tab="pane-pcw-references">7</a>). The largest RCT of coenzyme Q10—Q-SYMBIO
                                (Coenzyme Q10 as adjunctive treatment of chronic heart failure with focus on SYMptoms,
                                BIomarker status [Brain-Natriuretic Peptide], and long-term Outcome
                                [hospitalisations/mortality])—showed no changes in NYHA functional classification at 16
                                weeks, although the incidence of major adverse cardiovascular events at 2 years was
                                significantly reduced (hazard ratio, 0.50; 95% CI, 0.32-0.80; <i>P</i>=0.003) (<a
                                    class="tab-link" href="#bib700" data-tab="pane-pcw-references">8</a>). Despite these
                                findings, concerns about slow recruitment in this trial have tempered enthusiasm for
                                coenzyme Q10 supplementation in clinical practice (<a class="tab-link" href="#bib701"
                                    data-tab="pane-pcw-references">9</a>,<a class="tab-link" href="#bib723"
                                    data-tab="pane-pcw-references">31</a>). Hormonal therapies have been proposed for
                                the treatment of HF, but trials have shown a neutral effect of testosterone (<a
                                    class="tab-link" href="#bib732" data-tab="pane-pcw-references">40</a>,<a
                                    class="tab-link" href="#bib733" data-tab="pane-pcw-references">41</a>), growth
                                hormone (<a class="tab-link" href="#bib722" data-tab="pane-pcw-references">30</a>,<a
                                    class="tab-link" href="#bib734" data-tab="pane-pcw-references">42</a>), and thyroid
                                hormone (<a class="tab-link" href="#bib735" data-tab="pane-pcw-references">43-45</a>) in
                                HF outcomes.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5530">Nondihydropyridine calcium channel blockers—diltiazem and verapamil—are
                                myocardial depressants and generally not well tolerated in HF. Verapamil had no impact
                                of survival or major cardiac events post-MI, including in those patients with HFrEF
                                after acute MI (<a class="tab-link" href="#bib702"
                                    data-tab="pane-pcw-references">10</a>). In patients with nonischemic cardiomyopathy,
                                diltiazem had no impact on mortality (<a class="tab-link" href="#bib705"
                                    data-tab="pane-pcw-references">13</a>) but, in HFrEF after acute MI, diltiazem was
                                associated with a higher risk of recurrent HF (<a class="tab-link" href="#bib703"
                                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib704"
                                    data-tab="pane-pcw-references">12</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5535">In the CAST (Cardiac Arrhythmia Suppression) trial, patients with asymptomatic
                                ventricular arrhythmias post-MI on the class IC antiarrhythmics encainide or flecainide
                                had increased mortality (<a class="tab-link" href="#bib706"
                                    data-tab="pane-pcw-references">14</a>). The applicability of CAST to patients
                                without recent MI or to other class I antiarrhythmic drugs is uncertain, but class IC
                                antiarrhythmic agents are generally avoided in patients with structural heart disease.
                                In ANDROMEDA (Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating
                                Morbidity Decrease Study), for the class III antiarrhythmic dronedarone, patients with
                                HFrEF who were hospitalized had increased mortality (<a class="tab-link" href="#bib708"
                                    data-tab="pane-pcw-references">16</a>). In the SWORD (Survival With ORal D-sotalol)
                                trial of the class III antiarrhythmic sotalol, patients with HF post-MI had increased
                                mortality (<a class="tab-link" href="#bib707" data-tab="pane-pcw-references">15</a>).
                                However, SWORD was published in 1996, and whether sotalol would be harmful in the
                                current era of GDMT and ICDs is uncertain; sotalol may be used for refractory
                                atrial-ventricular arrhythmias with close monitoring for decompensation. Amiodarone (<a
                                    class="tab-link" href="#bib738" data-tab="pane-pcw-references">46</a>,<a
                                    class="tab-link" href="#bib739" data-tab="pane-pcw-references">47</a>) and
                                dofetilide (<a class="tab-link" href="#bib740" data-tab="pane-pcw-references">48</a>,<a
                                    class="tab-link" href="#bib741" data-tab="pane-pcw-references">49</a>) are the only
                                antiarrhythmic agents with neutral effects on mortality in clinical trials of patients
                                with HFrEF. Class IA antiarrhythmic agents such as quinidine and class IB agents such as
                                mexiletine have not been studied and may be indicated for the management of refractory
                                ventricular arrhythmias in the context of the individual patient’s risk benefit calculus
                                and in conjunction with electrophysiology consultation.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5540">Thiazolidinediones increase insulin sensitivity by activating nuclear
                                peroxisome proliferator-activated receptor gamma (PPAR-γ). Expressed in virtually all
                                tissues, PPAR-γ also regulates sodium reabsorption in the collecting ducts of the
                                kidney. In observational cohort studies (<a class="tab-link" href="#bib709"
                                    data-tab="pane-pcw-references">17</a>), meta-analysis (<a class="tab-link"
                                    href="#bib710" data-tab="pane-pcw-references">18</a>), and clinical trials (<a
                                    class="tab-link" href="#bib711" data-tab="pane-pcw-references">19-21</a>),
                                thiazolidinediones have been associated with increased incidence of fluid retention and
                                HF events in those patients with (<a class="tab-link" href="#bib711"
                                    data-tab="pane-pcw-references">19</a>,<a class="tab-link" href="#bib713"
                                    data-tab="pane-pcw-references">21</a>) or without (<a class="tab-link"
                                    href="#bib710" data-tab="pane-pcw-references">18</a>,<a class="tab-link"
                                    href="#bib712" data-tab="pane-pcw-references">20</a>) a previous history of HF.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">6.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5550">DPP-4 is a cell-surface enzyme that deactivates several peptides include
                                glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1. DPP-4
                                inhibitors affect glucose regulation through multiple mechanisms, including enhancement
                                of glucose-dependent insulin secretion, slowed gastric emptying, and reduction of
                                postprandial glucagon and of food intake. The impact of DPP-4 inhibitors on
                                cardiovascular outcomes in patients with diabetes and high cardiovascular risk has been
                                assessed in multiple RCTs. Saxagliptin increased the risk of hospitalization for HF (<a
                                    class="tab-link" href="#bib714" data-tab="pane-pcw-references">22</a>), as did
                                alogliptin in a post hoc analysis including only patients with no HF history (<a
                                    class="tab-link" href="#bib715" data-tab="pane-pcw-references">23</a>,<a
                                    class="tab-link" href="#bib742" data-tab="pane-pcw-references">50</a>), but
                                sitagliptin (<a class="tab-link" href="#bib743" data-tab="pane-pcw-references">51</a>,<a
                                    class="tab-link" href="#bib744" data-tab="pane-pcw-references">52</a>) and
                                linagliptin (<a class="tab-link" href="#bib745"
                                    data-tab="pane-pcw-references">53-55</a>) did not; these findings may have been a
                                result of baseline differences in the use of metformin, thiazolidinediones, and insulin,
                                which also affect HF risk. The FDA recommends discontinuation specifically of
                                saxagliptin and alogliptin in patients who develop HF (<a class="tab-link"
                                    href="#bib748" data-tab="pane-pcw-references">56</a>), and whether the risk of
                                worsening HF is a class effect of DPP-4 inhibitors is unclear.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">7.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5545">NSAIDs inhibit the synthesis of renal prostaglandins, which mediate
                                vasodilation in the kidneys and directly inhibit sodium resorption in the thick
                                ascending loop of Henle and collecting tubule. Hence, NSAIDs can cause sodium and water
                                retention and blunt the effects of diuretics. Several observational cohort studies have
                                revealed increased morbidity and mortality in patients with HF using either nonselective
                                or selective NSAIDs (<a class="tab-link" href="#bib717"
                                    data-tab="pane-pcw-references">25-28</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.3" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.3">
                <div id="acsectitle0305" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0305">7.3.8 GDMT Dosing: Sequencing and Uptitration</h4>
            <div id="undtbl24" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl24">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0590">Recommendations for GDMT Dosing: Sequencing and Uptitration</p>
                            <p id="tspara0595">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0515" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1515"><strong>In patients with HFrEF, titration of
                                                        guideline-directed medication dosing to achieve target doses
                                                        showed to be efficacious in RCTs is recommended, to reduce
                                                        cardiovascular mortality and HF hospitalizations, unless not
                                                        well tolerated</strong> (<a class="tab-link" href="#bib750"
                                                        data-tab="pane-pcw-references">1-10</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-EO</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0520" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1520"><strong>In patients with HFrEF, titration and optimization
                                                        of guideline-directed medications as frequently as every 1 to 2
                                                        weeks depending on the patient’s symptoms, vital signs, and
                                                        laboratory findings can be useful to optimize
                                                        management.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5565"><strong>Synopsis</strong></p>
            <p id="p5570">Clinical trials of ACEi, ARB, ARNi, beta blockers, and most other HFrEF medications had
                therapy initiated at low dose by trial protocol (<a class="tab-link" href="#bib750"
                    data-tab="pane-pcw-references">1-9</a>,<a class="tab-link" href="#bib760"
                    data-tab="pane-pcw-references">11-14</a>). If the initial dose was tolerated, the protocol would
                then direct the uptitration of medication dose over time to a specified target dose (<a
                    class="ref showTableEvent" data-id="tbl14" href="#tbl14">Table 14</a>), unless not well tolerated.
                Even if symptoms improved or other indicators of response were shown at lower doses, the medication dose
                would still be increased to the trial-defined target doses. Because these target doses were the ones
                that established the efficacy and safety of these medications in HFrEF and serve as the basis of the
                guideline recommendations (<a class="ref showTableEvent" data-id="tbl15" href="#tbl15">Table 15</a>),
                use of these target doses is recommended, if tolerated (<a class="tab-link" href="#bib750"
                    data-tab="pane-pcw-references">1-9</a>,<a class="tab-link" href="#bib760"
                    data-tab="pane-pcw-references">11-14</a>). Use of all 4 drug classes has been estimated to reduce
                all-cause mortality by 73% compared with no treatment (<a class="tab-link" href="#bib764"
                    data-tab="pane-pcw-references">15</a>).</p>
            <div id="tbl14" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl14">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0140"><span class="captionLabel">Table 14</span> Drugs Commonly Used for HFrEF
                                (Stage C HF)</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Drug</th>
                            <th colspan="1" rowspan="1">Initial Daily Dose(s)</th>
                            <th colspan="1" rowspan="1">Target Doses(s)</th>
                            <th colspan="1" rowspan="1">Mean Doses Achieved in Clinical Trials</th>
                            <th colspan="1" rowspan="1">References</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="5" rowspan="1"><strong>ACEi</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Captopril</td>
                            <td align="center" colspan="1" rowspan="1">6.25 mg 3 times daily</td>
                            <td align="center" colspan="1" rowspan="1">50 mg 3 times daily</td>
                            <td align="center" colspan="1" rowspan="1">122.7 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib768"
                                    data-tab="pane-pcw-references">19</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Enalapril</td>
                            <td align="center" colspan="1" rowspan="1">2.5 mg twice daily</td>
                            <td align="center" colspan="1" rowspan="1">10–20 mg twice daily</td>
                            <td align="center" colspan="1" rowspan="1">16.6 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib752"
                                    data-tab="pane-pcw-references">3</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Fosinopril</td>
                            <td align="center" colspan="1" rowspan="1">5–10 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">40 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">NA</td>
                            <td align="center" colspan="1" rowspan="1">…</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Lisinopril</td>
                            <td align="center" colspan="1" rowspan="1">2.5–5 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">20–40 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">32.5–35.0 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib766"
                                    data-tab="pane-pcw-references">17</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Perindopril</td>
                            <td align="center" colspan="1" rowspan="1">2 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">8–16 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">NA</td>
                            <td align="center" colspan="1" rowspan="1">…</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Quinapril</td>
                            <td align="center" colspan="1" rowspan="1">5 mg twice daily</td>
                            <td align="center" colspan="1" rowspan="1">20 mg twice daily</td>
                            <td align="center" colspan="1" rowspan="1">NA</td>
                            <td align="center" colspan="1" rowspan="1">…</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Ramipril</td>
                            <td align="center" colspan="1" rowspan="1">1.25–2.5 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">10 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">NA</td>
                            <td align="center" colspan="1" rowspan="1">…</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Trandolapril</td>
                            <td align="center" colspan="1" rowspan="1">1 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">4 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">NA</td>
                            <td align="center" colspan="1" rowspan="1">…</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="5" rowspan="1"><strong>ARB</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Candesartan</td>
                            <td align="center" colspan="1" rowspan="1">4–8 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">32 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">24 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib769"
                                    data-tab="pane-pcw-references">20</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Losartan</td>
                            <td align="center" colspan="1" rowspan="1">25–50 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">50–150 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">129 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib767"
                                    data-tab="pane-pcw-references">18</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Valsartan</td>
                            <td align="center" colspan="1" rowspan="1">20–40 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">160 mg twice daily</td>
                            <td align="center" colspan="1" rowspan="1">254 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib770"
                                    data-tab="pane-pcw-references">21</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="5" rowspan="1"><strong>ARNi</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Sacubitril-valsartan</td>
                            <td align="center" colspan="1" rowspan="1">49 mg sacubitril and 51 mg valsartan twice daily
                                (therapy may be initiated at 24 mg sacubitril and 26 mg valsartan twice daily)</td>
                            <td align="center" colspan="1" rowspan="1">97 mg sacubitril and 103 mg valsartan twice daily
                            </td>
                            <td align="center" colspan="1" rowspan="1">182 mg sacubitril and 193 mg valsartan total
                                daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib771"
                                    data-tab="pane-pcw-references">22</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="5" rowspan="1"><strong>Beta blockers</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Bisoprolol</td>
                            <td align="center" colspan="1" rowspan="1">1.25 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">10 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">8.6 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib750"
                                    data-tab="pane-pcw-references">1</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Carvedilol</td>
                            <td align="center" colspan="1" rowspan="1">3.125 mg twice daily</td>
                            <td align="center" colspan="1" rowspan="1">25–50 mg twice daily</td>
                            <td align="center" colspan="1" rowspan="1">37 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib772"
                                    data-tab="pane-pcw-references">23</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Carvedilol CR</td>
                            <td align="center" colspan="1" rowspan="1">10 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">80 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">NA</td>
                            <td align="center" colspan="1" rowspan="1">…</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Metoprolol succinate extended release (metoprolol CR/XL)</td>
                            <td align="center" colspan="1" rowspan="1">12.5–25 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">200 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">159 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib760"
                                    data-tab="pane-pcw-references">11</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="5" rowspan="1"><strong>Mineralocorticoid receptor antagonists</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Spironolactone</td>
                            <td align="center" colspan="1" rowspan="1">12.5–25 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">25–50 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">26 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib755"
                                    data-tab="pane-pcw-references">6</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Eplerenone</td>
                            <td align="center" colspan="1" rowspan="1">25 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">50 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">42.6 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib762"
                                    data-tab="pane-pcw-references">13</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="5" rowspan="1"><strong>SGLT2i</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Dapagliflozin</td>
                            <td align="center" colspan="1" rowspan="1">10 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">10 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">9.8 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib757"
                                    data-tab="pane-pcw-references">8</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Empagliflozin</td>
                            <td align="center" colspan="1" rowspan="1">10 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">10 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">NR</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib758"
                                    data-tab="pane-pcw-references">9</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="5" rowspan="1"><strong>Isosorbide dinitrate and hydralazine</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Fixed dose combination</td>
                            <td align="center" colspan="1" rowspan="1">20 mg isosorbide dinitrate and 37.5 mg
                                hydralazine 3 times daily</td>
                            <td align="center" colspan="1" rowspan="1">40 mg isosorbide dinitrate and 75 mg hydralazine
                                3 times daily</td>
                            <td align="center" colspan="1" rowspan="1">90 mg isosorbide dinitrate and ∼175 mg
                                hydralazine total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib759"
                                    data-tab="pane-pcw-references">10</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Isosorbide dinitrate and hydralazine</td>
                            <td align="center" colspan="1" rowspan="1">20–30 mg isosorbide dinitrate and 25–50 mg
                                hydralazine 3–4 times daily</td>
                            <td align="center" colspan="1" rowspan="1">120 mg isosorbide dinitrate total daily in
                                divided doses and 300 mg hydralazine total daily in divided doses</td>
                            <td align="center" colspan="1" rowspan="1">NA</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib773"
                                    data-tab="pane-pcw-references">24</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="5" rowspan="1"><strong>I</strong><sub><strong>f</strong></sub><strong>Channel
                                    inhibitor</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Ivabradine</td>
                            <td align="center" colspan="1" rowspan="1">5 mg twice daily</td>
                            <td align="center" colspan="1" rowspan="1">7.5 mg twice daily</td>
                            <td align="center" colspan="1" rowspan="1">12.8 total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib774"
                                    data-tab="pane-pcw-references">25-27</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="5" rowspan="1"><strong>Soluble guanylate cyclase stimulator</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Vericiguat</td>
                            <td align="center" colspan="1" rowspan="1">2.5 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">10 mg once daily</td>
                            <td align="center" colspan="1" rowspan="1">9.2 mg total daily</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib777"
                                    data-tab="pane-pcw-references">28</a>)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Digoxin</td>
                            <td align="center" colspan="1" rowspan="1">0.125–0.25 mg daily (modified according to
                                monogram)</td>
                            <td align="center" colspan="1" rowspan="1">Individualized variable dose to achieve serum
                                digoxin concentration 0.5–&lt;0.9 ng/mL</td>
                            <td align="center" colspan="1" rowspan="1">NA</td>
                            <td align="center" colspan="1" rowspan="1">(<a class="tab-link" href="#bib778"
                                    data-tab="pane-pcw-references">29</a>,<a class="tab-link" href="#bib779"
                                    data-tab="pane-pcw-references">30</a>)</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0145">ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor
                                blocker; CR, controlled release; CR/XL, controlled release/extended release; HF, heart
                                failure; HFrEF, heart failure with reduced ejection fraction; NA, not applicable; NR,
                                not reported; and SGLT2i, sodium glucose cotransporter 2 inhibitor.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="tbl15" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl15">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0150"><span class="captionLabel">Table 15</span> Benefits of Evidence-Based
                                Therapies for Patients With HFrEF (<a class="tab-link" href="#bib752"
                                    data-tab="pane-pcw-references">3-6</a>,<a class="tab-link" href="#bib757"
                                    data-tab="pane-pcw-references">8</a>,<a class="tab-link" href="#bib759"
                                    data-tab="pane-pcw-references">10-14</a>,<a class="tab-link" href="#bib772"
                                    data-tab="pane-pcw-references">23</a>,<a class="tab-link" href="#bib780"
                                    data-tab="pane-pcw-references">31-42</a>)</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Evidence-Based Therapy</th>
                            <th colspan="1" rowspan="1">Relative Risk Reduction in All-Cause Mortality in Pivotal RCTs,
                                %</th>
                            <th colspan="1" rowspan="1">NNT to Prevent All-Cause Mortality Over Time<a
                                    class="ref table-fn" id="tbl15fnlowast"
                                    href="javascript:popRef('tbl15fnlowast')"><sup>∗</sup></a></th>
                            <th colspan="1" rowspan="1">NNT for All-Cause Mortality (Standardized to 12 mo)</th>
                            <th colspan="1" rowspan="1">NNT for All- Cause Mortality (Standardized to 36 mo)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ACEi or ARB</td>
                            <td align="char" char="." colspan="1" rowspan="1">17</td>
                            <td align="center" colspan="1" rowspan="1">22 over 42 mo</td>
                            <td align="char" char="." colspan="1" rowspan="1">77</td>
                            <td align="char" char="." colspan="1" rowspan="1">26</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ARNi<a class="ref table-fn" id="tbl15fndagger"
                                    href="javascript:popRef('tbl15fndagger')"><sup>†</sup></a></td>
                            <td align="char" char="." colspan="1" rowspan="1">16</td>
                            <td align="center" colspan="1" rowspan="1">36 over 27 mo</td>
                            <td align="char" char="." colspan="1" rowspan="1">80</td>
                            <td align="char" char="." colspan="1" rowspan="1">27</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Beta blocker</td>
                            <td align="char" char="." colspan="1" rowspan="1">34</td>
                            <td align="center" colspan="1" rowspan="1">28 over 12 mo</td>
                            <td align="char" char="." colspan="1" rowspan="1">28</td>
                            <td align="char" char="." colspan="1" rowspan="1">9</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Mineralocorticoid receptor antagonist</td>
                            <td align="char" char="." colspan="1" rowspan="1">30</td>
                            <td align="center" colspan="1" rowspan="1">9 over 24 mo</td>
                            <td align="char" char="." colspan="1" rowspan="1">18</td>
                            <td align="char" char="." colspan="1" rowspan="1">6</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">SGLT2i</td>
                            <td align="char" char="." colspan="1" rowspan="1">17</td>
                            <td align="center" colspan="1" rowspan="1">43 over 18 mo</td>
                            <td align="char" char="." colspan="1" rowspan="1">63</td>
                            <td align="char" char="." colspan="1" rowspan="1">22</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Hydralazine or nitrate<a class="ref table-fn"
                                    id="tbl15fnddagger" href="javascript:popRef('tbl15fnddagger')">‡</a></td>
                            <td align="char" char="." colspan="1" rowspan="1">43</td>
                            <td align="center" colspan="1" rowspan="1">25 over 10 mo</td>
                            <td align="char" char="." colspan="1" rowspan="1">21</td>
                            <td align="char" char="." colspan="1" rowspan="1">7</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CRT</td>
                            <td align="char" char="." colspan="1" rowspan="1">36</td>
                            <td align="center" colspan="1" rowspan="1">12 over 24 mo</td>
                            <td align="char" char="." colspan="1" rowspan="1">24</td>
                            <td align="char" char="." colspan="1" rowspan="1">8</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ICD</td>
                            <td align="char" char="." colspan="1" rowspan="1">23</td>
                            <td align="center" colspan="1" rowspan="1">14 over 60 mo</td>
                            <td align="char" char="." colspan="1" rowspan="1">70</td>
                            <td align="char" char="." colspan="1" rowspan="1">23</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0155">ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin
                                receptor blocker; ARNi, angiotensin receptor neprilysin inhibitor; CRT, cardiac
                                resynchronization therapy; HFrEF, heart failure with reduced ejection fraction; ICD,
                                implantable cardioverter-defibrillator; NNT, number needed to treat; RCT, randomized
                                controlled trial; and SGLT2i, sodium-glucose cotransporter-2 inhibitor.</p>
                        </fn>
                        <fn id="tbl15fnlowast">
                            <p id="ntpara0025">∗ Median duration follow-up in the respective clinical trial.</p>
                        </fn>
                        <fn id="tbl15fndagger">
                            <p id="ntpara0030">† Benefit of ARNi therapy incremental to that achieved with ACEi therapy.
                                For the other medications shown, the benefits are based on comparisons to placebo
                                control.</p>
                        </fn>
                        <fn id="tbl15fnddagger">
                            <p id="ntpara0035">‡ Benefit of hydralazine-nitrate therapy was limited to African American
                                patients in this trial.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p5575">If the target dose cannot be achieved or is not well tolerated, then the highest tolerated
                dose is recommended. There are no direct data showing that use of lower doses of HFrEF medications among
                patients, where higher target doses could be tolerated, would produce the same or similar degree of
                clinical benefit. In trials that have evaluated dose response for outcomes, composite event rates were
                lower with target doses compared with lower dose (<a class="tab-link" href="#bib765"
                    data-tab="pane-pcw-references">16-18</a>).</p>
            <p id="p5580"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1265" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5585">The use of these specific medications for HFrEF should involve initiation at
                                low-starting doses, uptitration at specified intervals as tolerated, and
                                achieving-maintaining the target doses shown to be effective in major clinical trials.
                                Every effort should be made by clinicians to achieve and maintain the clinical
                                trial–defined target doses (<a class="ref showTableEvent" data-id="tbl13"
                                    href="#tbl13">Table 13</a>) of guideline-directed medications, as long as they are
                                well tolerated by the patient. Patients should be monitored for changes in heart rate,
                                blood pressure, electrolytes, renal function, and symptoms during this uptitration
                                period. Planned uptitration of a HF medication should be delayed until any adverse
                                effects observed with lower doses have resolved. When such a strategy is used for dose
                                titration, most patients (approximately 70%–85%) enrolled in clinical trials who
                                received these medications were able to tolerate short-, intermediate-, and long-term
                                treatment with these agents and achieve and maintain the trial defined target dose (<a
                                    class="tab-link" href="#bib750" data-tab="pane-pcw-references">1-9</a>,<a
                                    class="tab-link" href="#bib760" data-tab="pane-pcw-references">11-14</a>). Repeated
                                attempts at uptitration can result in optimization, even if initial attempts may fail.
                                In patients with HFrEF, beta blockers provide dose-dependent improvements in LVEF,
                                reduction in HF hospitalizations, and reduction in all-cause mortality (<a
                                    class="tab-link" href="#bib766" data-tab="pane-pcw-references">17</a>). Trials of
                                lower versus higher dose of ACEi and ARB have shown lower risk of cardiovascular death
                                or HF hospitalization with higher doses, with similar safety and tolerability (<a
                                    class="tab-link" href="#bib766" data-tab="pane-pcw-references">17</a>,<a
                                    class="tab-link" href="#bib767" data-tab="pane-pcw-references">18</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5590">Initiation and titration should be individualized and optimized without delay
                                according to patient’s symptoms, vital signs, functional status, tolerance, renal
                                function, electrolytes, comorbidities, specific cause of HF, and ability of follow-up.
                                In patients with HFrEF, simultaneous initiation or sequencing, and order of
                                guideline-directed medications are usually individualized according to patient’s
                                symptoms, vital signs, functional status, tolerance, renal function, electrolytes,
                                comorbidities, specific cause of HF, and ability of follow-up, and does not necessarily
                                need to be done according to the sequence of trial publications and should not be
                                delayed.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.3" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.3">
                <div id="acsectitle0310" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0310">7.3.9 Additional Medical Therapies</h4>
            <div id="acsec11.3.9" class="anchor-spacer"></div>
            <h4 class="article-section__subtitle" id="sec11.3.9">
                <div id="acsectitle0315" class="anchor-spacer"></div>
            </h4>
            <h4 class="article-section__subtitle" id="sectitle0315">7.3.9.1 Management of Stage C HF: Ivabradine</h4>
            <div id="undtbl25" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl25">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0600">Recommendation for the Management of Stage C HF: Ivabradine</p>
                            <p id="tspara0605">Referenced studies that support the recommendation are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0525" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1525"><strong>For patients with symptomatic (NYHA class II to
                                                        III) stable chronic HFrEF (LVEF ≤35%) who are receiving GDMT,
                                                        including a beta blocker at maximum tolerated dose, and who are
                                                        in sinus rhythm with a heart rate of ≥70 bpm at rest, ivabradine
                                                        can be beneficial to reduce HF hospitalizations and
                                                        cardiovascular death (</strong><a class="tab-link"
                                                        href="#bib792"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib793"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5610"><strong>Synopsis</strong></p>
            <p id="p5615">Heart rate is a strong predictor of cardiovascular outcomes in the general population and in
                patients with CVD, including HF. The SHIFT (Ivabradine and Outcomes in Chronic Heart Failure) trial
                tested the hypothesis that reducing heart rate in patients with HF improves cardiovascular outcomes (<a
                    class="tab-link" href="#bib792" data-tab="pane-pcw-references">1</a>). SHIFT demonstrated the
                efficacy of ivabradine, a sinoatrial node modulator that selectively inhibits the I<sub>f</sub> current,
                in reducing the composite endpoint of cardiovascular death or HF hospitalization in patients with HF.
                See <a data-tab="pane-pcw-Figures" href="#fig7" id="fig7R" class="">Figure 7</a> for a summary of
                additional medical therapy recommendations.</p>
            <section class="article-section__inline-figure">
                <figure id="fig7" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/ec5d27a8-df1b-4485-874f-62fb84588406/gr7.jpg"
                        data-lg-src="/cms/asset/7ca9fc38-9000-4e76-b69f-c51b73110782/gr7.jpg" alt="Figure 7">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/7ca9fc38-9000-4e76-b69f-c51b73110782/gr7.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig7&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 7</span></strong>
                        <p>Additional Medical Therapies for Patients With HFrEF</p>
                        <p><strong>Colors correspond to COR in</strong> <a class="ref showTableEvent" data-id="tbl2"
                                href="#tbl2"><strong>Table 2</strong></a><strong>.</strong> Recommendations for
                            additional medical therapies that may be considered for patients with HF are shown. GDMT
                            indicates guideline-directed medical therapy; HF, heart failure; HFH, heart failure
                            hospitalization; HFrEF, heart failure with reduced ejection fraction; IV, intravenous; LVEF,
                            left ventricular ejection fraction; LVESD, left ventricular end systolic dimension; MV,
                            mitral valve; MR, mitral regurgitation; NP, natriuretic peptide; NSR, normal sinus rhythm;
                            and NYHA, New York Heart Association; RAASi, renin-angiotensin-aldosterone system
                            inhibitors.</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p5620"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1270" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5625">Although the primary outcome in SHIFT was a composite of hospitalization and
                                cardiovascular death, the greatest benefit was a reduction in HF hospitalization. SHIFT
                                included patients with HFrEF and LVEF ≤35% who were in sinus rhythm with a resting heart
                                rate of ≥70 bpm. Participants were predominantly NYHA class II and III. Participants had
                                been hospitalized for HF in the preceding 12 months and were on stable GDMT for 4 weeks
                                before initiation of ivabradine therapy (<a class="tab-link" href="#bib792"
                                    data-tab="pane-pcw-references">1-4</a>). The target of ivabradine is heart rate, and
                                the benefit of ivabradine results from a reduction in heart rate. However, only 25% of
                                patients studied in SHIFT were on optimal doses of beta-blocker therapy. Given the
                                well-proven mortality benefits of beta-blocker therapy, these agents should be initiated
                                and uptitrated to target doses, as tolerated, before assessing the resting heart rate
                                for consideration of ivabradine initiation (<a class="tab-link" href="#bib796"
                                    data-tab="pane-pcw-references">5</a>,<a class="tab-link" href="#bib797"
                                    data-tab="pane-pcw-references">6</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.3.9" class="anchor-spacer"></div>
            <h4 class="article-section__subtitle" id="sec11.3.9">
                <div id="acsectitle0320" class="anchor-spacer"></div>
            </h4>
            <h4 class="article-section__subtitle" id="sectitle0320">7.3.9.2 Pharmacological Treatment for Stage C HFrEF:
                Digoxin</h4>
            <div id="undtbl26" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl26">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0610">Recommendation for the Pharmacological Treatment for Stage C HFrEF:
                                Digoxin</p>
                            <p id="tspara0615">Referenced studies that support the recommendation are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0530" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1530"><strong>In patients with symptomatic HFrEF despite GDMT
                                                        (or who are unable to tolerate GDMT), digoxin might be
                                                        considered to decrease hospitalizations for HF (</strong><a
                                                        class="tab-link" href="#bib798"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib799"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5635"><strong>Synopsis</strong></p>
            <p id="p5640">To date, there has been only 1 large-scale, RCT of digoxin in patients with HF (<a
                    class="tab-link" href="#bib798" data-tab="pane-pcw-references">1</a>). This trial, which predated
                current GDMT, primarily enrolled patients with NYHA class II to III HF and showed that treatment with
                digoxin for 2 to 5 years had no effect on mortality but modestly reduced the combined risk of death and
                hospitalization. The trial also found no significant effect on health-related QOL in a subset of the
                trial patients (<a class="tab-link" href="#bib800" data-tab="pane-pcw-references">3</a>). The effect of
                digoxin on hospitalizations has been supported by retrospective analyses and meta-analyses (<a
                    class="tab-link" href="#bib799" data-tab="pane-pcw-references">2</a>,<a class="tab-link"
                    href="#bib801" data-tab="pane-pcw-references">4-6</a>). Additionally, observational studies and
                retrospective analyses have shown improvement in symptoms and exercise tolerance in mild to moderate HF;
                however, they have mostly shown either lack of mortality benefit or increased mortality associated with
                digoxin (<a class="tab-link" href="#bib804" data-tab="pane-pcw-references">7</a>). The benefit in
                patients on current GDMT is unclear because most trials preceded current GDMT. Thus, use of digoxin
                requires caution in patients with HF and is reserved for those who remain symptomatic despite
                optimization of GDMT.</p>
            <p id="p5645"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1275" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5650">Digoxin is usually initiated at a low dose because higher doses are rarely
                                required in the management of HF and are potentially detrimental. Two retrospective
                                analyses of large-scale clinical trials have shown a linear relationship between
                                mortality and digoxin serum concentration in patients with AF and at risk for stroke,
                                including those with HF, and in patients with HF. The risk of death was independently
                                associated with serum digoxin concentration, with a significantly higher risk observed
                                in those with concentrations ≥1.2 ng/mL and ≥1.6 ng/mL (<a class="tab-link"
                                    href="#bib805" data-tab="pane-pcw-references">8</a>,<a class="tab-link"
                                    href="#bib806" data-tab="pane-pcw-references">9</a>). The benefit of digoxin in
                                patients with HF remains controversial. GDMT is expected to be optimized before
                                considering the addition of digoxin. Clinical worsening after withdrawal of digoxin has
                                been shown (<a class="tab-link" href="#bib807" data-tab="pane-pcw-references">10</a>).
                                Therapy with digoxin may either be continued in the absence of a contraindication or
                                discontinued with caution (<a class="tab-link" href="#bib808"
                                    data-tab="pane-pcw-references">11</a>). Therapy with digoxin is commonly initiated
                                and maintained at a dose of 0.125 to 0.25 mg daily. Low doses (0.125 mg daily or every
                                other day) should be used initially if the patient is &gt;70 years of age, has impaired
                                renal function, or has a low lean body mass. Higher doses (e.g., digoxin 0.375 to 0.50
                                mg daily) are rarely used or needed in the management of patients with HF.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.3.9" class="anchor-spacer"></div>
            <h4 class="article-section__subtitle" id="sec11.3.9">
                <div id="acsectitle0325" class="anchor-spacer"></div>
            </h4>
            <h4 class="article-section__subtitle" id="sectitle0325">7.3.9.3 Pharmacological Treatment for Stage C HFrEF:
                Soluble Guanylyl Cyclase Stimulators</h4>
            <div id="undtbl27" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl27">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0620">Recommendation for Pharmacological Treatment for Stage C HFrEF: Soluble
                                Guanylyl Cyclase Stimulators</p>
                            <p id="tspara0625">Referenced studies that support the recommendation are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0535" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1535"><strong>In selected high-risk patients with HFrEF and
                                                        recent worsening of HF already on GDMT, an oral soluble
                                                        guanylate cyclase stimulator (vericiguat) may be considered to
                                                        reduce HF hospitalization and cardiovascular death</strong> (<a
                                                        class="tab-link" href="#bib809"
                                                        data-tab="pane-pcw-references">1</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5660"><strong>Synopsis</strong></p>
            <p id="p5665">In patients with progression of HFrEF despite GDMT, there may be a role for novel therapeutic
                agents. Oral soluble guanylyl cyclase stimulator (e.g., vericiguat) directly binds and stimulates sGC
                and increases cGMP production. cGMP has several potentially beneficial effects in patients with HF,
                including vasodilation, improvement in endothelial function, as well as decrease in fibrosis and
                remodeling of the heart (<a class="tab-link" href="#bib810" data-tab="pane-pcw-references">2-7</a>). The
                VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial
                randomized 5050 higher-risk patients with worsening HFrEF to vericiguat versus placebo (<a
                    class="tab-link" href="#bib809" data-tab="pane-pcw-references">1</a>).</p>
            <p id="p5670"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1280" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5675">Patients with HFrEF in the VICTORIA trial had LVEF &lt;45%, NYHA class II to
                                IV, were on GDMT, with elevated natriuretic peptides (BNP ≥300 pg/mL or NT-proBNP ≥1000
                                pg/mL if in sinus rhythm; higher cutoffs with AF), and recent HF worsening (hospitalized
                                within 6 months or recently received intravenous diuretic therapy without
                                hospitalization). Patients on long-acting nitrates, with SBP &lt;100 mm Hg, or eGFR
                                &lt;15 mL/min/1.73 m<sup>2</sup> were excluded (<a class="tab-link" href="#bib809"
                                    data-tab="pane-pcw-references">1</a>). Over a median follow-up of 10.8 months, the
                                primary outcome, cardiovascular death or HF hospitalization, occurred in 35.5% with
                                vericiguat compared with 38.5% with placebo (HR, 0.90; <i>P</i>=0.019). All-cause
                                mortality occurred in 20.3% in the vericiguat group and 21.2% in the placebo group (HR,
                                0.95; 95% CI, 0.84-1.07; <i>P</i>=0.38) and composite of any-cause death or HF
                                hospitalization was also lower in the vericiguat group versus placebo group (HR, 0.90;
                                95% CI, 0.83–0.98; <i>P</i>=0.02). The relative risk reduction of 10% in the primary
                                outcome was lower than expected, even in a higher risk population. Although not
                                statistically significant, symptomatic hypotension (9.1% versus 7.9%; <i>P</i>=0.12) and
                                syncope (4.0% versus 3.5%; <i>P</i>=0.30) were numerically higher in the vericiguat
                                group versus placebo. There was heterogeneity by subgroup analysis, and patients in the
                                highest quartile of NT-proBNP subgroup (NT proBNP level &gt;5314 pg/mL) did not have
                                benefit from vericiguat when compared with placebo.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec11">
                <div id="acsectitle0330" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0330">7.4 Device and Interventional Therapies for HFrEF
            </h3>
            <div id="acsec11.4" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.4">
                <div id="acsectitle0335" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0335">7.4.1 ICDs and CRTs</h4>
            <div id="undtbl28" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl28">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0630">Recommendations for ICDs and CRTs</p>
                            <p id="tspara0635">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0540" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1540"><strong>In patients with nonischemic DCM or ischemic heart
                                                        disease at least 40 days post-MI with LVEF ≤35% and NYHA class
                                                        II or III symptoms on chronic GDMT, who have reasonable
                                                        expectation of meaningful survival for &gt;1 year, ICD therapy
                                                        is recommended for primary prevention of SCD to reduce total
                                                        mortality</strong> (<a class="tab-link" href="#bib816"
                                                        data-tab="pane-pcw-references">1-9</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: High Value (A)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0545" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1545"><strong>A transvenous ICD provides high economic value in
                                                        the primary prevention of SCD particularly when the patient’s
                                                        risk of death caused by ventricular arrythmia is deemed high and
                                                        the risk of nonarrhythmic death (either cardiac or noncardiac)
                                                        is deemed low based on the patient’s burden of comorbidities and
                                                        functional status</strong> (<a class="tab-link" href="#bib825"
                                                        data-tab="pane-pcw-references">10-15</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0550" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1550"><strong>In patients at least 40 days post-MI with LVEF
                                                        ≤30% and NYHA class I symptoms while receiving GDMT, who have
                                                        reasonable expectation of meaningful survival for &gt;1 year,
                                                        ICD therapy is recommended for primary prevention of SCD to
                                                        reduce total mortality</strong> (<a class="tab-link"
                                                        href="#bib821"
                                                        data-tab="pane-pcw-references">6</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0555" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1555"><strong>For patients who have LVEF ≤35%, sinus rhythm,
                                                        left bundle branch block (LBBB) with a QRS duration ≥150 ms, and
                                                        NYHA class II, III, or ambulatory IV symptoms on GDMT, CRT is
                                                        indicated to reduce total mortality, reduce hospitalizations,
                                                        and improve symptoms and QOL</strong> (<a class="tab-link"
                                                        href="#bib831"
                                                        data-tab="pane-pcw-references">16-21</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: High Value (B-NR)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0560" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1560"><strong>For patients who have LVEF ≤35%, sinus rhythm,
                                                        LBBB with a QRS duration of ≥150 ms, and NYHA class II, III, or
                                                        ambulatory IV symptoms on GDMT, CRT implantation provides high
                                                        economic value</strong> (<a class="tab-link" href="#bib837"
                                                        data-tab="pane-pcw-references">22-27</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0565" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">6.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1565"><strong>For patients who have LVEF ≤35%, sinus rhythm, a
                                                        non-LBBB pattern with a QRS duration ≥150 ms, and NYHA class II,
                                                        III, or ambulatory class IV symptoms on GDMT, CRT can be useful
                                                        to reduce total mortality, reduce hospitalizations, and improve
                                                        symptoms and QOL (</strong><a class="tab-link" href="#bib831"
                                                        data-tab="pane-pcw-references"><strong>16-21</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib843"
                                                        data-tab="pane-pcw-references"><strong>28-33</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0585" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">7.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1585"><strong>In patients with high-degree or complete heart
                                                        block and LVEF of 36% to 50%, CRT is reasonable to reduce total
                                                        mortality, reduce hospitalizations, and improve symptoms and QOL
                                                        (</strong><a class="tab-link" href="#bib849"
                                                        data-tab="pane-pcw-references"><strong>34</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib850"
                                                        data-tab="pane-pcw-references"><strong>35</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0570" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">8.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1570"><strong>For patients who have LVEF ≤35%, sinus rhythm,
                                                        LBBB with a QRS duration of 120 to 149 ms, and NYHA class II,
                                                        III, or ambulatory IV symptoms on GDMT, CRT can be useful to
                                                        reduce total mortality, reduce hospitalizations, and improve
                                                        symptoms and QOL (</strong><a class="tab-link" href="#bib831"
                                                        data-tab="pane-pcw-references"><strong>16-21</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib843"
                                                        data-tab="pane-pcw-references"><strong>28-33</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0575" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">9.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1575"><strong>In patients with AF and LVEF ≤35% on GDMT, CRT can
                                                        be useful to reduce total mortality, improve symptoms and QOL,
                                                        and increase LVEF, if: a) the patient requires ventricular
                                                        pacing or otherwise meets CRT criteria and b) atrioventricular
                                                        nodal ablation or pharmacological rate control will allow near
                                                        100% ventricular pacing with CRT (</strong><a class="tab-link"
                                                        href="#bib831"
                                                        data-tab="pane-pcw-references"><strong>16-21</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib843"
                                                        data-tab="pane-pcw-references"><strong>28-33</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0580" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">10.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1580"><strong>For patients on GDMT who have LVEF ≤35% and are
                                                        undergoing placement of a new or replacement device implantation
                                                        with anticipated requirement for significant (&gt;40%)
                                                        ventricular pacing, CRT can be useful to reduce total mortality,
                                                        reduce hospitalizations, and improve symptoms and QOL
                                                        (</strong><a class="tab-link" href="#bib831"
                                                        data-tab="pane-pcw-references"><strong>16-21</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib843"
                                                        data-tab="pane-pcw-references"><strong>28-33</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0590" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">11.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1590"><strong>In patients with genetic arrhythmogenic
                                                        cardiomyopathy with high-risk features of sudden death, with EF
                                                        ≤45%, implantation of ICD is reasonable to decrease sudden death
                                                        (</strong><a class="tab-link" href="#bib851"
                                                        data-tab="pane-pcw-references"><strong>36</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib852"
                                                        data-tab="pane-pcw-references"><strong>37</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0595" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">12.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1595"><strong>For patients who have LVEF ≤35%, sinus rhythm, a
                                                        non-LBBB pattern with QRS duration of 120 to 149 ms, and NYHA
                                                        class III or ambulatory class IV on GDMT, CRT may be considered
                                                        to reduce total mortality, reduce hospitalizations, and improve
                                                        symptoms and QOL (</strong><a class="tab-link" href="#bib831"
                                                        data-tab="pane-pcw-references"><strong>16-21</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib843"
                                                        data-tab="pane-pcw-references"><strong>28-33</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0600" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">13.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1600"><strong>For patients who have LVEF ≤30%, ischemic cause of
                                                        HF, sinus rhythm, LBBB with a QRS duration ≥150 ms, and NYHA
                                                        class I symptoms on GDMT, CRT may be considered to reduce
                                                        hospitalizations and improve symptoms and QOL (</strong><a
                                                        class="tab-link" href="#bib831"
                                                        data-tab="pane-pcw-references"><strong>16-21</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib843"
                                                        data-tab="pane-pcw-references"><strong>28-33</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: No Benefit</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0605" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">14.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1605"><strong>In patients with QRS duration &lt;120 ms, CRT is
                                                        not recommended</strong> (<a class="tab-link" href="#bib851"
                                                        data-tab="pane-pcw-references">36-41</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: No Benefit</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0610" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">15.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1610"><strong>For patients with NYHA class I or II symptoms and
                                                        non-LBBB pattern with QRS duration &lt;150 ms, CRT is not
                                                        recommended (</strong><a class="tab-link" href="#bib831"
                                                        data-tab="pane-pcw-references"><strong>16-21</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib843"
                                                        data-tab="pane-pcw-references"><strong>28-33</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: No Benefit</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0615" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">16.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1615"><strong>For patients whose comorbidities or frailty limit
                                                        survival with good functional capacity to &lt;1 year, ICD and
                                                        cardiac resynchronization therapy with defibrillation (CRT-D)
                                                        are not indicated (</strong><a class="tab-link" href="#bib816"
                                                        data-tab="pane-pcw-references"><strong>1-9</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib831"
                                                        data-tab="pane-pcw-references"><strong>16-21</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5690"><strong>Synopsis</strong></p>
            <p id="p5695">RCTs have informed the decisions regarding cardiac implantable devices (ICDs and CRTs) over
                the past 20 years. In fact, the seminal RCTs for ICDs and CRTs are unlikely to be repeated. Subgroup
                analyses of these trials have also informed decisions, but these were not the primary endpoints of these
                studies and thus should be interpreted with caution. GDMT is optimized before ICD and CRT implantation
                to assess whether the LVEF improves. <a data-tab="pane-pcw-Figures" href="#fig8" id="fig8R"
                    class="">Figures 8</a> and <a data-tab="pane-pcw-Figures" href="#fig9" id="fig9R" class="">9</a>
                summarize device and interventional therapy recommendations.</p>
            <section class="article-section__inline-figure">
                <figure id="fig8" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/6cf241ac-c451-4924-8b9c-7906f2676977/gr8.jpg"
                        data-lg-src="/cms/asset/281b1bf8-50d6-467f-9a2a-98b422c09d87/gr8.jpg" alt="Figure 8">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/281b1bf8-50d6-467f-9a2a-98b422c09d87/gr8.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig8&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 8</span></strong>
                        <p>Algorithm for CRT Indications in Patients With Cardiomyopathy or HFrEF</p>
                        <p><strong>Colors correspond to COR in</strong> <a class="ref showTableEvent" data-id="tbl2"
                                href="#tbl2"><strong>Table 2</strong></a><strong>.</strong> Recommendations for cardiac
                            resynchronization therapy (CRT) are displayed. AF indicates atrial fibrillation; Amb,
                            ambulatory; CM, cardiomyopathy; GDMT, guideline-directed medical therapy; HB, heart block;
                            HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LBBB, left bundle
                            branch block; LV, left ventricular; LVEF, left ventricular ejection fraction; NSR, normal
                            sinus rhythm; NYHA, New York Heart Association; and RV, right ventricular.</p>
                    </figcaption>
                </figure>
            </section>
            <section class="article-section__inline-figure">
                <figure id="fig9" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/2cb0ef53-ab5e-4c55-9fdb-25dd58c689a1/gr9.jpg"
                        data-lg-src="/cms/asset/5aa9d9d9-bb5a-4959-879f-c6e474130cc1/gr9.jpg" alt="Figure 9">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/5aa9d9d9-bb5a-4959-879f-c6e474130cc1/gr9.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig9&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 9</span></strong>
                        <p>Additional Device Therapies</p>
                        <p><strong>Colors correspond to COR in</strong> <a class="ref showTableEvent" data-id="tbl2"
                                href="#tbl2"><strong>Table 2</strong></a><strong>.</strong> Recommendations for
                            additional nonpharmaceutical interventions that may be considered for patients with HF are
                            shown. GDMT indicates guideline-directed medical therapy; HF, heart failure; HFH, heart
                            failure hospitalization; HFrEF, heart failure with reduced ejection fraction; IV,
                            intravenous; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic
                            dimension; MV, mitral valve; MR, mitral regurgitation; NP, natriuretic peptide; NSR, normal
                            sinus rhythm; NYHA, New York Heart Association; and PASP, pulmonary artery systolic
                            pressure.</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p5700"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1285" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5705">ICDs were first assessed in patients who had been resuscitated from a cardiac
                                arrest. In AVID (Antiarrhythmics versus Implantable Defibrillators trial), CASH (Cardiac
                                Arrest Study Hamburg), and CIDS (Canadian Implantable Defibrillator StudyS), benefit was
                                observed in those who were randomized to ICDs (<a class="tab-link" href="#bib816"
                                    data-tab="pane-pcw-references">1-3</a>). Extension of benefit was then shown in
                                other patient populations that were at perceived risk of SCD. In the first MADIT
                                (Multicenter Automated Defibrillator Implantation Trial) trial, patients with previous
                                MI, LVEF ≤35% with nonsustained VT had a mortality benefit with ICD (<a class="tab-link"
                                    href="#bib819" data-tab="pane-pcw-references">4</a>). Similar populations in MUSTT
                                (Multicenter UnSustained Tachycardia Trial) also showed benefit (<a class="tab-link"
                                    href="#bib820" data-tab="pane-pcw-references">5</a>). In MADIT-II (Multicenter
                                Automatic Defibrillator Implantation Trial II), patients with no arrhythmia qualifier
                                but with previous MIs and LVEF ≤30% derived benefit from ICD (<a class="tab-link"
                                    href="#bib821" data-tab="pane-pcw-references">6</a>). The DEFINITE (Defibrillators
                                in Non-Ischemic Cardiomyopathy Treatment Evaluation) study included only nonischemic
                                patients with LVEF ≤35% and frequent premature ventricular contractions (PVCs) or
                                nonsustained ventricular tachycardia (VT) (<a class="tab-link" href="#bib822"
                                    data-tab="pane-pcw-references">7</a>). There was a trend to mortality benefit, but
                                it ultimately did not achieve significance. In SCD-HEFT (Sudden Cardiac Death in Heart
                                Failure Trial), patients with ischemic and nonischemic cardiomyopathy, LVEF ≤35%, and HF
                                class II to III showed benefit with an ICD compared with either amiodarone or placebo
                                (<a class="tab-link" href="#bib823" data-tab="pane-pcw-references">8</a>). More
                                recently, the DANISH (Defibrillator Implantation in Patients with Nonischemic Systolic
                                Heart Failure) trial enrolled patients with nonischemic cardiomyopathy and LVEF ≤35% to
                                ICD or standard care (<a class="tab-link" href="#bib824"
                                    data-tab="pane-pcw-references">9</a>). There was no reduction in the primary
                                endpoint of total mortality, but there was a reduction in SCD risk. In the DANISH trial,
                                58% of patients in each limb received CRT, possibly mitigating the benefit of an ICD.
                            </p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5710">Economic outcomes of ICD implantation for primary prevention of SCD were
                                assessed in 3 RCTs (MADIT-I [<a class="tab-link" href="#bib828"
                                    data-tab="pane-pcw-references">13</a>], MADIT-II [<a class="tab-link" href="#bib830"
                                    data-tab="pane-pcw-references">15</a>], and SCD-HeFT [<a class="tab-link"
                                    href="#bib827" data-tab="pane-pcw-references">12</a>]), 1 observational study (<a
                                    class="tab-link" href="#bib825" data-tab="pane-pcw-references">10</a>), and 3
                                simulation models (<a class="tab-link" href="#bib826"
                                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib829"
                                    data-tab="pane-pcw-references">14</a>,<a class="tab-link" href="#bib857"
                                    data-tab="pane-pcw-references">42</a>), all of which had generally consistent
                                results. All studies reported increased survival and life expectancy and higher lifetime
                                costs of medical care with an ICD than without an ICD. The incremental
                                cost-effectiveness ratios were generally &lt;$60,000 per year of life added by an ICD,
                                which provides high value according to the benchmarks adopted for the current guideline.
                                The value provided by an ICD was consistently high when life expectancy was projected to
                                increase by &gt;1.4 years (<a class="tab-link" href="#bib829"
                                    data-tab="pane-pcw-references">14</a>). In contrast, when survival was not increased
                                by ICD implantation, as in the coronary artery bypass graft (CABG) Patch trial (<a
                                    class="tab-link" href="#bib858" data-tab="pane-pcw-references">43</a>), the ICD did
                                not provide value, because the higher costs were unaccompanied by a gain in life
                                expectancy (<a class="tab-link" href="#bib829" data-tab="pane-pcw-references">14</a>).
                            </p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5715">The MADIT-II trial randomized patients with previous MI and LVEF &lt;30%,
                                without any limitation of HF class, to ICDs or not (<a class="tab-link" href="#bib821"
                                    data-tab="pane-pcw-references">6</a>). Thirty-seven percent of the patients were in
                                class I congestive heart failure (CHF). Mortality was reduced with an ICD.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5720">Most of the relevant data for the guidelines of CRT in HF come from seminal
                                trials published from 2002 to 2010. The first of these was the MIRACLE (Multicenter
                                InSync Randomized Clinical Evaluation) trial, which took patients with LVEF ≤35%,
                                moderate to severe HF, and QRS duration ≥130 ms (<a class="tab-link" href="#bib831"
                                    data-tab="pane-pcw-references">16</a>). There was a benefit in the 6-minute walk
                                test, QOL, functional HF classification, and LVEF. The COMPANION (Comparison of Medical
                                Therapy, Pacing and Defibrillation in Heart Failure) trial, which enrolled NYHA class
                                III to IV patients with QRS ≥120 ms, included 3 arms: GDMT, CRT-D, and CRT pacemaker
                                (CRT-P) (<a class="tab-link" href="#bib832" data-tab="pane-pcw-references">17</a>). The
                                primary endpoint of death or hospitalization was decreased with CRT-P and CRT-D. The
                                CARE-HF (Cardiac Resynchronization Heart Failure) trial included a similar group with
                                NYHA class III to IV, LVEF ≤35%, QRS &gt;120 ms, and showed a significant reduction in
                                primary and endpoint of death or hospitalization (<a class="tab-link" href="#bib833"
                                    data-tab="pane-pcw-references">18</a>). In the REVERSE (Resynchronization Reverses
                                Remodeling in Systolic Left Ventricular Dysfunction) trial, patients with NYHA class I
                                to II and LVEF ≤40% were randomized to CRT-D on for 1 year and CRT-D off for 1 year or
                                vice versa (<a class="tab-link" href="#bib834" data-tab="pane-pcw-references">19</a>). A
                                HF composite endpoint was less common when CRT was activated. MADIT-CRT enrolled NYHA
                                class I and II HF with LVEF ≤30% and QRS ≥130 ms and compared CRT-D with ICD (<a
                                    class="tab-link" href="#bib835" data-tab="pane-pcw-references">20</a>). The primary
                                endpoint of death or HF was reduced by CRT-D. The RAFT (Resynchronization-Defibrillation
                                for Ambulatory Heart Failure) trial randomized patients with NYHA class II to III HF,
                                LVEF ≤30%, QRS &gt;120 ms, or paced QRS ≥200 ms and compared CRT-D with ICD (<a
                                    class="tab-link" href="#bib836" data-tab="pane-pcw-references">21</a>). Again, there
                                was a reduction in the primary endpoint of death or HF hospitalization.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5725">The economic value of CRT has been evaluated by 3 RCTs (COMPANION [<a
                                    class="tab-link" href="#bib837" data-tab="pane-pcw-references">22</a>], MADIT-CRT
                                [<a class="tab-link" href="#bib841" data-tab="pane-pcw-references">26</a>], and REVERSE
                                [<a class="tab-link" href="#bib838" data-tab="pane-pcw-references">23</a>]), 2
                                model-based analyses (<a class="tab-link" href="#bib840"
                                    data-tab="pane-pcw-references">25</a>,<a class="tab-link" href="#bib842"
                                    data-tab="pane-pcw-references">27</a>), and 1 observational study (<a
                                    class="tab-link" href="#bib839" data-tab="pane-pcw-references">24</a>). These
                                analyses consistently found CRT increased survival and QOL in addition to increasing
                                health care costs. However, the economic value of CRT likely varies as a result of the
                                shown variation in treatment effect (<a class="tab-link" href="#bib841"
                                    data-tab="pane-pcw-references">26</a>). Among populations with larger expected
                                mortality reduction and improvement in QOL, such as patients with a LBBB with QRS
                                duration &gt;150 ms, the cost per QALY is &lt;$60,000 (<a class="tab-link"
                                    href="#bib837" data-tab="pane-pcw-references">22</a>,<a class="tab-link"
                                    href="#bib841" data-tab="pane-pcw-references">26</a>,<a class="tab-link"
                                    href="#bib842" data-tab="pane-pcw-references">27</a>). Among other populations
                                expected to have smaller treatment benefit, the economic value is more uncertain.
                                However, a model-based analysis of patients with NYHA class I to II found the
                                incremental cost-effectiveness ratio remained &lt;$150,000 per QALY with even small
                                reductions in all-cause mortality (<a class="tab-link" href="#bib842"
                                    data-tab="pane-pcw-references">27</a>). Therefore, CRT likely provides at least
                                intermediate value for patients with other guideline-indicated recommendations in which
                                CRT is expected to reduce mortality.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">6.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5730">Subgroup analysis of the previously mentioned trials has informed us of the
                                predictors of benefit, including longer QRS duration, and LBBB versus non-LBBB (<a
                                    class="tab-link" href="#bib843" data-tab="pane-pcw-references">28</a>). The most
                                benefit was gained with wider QRS durations and with LBBB. This was true in COMPANION,
                                CARE-HF, MADIT-CRT, REVERSE, and RAFT (<a class="tab-link" href="#bib832"
                                    data-tab="pane-pcw-references">17</a>,<a class="tab-link" href="#bib844"
                                    data-tab="pane-pcw-references">29-32</a>). A QRS duration &gt;150 ms was also a
                                predictor of response, and in those with non-LBBB, a prolonged PR predicted benefit in
                                MADIT-CRT but not in REVERSE (<a class="tab-link" href="#bib848"
                                    data-tab="pane-pcw-references">33</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">7.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5750">Extension of benefit to those with LVEF between 35% and 50% has been seen. In
                                the BLOCK-HF (Biventricular versus Right Ventricular Pacing in Heart Failure) trial,
                                patients with NYHA class I to III HF, LVEF ≤50%, and atrioventricular block randomized
                                to RV pacing or CRT, there was benefit to CRT in reduction in the primary outcome of
                                death, urgent HF visit, or 15% increase in LV end systolic volume (<a class="tab-link"
                                    href="#bib849" data-tab="pane-pcw-references">34</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">8.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5735">In the previously mentioned CRT trials, there was some benefit for those with
                                LBBB and QRS durations between 120 and 149, but not as much benefit as those with LBBB
                                ≥150 ms (<a class="tab-link" href="#bib832" data-tab="pane-pcw-references">17</a>,<a
                                    class="tab-link" href="#bib843" data-tab="pane-pcw-references">28-32</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">9.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5740">Several trials have included patients with AF. In the MUSTIC AF (Multisite
                                Stimulation in Cardiomyopathies) (<a class="tab-link" href="#bib859"
                                    data-tab="pane-pcw-references">44</a>), RAFT (<a class="tab-link" href="#bib860"
                                    data-tab="pane-pcw-references">45</a>), and the SPARE (Spanish Atrial Fibrillation
                                and Resynchronization) (<a class="tab-link" href="#bib861"
                                    data-tab="pane-pcw-references">46</a>) trials, there were benefits in patients with
                                AF, while in COMPANION (<a class="tab-link" href="#bib862"
                                    data-tab="pane-pcw-references">47</a>), AF attenuated the benefit of CRT. In the
                                PAVE (Post AV Nodal Ablation Evaluation) study, patients with NYHA class II to III, mean
                                LVEF of 46%, and AF undergoing atrioventricular node ablation, CRT improved the 6-minute
                                walk test and LVEF compared with those who were RV paced (<a class="tab-link"
                                    href="#bib850" data-tab="pane-pcw-references">35</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">10.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5745">In patients in whom there is an expected high burden of ventricular pacing,
                                especially if &gt;40%, CRT may be used to reduce mortality, reduce hospitalizations, and
                                improve symptoms and QOL (<a class="tab-link" href="#bib850"
                                    data-tab="pane-pcw-references">35</a>,<a class="tab-link" href="#bib863"
                                    data-tab="pane-pcw-references">48</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">11.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5755">Identification of specific arrhythmogenic genetic variants such as
                                <i>LMNA/C</i>, desmosomal proteins, phospholamban, and Filamin-C carry implications for
                                implantation of ICDs for primary prevention of sudden death even in patients who have
                                LVEF &gt;35%, or &lt;3 months of GDMT. Most patients with <i>LMNA/C</i> cardiomyopathy
                                will progress to cardiac transplantation, sometimes precipitated by refractory
                                arrhythmias more than by pump failure (<a class="tab-link" href="#bib851"
                                    data-tab="pane-pcw-references">36-38</a>,<a class="tab-link" href="#bib864"
                                    data-tab="pane-pcw-references">49</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">12.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5760">Subgroup analysis of the CRT RCTs has shown that patients with LVEFs ≤35%,
                                non-LBBB, and QRS duration of 120 to 149 ms and NYHA class III to ambulatory class IV
                                did not derive as much benefit as those with LBBB ≥120 ms (<a class="tab-link"
                                    href="#bib832" data-tab="pane-pcw-references">17</a>,<a class="tab-link"
                                    href="#bib843" data-tab="pane-pcw-references">28-32</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">13.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5765">The MADIT-CRT trial included NYHA class I (and class II) patients with
                                ischemic heart disease, LVEF ≤30%, and QRS &gt;130 ms (<a class="tab-link"
                                    href="#bib854" data-tab="pane-pcw-references">39</a>). Patients with nonischemic
                                cardiomyopathy were enrolled if they had NYHA class II HF.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">14.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5770">Extension of benefit to patients with narrow QRS has been attempted but has
                                generally failed. In the RETHINQ (Cardiac Resynchronization Therapy in Patients with
                                Heart Failure and Narrow QRS) trial, patients with QRS duration &lt;130 ms were
                                randomized to CRT or not (<a class="tab-link" href="#bib855"
                                    data-tab="pane-pcw-references">40</a>). There was no benefit from CRT, but subgroup
                                analysis showed there was a benefit with QRS durations between 120 and 130 ms. In the
                                ECHO-CRT (Echocardiography Guided Cardiac Resynchronization Therapy) trial, patients
                                with NYHA class III to IV HF, LVEF ≤35% and a QRS duration ≤130 ms, and mechanical
                                dysynchrony on echocardiography underwent randomization to CRT (<a class="tab-link"
                                    href="#bib865" data-tab="pane-pcw-references">50</a>). There was no benefit to CRT
                                in this trial. And in the LESSER-EARTH (Evaluation of Resynchronization Therapy for
                                Heart Failure) trial, patients with severe LV dysfunction and QRS &lt;120 ms derived no
                                benefit from CRT (<a class="tab-link" href="#bib866"
                                    data-tab="pane-pcw-references">51</a>). The NARROW-CRT (Narrow QRS Ischemic Patients
                                Treated With Cardiac Resynchronization Therapy) was the only trial that showed a benefit
                                in a clinical composite score in patients with an indication for an ICD and QRS &lt;120
                                ms (<a class="tab-link" href="#bib867" data-tab="pane-pcw-references">52</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">15.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5775">Subgroup analysis of the CRT trials has shown no benefit for those with LVEF
                                ≤35%, non-LBBB 120 to 149, and NYHA class I-II HF (<a class="tab-link" href="#bib832"
                                    data-tab="pane-pcw-references">17</a>,<a class="tab-link" href="#bib843"
                                    data-tab="pane-pcw-references">28-32</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">16.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5780">The 1-year survival is a standard inclusion for ICD and CRT trials (<a
                                    class="tab-link" href="#bib816" data-tab="pane-pcw-references">1-9</a>,<a
                                    class="tab-link" href="#bib831" data-tab="pane-pcw-references">16-21</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.4" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.4">
                <div id="acsectitle0340" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0340">7.4.2 Other Implantable Electrical Interventions
            </h4>
            <p id="p5790">Autonomic nervous system modulation is intriguing as a treatment for HFrEF because of the
                heightened sympathetic response and decreased parasympathetic response in HF (<a class="tab-link"
                    href="#bib868" data-tab="pane-pcw-references">1</a>). Trials of device stimulation of the vagus
                nerve, spinal cord, and baroreceptors have had mixed responses (<a class="tab-link" href="#bib869"
                    data-tab="pane-pcw-references">2</a>). An implantable device that electrically stimulates the
                baroreceptors of the carotid artery has been approved by the FDA for the improvement of symptoms in
                patients with advanced HF who are unsuited for treatment with other HF devices including CRT. In a
                prospective, multicenter, RCT with a total of 408 patients with current or recent NYHA class III HF,
                LVEF ≤35%, baroreceptor stimulation was associated with improvements in QOL, exercise capacity, and
                NT-proBNP levels (<a class="tab-link" href="#bib870" data-tab="pane-pcw-references">3</a>). To date,
                there are no mortality or hospitalization rates results available with this device. Although early
                trials of vagus nerve stimulation were positive, the largest and latest trial did not show a reduction
                in mortality and HF hospitalizations (<a class="tab-link" href="#bib871"
                    data-tab="pane-pcw-references">4</a>). Multisite LV pacing studies initially were promising (<a
                    class="tab-link" href="#bib872" data-tab="pane-pcw-references">5</a>,<a class="tab-link"
                    href="#bib873" data-tab="pane-pcw-references">6</a>). However, more recent data have not confirmed
                benefit, and the larger phase 2 trial was terminated early for low probability of benefit (<a
                    class="tab-link" href="#bib874" data-tab="pane-pcw-references">7</a>). His bundle and left bundle
                pacing are attractive because they use the intrinsic conduction system. In observational data, there
                does appear to be a benefit over RV pacing (<a class="tab-link" href="#bib875"
                    data-tab="pane-pcw-references">8</a>); however, comparisons to CRT are limited (<a class="tab-link"
                    href="#bib876" data-tab="pane-pcw-references">9</a>,<a class="tab-link" href="#bib877"
                    data-tab="pane-pcw-references">10</a>). Cardiac contractility modulation (CCM), a device-based
                therapy that involves applying relatively high-voltage, long-duration electric signals to the RV septal
                wall during the absolute myocardial refractory period, has been associated with augmentation of LV
                contractile performance. CCM is FDA-approved for patients with NYHA class III with LVEF of 25% to 45%
                who are not candidates for CRT. Four RCTs have shown benefits in exercise capacity and QOL but, as of
                yet, no benefits in death or hospitalizations (<a class="tab-link" href="#bib878"
                    data-tab="pane-pcw-references">11-14</a>). Most patients in these trials were class III CHF (<a
                    class="tab-link" href="#bib870" data-tab="pane-pcw-references">3</a>).</p>
            <div id="acsec11.4" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.4">
                <div id="acsectitle0345" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0345">7.4.3 Revascularization for CAD</h4>
            <div id="undtbl29" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl29">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0640">Recommendation for Revascularization for CAD</p>
                            <p id="tspara0645">Referenced studies that support the recommendation are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0620" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1620"><strong>In selected patients with HF, reduced EF (EF
                                                        ≤35%), and suitable coronary anatomy, surgical revascularization
                                                        plus GDMT is beneficial to improve symptoms, cardiovascular
                                                        hospitalizations, and long-term all-cause mortality</strong> (<a
                                                        class="tab-link" href="#bib882"
                                                        data-tab="pane-pcw-references">1-8</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5800"><strong>Synopsis</strong></p>
            <p id="p5805">CAD is commonly associated with HF, necessitating revascularization in selected patients with
                angina or HF symptoms. Data from the STICH Trial showed that, compared with optimal medical management
                alone, CABG surgery plus GDMT did not reduce the primary endpoint of all-cause mortality at a median of
                56 months; however, at 10 years’ follow-up, CABG+GDMT resulted in significant reductions in all-cause
                mortality, cardiovascular mortality, and death from any cause or cardiovascular hospitalization in
                patients with LVEF ≤35% and ischemic cardiomyopathy (<a class="tab-link" href="#bib888"
                    data-tab="pane-pcw-references">7</a>,<a class="tab-link" href="#bib889"
                    data-tab="pane-pcw-references">8</a>). Furthermore, a retrospective analysis showed significant
                reductions in first and recurrent all-cause, cardiovascular, and HF hospitalizations at 10 years in
                patients receiving CABG+ optimal medical therapy compared with optimal medical therapy alone (<a
                    class="tab-link" href="#bib883" data-tab="pane-pcw-references">2</a>). Similar benefits from
                percutaneous coronary intervention revascularization, in this cohort, have not yet been shown in an RCT,
                although the REVIVED-BCIS2 (Study of Efficacy and Safety of Percutaneous Coronary Intervention to
                Improve Survival in Heart Failure) trial, which compares percutaneous coronary intervention with medical
                therapy in a similar population, is ongoing (<a class="tab-link" href="#bib890"
                    data-tab="pane-pcw-references">9</a>). Recent data continue to show a benefit of CABG over
                percutaneous coronary intervention in patients with diabetes, CAD, and LV dysfunction and in patients
                with left main CAD and moderate or severe LV dysfunction (<a class="tab-link" href="#bib885"
                    data-tab="pane-pcw-references">4</a>,<a class="tab-link" href="#bib887"
                    data-tab="pane-pcw-references">6</a>,<a class="tab-link" href="#bib891"
                    data-tab="pane-pcw-references">10</a>). <a data-tab="pane-pcw-Figures" href="#fig9" id="fig9R"
                    class="">Figure 9</a> summarizes revascularization and additional device therapy recommendations.
            </p>
            <p id="p5810"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1290" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5815">CABG has been shown to improve outcomes in patients with left main or left
                                main equivalent disease and HF (<a class="tab-link" href="#bib882"
                                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib885"
                                    data-tab="pane-pcw-references">4</a>,<a class="tab-link" href="#bib891"
                                    data-tab="pane-pcw-references">10-14</a>). Long-term follow-up shows a reduction in
                                all-cause, cardiovascular, and HF hospitalizations and in all-cause and cardiovascular
                                mortality in patients with LV dysfunction who receive CABG and GDMT compared with GDMT
                                alone (<a class="tab-link" href="#bib883" data-tab="pane-pcw-references">2</a>,<a
                                    class="tab-link" href="#bib888" data-tab="pane-pcw-references">7</a>). The long-term
                                survival benefit is greater in those with more advanced ischemic cardiomyopathy (lower
                                EF or 3-vessel disease) and diminishes with increasing age (<a class="tab-link"
                                    href="#bib886" data-tab="pane-pcw-references">5</a>,<a class="tab-link"
                                    href="#bib888" data-tab="pane-pcw-references">7</a>). CABG also improves QOL
                                compared with GDMT alone (<a class="tab-link" href="#bib884"
                                    data-tab="pane-pcw-references">3</a>). An RCT of CABG combined with surgical
                                ventricular remodeling compared with CABG alone did not show a reduction in death or
                                hospitalization, or improvement in symptoms with surgical ventricular remodeling (<a
                                    class="tab-link" href="#bib896" data-tab="pane-pcw-references">15</a>). Surgical
                                ventricular remodeling performed at the time of CABG may be useful in patients with
                                intractable HF, large thrombus, or persistent arrhythmias resulting from well-defined
                                aneurysm or scar, if other therapies are ineffective or contraindicated (<a
                                    class="tab-link" href="#bib896" data-tab="pane-pcw-references">15</a>,<a
                                    class="tab-link" href="#bib897" data-tab="pane-pcw-references">16</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec11">
                <div id="acsectitle0350" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0350">7.5 Valvular Heart Disease</h3>
            <div id="undtbl30" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl30">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0650">Recommendations for Valvular Heart Disease</p>
                            <p id="tspara0655">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0625" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1625"><strong>In patients with HF, VHD should be managed in a
                                                        multidisciplinary manner in accordance with clinical practice
                                                        guidelines for VHD to prevent worsening of HF and adverse
                                                        clinical outcomes</strong> (<a class="tab-link" href="#bib898"
                                                        data-tab="pane-pcw-references">1-11</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0630" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1630"><strong>In patients with chronic severe secondary MR and
                                                        HFrEF, optimization of GDMT is recommended before any
                                                        intervention for secondary MR related to LV dysfunction
                                                        (</strong><a class="tab-link" href="#bib900"
                                                        data-tab="pane-pcw-references"><strong>3-5</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib909"
                                                        data-tab="pane-pcw-references"><strong>12-14</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5830"><strong>Synopsis</strong></p>
            <p id="p5835">GDMT applies to all patients with HFrEF, irrespective of the presence of VHD. Significant
                valve disease warrants evaluation by a multidisciplinary team with expertise in VHD, and management
                should proceed in accordance with the VHD guidelines (<a class="tab-link" href="#bib912"
                    data-tab="pane-pcw-references">15</a>).</p>
            <p id="p5840"><strong>Mitral Regurgitation</strong></p>
            <p id="p5845">Optimization of GDMT can improve secondary MR associated with LV dysfunction and obviate the
                need for intervention (<a class="tab-link" href="#bib911" data-tab="pane-pcw-references">14</a>,<a
                    class="tab-link" href="#bib913" data-tab="pane-pcw-references">16</a>,<a class="tab-link"
                    href="#bib914" data-tab="pane-pcw-references">17</a>). Therefore, optimizing GDMT and reassessing MR
                before MV interventions are important. Patients with persistent severe secondary MR despite GDMT may
                benefit from either surgical or transcatheter repair, depending on clinical scenario. Thus,
                patient-centric conversation with a multidisciplinary cardiovascular team that includes a cardiologist
                with expertise in HF is essential when considering MV intervention (<a class="tab-link" href="#bib912"
                    data-tab="pane-pcw-references">15</a>). Two RCTs of transcatheter mitral valve edge-to-edge repair
                (TEER) in patients with HFrEF and severe secondary MR have been performed. The COAPT trial showed
                significant reduction in HF and all-cause mortality in patients treated with TEER and GDMT compared with
                GDMT alone, while MITRA-FR (Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in
                Patients With Severe Secondary Mitral Regurgitation) showed no benefit of TEER over GDMT in reducing
                death or hospitalization (<a class="tab-link" href="#bib903" data-tab="pane-pcw-references">6</a>).
                Specifically, transcatheter edge-to-edge MV repair has been shown to be beneficial in patients with
                persistent symptoms despite GDMT, appropriate anatomy on transesophageal echocardiography and with LVEF
                between 20% and 50%, LVESD ≤70 mm, and pulmonary artery systolic pressure ≤70 mm Hg (<a class="tab-link"
                    href="#bib903" data-tab="pane-pcw-references">6</a>) (<a data-tab="pane-pcw-Figures" href="#fig10"
                    id="fig10R" class="">Figure 10</a>). Optimal management of secondary MR may depend on the degree of
                MR relative to LV remodeling (<a class="tab-link" href="#bib901" data-tab="pane-pcw-references">4</a>,<a
                    class="tab-link" href="#bib902" data-tab="pane-pcw-references">5</a>,<a class="tab-link"
                    href="#bib911" data-tab="pane-pcw-references">14</a>,<a class="tab-link" href="#bib915"
                    data-tab="pane-pcw-references">18-22</a>). Disproportionate MR (MR out of proportion to LV
                remodeling) may respond better to procedural interventions that reduce MR, such as CRT, TEER, and MV
                surgery. Proportionate MR may respond to measures that reverse LV remodeling and reduce LV volumes, such
                as GDMT and CRT.</p>
            <section class="article-section__inline-figure">
                <figure id="fig10" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/ee7fe0cb-9508-4ba3-b53f-4488aa418cc9/gr10.jpg"
                        data-lg-src="/cms/asset/79de3443-b576-4574-9d8a-c11483bc929d/gr10.jpg" alt="Figure 10">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/79de3443-b576-4574-9d8a-c11483bc929d/gr10.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig10&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 10</span></strong>
                        <p>Treatment Approach in Secondary Mitral Regurgitation</p>
                        <p><strong>Colors correspond to</strong> <a class="ref showTableEvent" data-id="tbl2"
                                href="#tbl2"><strong>Table 2</strong></a><strong>.</strong> AF indicates atrial
                            fibrillation; CABG, coronary artery bypass graft; ERO, effective regurgitant orifice; GDMT,
                            guideline-directed medical therapy; HF, heart failure; LVEF, left ventricular ejection
                            fraction; LVESD, left ventricular end-systolic diameter; MR, mitral regurgitation; MV,
                            mitral valve; PASP, pulmonary artery systolic pressure; RF, regurgitant fraction; RVol,
                            regurgitant volume; and Rx, medication. ∗Chordal-sparing MV replacement may be reasonable to
                            choose over downsized annuloplasty repair.</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p5850"><strong>Aortic Stenosis</strong></p>
            <p id="p5855">In patients with symptomatic aortic stenosis, transcatheter and surgical aortic valve repair
                can improve survival, symptoms, and LV function (<a class="tab-link" href="#bib912"
                    data-tab="pane-pcw-references">15</a>). However, the choice of transcatheter aortic valve
                implantation versus surgical aortic valve replacement is based on shared decision-making, indications,
                and assessment of the risk-benefit profile (<a class="tab-link" href="#bib920"
                    data-tab="pane-pcw-references">23</a>,<a class="tab-link" href="#bib921"
                    data-tab="pane-pcw-references">24</a>). The benefit of GDMT in nonsevere aortic stenosis and HFrEF
                is being evaluated in the TAVR UNLOAD (Transcatheter Aortic Valve Replacement to Unload the Left
                Ventricle in Patients With Advanced Heart Failure) trial (<a class="tab-link" href="#bib922"
                    data-tab="pane-pcw-references">25</a>). GDMT is usually continued in conjunction with clinical
                surveillance and imaging in patients with nonsevere aortic stenosis and reduced EF.</p>
            <p id="p5860"><strong>Tricuspid Regurgitation</strong></p>
            <p id="p5865">The severity of secondary tricuspid regurgitation may be dynamic, depending on RV function and
                pulmonary hypertension, and management entails focusing on underlying causes, such as pulmonary
                hypertension, RV failure, and HFrEF. Referral to the multidisciplinary team for consideration of
                intervention might be helpful in patients with refractory tricuspid regurgitation.</p>
            <p id="p5870"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1295" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5875">VHD is a significant cause of HF. In patients with HF, management of VHD
                                should be performed by a multidisciplinary team with expertise in HF and VHD, in
                                accordance with the VHD guidelines (<a class="tab-link" href="#bib912"
                                    data-tab="pane-pcw-references">15</a>). Cardiologists with expertise in the
                                management of HF are integral to the multidisciplinary team and to guiding the
                                optimization of GDMT in patients with HF and coexisting valve disease. Severe aortic
                                stenosis, aortic regurgitation, MR, and tricuspid regurgitation are associated with
                                adverse outcomes and require timely assessment, optimization of medical therapies, and
                                consideration of surgical or transcatheter interventions accordingly to prevent
                                worsening of HF and other adverse outcomes (<a class="tab-link" href="#bib898"
                                    data-tab="pane-pcw-references">1-10</a>,<a class="tab-link" href="#bib909"
                                    data-tab="pane-pcw-references">12-20</a>,<a class="tab-link" href="#bib919"
                                    data-tab="pane-pcw-references">22-35</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5880">GDMT, including RAAS inhibition, beta blockers, and biventricular pacing,
                                improves MR and LV dimensions in patients with HFrEF and secondary MR, particularly MR
                                that is proportionate to LV dilatation (<a class="tab-link" href="#bib898"
                                    data-tab="pane-pcw-references">1-5</a>,<a class="tab-link" href="#bib909"
                                    data-tab="pane-pcw-references">12</a>,<a class="tab-link" href="#bib910"
                                    data-tab="pane-pcw-references">13</a>,<a class="tab-link" href="#bib914"
                                    data-tab="pane-pcw-references">17</a>). In a small RCT, sacubitril-valsartan
                                resulted in a significant reduction in effective regurgitant area and in regurgitant
                                volume when compared with valsartan. The COAPT trial showed a mortality benefit with
                                TEER in patients with severe secondary MR, LVEF between 20% and 50%, LV end-systolic
                                diameter ≤70 mm, PA systolic pressure ≤70 mm Hg, and persistent symptoms (NYHA class II
                                to IV) while on optimal GDMT (<a class="tab-link" href="#bib925"
                                    data-tab="pane-pcw-references">28</a>), and these criteria apply when considering
                                TEER. A cardiologist with expertise in the management of HF is integral to shared
                                decision-making for valve intervention and should guide optimization of GDMT to ensure
                                that medical options for HF and secondary MR have been effectively applied for an
                                appropriate time period and exhausted before considering intervention.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec11">
                <div id="acsectitle0355" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0355">7.6 Heart Failure With Mildly Reduced EF (HFmrEF)
                and Improved EF (HFimpHF)</h3>
            <div id="acsec11.6" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.6">
                <div id="acsectitle0360" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0360">7.6.1 HF With Mildly Reduced Ejection Fraction</h4>
            <div id="undtbl31" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl31">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0660">Recommendations for HF With Mildly Reduced Ejection Fraction</p>
                            <p id="tspara0665">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0635" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1635"><strong>In patients with HFmrEF, SGLT2i can be beneficial
                                                        in decreasing HF hospitalizations and cardiovascular
                                                        mortality</strong> (<a class="tab-link" href="#bib933"
                                                        data-tab="pane-pcw-references">1</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0640" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1640"><strong>Among patients with current or previous
                                                        symptomatic HFmrEF (LVEF, 41%–49%), use of evidence-based beta
                                                        blockers for HFrEF, ARNi, ACEi, or ARB, and MRAs may be
                                                        considered to reduce the risk of HF hospitalization and
                                                        cardiovascular mortality, particularly among patients with LVEF
                                                        on the lower end of this spectrum</strong> (<a class="tab-link"
                                                        href="#bib934"
                                                        data-tab="pane-pcw-references">2-9</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5895"><strong>Synopsis</strong></p>
            <p id="p5900">There are no prospective RCTs for patients specifically with HFmrEF (LVEF, 41%–49%). All data
                for HFmrEF are from post hoc or subsets of analyses from previous HF trials with patients now classified
                as HFmrEF. LVEF is a spectrum, and among patients with LVEF 41% to 49%, patients with LVEF on the lower
                end of this spectrum appear to respond to medical therapies similarly to patients with HFrEF. Thus, it
                may be reasonable to treat these patients with GDMT used for treatment of HFrEF. Patients with HFmrEF
                should have repeat evaluation of LVEF to determine the trajectory of their disease process. Future
                prospective studies are needed to further clarify treatment recommendations for patients with HFmrEF. <a
                    data-tab="pane-pcw-Figures" href="#fig11" id="fig11R" class="">Figure 11</a> summarizes COR 1, 2a,
                and 2b for HFmrEF.</p>
            <section class="article-section__inline-figure">
                <figure id="fig11" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/885df003-65b3-4ff0-b4af-315746673fdb/gr11.jpg"
                        data-lg-src="/cms/asset/bf723875-ecc1-4f2b-ae5f-177b690afab9/gr11.jpg" alt="Figure 11">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/bf723875-ecc1-4f2b-ae5f-177b690afab9/gr11.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig11&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 11</span></strong>
                        <p>Recommendations for Patients With Mildly Reduced LVEF (41%–49%)</p>
                        <p><strong>Colors correspond to COR in</strong> <a class="ref showTableEvent" data-id="tbl2"
                                href="#tbl2"><strong>Table 2</strong></a><strong>.</strong> Medication recommendations
                            for HFmrEF are displayed. ACEi indicates angiotensin-converting enzyme inhibitor; ARB,
                            angiotensin receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; HFmrEF, heart
                            failure with mildly reduced ejection fraction; HFrEF, heart failure with reduced ejection
                            fraction; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor
                            antagonist; and SGLT2i, sodium- glucose cotransporter 2 inhibitor.</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p5905"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1300" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5910">EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart
                                Failure with Preserved Ejection Fraction) showed a significant benefit of the SGLT2i,
                                empagliflozin, in patients with symptomatic HF, with LVEF &gt;40% and elevated
                                natriuretic peptides (<a class="tab-link" href="#bib933"
                                    data-tab="pane-pcw-references">1</a>). The 21% reduction in the primary composite
                                endpoint of time to HF hospitalization or cardiovascular death was driven mostly by a
                                significant 29% reduction in time to HF hospitalization (nonsignificant lower
                                cardiovascular death [HR, 0.91; 95% CI, 0.76–1.0]), with no benefit on all-cause
                                mortality. Empagliflozin also resulted in a significant reduction in total HF
                                hospitalizations, decrease in the slope of the eGFR decline, and a modest improvement in
                                QOL at 52 weeks. Of note, the benefit was similar irrespective of the presence or
                                absence of diabetes at baseline. In a subgroup of 1983 patients with LVEF 41% to 49% in
                                EMPEROR-Preserved, empagliflozin, a SGLT2i, reduced the risk of the primary composite
                                endpoint of cardiovascular death or hospitalization for HF (<a class="tab-link"
                                    href="#bib933" data-tab="pane-pcw-references">1</a>). Although the benefit in the
                                primary endpoint did not have a significant interaction by LVEF subgroups (41%–49%,
                                50%–&lt;60%, and &gt;60%) (<a class="tab-link" href="#bib933"
                                    data-tab="pane-pcw-references">1</a>), in a subgroup analysis by EF, there was a
                                signal for lower benefit on the primary composite endpoint, first and recurrent
                                hospitalizations for HF at higher LVEFs &gt;62.5% (<a class="tab-link" href="#bib942"
                                    data-tab="pane-pcw-references">10</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5915">Post hoc and subsets of analyses of HFrEF trials that included HFmrEF (LVEF
                                41%–49%) have suggested benefit from use of GDMT for HFrEF (i.e., beta blockers, ARNi,
                                ACEi or ARB, and spironolactone) (<a class="tab-link" href="#bib934"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib935"
                                    data-tab="pane-pcw-references">3</a>,<a class="tab-link" href="#bib937"
                                    data-tab="pane-pcw-references">5-8</a>). The BBmeta-HF (Beta-blockers in Heart
                                Failure Collaborative Group) performed a meta-analysis of 11 HF trials; in a subgroup of
                                575 patients with LVEF 40% to 49% in sinus rhythm, beta blockers reduced the primary
                                outcome of all-cause and cardiovascular mortality (<a class="tab-link" href="#bib934"
                                    data-tab="pane-pcw-references">2</a>). A subgroup analysis of the PARAGON-HF
                                (Prospective Comparison of ARNi with ARB Global Outcomes in HF with Preserved Ejection
                                Fraction) trial for patients with LVEF 45% to 57% (lower range of EFs in the trial)
                                suggested benefit of sacubitril-valsartan versus valsartan alone (rate ratio, 0.78; 95%
                                CI, 0.64-0.95) (<a class="tab-link" href="#bib935"
                                    data-tab="pane-pcw-references">3</a>). In a subgroup of 1322 patients with LVEF 41%
                                to 49% in a post hoc analysis of pooled data from the CHARM (Candesartan in Heart
                                failure-Assessment of Reduction in Mortality and morbidity) trials, candesartan reduced
                                risk of cardiovascular death and HF hospitalization, the risk of first HF
                                hospitalization, and the risk of recurrent HF hospitalization (<a class="tab-link"
                                    href="#bib937" data-tab="pane-pcw-references">5</a>). In a subgroup of 520 patients
                                with LVEF 44% to 49% in a post hoc analysis of TOPCAT (Treatment of Preserved Cardiac
                                Function Heart Failure With an Aldosterone Antagonist), spironolactone reduced the risk
                                of the primary composite endpoint of cardiovascular death, HF hospitalization, or
                                resuscitated sudden death, which was mostly caused by a reduction in cardiovascular
                                mortality with spironolactone and among patients enrolled in North and South America (<a
                                    class="tab-link" href="#bib938" data-tab="pane-pcw-references">6</a>).
                                Spironolactone is preferred among HFmrEF patients with poorly controlled hypertension
                                given previous evidence supporting its use for blood pressure management (<a
                                    class="tab-link" href="#bib933" data-tab="pane-pcw-references">1</a>). Continuation
                                of GDMT for patients with improved HFrEF and HFmrEF is important to reduce risk of
                                recrudescent HF (<a class="tab-link" href="#bib936"
                                    data-tab="pane-pcw-references">4</a>). Meta-analyses report diverse findings with
                                neurohormonal antagonism in patients with HFmrEF, specifying benefit in certain
                                subgroups, underlining the heterogeneity of this phenotype (<a class="tab-link"
                                    href="#bib934" data-tab="pane-pcw-references">2</a>,<a class="tab-link"
                                    href="#bib941" data-tab="pane-pcw-references">9</a>). Patients with HFmrEF should
                                have repeat evaluation of LVEF to determine the trajectory of their disease process and
                                should undergo testing as clinically indicated to diagnose conditions warranting
                                disease-specific therapy (e.g., CAD, sarcoidosis, amyloidosis).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.6" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.6">
                <div id="acsectitle0365" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0365">7.6.2 HF With Improved Ejection Fraction</h4>
            <div id="undtbl32" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl32">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0670">Recommendation for HF With Improved Ejection Fraction</p>
                            <p id="tspara0675">Referenced studies that support the recommendation are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0645" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1645"><strong>In patients with HFimpEF after treatment, GDMT
                                                        should be continued to prevent relapse of HF and LV dysfunction,
                                                        even in patients who may become asymptomatic</strong> (<a
                                                        class="tab-link" href="#bib943"
                                                        data-tab="pane-pcw-references">1</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p5930"><strong>Synopsis</strong></p>
            <p id="p5935">Although GDMT can result in improvement in symptoms, functional capacity, LVEF, and reverse
                remodeling in patients with HFrEF (<a class="tab-link" href="#bib944"
                    data-tab="pane-pcw-references">2</a>), in most patients, LV function and structural abnormalities do
                not fully normalize, and symptoms and biomarker abnormalities may persist or reoccur. Many patients
                deemed to have recovered from HF with resolution of symptoms and improvement of LVEF and natriuretic
                peptide levels will relapse after withdrawal of GDMT (<a class="tab-link" href="#bib943"
                    data-tab="pane-pcw-references">1</a>). Resolution of symptoms and improvement in cardiac function
                and biomarkers after treatment does not reflect full and sustained recovery but, rather, remission,
                which requires treatment to be maintained (<a class="tab-link" href="#bib945"
                    data-tab="pane-pcw-references">3</a>). Stage C HF patients are defined as patients with structural
                heart disease with previous or current symptoms of HF. In those patients who do not improve (i.e.,
                patients who remain symptomatic or with LV dysfunction), GDMT should not only be continued but also
                optimized.</p>
            <p id="p5940"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1305" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5945">In an open-label RCT (<a class="tab-link" href="#bib943"
                                    data-tab="pane-pcw-references">1</a>), phased withdrawal of HF medications in
                                patients with previous DCM—who were now asymptomatic, whose LVEF had improved from
                                &lt;40% to ≥50%, whose left ventricular end-diastolic volume (LVEDV) had normalized, and
                                who had an NT-proBNP concentration &lt;250 ng/L—resulted in relapse of cardiomyopathy
                                and HF in 40% of the patients within 6 months. Relapse was defined by at least 1 of
                                these: 1) a reduction in LVEF by &gt;10% and &lt;50%; 2) an increase in LVEDV by &gt;10%
                                and to higher than the normal range; 3) a 2-fold rise in NT-proBNP concentration and to
                                &gt;400 ng/L; or 4) clinical evidence of HF. Treatment was withdrawn successfully in
                                only 50% of patients (<a class="tab-link" href="#bib943"
                                    data-tab="pane-pcw-references">1</a>). Secondary analyses showed worsening Kansas
                                City Cardiomyopathy Questionnaire scores, a substantial reduction in LVEF, and
                                nonsignificant increases in NT-proBNP and LV volumes with withdrawal of HF medications.
                            </p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec11">
                <div id="acsectitle0370" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0370">7.7 Preserved EF (HFpEF)</h3>
            <div id="acsec11.7" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.7">
                <div id="acsectitle0375" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0375">7.7.1 HF With Preserved Ejection Fraction</h4>
            <div id="undtbl33" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl33">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0680">Recommendations for HF With Preserved Ejection Fraction<a
                                    class="ref table-fn" id="dtbl2fnlowast"
                                    href="javascript:popRef('dtbl2fnlowast')"><sup>∗</sup></a></p>
                            <p id="tspara0685">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0650" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1650"><strong>Patients with HFpEF and hypertension should have
                                                        medication titrated to attain blood pressure targets in
                                                        accordance with published clinical practice guidelines to
                                                        prevent morbidity</strong> (<a class="tab-link" href="#bib946"
                                                        data-tab="pane-pcw-references">1-3</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0655" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1655"><strong>In patients with HFpEF, SGLT2i can be beneficial
                                                        in decreasing HF hospitalizations and cardiovascular
                                                        mortality</strong> (<a class="tab-link" href="#bib949"
                                                        data-tab="pane-pcw-references">4</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-EO</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0660" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1660"><strong>In patients with HFpEF, management of AF can be
                                                        useful to improve symptoms.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0665" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1665"><strong>In selected patients with HFpEF, MRAs may be
                                                        considered to decrease hospitalizations, particularly among
                                                        patients with LVEF on the lower end of this spectrum</strong>
                                                    (<a class="tab-link" href="#bib950"
                                                        data-tab="pane-pcw-references">5-7</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0670" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1670"><strong>In selected patients with HFpEF, the use of ARB
                                                        may be considered to decrease hospitalizations, particularly
                                                        among patients with LVEF on the lower end of this spectrum
                                                        (</strong><a class="tab-link" href="#bib953"
                                                        data-tab="pane-pcw-references"><strong>8</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib954"
                                                        data-tab="pane-pcw-references"><strong>9</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0675" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">6.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1675"><strong>In selected patients with HFpEF, ARNi may be
                                                        considered to decrease hospitalizations, particularly among
                                                        patients with LVEF on the lower end of this spectrum
                                                        (</strong><a class="tab-link" href="#bib955"
                                                        data-tab="pane-pcw-references"><strong>10</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib956"
                                                        data-tab="pane-pcw-references"><strong>11</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: No-Benefit</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0680" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">7.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1680"><strong>In patients with HFpEF, routine use of nitrates or
                                                        phosphodiesterase-5 inhibitors to increase activity or QOL is
                                                        ineffective (</strong><a class="tab-link" href="#bib957"
                                                        data-tab="pane-pcw-references"><strong>12</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib958"
                                                        data-tab="pane-pcw-references"><strong>13</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn id="dtbl2fnlowast">
                            <p id="ntpara0075">∗ See <a class="ref sec" id="crosref1745" href="#sec11.2">Section
                                    7.2</a>, “Diuretics and Decongestion Strategies in Patients with HF,” and <a
                                    class="ref sec" id="crosref1750" href="#sec14.2">Section 10.2</a>, “Management of
                                Atrial Fibrillation (AF) in HF” for recommendations for use of diuretics and management
                                of AF in HF.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p5955"><strong>Synopsis</strong></p>
            <p id="p5960">HFpEF (LVEF ≥50%) is highly prevalent, accounting for up to 50% of all patients with HF, and
                is associated with significant morbidity and mortality (<a class="tab-link" href="#bib959"
                    data-tab="pane-pcw-references">14</a>). HFpEF is a heterogenous disorder, contributed to by
                comorbidities that include hypertension, diabetes, obesity, CAD, CKD, and specific causes such as
                cardiac amyloidosis (<a class="tab-link" href="#bib960" data-tab="pane-pcw-references">15-17</a>).
                Clinical trials have used variable definitions of HFpEF (e.g., LVEF ≥40%, 45%, or 50%, and the varying
                need for accompanying evidence of structural heart disease or elevated levels of natriuretic peptides)
                (<a class="tab-link" href="#bib963" data-tab="pane-pcw-references">18</a>). Until recently, clinical
                trials had been generally disappointing, with no benefit on mortality and marginal benefits on HF
                hospitalizations (<a class="tab-link" href="#bib950" data-tab="pane-pcw-references">5</a>,<a
                    class="tab-link" href="#bib953" data-tab="pane-pcw-references">8</a>,<a class="tab-link"
                    href="#bib956" data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib964"
                    data-tab="pane-pcw-references">19</a>,<a class="tab-link" href="#bib965"
                    data-tab="pane-pcw-references">20</a>). Currently, recommended management is that used for HF in
                general with use of diuretics to reduce congestion and improve symptoms (see <a class="ref sec"
                    id="crosref6785" href="#sec11.1.1">Section 7.1.1</a> for recommendations for nonpharmacological
                management and <a class="ref sec" id="crosref6790" href="#sec11.2">Section 7.2</a> for recommendations
                for diuretics), identification and treatment of specific causes such as amyloidosis, and management of
                contributing comorbidities such as hypertension, CAD, and AF (see <a class="ref sec" id="crosref6795"
                    href="#sec14.2">Section 10.2</a> for recommendations on management of AF). <a
                    data-tab="pane-pcw-Figures" href="#fig12" id="fig12R" class="">Figure 12</a> summarizes COR 1, 2a,
                and 2b for HFpEF.</p>
            <section class="article-section__inline-figure">
                <figure id="fig12" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/9ee9e14d-3164-4359-a6c7-f104e10298f8/gr12.jpg"
                        data-lg-src="/cms/asset/d8f99cc4-9edd-4287-b664-d1b9dc77132a/gr12.jpg" alt="Figure 12">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/d8f99cc4-9edd-4287-b664-d1b9dc77132a/gr12.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig12&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 12</span></strong>
                        <p>Recommendations for Patients With Preserved LVEF (≥50%)</p>
                        <p><strong>Colors correspond to COR in</strong> <a class="ref showTableEvent" data-id="tbl2"
                                href="#tbl2"><strong>Table 2</strong></a><strong>.</strong> Medication recommendations
                            for HFpEF are displayed. ARB indicates angiotensin receptor blocker; ARNi, angiotensin
                            receptor-neprilysin inhibitor; HF, heart failure; HFpEF, heart failure with preserved
                            ejection fraction; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor
                            antagonist; and SGLT2i, sodium-glucose cotransporter-2 inhibitor. ∗Greater benefit in
                            patients with LVEF closer to 50%.</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p5965"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1310" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5970">The role of blood pressure control is well established for the prevention of
                                HF, as well as for reduction of other cardiovascular events and HF mortality in patients
                                without prevalent baseline HF (<a class="tab-link" href="#bib946"
                                    data-tab="pane-pcw-references">1-3</a>,<a class="tab-link" href="#bib966"
                                    data-tab="pane-pcw-references">21-24</a>). The SPRINT (Systolic Blood Pressure
                                Intervention) trial and meta-analyses established that more intensive blood pressure
                                control in patients with high cardiovascular risk significantly reduces HF and other
                                cardiovascular outcomes (<a class="tab-link" href="#bib947"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib948"
                                    data-tab="pane-pcw-references">3</a>,<a class="tab-link" href="#bib970"
                                    data-tab="pane-pcw-references">25</a>). In recent clinical practice guidelines for
                                hypertension, blood pressure targets in HFpEF are extrapolated from those for treatment
                                of patients with hypertension in general (<a class="tab-link" href="#bib971"
                                    data-tab="pane-pcw-references">26</a>). However, the optimal blood pressure goal and
                                antihypertensive regimens are not known for patients with HFpEF. RAAS antagonists
                                including ACEi, ARB, MRA, and possibly ARNi, could be first-line agents given experience
                                with their use in HFpEF trials (<a class="tab-link" href="#bib953"
                                    data-tab="pane-pcw-references">8</a>,<a class="tab-link" href="#bib955"
                                    data-tab="pane-pcw-references">10</a>,<a class="tab-link" href="#bib961"
                                    data-tab="pane-pcw-references">16</a>,<a class="tab-link" href="#bib965"
                                    data-tab="pane-pcw-references">20</a>,<a class="tab-link" href="#bib972"
                                    data-tab="pane-pcw-references">27</a>,<a class="tab-link" href="#bib973"
                                    data-tab="pane-pcw-references">28</a>). Beta blockers may be used to treat
                                hypertension in patients with a history of MI (<a class="tab-link" href="#bib972"
                                    data-tab="pane-pcw-references">27</a>), symptomatic CAD, or AF with rapid
                                ventricular response. These effects need to be balanced with the potential contribution
                                of chronotropic incompetence to exercise intolerance in some patients (<a
                                    class="tab-link" href="#bib974" data-tab="pane-pcw-references">29</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5975">EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart
                                Failure with Preserved Ejection Fraction) showed a significant benefit of the SGLT2i,
                                empagliflozin, in symptomatic patients with HF with LVEF &gt;40% and elevated
                                natriuretic peptides (<a class="tab-link" href="#bib975"
                                    data-tab="pane-pcw-references">30</a>). The 21% reduction in the primary composite
                                endpoint of time to HF hospitalization or cardiovascular death was driven mostly by a
                                significant 29% reduction in time to HF hospitalization (nonsignificant lower
                                cardiovascular death [HR, 0.91; 95% CI, 0.76-1.0]), with no benefit on all-cause
                                mortality. Empagliflozin also resulted in a significant reduction in total HF
                                hospitalizations, decrease in the slope of the eGFR decline, and a modest improvement in
                                QOL at 52 weeks. Of note, the benefit was similar irrespective of the presence or
                                absence of diabetes at baseline. Although the benefit in the primary endpoint did not
                                have a significant interaction by LVEF subgroups (&lt;50%, 50%–&lt;60%, and &gt;60%) (<a
                                    class="tab-link" href="#bib975" data-tab="pane-pcw-references">30</a>), in a
                                subgroup analysis by EF, there was a signal for lower benefit on the primary composite
                                endpoint, first and recurrent HF hospitalizations at higher LVEFs &gt;62.5% (<a
                                    class="tab-link" href="#bib976" data-tab="pane-pcw-references">31</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5980">Large, randomized clinical trial data are unavailable to specifically guide
                                therapy in patients with HFpEF and AF. Currently, the comprehensive care of AF can be
                                extrapolated from the clinical practice guidelines for AF, with individualization of
                                strategies for rate or rhythm control in patients with HFpEF (see also <a
                                    class="ref sec" id="crosref6880" href="#sec14.2">Section 10.2</a>, “Management of
                                Atrial Fibrillation (AF) in HF,” for HF specific recommendations for AF). Although beta
                                blockers and nondihydropyridine calcium channel blockers are often considered as
                                first-line agents for heart rate control in patients with HFpEF, a recent smaller
                                open-label trial, RATE-AF in elderly patients with AF and symptoms of HF (most with
                                preserved LVEF), compared the use of the beta blocker, bisoprolol, to digoxin (<a
                                    class="tab-link" href="#bib977" data-tab="pane-pcw-references">32</a>). At 6 months,
                                the primary endpoint of QOL was similar between the 2 groups. However, several secondary
                                QOL endpoints, functional capacity, and reduction in NT-proBNP favored digoxin at 12
                                months. There was a similar heart rate reduction in both groups. Of note, more adverse
                                events such as higher rates of dizziness, lethargy, and hypotension occurred with beta
                                blockers than digoxin. The comprehensive care of AF is beyond the scope of these
                                guidelines. AF-specific care recommendations can be found in separate ACC/AHA clinical
                                practice guidelines (<a class="tab-link" href="#bib978"
                                    data-tab="pane-pcw-references">33</a>,<a class="tab-link" href="#bib979"
                                    data-tab="pane-pcw-references">34</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5985">MRAs improve diastolic function in patients with HFpEF (<a class="tab-link"
                                    href="#bib980" data-tab="pane-pcw-references">35</a>). The TOPCAT trial investigated
                                the effects of spironolactone in patients with HFpEF. The small reduction (HR, 0.89) in
                                the composite of death, aborted cardiac death, and HF hospitalization was not
                                statistically significant, although HF hospitalization was reduced (HR, 0.83); adverse
                                effects of hyperkalemia and increasing creatinine levels were more common in the
                                treatment group (<a class="tab-link" href="#bib950"
                                    data-tab="pane-pcw-references">5</a>). A post hoc analysis (<a class="tab-link"
                                    href="#bib951" data-tab="pane-pcw-references">6</a>) showed efficacy in the Americas
                                (HR 0.83) but not in Russia-Georgia (HR 1.10). A sample of the Russia-Georgia population
                                in the active treatment arm had nondetectable levels of a spironolactone metabolite.
                                Post hoc analyses have limitations, but they suggest a possibility of benefit in
                                appropriately selected patients with symptomatic HFpEF (LVEF ≥45%, elevated BNP level or
                                HF admission within 1 year, eGFR &gt;30 mL/min/1.73 m<sup>2</sup>, creatinine &lt;2.5
                                mg/dL, and potassium &lt;5.0 mEq/L). Furthermore, another post hoc analysis suggested
                                that the potential efficacy of spironolactone was greatest at the lower end of the LVEF
                                spectrum (<a class="tab-link" href="#bib952" data-tab="pane-pcw-references">7</a>).
                                Careful monitoring of potassium, renal function, and diuretic dosing at initiation and
                                follow-up are key to minimizing the risk of hyperkalemia and worsening renal function.
                            </p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5990">Although RAAS inhibition strategies have been successful in the treatment of
                                HFrEF, and RAAS activation is suggested in HFpEF (<a class="tab-link" href="#bib981"
                                    data-tab="pane-pcw-references">36</a>,<a class="tab-link" href="#bib982"
                                    data-tab="pane-pcw-references">37</a>), clinical trials with RAAS inhibition have
                                not showed much benefit in patients HFpEF. In the CHARM-Preserved (Candesartan in
                                patients with chronic HF and preserved left-ventricular ejection fraction) trial,
                                patients with LVEF &gt;40% were randomized to an ARB, candesartan, or to placebo (<a
                                    class="tab-link" href="#bib983" data-tab="pane-pcw-references">38</a>). The primary
                                endpoint (cardiovascular death or HF hospitalization) was not significantly different
                                between the 2 groups (HR, 0.89; 95% CI, 0.77–1.03, <i>P</i>=0.118; covariate-adjusted
                                HR, 0.86; <i>P</i>=0.051). Cardiovascular mortality was identical in the 2 groups; HF
                                hospitalizations were lower in the candesartan arm, with borderline statistical
                                significance on the covariate-adjusted analysis only (HR, 0.84; 95% CI, 0.70–1.00;
                                <i>P</i>=0.047; unadjusted <i>P</i>=0.072). The number of individuals hospitalized for
                                HF (reported by the investigator) was lower in the candesartan group than placebo (230
                                versus 279; <i>P</i>=0.017). A post hoc analysis of the CHARM trials showed that
                                improvement in outcomes with candesartan was greater at the lower end the LVEF spectrum
                                (<a class="tab-link" href="#bib984" data-tab="pane-pcw-references">39</a>). In a
                                meta-analysis of 7694 patients with HFpEF in 4 trials evaluating ARB, there was no
                                signal for benefit on cardiovascular mortality (HR, 1.02), all-cause mortality (HR,
                                1.02), or HF hospitalization (HR, 0.92; 95% CI, 0.83–1.02) (<a class="tab-link"
                                    href="#bib985" data-tab="pane-pcw-references">40</a>,<a class="tab-link"
                                    href="#bib986" data-tab="pane-pcw-references">41</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">6.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p5995">In the PARAMOUNT-HF (Prospective Comparison of ARNi With ARB on Management of
                                Heart Failure With Preserved Ejection Fraction) trial, a phase II RCT in patients with
                                HFpEF (LVEF ≥45%), sacubitril-valsartan resulted in a lower level of NT-proBNP after 12
                                weeks of treatment compared with the ARB, valsartan (<a class="tab-link" href="#bib987"
                                    data-tab="pane-pcw-references">42</a>). In the PARAGON-HF (Prospective Comparison of
                                Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global
                                Outcomes in Heart Failure and Preserved Left Ventricular Ejection Fraction) trial, in
                                4822 patients with HFpEF (LVEF ≥45%, HF admission within 9 months or elevated
                                natriuretic peptide levels, and eGFR ≥30 mL/min/m<sup>2</sup>), sacubitril-valsartan
                                compared with valsartan did not achieve a significant reduction in the primary composite
                                endpoint of cardiovascular death or total (first and recurrent) HF hospitalizations
                                (rate ratio, 0.87; 95% CI, 0.75-1.01; <i>P</i>=0.06) (<a class="tab-link" href="#bib955"
                                    data-tab="pane-pcw-references">10</a>). Given the primary outcome was not met, other
                                analyses are exploratory. There was no benefit of sacubitril-valsartan on cardiovascular
                                death (HR, 0.95) or total mortality (HR, 0.97). There was a signal of benefit for the
                                ARNi for HF hospitalizations (rate ratio, 0.85; 95% CI, 0.72–1.00; <i>P</i>=0.056). The
                                occurrence of hyperkalemia and the composite outcome of decline in renal function
                                favored sacubitril-valsartan, but it was associated with a higher incidence of
                                hypotension and angioedema. In prespecified subgroup analyses, a differential effect by
                                LVEF and sex was noted. A benefit of sacubitril-valsartan compared with valsartan was
                                observed in patients with LVEF below the median (45%–57%; rate ratio, 0.78; 95% CI,
                                0.64–0.95), and in women (rate ratio, 0.73; 95% CI, 0.59–0.90) (<a class="tab-link"
                                    href="#bib955" data-tab="pane-pcw-references">10</a>,<a class="tab-link"
                                    href="#bib988" data-tab="pane-pcw-references">43</a>,<a class="tab-link"
                                    href="#bib989" data-tab="pane-pcw-references">44</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">7.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6000">Nitrate therapy can reduce pulmonary congestion and improve exercise tolerance
                                in patients with HFrEF. However, the NEAT-HFpEF (Nitrate’s Effect on Activity Tolerance
                                in Heart Failure With Preserved Ejection Fraction) trial (<a class="tab-link"
                                    href="#bib990" data-tab="pane-pcw-references">45</a>) randomized 110 patients with
                                EF ≥50% on stable HF therapy, not including nitrates, and with activity limited by
                                dyspnea, fatigue, or chest pain, to either isosorbide mononitrate or placebo and found
                                no beneficial effects on activity levels, QOL, exercise tolerance, or NT-proBNP levels.
                                Although the routine use of nitrates in patients with HFpEF does not appear beneficial,
                                patients with HFpEF and symptomatic CAD may still receive symptomatic relief with
                                nitrates. Phosphodiesterase-5 inhibition augments the nitric oxide system by
                                upregulating cGMP activity. The RELAX (Phosphodiesterase-5 Inhibition to Improve
                                Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction)
                                trial (<a class="tab-link" href="#bib958" data-tab="pane-pcw-references">13</a>)
                                randomized 216 patients with EF ≥50% on stable HF therapy and with reduced exercise
                                tolerance (peak observed VO<sub>2</sub>, &lt;60% of predicted) to phosphodiesterase-5
                                inhibition with sildenafil or placebo. This study did not show improvement in oxygen
                                consumption or exercise tolerance.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec11">
                <div id="acsectitle0380" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0380">7.8 Cardiac Amyloidosis</h3>
            <div id="acsec11.8" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.8">
                <div id="acsectitle0385" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0385">7.8.1 Diagnosis of Cardiac Amyloidosis</h4>
            <div id="undtbl34" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl34">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0690">Recommendations for Diagnosis of Cardiac Amyloidosis</p>
                            <p id="tspara0695">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0685" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1685"><strong>Patients for whom there is a clinical suspicion
                                                        for cardiac amyloidosis</strong><a class="ref table-fn"
                                                        id="dtbl3fnlowast"
                                                        href="javascript:popRef('dtbl3fnlowast')"><strong><sup>∗</sup></strong></a>
                                                    (<a class="tab-link" href="#bib991"
                                                        data-tab="pane-pcw-references">1-5</a>) <strong>should have
                                                        screening for serum and urine monoclonal light chains with serum
                                                        and urine immunofixation electrophoresis and serum free light
                                                        chains</strong> (<a class="tab-link" href="#bib996"
                                                        data-tab="pane-pcw-references">6</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0690" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1690"><strong>In patients with high clinical suspicion for
                                                        cardiac amyloidosis, without evidence of serum or urine
                                                        monoclonal light chains, bone scintigraphy should be performed
                                                        to confirm the presence of transthyretin cardiac
                                                        amyloidosis</strong> (<a class="tab-link" href="#bib997"
                                                        data-tab="pane-pcw-references">7</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0695" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1695"><strong>In patients for whom a diagnosis of transthyretin
                                                        cardiac amyloidosis is made, genetic testing with <i>TTR</i>
                                                        gene sequencing is recommended to differentiate hereditary
                                                        variant from wild-type transthyretin cardiac
                                                        amyloidosis</strong> (<a class="tab-link" href="#bib998"
                                                        data-tab="pane-pcw-references">8</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn id="dtbl3fnlowast">
                            <p id="ntpara0080">∗ LV wall thickness ≥14 mm in conjunction with fatigue, dyspnea, or
                                edema, especially in the context of discordance between wall thickness on echocardiogram
                                and QRS voltage on ECG, and in the context of aortic stenosis, HFpEF, carpal tunnel
                                syndrome, spinal stenosis, and autonomic or sensory polyneuropathy.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p6015"><strong>Synopsis</strong></p>
            <p id="p6020">Cardiac amyloidosis is a restrictive cardiomyopathy with extracellular myocardial protein
                deposition, most commonly monoclonal immunoglobulin light chains (amyloid cardiomyopathy [AL-CM]) or
                transthyretin amyloidosis (ATTR-CM). ATTR can be caused by pathogenic variants in the transthyretin gene
                <i>TTR</i> (variant transthyretin amyloidosis, ATTRv) or wild-type transthyretin (wild-type
                transthyretin amyloidosis, ATTRwt). A diagnostic approach is outlined in <a data-tab="pane-pcw-Figures"
                    href="#fig13" id="fig13R" class="">Figure 13</a> (<a class="tab-link" href="#bib999"
                    data-tab="pane-pcw-references">9</a>).</p>
            <section class="article-section__inline-figure">
                <figure id="fig13" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/9ecdd3d4-dd37-4e3c-aea3-2bad8312b333/gr13.jpg"
                        data-lg-src="/cms/asset/c81d8cf5-03a8-4857-96e8-81c9ff842ecc/gr13.jpg" alt="Figure 13">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/c81d8cf5-03a8-4857-96e8-81c9ff842ecc/gr13.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig13&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 13</span></strong>
                        <p>Diagnostic and Treatment of Transthyretin Cardiac Amyloidosis Algorithm</p>
                        <p><strong>Colors correspond to COR in</strong> <a class="ref showTableEvent" data-id="tbl2"
                                href="#tbl2"><strong>Table 2</strong></a><strong>.</strong> AF indicates atrial
                            fibrillation; AL-CM, amyloid cardiomyopathy; ATTR-CM, transthyretin amyloid cardiomyopathy;
                            ATTRv, variant transthyretin amyloidosis; ATTRwt, wild-type transthyretin amyloidosis;
                            CHA<sub>2</sub>DS<sub>2</sub>-VASc, congestive heart failure, hypertension, age ≥75 years,
                            diabetes mellitus, stroke or transient ischemic attack (TIA), vascular disease, age 65 to 74
                            years, sex category; ECG, electrocardiogram; H/CL, heart to contralateral chest; HFrEF,
                            heart failure with reduced ejection fraction; IFE, immunofixation electrophoresis; MRI,
                            magnetic resonance imaging; NYHA, New York Heart Association; PYP, pyrophosphate; Tc,
                            technetium; and TTR, transthyretin.</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p6025"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1315" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6030">Diagnosis of ATTR-CM requires a high index of suspicion. LV thickening (wall
                                thickness ≥14 mm) along with fatigue, dyspnea, or edema should trigger consideration of
                                ATTR-CM, especially with discordance between wall thickness on echocardiogram and QRS
                                voltage on ECG (<a class="tab-link" href="#bib1000"
                                    data-tab="pane-pcw-references">10</a>), or other findings such as apical sparing of
                                LV longitudinal strain impairment on echocardiography and diffuse late-gadolinium
                                enhancement on cardiac MRI. ATTR-CM is prevalent in severe aortic stenosis (<a
                                    class="tab-link" href="#bib991" data-tab="pane-pcw-references">1</a>), HFpEF (<a
                                    class="tab-link" href="#bib992" data-tab="pane-pcw-references">2</a>), carpal tunnel
                                syndrome (<a class="tab-link" href="#bib993" data-tab="pane-pcw-references">3</a>),
                                lumbar spinal stenosis (<a class="tab-link" href="#bib994"
                                    data-tab="pane-pcw-references">4</a>), and autonomic or sensory polyneuropathy (<a
                                    class="tab-link" href="#bib995" data-tab="pane-pcw-references">5</a>). Practically,
                                screening for the presence of a monoclonal light chain and technetium pyrophosphate
                                (<sup>99m</sup>Tc-PYP) scan can be ordered at the same time for convenience, but the
                                results of the <sup>99m</sup>Tc-PYP scan are interpreted only on the context of a
                                negative monoclonal light chain screen. <sup>99m</sup>Tc-PYP scans may be positive even
                                in AL amyloidosis (<a class="tab-link" href="#bib997"
                                    data-tab="pane-pcw-references">7</a>) and, thus, a bone scintigraphy scan alone,
                                without concomitant testing for light chains, cannot distinguish ATTR-CM from AL-CM.
                                Serum free light chain (FLC) concentration and serum and urine immunofixation
                                electrophoresis (IFE) are assessed to rule out AL-CM. IFE is preferred because serum
                                plasma electrophoresis and urine plasma electrophoresis are less sensitive. Together,
                                measurement of serum IFE, urine IFE, and serum FLC is &gt;99% sensitive for AL
                                amyloidosis (<a class="tab-link" href="#bib996" data-tab="pane-pcw-references">6</a>,<a
                                    class="tab-link" href="#bib1001" data-tab="pane-pcw-references">11</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6035">The use of <sup>99m</sup>Tc bone-avid compounds for bone scintigraphy allows
                                for noninvasive diagnosis of ATTR-CM (<a class="tab-link" href="#bib997"
                                    data-tab="pane-pcw-references">7</a>). <sup>99m</sup>Tc compounds include PYP,
                                3,3-diphosphono-1,2-propanodicarboxylic acid, and hydromethylene diphosphonate, and PYP
                                is used in the United States. In the absence of a light-chain abnormality, the
                                <sup>99m</sup>Tc-PYP scan is diagnostic of ATTR-CM if there is grade 2/3 cardiac uptake
                                or an H/CL ratio of &gt;1.5. In fact, the presence of grade 2/3 cardiac uptake in the
                                absence of a monoclonal protein in serum or urine has a very high specificity and
                                positive predictive value for ATTR-CM (<a class="tab-link" href="#bib997"
                                    data-tab="pane-pcw-references">7</a>). SPECT is assessed in all positive scans to
                                confirm that uptake represents myocardial retention of the tracer and not blood pool or
                                rib uptake signal (<a class="tab-link" href="#bib1002"
                                    data-tab="pane-pcw-references">12</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6040">If ATTR-CM is identified, then genetic sequencing of the <i>TTR</i> gene will
                                determine if the patient has a pathological variant (ATTRv) or wild-type (ATTRwt)
                                disease (<a class="tab-link" href="#bib1002" data-tab="pane-pcw-references">12</a>).
                                Differentiating ATTRv from ATTRwt is important because confirmation of ATTRv would
                                trigger genetic counseling and potential screening of family members and therapies,
                                inotersen and patisiran, which are presently approved only for ATTRv with polyneuropathy
                                (<a class="tab-link" href="#bib1003" data-tab="pane-pcw-references">13</a>,<a
                                    class="tab-link" href="#bib1004" data-tab="pane-pcw-references">14</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec11.8" class="anchor-spacer"></div>
            <h3 class="article-section__subtitle" id="sec11.8">
                <div id="acsectitle0390" class="anchor-spacer"></div>
            </h3>
            <h4 class="article-section__subtitle" id="sectitle0390">7.8.2 Treatment of Cardiac Amyloidosis</h4>
            <div id="undtbl35" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl35">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0700">Recommendations for Treatment of Cardiac Amyloidosis</p>
                            <p id="tspara0705">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0700" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1700"><strong>In select patients with wild-type or variant
                                                        transthyretin cardiac amyloidosis and NYHA class I to III HF
                                                        symptoms, transthyretin tetramer stabilizer therapy (tafamidis)
                                                        is indicated to reduce cardiovascular morbidity and
                                                        mortality</strong> (<a class="tab-link" href="#bib1005"
                                                        data-tab="pane-pcw-references">1</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: Low Value (B-NR)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0705" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1705"><strong>At 2020 list prices, tafamidis provides low
                                                        economic value (&gt;$180,000 per QALY gained) in patients with
                                                        HF with wild-type or variant transthyretin cardiac
                                                        amyloidosis</strong> (<a class="tab-link" href="#bib1006"
                                                        data-tab="pane-pcw-references">2</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0710" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1710"><strong>In patients with cardiac amyloidosis and AF,
                                                        anticoagulation is reasonable to reduce the risk of stroke
                                                        regardless of the
                                                        CHA</strong><sub><strong>2</strong></sub><strong>DS</strong><sub><strong>2</strong></sub><strong>-VASc
                                                        (congestive heart failure, hypertension, age ≥75 years, diabetes
                                                        mellitus, stroke or transient ischemic attack [TIA], vascular
                                                        disease, age 65 to 74 years, sex category) score (</strong><a
                                                        class="tab-link" href="#bib1007"
                                                        data-tab="pane-pcw-references"><strong>3</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1008"
                                                        data-tab="pane-pcw-references"><strong>4</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6050"><strong>Synopsis</strong></p>
            <p id="p6055">For patients with ATTR-CM and EF ≤40%, GDMT may be poorly tolerated. The vasodilating effects
                of ARNi, ACEi, and ARB may exacerbate hypotension, especially with amyloid-associated autonomic
                dysfunction. Beta blockers may worsen HF symptoms as patients with ATTR-CM rely on heart rate response
                to maintain cardiac output. The benefit of ICDs in ATTR-CM has not been studied in randomized trials,
                and a case-control study showed unclear benefit (<a class="tab-link" href="#bib1009"
                    data-tab="pane-pcw-references">5</a>). CRT has not been studied in ATTR-CM with HFrEF.
                Disease-modifying therapies include TTR silencers (disrupt hepatic synthesis via mRNA
                inhibition/degradation: inotersen and patisiran), TTR stabilizers (prevent misfolding/deposition:
                diflunisal and tafamidis), and TTR disruptors (target tissue clearance: doxycycline,
                tauroursodeoxycholic acid [TUDCA], and epigallocatechin-3-gallate [EGCG] in green tea). Light chain
                cardiac amyloidosis is managed by hematology-oncology specialists and beyond the scope of cardiologists,
                but diagnosis is often made by cardiologists when cardiac amyloid becomes manifest (<a
                    data-tab="pane-pcw-Figures" href="#fig13" id="fig13R" class="">Figure 13</a>). AL amyloidosis is
                treatable, and patients with AL amyloidosis with cardiac involvement should promptly be referred to
                hematology-oncology for timely treatment. Inotersen and patisiran are associated with slower progression
                of amyloidosis-related polyneuropathy in ATTRv-CM (<a class="tab-link" href="#bib1010"
                    data-tab="pane-pcw-references">6</a>,<a class="tab-link" href="#bib1011"
                    data-tab="pane-pcw-references">7</a>). There are ongoing trials of the impact of inotersen and
                patisiran and newer generation mRNA inhibitors-degraders on cardiovascular morbidity or mortality. There
                is limited benefit of diflunisal (<a class="tab-link" href="#bib1012"
                    data-tab="pane-pcw-references">8</a>), doxycycline plus TUDCA (<a class="tab-link" href="#bib1013"
                    data-tab="pane-pcw-references">9</a>,<a class="tab-link" href="#bib1014"
                    data-tab="pane-pcw-references">10</a>), and EGCG (<a class="tab-link" href="#bib1015"
                    data-tab="pane-pcw-references">11</a>), on surrogate endpoints such as LV mass, but the impact of
                these agents on cardiovascular morbidity and mortality has not been assessed. Evaluation and management
                of autonomic dysfunction, volume status, and arrhythmia are important.</p>
            <p id="p6060"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1320" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6065">Tafamidis is currently the only therapy to improve cardiovascular outcomes in
                                ATTR-CM (<a class="tab-link" href="#bib1005" data-tab="pane-pcw-references">1</a>).
                                Tafamidis binds the thyroxin-binding site of TTR. In the ATTR-ACT (Safety and Efficacy
                                of Tafamidis in Patients With Transthyretin Cardiomyopathy) clinical trial, a randomized
                                trial of patients with ATTRwt-CM or ATTRv-CM and NYHA class I to III symptoms, tafamidis
                                had lower all-cause mortality (29.5% versus 42.9%) and lower cardiovascular-related
                                hospitalization (0.48 versus 0.70 per year) after 30 months (<a class="tab-link"
                                    href="#bib1005" data-tab="pane-pcw-references">1</a>). There was a higher rate of
                                cardiovascular-related hospitalizations in patients with NYHA class III HF, potentially
                                attributable to longer survival during a more severe period of disease. Given that
                                tafamidis prevents but does not reverse amyloid deposition, tafamidis is expected to
                                have greater benefit when administered early in the disease course. As the survival
                                curves separate after 18 months, patients for whom noncardiac disease is not expected to
                                limit survival should be selected. Benefit has not been observed in patients with class
                                IV symptoms, severe aortic stenosis, or impaired renal function (eGFR &lt;25
                                mL·min<sup>−1</sup>·1.73 m<sup>−2</sup> body surface area). Tafamidis is available in 2
                                formulations: tafamidis meglumine is available in 20-mg capsules; and the FDA-approved
                                dose is 80 mg (4 capsules) once daily. Tafamidis is also available in 61-mg capsules;
                                the FDA-approved dose for this new formulation is 61 mg once daily.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6070">One model-based analyses used the results of the ATTR-ACT study (<a
                                    class="tab-link" href="#bib1005" data-tab="pane-pcw-references">1</a>) to evaluate
                                the cost-effectiveness of chronic tafamidis compared with no amyloidosis-specific
                                therapy among patients with wild-type or variant transthyretin amyloidosis and NYHA
                                class I to III HF (<a class="tab-link" href="#bib1006"
                                    data-tab="pane-pcw-references">2</a>). With assumptions that tafamidis remained
                                effective beyond the clinical trial duration, they estimated tafamidis increased average
                                survival by 1.97 years and QALY by 1.29. Despite these large clinical benefits,
                                tafamidis (with an annual cost of $225,000) had an incremental cost-effectiveness ratio
                                &gt;$180,000 per QALY gained, the benchmark used by this guideline for low value. The
                                cost of tafamidis would need to decrease by approximately 80% for it to be intermediate
                                value with a cost per QALY &lt;$180,000.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6075">Intracardiac thrombosis occurs in approximately one-third of patients with
                                cardiac amyloidosis, in some cases in the absence of diagnosed AF (<a class="tab-link"
                                    href="#bib1007" data-tab="pane-pcw-references">3</a>,<a class="tab-link"
                                    href="#bib1008" data-tab="pane-pcw-references">4</a>,<a class="tab-link"
                                    href="#bib1016" data-tab="pane-pcw-references">12</a>) and regardless of
                                CHA<sub>2</sub>DS<sub>2</sub>-VASc score (<a class="tab-link" href="#bib1017"
                                    data-tab="pane-pcw-references">13</a>). The use of anticoagulation reduced the risk
                                of intracardiac thrombi in a retrospective study (<a class="tab-link" href="#bib1008"
                                    data-tab="pane-pcw-references">4</a>). The choice of direct oral anticoagulants
                                (DOAC) versus warfarin has not been studied in patients with ATTR, nor has the role of
                                left atrial appendage closure devices. The risk of anticoagulation on bleeding risk in
                                patients with ATTR-CM and AF has not been established. However, although patients with
                                AL amyloidosis may have acquired hemostatic abnormalities, including coagulation factor
                                deficiencies, hyperfibrinolysis, and platelet dysfunction, TTR amyloidosis is not
                                associated with hemostatic defects.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acd247731e10738" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e10738">
                <div id="acsectitle0395" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0395">8 Stage D (Advanced) HF</h2>
            <div id="acsec12" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec12">
                <div id="acsectitle0400" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0400">8.1 Specialty Referral for Advanced HF</h3>
            <div id="undtbl36" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl36">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0710">Recommendation for Specialty Referral for Advanced HF</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0715" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1715"><strong>In patients with advanced HF, when consistent with
                                                        the patient’s goals of care, timely referral for HF specialty
                                                        care is recommended to review HF management and assess
                                                        suitability for advanced HF therapies (e.g., LVAD, cardiac
                                                        transplantation, palliative care, and palliative
                                                        inotropes)</strong> (<a class="tab-link" href="#bib1018"
                                                        data-tab="pane-pcw-references">1-6</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6090"><strong>Synopsis</strong></p>
            <p id="p6095">A subset of patients with chronic HF will continue to progress and develop persistently severe
                symptoms despite maximum GDMT. Several terms have been used to describe this population, including
                “end-stage,” “advanced,” and “refractory” HF. In 2018, the European Society of Cardiology updated its
                definition of advanced HF (<a class="ref showTableEvent" data-id="tbl16" href="#tbl16">Table 16</a>),
                which now includes 4 distinct criteria (<a class="tab-link" href="#bib1018"
                    data-tab="pane-pcw-references">1</a>). The revised definition focuses on refractory symptoms rather
                than cardiac function and more clearly acknowledges that advanced HF can occur in patients without
                severely reduced EF, including those with isolated RV dysfunction, uncorrectable valvular or congenital
                heart disease, and in patients with preserved and mildly reduced EF (<a class="tab-link" href="#bib1018"
                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib1020"
                    data-tab="pane-pcw-references">3</a>). The INTERMACS (Interagency Registry for Mechanically Assisted
                Circulatory Support) has developed 7 profiles that further stratify patients with advanced HF (<a
                    class="ref showTableEvent" data-id="tbl17" href="#tbl17">Table 17</a>) (<a class="tab-link"
                    href="#bib1024" data-tab="pane-pcw-references">7</a>).</p>
            <div id="tbl16" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl16">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0160"><span class="captionLabel">Table 16</span> ESC Definition of Advanced HF
                            </p>
                        </strong></caption>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">All these criteria must be present despite optimal
                                guideline-directed treatment:</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> 
                                <table class="listgroup" border="0" width="95%" id="olist0010" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0125">Severe and persistent symptoms of HF (NYHA class III
                                                    [advanced] or IV)</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> 
                                <table class="listgroup" border="0" width="95%" id="olist0015" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0130">Severe cardiac dysfunction defined by ≥1 of these:</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0065" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0135">LVEF ≤30%</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0070" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0140">Isolated RV failure</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0075" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0145">Nonoperable severe valve abnormalities</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0080" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0150">Nonoperable severe congenital heart disease</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0085" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0155">EF ≥40%, elevated natriuretic peptide levels and evidence
                                                    of significant diastolic dysfunction</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> 
                                <table class="listgroup" border="0" width="95%" id="olist0020" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0160">Hospitalizations or unplanned visits in the past 12 mo for
                                                    episodes of:</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0090" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0165">Congestion requiring high-dose intravenous diuretics or
                                                    diuretic combinations</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0095" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0170">Low output requiring inotropes or vasoactive medications
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0100" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0175">Malignant arrhythmias</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> 
                                <table class="listgroup" border="0" width="95%" id="olist0025" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0180">Severe impairment of exercise capacity with inability to
                                                    exercise or low 6-minute walk test distance (&lt;300 m) or peak
                                                    VO<sub>2</sub> (&lt;12–14 mL/kg/min) estimated to be of cardiac
                                                    origin</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Criteria 1 and 4 can be met in patients with cardiac dysfunction
                                (as described in criterion 2) but who also have substantial limitations as a result of
                                other conditions (e.g., severe pulmonary disease, noncardiac cirrhosis, renal disease).
                                The therapeutic options for these patients may be more limited.</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0165">EF indicates ejection fraction; ESC, European Society of Cardiology; HF,
                                heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart
                                Association; RV, right ventricular; and VO<sub>2</sub>, oxygen consumption/oxygen
                                uptake.</p>
                            <p id="tspara0170">Adapted with permission from Crespo-Leiro et al. (<a class="tab-link"
                                    href="#bib1018" data-tab="pane-pcw-references">1</a>)</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="tbl17" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl17">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0175"><span class="captionLabel">Table 17</span> INTERMACS Profiles</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Profile<a class="ref table-fn" id="tbl17fnlowast"
                                    href="javascript:popRef('tbl17fnlowast')"><sup>∗</sup></a></th>
                            <th colspan="1" rowspan="1">Profile Description</th>
                            <th colspan="1" rowspan="1">Features</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">1</td>
                            <td colspan="1" rowspan="1">Critical cardiogenic shock</td>
                            <td colspan="1" rowspan="1">Life-threatening hypotension and rapidly escalating
                                inotropic/pressor support, with critical organ hypoperfusion often confirmed by
                                worsening acidosis and lactate levels.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">2</td>
                            <td colspan="1" rowspan="1">Progressive decline</td>
                            <td colspan="1" rowspan="1">“Dependent” on inotropic support but nonetheless shows signs of
                                continuing deterioration in nutrition, renal function, fluid retention, or other major
                                status indicator. Can also apply to a patient with refractory volume overload, perhaps
                                with evidence of impaired perfusion, in whom inotropic infusions cannot be maintained
                                because of tachyarrhythmias, clinical ischemia, or other intolerance.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">3</td>
                            <td colspan="1" rowspan="1">Stable but inotrope dependent</td>
                            <td colspan="1" rowspan="1">Clinically stable on mild-moderate doses of intravenous
                                inotropes (or has a temporary circulatory support device) after repeated documentation
                                of failure to wean without symptomatic hypotension, worsening symptoms, or progressive
                                organ dysfunction (usually renal).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">4</td>
                            <td colspan="1" rowspan="1">Resting symptoms on oral therapy at home</td>
                            <td colspan="1" rowspan="1">Patient who is at home on oral therapy but frequently has
                                symptoms of congestion at rest or with activities of daily living (dressing or bathing).
                                He or she may have orthopnea, shortness of breath during dressing or bathing,
                                gastrointestinal symptoms (abdominal discomfort, nausea, poor appetite), disabling
                                ascites, or severe lower extremity edema.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">5</td>
                            <td colspan="1" rowspan="1">Exertion intolerant</td>
                            <td colspan="1" rowspan="1">Patient who is comfortable at rest but unable to engage in any
                                activity, living predominantly within the house or housebound.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">6</td>
                            <td colspan="1" rowspan="1">Exertion limited</td>
                            <td colspan="1" rowspan="1">Patient who is comfortable at rest without evidence of fluid
                                overload but who is able to do some mild activity. Activities of daily living are
                                comfortable, and minor activities outside the home such as visiting friends or going to
                                a restaurant can be performed, but fatigue results within a few minutes or with any
                                meaningful physical exertion.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">7</td>
                            <td colspan="1" rowspan="1">Advanced NYHA class III</td>
                            <td colspan="1" rowspan="1">Patient who is clinically stable with a reasonable level of
                                comfortable activity, despite a history of previous decompensation that is not recent.
                                This patient is usually able to walk more than a block. Any decompensation requiring
                                intravenous diuretics or hospitalization within the previous month should make this
                                person a Patient Profile 6 or lower.</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0180">ICD indicates implantable cardioverter-defibrillator; INTERMACS,
                                Interagency Registry for Mechanically Assisted Circulatory Support; and NYHA, New York
                                Heart Association.</p>
                            <p id="tspara0185">Adapted from Stevenson et al. (<a class="tab-link" href="#bib1024"
                                    data-tab="pane-pcw-references">7</a>), with permission from the International
                                Society for Heart and Lung Transplantation.</p>
                        </fn>
                        <fn id="tbl17fnlowast">
                            <p id="ntpara0040">∗ Modifier options: Profiles 3 to 6 can be modified for patients with
                                recurrent decompensations leading to frequent (generally at least 2 in past 3 mo or 3 in
                                past 6 mo) emergency department visits or hospitalizations for intravenous diuretics,
                                ultrafiltration, or brief inotropic therapy. Profile 3 can be modified in this manner if
                                the patient is usually at home. If a Profile 7 patient meets the modification of
                                frequent hospitalizations, the patient should be moved to Profile 6 or worse. Other
                                modifier options include arrhythmia, which should be used in the presence of recurrent
                                ventricular tachyarrhythmias contributing to the overall clinical course (e.g., frequent
                                ICD shocks or requirement of external defibrillation, usually more than twice weekly);
                                or temporary circulatory support for hospitalized patients Profiles 1 to 3.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p6100">Determining that HF and not a concomitant pulmonary disorder is the basis of dyspnea is
                important. Severely symptomatic patients presenting with a new diagnosis of HF can often improve
                substantially if they are initially stabilized. Patients should also be evaluated for nonadherence to
                medications (<a class="tab-link" href="#bib1025" data-tab="pane-pcw-references">8-11</a>). Finally, a
                careful review of medical management should be conducted to verify that all therapies likely to improve
                clinical status have been considered.</p>
            <p id="p6105"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1325" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6110">Clinical indicators of advanced HF that should trigger possible referral to an
                                advanced HF specialist are shown in <a class="ref showTableEvent" data-id="tbl18"
                                    href="#tbl18">Table 18</a> (<a class="tab-link" href="#bib1018"
                                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib1019"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib1029"
                                    data-tab="pane-pcw-references">12-14</a>). Timely referral for review and
                                consideration of advanced HF therapies is crucial to achieve optimal patient outcomes
                                (<a class="tab-link" href="#bib1032" data-tab="pane-pcw-references">15-17</a>). Acronyms
                                such as I-Need-Help…</p>
                            <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist1175">
                                <li id="u2730">
                                    <p class="inline">I, Intravenous inotropes</p>
                                </li>
                                <li id="u2735">
                                    <p class="inline">N, New York Heart Association (NYHA) class IIIB to IV or
                                        persistently elevated natriuretic peptides</p>
                                </li>
                                <li id="u2740">
                                    <p class="inline">E, End-organ dysfunction</p>
                                </li>
                                <li id="u2745">
                                    <p class="inline">E, EF ≤35%</p>
                                </li>
                                <li id="u2750">
                                    <p class="inline">D, Defibrillator shocks</p>
                                </li>
                                <li id="u2755">
                                    <p class="inline">H, Hospitalizations &gt;1</p>
                                </li>
                                <li id="u2760">
                                    <p class="inline">E, Edema despite escalating diuretics</p>
                                </li>
                                <li id="u2765">
                                    <p class="inline">L, Low systolic BP ≤90, high heart rate</p>
                                </li>
                                <li id="u2770">
                                    <p class="inline">P, Prognostic medication; progressive intolerance or
                                        down-titration of GDMT</p>
                                </li>
                            </ul>
                            <p></p>
                        </td>
                    </tr>
                </tbody>
            </table>…have been developed to assist in decision-making for referral to advanced HF (<a class="tab-link"
                href="#bib1035" data-tab="pane-pcw-references">18</a>). Indications and contraindications to durable
            mechanical support are listed in <a class="ref showTableEvent" data-id="tbl19" href="#tbl19">Table 19</a>.
            After patients develop end-organ dysfunction or cardiogenic shock, they may no longer qualify for advanced
            therapies (<a class="tab-link" href="#bib1036" data-tab="pane-pcw-references">19</a>,<a class="tab-link"
                href="#bib1037" data-tab="pane-pcw-references">20</a>). A complete assessment of the patient is not
            required before referral, because comprehensive, multidisciplinary assessment of cardiac disease and
            comorbid conditions is routinely performed when evaluating patients for advanced therapies (<a
                class="tab-link" href="#bib1037" data-tab="pane-pcw-references">19</a>,<a class="tab-link"
                href="#bib1037" data-tab="pane-pcw-references">20</a>). Decisions around evaluation and use of advanced
            therapies should be informed by the patient’s values, goals, and preferences. Discussion with HF specialists
            and other members of the multidisciplinary team may help ensure that the patient has adequate information to
            make an informed decision.<p></p>
            <div id="tbl18" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl18">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0190"><span class="captionLabel">Table 18</span> Clinical Indicators of
                                Advanced HF (<a class="tab-link" href="#bib1018" data-tab="pane-pcw-references">1</a>,<a
                                    class="tab-link" href="#bib1019" data-tab="pane-pcw-references">2</a>,<a
                                    class="tab-link" href="#bib1029" data-tab="pane-pcw-references">12</a>,<a
                                    class="tab-link" href="#bib1030" data-tab="pane-pcw-references">13</a>,<a
                                    class="tab-link" href="#bib1040" data-tab="pane-pcw-references">23-37</a>)</p>
                        </strong></caption>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Repeated hospitalizations or emergency department visits for HF
                                in the past 12 mo.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Need for intravenous inotropic therapy.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Persistent NYHA functional class III to IV symptoms despite
                                therapy.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Severely reduced exercise capacity (peak VO<sub>2</sub>, &lt;14
                                mL/kg/min or &lt;50% predicted, 6-min walk test distance &lt;300 m, or inability to walk
                                1 block on level ground because of dyspnea or fatigue).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Intolerance to RAASi because of hypotension or worsening renal
                                function.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Intolerance to beta blockers as a result of worsening HF or
                                hypotension.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Recent need to escalate diuretics to maintain volume status,
                                often reaching daily furosemide equivalent dose &gt;160 mg/d or use of supplemental
                                metolazone therapy.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Refractory clinical congestion.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Progressive deterioration in renal or hepatic function.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Worsening right HF or secondary pulmonary hypertension.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Frequent SBP ≤90 mm Hg.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Cardiac cachexia.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Persistent hyponatremia (serum sodium, &lt;134 mEq/L).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Refractory or recurrent ventricular arrhythmias; frequent ICD
                                shocks.</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Increased predicted 1-year mortality (e.g., &gt;20%) according
                                to HF survival models (e.g., MAGGIC [<a class="tab-link" href="#bib1038"
                                    data-tab="pane-pcw-references">21</a>], SHFM [<a class="tab-link" href="#bib1039"
                                    data-tab="pane-pcw-references">22</a>]).</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0195">HF indicates heart failure; ICD, implantable cardioverter-defibrillator;
                                MAGGIC, Meta-analysis Global Group in Chronic Heart Failure; NYHA, New York Heart
                                Association; RAASi, renin-angiotensin-aldosterone system inhibitors; SBP, systolic blood
                                pressure; SHFM, Seattle Heart Failure model; and VO<sub>2</sub>, oxygen
                                consumption/oxygen uptake.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="tbl19" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl19">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0200"><span class="captionLabel">Table 19</span> Indications and
                                Contraindications to Durable Mechanical Support (<a class="tab-link" href="#bib1054"
                                    data-tab="pane-pcw-references">37</a>)</p>
                        </strong></caption>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Indications (combination of these):</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0105" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0185">Frequent hospitalizations for HF</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0110" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0190">NYHA class IIIb to IV functional limitations despite
                                                    maximal therapy</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0115" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0195">Intolerance of neurohormonal antagonists</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0120" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0200">Increasing diuretic requirement</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0125" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0205">Symptomatic despite CRT</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0130" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0210">Inotrope dependence</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0135" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0215">Low peak VO<sub>2</sub> (&lt;14–16)</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0140" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0220">End-organ dysfunction attributable to low cardiac output
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Contraindications:</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> <strong>Absolute</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0145" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0225">Irreversible hepatic disease</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0150" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0230">Irreversible renal disease</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0155" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0235">Irreversible neurological disease</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0160" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0240">Medical nonadherence</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0165" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0245">Severe psychosocial limitations</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"> <strong>Relative</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0170" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0250">Age &gt;80 y for destination therapy</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0175" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0255">Obesity or malnutrition</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0180" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0260">Musculoskeletal disease that impairs rehabilitation</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0185" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0265">Active systemic infection or prolonged intubation</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0190" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0270">Untreated malignancy</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0195" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0275">Severe PVD</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0200" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0280">Active substance abuse</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0205" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0285">Impaired cognitive function</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0210" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0290">Unmanaged psychiatric disorder</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0215" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0295">Lack of social support</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0205">CRT indicates cardiac resynchronization therapy; HF, heart failure; NYHA,
                                New York Heart Association; VO<sub>2,</sub> oxygen consumption; and PVD, peripheral
                                vascular disease.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="acsec12" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec12">
                <div id="acsectitle0405" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0405">8.2 Nonpharmacological Management: Advanced HF</h3>
            <div id="undtbl37" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl37">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0715">Recommendation for Nonpharmacological Management: Advanced HF</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0720" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1720"><strong>For patients with advanced HF and hyponatremia,
                                                        the benefit of fluid restriction to reduce congestive symptoms
                                                        is uncertain</strong> (<a class="tab-link" href="#bib1055"
                                                        data-tab="pane-pcw-references">1-4</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6175"><strong>Synopsis</strong></p>
            <p id="p6180">Hyponatremia and diuretic-refractory congestion is common in advanced HF and is associated
                with poor clinical (<a class="tab-link" href="#bib1059" data-tab="pane-pcw-references">5</a>,<a
                    class="tab-link" href="#bib1060" data-tab="pane-pcw-references">6</a>) and patient-reported outcomes
                (<a class="tab-link" href="#bib1061" data-tab="pane-pcw-references">7</a>). Moreover, improvement in
                hyponatremia has been shown to improve clinical outcomes (<a class="tab-link" href="#bib1062"
                    data-tab="pane-pcw-references">8</a>,<a class="tab-link" href="#bib1063"
                    data-tab="pane-pcw-references">9</a>). Fluid restriction is commonly prescribed for patients with
                hyponatremia in acute HF but only improves hyponatremia modestly (<a class="tab-link" href="#bib1055"
                    data-tab="pane-pcw-references">1</a>). Although restricting fluid is a common recommendation for
                patients with HF, evidence in this area is of low quality (<a class="tab-link" href="#bib1064"
                    data-tab="pane-pcw-references">10</a>), and many studies have not included patients with advanced HF
                specifically. Moreover, fluid restriction has limited-to-no effect on clinical outcomes or diuretic use
                (<a class="tab-link" href="#bib1058" data-tab="pane-pcw-references">4</a>). Although HF nutritional
                counseling typically focuses on restricting sodium and fluid, patients with advanced HF have the
                greatest risk of developing cachexia or malnutrition (<a class="tab-link" href="#bib1065"
                    data-tab="pane-pcw-references">11</a>). Hence, dietary restrictions and recommendation should be
                both evidence-based and comprehensive.</p>
            <p id="p6185"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1330" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6190">In a registry study of hyponatremia in acute decompensated HF, fluid
                                restriction only improved hyponatremia marginally (<a class="tab-link" href="#bib1055"
                                    data-tab="pane-pcw-references">1</a>). A registered dietitian-guided fluid and
                                sodium restriction intervention improved NYHA functional classification and leg edema in
                                patients with HFrEF who were not in stage D HF (<a class="tab-link" href="#bib1056"
                                    data-tab="pane-pcw-references">2</a>), and fluid restriction improved QOL in a pilot
                                RCT of patients with HFrEF and HFpEF (NYHA class I to IV) (<a class="tab-link"
                                    href="#bib1057" data-tab="pane-pcw-references">3</a>). In a meta-analysis of RCTs on
                                fluid restriction in HF in general, restricted fluid intake compared with free fluid
                                consumption did not result in reduced hospitalization or mortality rates, changes in
                                thirst, the duration of intravenous diuretic use, serum creatinine, or serum sodium
                                levels (<a class="tab-link" href="#bib1058" data-tab="pane-pcw-references">4</a>). The
                                validity of a previous trial supporting clinical benefits of fluid restriction in HF is
                                in serious question (<a class="tab-link" href="#bib1066"
                                    data-tab="pane-pcw-references">12</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec12" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec12">
                <div id="acsectitle0410" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0410">8.3 Inotropic Support</h3>
            <div id="undtbl38" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl38">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0720">Recommendations for Inotropic Support</p>
                            <p id="tspara0725">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0725" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1725"><strong>In patients with advanced (stage D) HF refractory
                                                        to GDMT and device therapy who are eligible for and awaiting MCS
                                                        or cardiac transplantation, continuous intravenous inotropic
                                                        support is reasonable as “bridge therapy”</strong> (<a
                                                        class="tab-link" href="#bib1067"
                                                        data-tab="pane-pcw-references">1-4</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0730" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1730"><strong>In select patients with stage D HF, despite
                                                        optimal GDMT and device therapy who are ineligible for either
                                                        MCS or cardiac transplantation, continuous intravenous inotropic
                                                        support may be considered as palliative therapy for symptom
                                                        control and improvement in functional status</strong> (<a
                                                        class="tab-link" href="#bib1071"
                                                        data-tab="pane-pcw-references">5-7</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0735" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1735"><strong>In patients with HF, long-term use of either
                                                        continuous or intermittent intravenous inotropic agents, for
                                                        reasons other than palliative care or as a bridge to advanced
                                                        therapies, is potentially harmful (</strong><a class="tab-link"
                                                        href="#bib1071"
                                                        data-tab="pane-pcw-references"><strong>5</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1072"
                                                        data-tab="pane-pcw-references"><strong>6</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1074"
                                                        data-tab="pane-pcw-references"><strong>8-11</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6200"><strong>Synopsis</strong></p>
            <p id="p6205">Despite improving hemodynamic compromise, positive inotropic agents have not shown improved
                survival in patients with HF in either the hospital or the outpatient setting (<a class="tab-link"
                    href="#bib1072" data-tab="pane-pcw-references">6</a>). Regardless of their mechanism of action
                (e.g., inhibition of phosphodiesterase, stimulation of adrenergic or dopaminergic receptors, calcium
                sensitization), parenteral inotropes remain an option to help the subset of patients with HF who are
                refractory to other therapies and are suffering consequences from end-organ hypoperfusion. In
                hospitalized patients presenting with documented severe systolic dysfunction who present with low blood
                pressure and significantly low cardiac index, short-term, continuous intravenous inotropic support may
                be reasonable to maintain systemic perfusion and preserve end-organ performance (<a class="tab-link"
                    href="#bib1074" data-tab="pane-pcw-references">8</a>,<a class="tab-link" href="#bib1077"
                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib1078"
                    data-tab="pane-pcw-references">12</a>). There continues to be lack of robust evidence to suggest the
                clear benefit of 1 inotrope over another (<a class="tab-link" href="#bib1079"
                    data-tab="pane-pcw-references">13</a>). To minimize adverse effects, lower doses of parenteral
                inotropic drugs are preferred, although the development of tachyphylaxis should be acknowledged, and the
                choice of agent may need to be changed during longer periods of support. Similarly, the ongoing need for
                inotropic support and the possibility of discontinuation should be regularly assessed. <a
                    class="ref showTableEvent" data-id="tbl20" href="#tbl20">Table 20</a> compares commonly used
                inotropes.</p>
            <div id="tbl20" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl20">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0210"><span class="captionLabel">Table 20</span> Intravenous Inotropic Agents
                                Used in the Management of HF</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="2">Inotropic Agent</th>
                            <th colspan="2" rowspan="1">Dose (mcg/kg)</th>
                            <th colspan="1" rowspan="2">Drug Kinetics and Metabolism</th>
                            <th colspan="4" rowspan="1">Effects</th>
                            <th colspan="1" rowspan="2">Adverse Effects</th>
                            <th colspan="1" rowspan="2">Special Considerations</th>
                        </tr>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Bolus</th>
                            <th colspan="1" rowspan="1">Infusion (/min)</th>
                            <th colspan="1" rowspan="1">CO</th>
                            <th colspan="1" rowspan="1">HR</th>
                            <th colspan="1" rowspan="1">SVR</th>
                            <th colspan="1" rowspan="1">PVR</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="3" rowspan="1"><strong>Adrenergic agonists</strong></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Dopamine</td>
                            <td align="center" colspan="1" rowspan="1">NA</td>
                            <td align="center" colspan="1" rowspan="1">5–10</td>
                            <td align="center" colspan="1" rowspan="1">t<sub>1/2</sub>: 2–20 min</td>
                            <td align="center" colspan="1" rowspan="1">↑</td>
                            <td align="center" colspan="1" rowspan="1">↑</td>
                            <td align="center" colspan="1" rowspan="1">↔</td>
                            <td align="center" colspan="1" rowspan="1">↔</td>
                            <td align="center" colspan="1" rowspan="2">T, HA, N, tissue necrosis</td>
                            <td align="center" colspan="1" rowspan="1">Caution: MAO-I</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"></td>
                            <td align="center" colspan="1" rowspan="1">NA</td>
                            <td align="center" colspan="1" rowspan="1">10–15</td>
                            <td align="center" colspan="1" rowspan="1">R, H, P</td>
                            <td align="center" colspan="1" rowspan="1">↑</td>
                            <td align="center" colspan="1" rowspan="1">↑</td>
                            <td align="center" colspan="1" rowspan="1">↑</td>
                            <td align="center" colspan="1" rowspan="1">↔</td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Dobutamine</td>
                            <td align="center" colspan="1" rowspan="2">NA</td>
                            <td align="center" colspan="1" rowspan="2">2.5–20</td>
                            <td align="center" colspan="1" rowspan="2">t<sub>1/2</sub>: 2–3 min H</td>
                            <td align="center" colspan="1" rowspan="2">↑</td>
                            <td align="center" colspan="1" rowspan="2">↑</td>
                            <td align="center" colspan="1" rowspan="2">↔</td>
                            <td align="center" colspan="1" rowspan="2">↔</td>
                            <td align="center" colspan="1" rowspan="2">↑/↓BP, HA, T, N, F, hypersensitivity</td>
                            <td align="center" colspan="1" rowspan="2">Caution: MAO-I; CI: sulfite allergy</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="3" rowspan="1"><strong>PDE 3 inhibitor</strong></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Milrinone</td>
                            <td align="center" colspan="1" rowspan="1">NR</td>
                            <td align="center" colspan="1" rowspan="1">0.125–0.75</td>
                            <td align="center" colspan="1" rowspan="1">t<sub>1/2</sub>: 2.5 h H</td>
                            <td align="center" colspan="1" rowspan="1">↑</td>
                            <td align="center" colspan="1" rowspan="1">↑</td>
                            <td align="center" colspan="1" rowspan="1">↓</td>
                            <td align="center" colspan="1" rowspan="1">↓</td>
                            <td align="center" colspan="1" rowspan="1">T, ↓BP</td>
                            <td align="center" colspan="1" rowspan="1">Accumulation may occur in setting of renal
                                failure; monitor kidney function and LFTs</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="3" rowspan="1"><strong>Vasopressors</strong></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="2">Epinephrine</td>
                            <td align="center" colspan="1" rowspan="2">NR</td>
                            <td align="center" colspan="1" rowspan="1">5–15 mcg/min</td>
                            <td align="center" colspan="1" rowspan="1">t<sub>1/2</sub>: 2–3 min</td>
                            <td align="center" colspan="1" rowspan="1">↑</td>
                            <td align="center" colspan="1" rowspan="1">↑</td>
                            <td align="center" colspan="1" rowspan="1">↑ (↓)</td>
                            <td align="center" colspan="1" rowspan="1">↔</td>
                            <td align="center" colspan="1" rowspan="1">HA, T</td>
                            <td align="center" colspan="1" rowspan="1">Caution: MAO-I</td>
                        </tr>
                        <tr valign="top">
                            <td align="center" colspan="1" rowspan="1">15–20 mcg/min</td>
                            <td align="center" colspan="1" rowspan="1">t<sub>1/2</sub>: 2–3 min</td>
                            <td align="center" colspan="1" rowspan="1">↑</td>
                            <td align="center" colspan="1" rowspan="1">↑↑</td>
                            <td align="center" colspan="1" rowspan="1">↑↑</td>
                            <td align="center" colspan="1" rowspan="1">↔</td>
                            <td align="center" colspan="1" rowspan="1">HA, T</td>
                            <td align="center" colspan="1" rowspan="1">Caution: MAO-I</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Norepinephrine</td>
                            <td align="center" colspan="1" rowspan="1">NR</td>
                            <td align="center" colspan="1" rowspan="1">0.5–30 mcg/min</td>
                            <td align="center" colspan="1" rowspan="1">t<sub>1/2</sub>: 2.5 min</td>
                            <td align="center" colspan="1" rowspan="1">↔</td>
                            <td align="center" colspan="1" rowspan="1">↑</td>
                            <td align="center" colspan="1" rowspan="1">↑↑</td>
                            <td align="center" colspan="1" rowspan="1">↔</td>
                            <td align="center" colspan="1" rowspan="1">↓ HR, tissue necrosis</td>
                            <td align="center" colspan="1" rowspan="1">Caution: MAO-I</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0215">BP indicates blood pressure; CI, contraindication; CO, cardiac output; F,
                                fever; H, hepatic; HA, headache; HF, heart failure; HR, heart rate; LFT, liver function
                                test; MAO-I, monoamine oxidase inhibitor; N, nausea; NA, not applicable; NR, not
                                recommended; P, plasma; PDE, phosphodiesterase; PVR, pulmonary vascular resistance; R,
                                renal; SVR, systemic vascular resistance; T, tachyarrhythmias; and t<sub>1/2</sub>,
                                elimination half-life.</p>
                            <p id="tspara0220">Up arrow means increase.</p>
                            <p id="tspara0225">Side arrow means no change.</p>
                            <p id="tspara0230">Down arrow means decrease.</p>
                            <p id="tspara0235">Up/down arrow means either increase or decrease.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p6210"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1335" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6215">More prolonged use of inotropes as “bridge” therapy for those awaiting either
                                heart transplantation or MCS may have benefit in reducing pulmonary hypertension and
                                maintaining end-organ perfusion beyond initial stabilization of patients (<a
                                    class="tab-link" href="#bib1067" data-tab="pane-pcw-references">1-4</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6220">The use of inotropes for palliation does carry with it risks for arrhythmias
                                and catheter-related infections, although the presence of an ICD does decrease the
                                mortality associated with arrhythmias. This risk should be shared with patients if there
                                is planned use of inotropes in a patient without an ICD, or in whom the preference is to
                                deactivate the ICD for palliative purposes. The rate of inappropriate shocks for sinus
                                tachycardia is relatively low, and the concomitant use of beta blockers may help in
                                these patients. Patients may elect to have their shocking devices deactivated,
                                especially if they receive numerous shocks (<a class="tab-link" href="#bib1080"
                                    data-tab="pane-pcw-references">14</a>,<a class="tab-link" href="#bib1081"
                                    data-tab="pane-pcw-references">15</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6225">With the currently available inotropic agents, the benefit of hemodynamic
                                support and stabilization may be compromised by increased myocardial oxygen demand and
                                increased arrhythmic burden. As newer agents are developed, more options may not have
                                these known risks. There are investigational inotropic agents that may provide more
                                options for the management of patients with HF and represent different classes of agents
                                (<a class="tab-link" href="#bib1082" data-tab="pane-pcw-references">16</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec12" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec12">
                <div id="acsectitle0415" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0415">8.4 Mechanical Circulatory Support</h3>
            <div id="undtbl39" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl39">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0730">Recommendations for Mechanical Circulatory Support</p>
                            <p id="tspara0735">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0740" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1740"><strong>In select patients with advanced HFrEF with NYHA
                                                        class IV symptoms who are deemed to be dependent on continuous
                                                        intravenous inotropes or temporary MCS, durable LVAD
                                                        implantation is effective to improve functional status, QOL, and
                                                        survival</strong> (<a class="tab-link" href="#bib1083"
                                                        data-tab="pane-pcw-references">1-18</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0745" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1745"><strong>In select patients with advanced HFrEF who have
                                                        NYHA class IV symptoms despite GDMT, durable MCS can be
                                                        beneficial to improve symptoms, improve functional class, and
                                                        reduce mortality (</strong><a class="tab-link" href="#bib1084"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1086"
                                                        data-tab="pane-pcw-references"><strong>4</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1089"
                                                        data-tab="pane-pcw-references"><strong>7</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1092"
                                                        data-tab="pane-pcw-references"><strong>10</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1094"
                                                        data-tab="pane-pcw-references"><strong>12-17</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1101"
                                                        data-tab="pane-pcw-references"><strong>19</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: Uncertain Value (B-NR)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0750" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1750"><strong>In patients with advanced HFrEF who have NYHA
                                                        class IV symptoms despite GDMT, durable MCS devices provide low
                                                        to intermediate economic value based on current costs and
                                                        outcomes</strong> (<a class="tab-link" href="#bib1102"
                                                        data-tab="pane-pcw-references">20-24</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0755" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1755"><strong>In patients with advanced HFrEF and hemodynamic
                                                        compromise and shock, temporary MCS, including percutaneous and
                                                        extracorporeal ventricular assist devices, are reasonable as a
                                                        “bridge to recovery” or “bridge to decision”</strong> (<a
                                                        class="tab-link" href="#bib1107"
                                                        data-tab="pane-pcw-references">25-29</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6240"><strong>Synopsis</strong></p>
            <p id="p6245">MCS is a therapeutic option for patients with advanced HFrEF to prolong life and improve
                functional capacity. Over the past 10 years, evolution and refinement of temporary and durable options
                has continued. MCS is differentiated by the implant location, approach, flow characteristics, pump
                mechanisms, and ventricle(s) supported. It can be effective for short-term support (hours to days) and
                for long-term management (months to years). There are anatomic and physiologic criteria that make
                durable MCS inappropriate for some patients; it is most appropriate for those with HFrEF and a dilated
                ventricle. With any form of MCS, the device will eventually be turned off, whether at the time of
                explant for transplantation or recovery, or to stop support in a patient who either no longer wishes to
                continue support, or in whom the continued functioning of an MCS prevents their death from other causes,
                such as a catastrophic neurologic event, or metastatic malignancy (<a class="tab-link" href="#bib1112"
                    data-tab="pane-pcw-references">30</a>). This topic should be addressed a priori with patients before
                discussions about MCS. Particularly with temporary devices, the potential need to either discontinue or
                to escalate support should be addressed at time of implantation.</p>
            <p id="p6250"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1340" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6255">Durable LVADs should be considered in selected patients with NHYA class IV
                                symptoms who are deemed dependent on IV inotropes or temporary MCS. The magnitude of the
                                survival benefit for durable LVAD support in advanced NYHA class IV patients has
                                progressively improved, with a 2-year survival &gt;80% in recent trials with newer
                                generation LVADs, which approaches the early survival after cardiac transplantation (<a
                                    class="tab-link" href="#bib1084" data-tab="pane-pcw-references">2</a>). The 2020
                                INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) report
                                showed that 87.6% of recent durable LVAD recipients were categorized as INTERMACS 1 to 3
                                before their implant surgery (<a class="tab-link" href="#bib1092"
                                    data-tab="pane-pcw-references">10</a>). It also showed improved mean survival, &gt;4
                                years for the destination LVAD cohort, and &gt;5 years for bridge-to-transplant
                                patients. Durable LVAD support has also achieved impressive functional improvement and
                                QOL improvement in multiple trials (<a class="tab-link" href="#bib1084"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib1089"
                                    data-tab="pane-pcw-references">7</a>,<a class="tab-link" href="#bib1113"
                                    data-tab="pane-pcw-references">31</a>), although patients remain tethered to
                                external electrical power supplies via a percutaneous lead can limit this improvement.
                                Most patients require rehospitalization within the first year post-implant. These
                                factors emphasize the need for a thorough evaluation and patient education before the
                                decision to proceed with the treatment. Appropriate patient selection benefits from
                                review by a multidisciplinary team that typically includes an HF cardiologist, surgeon,
                                social worker, nurse, pharmacist, dietician, and a palliative medicine specialist.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6260">Durable MCS should be considered in patients with NHYA class IV symptoms
                                despite optimal medical therapy or those deemed dependent on IV inotropes. Destination
                                therapy MCS provides considerable survival advantage in addition to improvement in
                                functional status and health-related QOL (<a class="tab-link" href="#bib1083"
                                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib1089"
                                    data-tab="pane-pcw-references">7</a>,<a class="tab-link" href="#bib1094"
                                    data-tab="pane-pcw-references">12</a>,<a class="tab-link" href="#bib1114"
                                    data-tab="pane-pcw-references">32</a>,<a class="tab-link" href="#bib1115"
                                    data-tab="pane-pcw-references">33</a>). There is no clear 1-risk model to assess
                                patient risk for complications, but factors such as elevated central venous pressure,
                                pulmonary hypertension, and coagulopathy have been linked to poorer outcomes (<a
                                    class="tab-link" href="#bib1097" data-tab="pane-pcw-references">15</a>,<a
                                    class="tab-link" href="#bib1116" data-tab="pane-pcw-references">34-36</a>). In
                                patients who are unable to tolerate anticoagulation after repeated challenges,
                                implantation of a durable MCS is associated with excess morbidity; incidents of pump
                                thrombosis, hemolysis, and ischemic neurologic events have been linked to subtherapeutic
                                international normalized ratios (<a class="tab-link" href="#bib1119"
                                    data-tab="pane-pcw-references">37-41</a>). In addition, implantation of MCS in
                                patients with INTERMACS profile of 1 has been associated with poorer outcome, while
                                those ambulatory patients with profiles 5 to 7 might be too well to have large
                                significant benefit, depending on their symptom burden (<a class="tab-link"
                                    href="#bib1101" data-tab="pane-pcw-references">19</a>). For patients who are
                                initially considered to be transplant ineligible because of pulmonary hypertension,
                                obesity, overall frailty, or other reasons, MCS can provide time to reverse or modify
                                these conditions (<a class="tab-link" href="#bib1117"
                                    data-tab="pane-pcw-references">35</a>,<a class="tab-link" href="#bib1124"
                                    data-tab="pane-pcw-references">42-44</a>). Continuing and uptitrating GDMT in
                                patients with durable MCS is recommended (<a class="tab-link" href="#bib1127"
                                    data-tab="pane-pcw-references">45</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6265">Multiple studies evaluated the cost-effectiveness of ventricular assist device
                                implantation for advanced HF between 2012 and 2017 (<a class="tab-link" href="#bib1102"
                                    data-tab="pane-pcw-references">20</a>,<a class="tab-link" href="#bib1103"
                                    data-tab="pane-pcw-references">21</a>,<a class="tab-link" href="#bib1105"
                                    data-tab="pane-pcw-references">23</a>). They consistently found device implantation
                                was of low economic value, with incremental cost-effectiveness ratios of $200,000 per
                                QALY gained compared with medical therapy alone among patients who potentially underwent
                                subsequent heart transplant and those who were ineligible for heart transplant. In these
                                studies, costs after implantation remained high given high rates of complication and
                                rehospitalization. However, these studies used earlier estimates of post-implant
                                outcomes and complication-related costs that have generally improved over time with
                                better care and newer devices (<a class="tab-link" href="#bib1128"
                                    data-tab="pane-pcw-references">46-48</a>). Additionally, limited recent data suggest
                                improvement in health care costs and intermediate economic value with LVAD among
                                patients with advanced HF who are either eligible or ineligible for subsequent heart
                                transplant (<a class="tab-link" href="#bib1104" data-tab="pane-pcw-references">22</a>,<a
                                    class="tab-link" href="#bib1106" data-tab="pane-pcw-references">24</a>). The
                                improvement may result from lower complication rates, increased survival, lower implant
                                costs, and higher estimated QOL. However, given the conflicting data and limited
                                analyses of contemporary data, the current value of LVAD therapy is uncertain.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6270">Temporary MCS can help stabilize patients and allow time for decisions about
                                the appropriateness of transitions to definitive management, such as durable MCS as a
                                bridge or destination therapy, stabilization until cardiac transplantation or, in the
                                case of improvement and recovery, suitability for device removal (<a class="tab-link"
                                    href="#bib1127" data-tab="pane-pcw-references">45</a>). These patients often present
                                in cardiogenic shock that cannot be managed solely with IV inotropes and in whom other
                                organ function is at risk. Temporary MCS is also appropriate for use to allow patients
                                to engage in decision-making for durable MCS or transplantation and for determination of
                                recovery of neurologic status.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec12" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec12">
                <div id="acsectitle0420" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0420">8.5 Cardiac Transplantation</h3>
            <div id="undtbl40" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl40">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0740">Recommendation for Cardiac Transplantation</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0760" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1760"><strong>For selected patients with advanced HF despite
                                                        GDMT, cardiac transplantation is indicated to improve survival
                                                        and QOL</strong> (<a class="tab-link" href="#bib1131"
                                                        data-tab="pane-pcw-references">1-3</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="2" rowspan="1"><strong>Value Statement: Intermediate Value (C-LD)</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0765" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1765"><strong>In patients with stage D (advanced) HF despite
                                                        GDMT, cardiac transplantation provides intermediate economic
                                                        value</strong> (<a class="tab-link" href="#bib1134"
                                                        data-tab="pane-pcw-references">4</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6280"><strong>Synopsis</strong></p>
            <p id="p6285">The evidence that cardiac transplantation provides a mortality and morbidity benefit to
                selected patients with stage D HF (refractory, advanced) is derived from observational cohorts. Datasets
                from the International Society for Heart and Lung Transplantation (<a class="tab-link" href="#bib1131"
                    data-tab="pane-pcw-references">1</a>) and United Network of Organ Sharing (<a class="tab-link"
                    href="#bib1132" data-tab="pane-pcw-references">2</a>) document the median survival of adult
                transplant recipients to be now &gt;12 years; the median survival of patients with stage D HF without
                advanced therapies is &lt;2 years. For comparison, the risk of death becomes greater than survival
                between 3 and 4 years on an LVAD, regardless of implant strategy (e.g., bridge-to-transplant,
                bridge-to-decision, destination therapy) (<a class="tab-link" href="#bib1133"
                    data-tab="pane-pcw-references">3</a>). Improvements in pre- and posttransplant management have also
                increased more patients to be eligible for transplant, and treated rejection rates in the first year
                after transplantation are now &lt;15% (<a class="tab-link" href="#bib1131"
                    data-tab="pane-pcw-references">1</a>). Minimizing waitlist mortality while maximizing posttransplant
                outcomes continues to be a priority in heart transplantation and was addressed with the recent changes
                in donor allocation policy instituted in 2018 (<a class="tab-link" href="#bib1135"
                    data-tab="pane-pcw-references">5</a>). Several analyses (<a class="tab-link" href="#bib1136"
                    data-tab="pane-pcw-references">6-11</a>) have confirmed a decrease in waitlist mortality as well as
                an increase in the use of temporary circulatory support devices, graft ischemic times, and distances
                between donor and recipient hospitals. The impact on posttransplant survival remains uncertain.
                Multiorgan transplantation remains uncommon and reserved for highly selected candidates. In 2018, 7% of
                all heart transplants involved another organ, in addition to the heart (<a class="tab-link"
                    href="#bib1131" data-tab="pane-pcw-references">1</a>).</p>
            <p id="p6290"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1345" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6295">Cardiac transplantation is the established treatment for eligible patients
                                with stage D HF refractory to GDMT, device, and surgical optimization. The survival of
                                adult recipients who received a transplantation between 2011 and 2013 at 1, 3, and 5
                                years is 90.3%, 84.7%, and 79.6%, respectively (<a class="tab-link" href="#bib1132"
                                    data-tab="pane-pcw-references">2</a>). Conditional survival now approaches 15 years
                                (<a class="tab-link" href="#bib1131" data-tab="pane-pcw-references">1</a>). Cardiac
                                transplantation also improves functional status and health-related QOL (<a
                                    class="tab-link" href="#bib1142" data-tab="pane-pcw-references">12-15</a>). Good
                                outcomes can be achieved in patients not only with HF that is primarily cardiovascular
                                in origin, including reversible pulmonary hypertension (<a class="tab-link"
                                    href="#bib1146" data-tab="pane-pcw-references">16</a>), congenital heart disease (<a
                                    class="tab-link" href="#bib1147" data-tab="pane-pcw-references">17</a>), and
                                hypertrophic cardiomyopathy (<a class="tab-link" href="#bib1148"
                                    data-tab="pane-pcw-references">18</a>), but also in patients with systemic
                                conditions complicated by HF, such as muscular dystrophy (<a class="tab-link"
                                    href="#bib1149" data-tab="pane-pcw-references">19</a>), sarcoidosis (<a
                                    class="tab-link" href="#bib1150" data-tab="pane-pcw-references">20</a>), and
                                amyloidosis (<a class="tab-link" href="#bib1151" data-tab="pane-pcw-references">21</a>).
                                CPET can refine candidate prognosis and selection (<a class="tab-link" href="#bib1152"
                                    data-tab="pane-pcw-references">22-28</a>). Appropriate patient selection should
                                include integration of comorbidity burden, caretaker status, and goals of care. The
                                listing criteria, evaluation, and management of patients undergoing cardiac
                                transplantation are described by the International Society for Heart and Lung
                                Transplantation (<a class="tab-link" href="#bib1159"
                                    data-tab="pane-pcw-references">29</a>). The United Network of Organ Sharing Heart
                                Transplant Allocation Policy was revised in 2018 with a broader geographic sharing
                                policy and a 6-tiered system to better prioritize more unstable patients and minimize
                                waitlist mortality (<a class="tab-link" href="#bib1135"
                                    data-tab="pane-pcw-references">5-11</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6300">One study evaluated the cost-effectiveness of heart transplantation compared
                                with medical therapy among patients with inotrope-dependent advanced HF (<a
                                    class="tab-link" href="#bib1160" data-tab="pane-pcw-references">30</a>). This
                                analysis found transplantation was of intermediate value. The results were similar
                                across a broad range of patient age, waitlist duration, and monthly mortality risk with
                                medical therapy.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acd247731e12126" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e12126">
                <div id="acsectitle0425" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0425">9 Patients Hospitalized With Acute
                Decompensated HF</h2>
            <div id="acsec13" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec13">
                <div id="acsectitle0430" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0430">9.1 Assessment of Patients Hospitalized With
                Decompensated HF</h3>
            <div id="undtbl41" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl41">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0740a">Recommendations for Assessment of Patients Hospitalized With
                                Decompensated HF</p>
                        </strong></caption>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0770" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1770"><strong>In patients hospitalized with HF, severity of
                                                        congestion and adequacy of perfusion should be assessed to guide
                                                        triage and initial therapy</strong> (<a class="tab-link"
                                                        href="#bib1161"
                                                        data-tab="pane-pcw-references">1-5</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0775" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1775"><strong>In patients hospitalized with HF, the common
                                                        precipitating factors and the overall patient trajectory should
                                                        be assessed to guide appropriate therapy (</strong><a
                                                        class="tab-link" href="#bib1165"
                                                        data-tab="pane-pcw-references"><strong>5</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1166"
                                                        data-tab="pane-pcw-references"><strong>6</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="3" rowspan="1"><strong>Goals for Optimization and Continuation of GDMT</strong>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0780" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1780"><strong>For patients admitted with HF, treatment should
                                                        address reversible factors, establish optimal volume status, and
                                                        advance GDMT toward targets for outpatient therapy</strong> (<a
                                                        class="tab-link" href="#bib1166"
                                                        data-tab="pane-pcw-references">6</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6310"><strong>Synopsis</strong></p>
            <p id="p6315">Initial triage includes clinical assessment of the hemodynamic profile for severity of
                congestion and adequacy of perfusion (<a class="tab-link" href="#bib1161"
                    data-tab="pane-pcw-references">1-5</a>). The diagnosis of cardiogenic shock warrants consideration
                of recommendations in <a class="ref sec" id="crosref7530" href="#sec13.5">Section 9.5</a>, “Evaluation
                and Management of Cardiogenic Shock,” but any concern for worsening hypoperfusion should also trigger
                involvement of the multidisciplinary team for hemodynamic assessment and intervention. Initial triage
                includes recognition of patients with ACS for whom urgent revascularization may be indicated. In the
                absence of ischemic disease, recent onset with accelerating hemodynamic decompensation may represent
                inflammatory heart disease, particularly when accompanied by conduction block or ventricular arrhythmias
                (<a class="tab-link" href="#bib1167" data-tab="pane-pcw-references">7</a>,<a class="tab-link"
                    href="#bib1168" data-tab="pane-pcw-references">8</a>). However, most HF hospitalizations for
                decompensation are not truly “acute” but follow a gradual increase of cardiac filling pressures on
                preexisting structural heart disease, often with precipitating factors that can be identified (<a
                    class="tab-link" href="#bib1163" data-tab="pane-pcw-references">3</a>,<a class="tab-link"
                    href="#bib1166" data-tab="pane-pcw-references">6</a>) (<a class="ref showTableEvent" data-id="tbl21"
                    href="#tbl21">Table 21</a>). Some patients present with pulmonary edema and severe hypertension,
                which require urgent treatment to reduce blood pressure, more commonly in patients with preserved LVEF.
                Patients require assessment and management of ischemia, arrhythmia and other precipitating factors and
                comorbidities. The presenting profile, reversible factors, appropriate workup for the cause of HF
                including ischemic and nonischemic causes, comorbidities, and potential for GDMT titration inform the
                plan of care to optimize the disease trajectory (<a class="tab-link" href="#bib1165"
                    data-tab="pane-pcw-references">5</a>).</p>
            <div id="tbl21" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl21">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0240"><span class="captionLabel">Table 21</span> Common Factors Precipitating
                                HF Hospitalization With Acute Decompensated HF</p>
                        </strong></caption>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">ACS</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Uncontrolled hypertension</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">AF and other arrhythmias</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Additional cardiac disease (e.g., endocarditis)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Acute infections (e.g., pneumonia, urinary tract)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Nonadherence with medication regimen or dietary intake</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Anemia</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Hyper- or hypothyroidism</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Medications that increase sodium retention (e.g., NSAID)</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Medications with negative inotropic effect (e.g., verapamil)
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0245">ACS indicates acute coronary syndrome; AF, atrial fibrillation; HF, heart
                                failure; and NSAID, nonsteroidal anti-inflammatory drug.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p6320"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1350" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1. and 2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6325">Most patients admitted with HF have clinical evidence of congestion without
                                apparent hypoperfusion (<a class="tab-link" href="#bib1161"
                                    data-tab="pane-pcw-references">1-5</a>,<a class="tab-link" href="#bib1169"
                                    data-tab="pane-pcw-references">9</a>,<a class="tab-link" href="#bib1170"
                                    data-tab="pane-pcw-references">10</a>). Although elevations of right- and left-sided
                                cardiac filling pressures are usually proportional in decompensation of chronic HF with
                                low EF, up to 1 in 4 patients have a mismatch between right- and left-sided filling
                                pressures (<a class="tab-link" href="#bib1169" data-tab="pane-pcw-references">9-11</a>).
                                Disproportionate elevation of right-sided pressures, particularly with TR, hinders
                                effective decongestion. Disproportionate elevation of left-sided filling pressures may
                                be underrecognized as the cause of dyspnea in the absence of jugular venous distention
                                and edema. Elevated natriuretic peptides can help identify HF in the urgent care setting
                                but with less utility in certain situations, including decreased sensitivity with
                                obesity and HFpEF and decreased specificity in the setting of sepsis. Resting
                                hypoperfusion is often underappreciated in patients with chronic HF but can be suspected
                                from narrow pulse pressure and cool extremities (<a class="tab-link" href="#bib1161"
                                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib1169"
                                    data-tab="pane-pcw-references">9</a>) and by intolerance to neurohormonal
                                antagonists. Elevated serum lactate levels may indicate hypoperfusion and impending
                                cardiogenic shock (<a class="tab-link" href="#bib1172"
                                    data-tab="pane-pcw-references">12</a>). When initial clinical assessment does not
                                suggest congestion or hypoperfusion, symptoms of HF may be a result of transient
                                ischemia, arrhythmias, or noncardiac disease such as chronic pulmonary disease or
                                pneumonia, and more focused hemodynamic assessment may be warranted. Assessment of
                                arrhythmia, device profiles such as percent LV pacing versus RV pacing in patients with
                                CRT, and device therapy and shocks in patients with ICD can provide important
                                information.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6330">Hospitalization for HF is a sentinel event that signals worse prognosis and
                                the need to restore hemodynamic compensation but also provides key opportunities to
                                redirect the disease trajectory. During the HF hospitalization, the approach to
                                management should include and address precipitating factors, comorbidities, and previous
                                limitations to ongoing disease management related to social determinants of health (<a
                                    class="tab-link" href="#bib1161" data-tab="pane-pcw-references">1</a>). Patients
                                require assessment and management of ischemia, arrhythmia, and other precipitating
                                factors and comorbidities. The presenting profile, reversible factors, appropriate
                                work-up for cause of HF including ischemic and nonischemic causes, comorbidities,
                                disease trajectory, and goals of care should be addressed. Establishment of optimal
                                volume status is a major goal, and patients with residual congestion merit careful
                                consideration for further intervention before and after discharge, because they face
                                higher risk for rehospitalization and death (<a class="tab-link" href="#bib1162"
                                    data-tab="pane-pcw-references">2-5</a>). The disease trajectory for patients
                                hospitalized with reduced EF is markedly improved by optimization of recommended medical
                                therapies, which should be initiated or increased toward target doses once the efficacy
                                of diuresis has been shown (<a class="tab-link" href="#bib1173"
                                    data-tab="pane-pcw-references">13</a>,<a class="tab-link" href="#bib1174"
                                    data-tab="pane-pcw-references">14</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec13" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec13">
                <div id="acsectitle0435" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0435">9.2 Maintenance or Optimization of GDMT During
                Hospitalization</h3>
            <div id="undtbl42" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl42">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0745">Recommendations for Maintenance or Optimization of GDMT During
                                Hospitalization</p>
                            <p id="tspara0750">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0785" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1785"><strong>In patients with HFrEF requiring hospitalization,
                                                        preexisting GDMT should be continued and optimized to improve
                                                        outcomes, unless contraindicated</strong> (<a class="tab-link"
                                                        href="#bib1175"
                                                        data-tab="pane-pcw-references">1-5</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0790" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1790"><strong>In patients experiencing mild decrease of renal
                                                        function or asymptomatic reduction of blood pressure during HF
                                                        hospitalization, diuresis and other GDMT should not routinely be
                                                        discontinued</strong> (<a class="tab-link" href="#bib1180"
                                                        data-tab="pane-pcw-references">6-11</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0795" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1795"><strong>In patients with HFrEF, GDMT should be initiated
                                                        during hospitalization after clinical stability is achieved
                                                        (</strong><a class="tab-link" href="#bib1176"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1177"
                                                        data-tab="pane-pcw-references"><strong>3</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1179"
                                                        data-tab="pane-pcw-references"><strong>5</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1186"
                                                        data-tab="pane-pcw-references"><strong>12-18</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0800" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1800"><strong>In patients with HFrEF, if discontinuation of GDMT
                                                        is necessary during hospitalization, it should be reinitiated
                                                        and further optimized as soon as possible</strong> (<a
                                                        class="tab-link" href="#bib1193"
                                                        data-tab="pane-pcw-references">19-22</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6345"><strong>Synopsis</strong></p>
            <p id="p6350">Hospitalization for HFrEF is a critical opportunity to continue, initiate, and further
                optimize GDMT (<a class="tab-link" href="#bib1197" data-tab="pane-pcw-references">23-25</a>).
                Continuation of oral GDMT during hospitalization for HF has been shown in registries to lower risk of
                postdischarge death and readmission compared with discontinuation (<a class="tab-link" href="#bib1175"
                    data-tab="pane-pcw-references">1-5</a>). Initiation of oral GDMT during hospitalization for HF is
                associated with numerous clinical outcome benefits (<a class="tab-link" href="#bib1176"
                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib1179"
                    data-tab="pane-pcw-references">5</a>,<a class="tab-link" href="#bib1186"
                    data-tab="pane-pcw-references">12</a>,<a class="tab-link" href="#bib1190"
                    data-tab="pane-pcw-references">16</a>,<a class="tab-link" href="#bib1191"
                    data-tab="pane-pcw-references">17</a>). Based on data from the CHAMP-HF (Change the Management of
                Patients with Heart Failure) registry, however, only 73%, 66%, and 33% of eligible patients with HFrEF
                were prescribed ACEi-ARB-ARNi, beta blockers, and MRA therapy, respectively (<a class="tab-link"
                    href="#bib1193" data-tab="pane-pcw-references">19</a>). Furthermore, based on information obtained
                from claims data, roughly 42% of patients are not prescribed any GDMT within 30 days postindex
                hospitalization (<a class="tab-link" href="#bib1194" data-tab="pane-pcw-references">20</a>), and 45% are
                prescribed either no oral GDMT or monotherapy within 1-year post-hospitalization (<a class="tab-link"
                    href="#bib1195" data-tab="pane-pcw-references">21</a>). In the management of patients with HFrEF in
                the community, very few receive target doses of oral GDMT (<a class="tab-link" href="#bib1180"
                    data-tab="pane-pcw-references">6</a>). Moreover, most patients with HFrEF have no changes made to
                oral GDMT over 12 months (<a class="tab-link" href="#bib1195" data-tab="pane-pcw-references">21</a>),
                despite being discharged on suboptimal doses or no GDMT (<a class="tab-link" href="#bib1196"
                    data-tab="pane-pcw-references">22</a>). It cannot be assumed that oral GDMT will be initiated or
                optimized after hospitalization for HFrEF.</p>
            <p id="p6355"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1355" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6360">In OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in
                                Hospitalized Patients with Heart Failure), discontinuation of beta blockers was
                                associated with a higher risk for mortality compared with those continued on beta
                                blockers (<a class="tab-link" href="#bib1175" data-tab="pane-pcw-references">1</a>). In
                                a meta-analysis of observational and trial data, discontinuation of beta blockers in
                                hospitalized patients with HFrEF also was associated with a higher risk of in-hospital
                                mortality, short-term mortality, and the combined endpoint of short-term
                                rehospitalization or mortality (<a class="tab-link" href="#bib1178"
                                    data-tab="pane-pcw-references">4</a>). Withholding or reducing beta-blocker therapy
                                should be considered in patients with marked volume overload or marginal low cardiac
                                output. In the Get With The Guidelines-Heart Failure (GWTG-HF) registry, withdrawal of
                                ACEi-ARB among patients hospitalized with HFrEF was associated with higher rates of
                                postdischarge mortality and readmission (<a class="tab-link" href="#bib1176"
                                    data-tab="pane-pcw-references">2</a>). In the COACH (Coordinating study evaluating
                                Outcomes of Advising and Counselling in Heart failure) study, continuation of
                                spironolactone among hospitalized patients with HFrEF was associated with lower 30-day
                                mortality and HF rehospitalization (<a class="tab-link" href="#bib1177"
                                    data-tab="pane-pcw-references">3</a>). From the ARIC (Atherosclerosis Risk in
                                Communities) study, discontinuation of any oral GDMT among patients hospitalized with
                                HFrEF was associated with higher mortality risk (<a class="tab-link" href="#bib1179"
                                    data-tab="pane-pcw-references">5</a>). Oral GDMT should not be withheld for mild or
                                transient reductions in blood pressure (<a class="tab-link" href="#bib1180"
                                    data-tab="pane-pcw-references">6-9</a>) or mild deteriorations in renal function (<a
                                    class="tab-link" href="#bib1184" data-tab="pane-pcw-references">10</a>,<a
                                    class="tab-link" href="#bib1185" data-tab="pane-pcw-references">11</a>). True
                                contraindications are rare, such as advanced degree atrioventricular block for beta
                                blockers in the absence of pacemakers; cardiogenic shock that may preclude use of
                                certain medications until resolution of shock state; or angioedema for ACEi or ARNi.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6365">In CHAMP-HF, very few patients with HF and SBP &lt;110 mm Hg received target
                                doses of beta blockers (17.5%) ACEi-ARB (6.2 %), or ARNi (1.8%) (<a class="tab-link"
                                    href="#bib1180" data-tab="pane-pcw-references">6</a>). In PARADIGM-HF, patients with
                                HF and lower SBP on sacubitril-valsartan had the same tolerance and relative benefit
                                over enalapril compared with patients with higher SBP (<a class="tab-link"
                                    href="#bib1181" data-tab="pane-pcw-references">7</a>). From the SENIORS (Study of
                                Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With
                                Heart Failure) trial, nebivolol had equivalent tolerance and benefits irrespective of
                                SBP (<a class="tab-link" href="#bib1182" data-tab="pane-pcw-references">8</a>). In
                                Val-HeFT (Valsartan Heart Failure Trial), decreases in SBP did not offset the beneficial
                                effects of valsartan on HF morbidity (<a class="tab-link" href="#bib1183"
                                    data-tab="pane-pcw-references">9</a>). In patients with HF on oral GDMT, small to
                                moderate worsening of renal function (defined as ≥20% decrease in eGFR in that study)
                                was not associated with AKI (<a class="tab-link" href="#bib1184"
                                    data-tab="pane-pcw-references">10</a>). Moreover, it has been shown that
                                spironolactone and beta blockers might be protective in patients with HF and worsening
                                renal function (<a class="tab-link" href="#bib1185"
                                    data-tab="pane-pcw-references">11</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6370">In OPTIMIZE-HF, discharge use of carvedilol was associated with a reduction in
                                60- to 90-day mortality and composite risk of mortality or rehospitalization compared
                                with no carvedilol use (<a class="tab-link" href="#bib1186"
                                    data-tab="pane-pcw-references">12</a>,<a class="tab-link" href="#bib1187"
                                    data-tab="pane-pcw-references">13</a>). Discharge use of beta blockers is also
                                associated with lower 30-day all-cause mortality and 4-year all-cause
                                mortality/all-cause readmission (<a class="tab-link" href="#bib1188"
                                    data-tab="pane-pcw-references">14</a>). Caution should be used when initiating beta
                                blockers in patients who have required inotropes during hospitalization. In GWTG-HF,
                                initiation of ACEi-ARB in patients hospitalized with HFrEF reduced 30-day and 1-year
                                mortality (<a class="tab-link" href="#bib1176" data-tab="pane-pcw-references">2</a>).
                                Among patients hospitalized with HFrEF, initiation of ACEi-ARB also is associated with
                                lower risk of 30-day all-cause readmission and all-cause mortality (<a class="tab-link"
                                    href="#bib1189" data-tab="pane-pcw-references">15</a>). In a claims study,
                                initiation of MRA therapy at hospital discharge was associated with improved HF
                                readmission but not mortality or cardiovascular readmission among older adults
                                hospitalized with HFrEF (<a class="tab-link" href="#bib1190"
                                    data-tab="pane-pcw-references">16</a>). In COACH, initiating spironolactone among
                                patients hospitalized with HFrEF was associated with lower 30-day mortality and HF
                                rehospitalization (<a class="tab-link" href="#bib1177"
                                    data-tab="pane-pcw-references">3</a>). In the PIONEER-HF trial, ARNi use was
                                associated with reduced NT-proBNP levels in patients hospitalized for acute
                                decompensated HF without increased rates of adverse events (worsening renal function,
                                hyperkalemia, symptomatic hypotension, angioedema) when compared with enalapril (<a
                                    class="tab-link" href="#bib1192" data-tab="pane-pcw-references">18</a>). In the ARIC
                                study, initiation of any oral GDMT was associated with reduced 1-year mortality among
                                patients hospitalized with HFrEF (<a class="tab-link" href="#bib1179"
                                    data-tab="pane-pcw-references">5</a>). In SOLOIST-WHF, initiation of sotagliflozin
                                before or shortly after discharge reduced cardiovascular mortality and hospitalization
                                (<a class="tab-link" href="#bib1191" data-tab="pane-pcw-references">17</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6375">Nearly half (46%) of patients with HFrEF have no changes made to oral GDMT in
                                the 12 months after hospitalization despite many being discharged on suboptimal doses
                                (<a class="tab-link" href="#bib1195" data-tab="pane-pcw-references">21</a>). From
                                claims-based studies, 42% of patients with HFrEF are not prescribed any GDMT within 30
                                days post-index hospitalization (<a class="tab-link" href="#bib1194"
                                    data-tab="pane-pcw-references">20</a>), and 45% are prescribed either no oral GDMT
                                or monotherapy within 1-year post-index hospitalization (<a class="tab-link"
                                    href="#bib1195" data-tab="pane-pcw-references">21</a>). From CHAMP-HF, initiation or
                                dose increases of beta blockers, ACEi-ARB-ARNi, and MRA occur in ≤10% of patients with
                                HFrEF within 1 year of hospitalization (<a class="tab-link" href="#bib1196"
                                    data-tab="pane-pcw-references">22</a>). Very few eligible patients with HFrEF
                                receive target doses of beta blockers (18.7%), ACEi-ARB (10.8%), or ARNi (2.0%) (<a
                                    class="tab-link" href="#bib1180" data-tab="pane-pcw-references">6</a>). Less than 1%
                                of patients with HFrEF are on target doses of ACEi-ARB-ARNi, beta blockers, and MRA
                                within 12 months of an index hospitalization (<a class="tab-link" href="#bib1196"
                                    data-tab="pane-pcw-references">22</a>). For patients with HFrEF, there is a graded
                                improvement in the risk of death or rehospitalization with monotherapy, dual therapy,
                                and triple therapy compared with no GDMT after an index hospitalization in Medicare
                                claims data (<a class="tab-link" href="#bib1195" data-tab="pane-pcw-references">21</a>).
                            </p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec13" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec13">
                <div id="acsectitle0440" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0440">9.3 Diuretics in Hospitalized Patients: Decongestion
                Strategy</h3>
            <div id="undtbl43" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl43">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0755">Recommendations for Diuretics in Hospitalized Patients: Decongestion
                                Strategy</p>
                            <p id="tspara0760">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0805" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1805"><strong>Patients with HF admitted with evidence of
                                                        significant fluid overload should be promptly treated with
                                                        intravenous loop diuretics to improve symptoms and reduce
                                                        morbidity</strong> (<a class="tab-link" href="#bib1200"
                                                        data-tab="pane-pcw-references">1</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0810" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1810"><strong>For patients hospitalized with HF, therapy with
                                                        diuretics and other guideline-directed medications should be
                                                        titrated with a goal to resolve clinical evidence of congestion
                                                        to reduce symptoms and rehospitalizations</strong> (<a
                                                        class="tab-link" href="#bib1200"
                                                        data-tab="pane-pcw-references">1-6</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0815" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1815"><strong>For patients requiring diuretic treatment during
                                                        hospitalization for HF, the discharge regimen should include a
                                                        plan for adjustment of diuretics to decrease
                                                        rehospitalizations</strong> (<a class="tab-link" href="#bib1206"
                                                        data-tab="pane-pcw-references">7</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0820" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1820"><strong>In patients hospitalized with HF when diuresis is
                                                        inadequate to relieve symptoms and signs of congestion, it is
                                                        reasonable to intensify the diuretic regimen using either: a.
                                                        higher doses of intravenous loop diuretics (</strong><a
                                                        class="tab-link" href="#bib1200"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1202"
                                                        data-tab="pane-pcw-references"><strong>3</strong></a><strong>);
                                                        or b. addition of a second diuretic</strong> (<a
                                                        class="tab-link" href="#bib1202"
                                                        data-tab="pane-pcw-references">3</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6385"><strong>Synopsis</strong></p>
            <p id="p6390">Intravenous loop diuretic therapy provides the most rapid and effective treatment for signs
                and symptoms of congestion leading to hospitalization for HF. Titration to achieve effective diuresis
                may require doubling of initial doses, adding a thiazide diuretic, or adding an MRA that has diuretic
                effects in addition to its cardiovascular benefits. A major goal of therapy is resolution of the signs
                and symptoms of congestion before discharge, as persistent congestion scored at discharge has been
                associated with higher rates of rehospitalizations and mortality. Most patients who have required
                intravenous diuretic therapy during hospitalization for HF will require prescription of loop diuretics
                at discharge to decrease recurrence of symptoms and hospitalization.</p>
            <p id="p6395"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1360" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6400">Diuretic therapy with oral furosemide was the cornerstone of HF therapy for
                                &gt;20 years before construction of the modern bases of evidence for HF therapies. The
                                pivotal RCTs showing benefit in ambulatory HFrEF have been conducted on the background
                                of diuretic therapy to treat and prevent recurrence of fluid retention. An RCT compared
                                intravenous diuretic doses and infusion to bolus dosing during hospitalization for HF
                                but without a placebo arm (<a class="tab-link" href="#bib1200"
                                    data-tab="pane-pcw-references">1</a>). Protocols for recent trials of other
                                medications in patients hospitalized with HF have all included intravenous diuretic
                                therapy as background therapy (<a class="tab-link" href="#bib1200"
                                    data-tab="pane-pcw-references">1-6</a>,<a class="tab-link" href="#bib1207"
                                    data-tab="pane-pcw-references">8</a>,<a class="tab-link" href="#bib1208"
                                    data-tab="pane-pcw-references">9</a>). There are no RCTs for hospitalized patients
                                comparing intravenous loop diuretics to placebo, for which equipoise is considered
                                unlikely (<a class="tab-link" href="#bib1209" data-tab="pane-pcw-references">10</a>).
                            </p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6405">Monitoring HF treatment includes careful measurement of fluid intake and
                                output, vital signs, standing body weight at the same time each day, and clinical signs
                                and symptoms of congestion and hypoperfusion. Daily laboratory tests during active
                                medication adjustment include serum electrolytes, urea nitrogen, and creatinine
                                concentrations. Signs and symptoms of congestion have been specified as inclusion
                                criteria in recent trials of patients hospitalized for HF, in which resolution of these
                                signs and symptoms has been defined as a goal to be achieved by hospital discharge (<a
                                    class="tab-link" href="#bib1200" data-tab="pane-pcw-references">1-6</a>,<a
                                    class="tab-link" href="#bib1207" data-tab="pane-pcw-references">8</a>,<a
                                    class="tab-link" href="#bib1208" data-tab="pane-pcw-references">9</a>), as it has in
                                the recent HF hospitalization pathway consensus document (<a class="tab-link"
                                    href="#bib1210" data-tab="pane-pcw-references">11</a>). Evidence of persistent
                                congestion at discharge has been reported in 25% to 50% of patients (<a class="tab-link"
                                    href="#bib1203" data-tab="pane-pcw-references">4</a>,<a class="tab-link"
                                    href="#bib1204" data-tab="pane-pcw-references">5</a>,<a class="tab-link"
                                    href="#bib1211" data-tab="pane-pcw-references">12</a>), who have higher rates of
                                mortality and readmission and are more likely to have elevated right atrial pressures,
                                TR, and renal dysfunction. Diuresis should not be discontinued prematurely because of
                                small changes in serum creatinine (<a class="tab-link" href="#bib1212"
                                    data-tab="pane-pcw-references">13</a>,<a class="tab-link" href="#bib1213"
                                    data-tab="pane-pcw-references">14</a>), because elevations in the range of 0.3 mg/dL
                                do not predict worse outcomes except when patients are discharged with persistent
                                congestion. Decongestion often requires not only diuresis but also adjustment of other
                                guideline-directed therapies, because elevated volume status and vasoconstriction can
                                contribute to elevated filling pressures.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6410">After discharge, ACEi-ARB, MRAs, and beta blockers all may decrease recurrent
                                congestion leading to hospitalization in HFrEF. Despite these therapies, most patients
                                with recent HF hospitalization require continued use of diuretics after discharge to
                                prevent recurrent fluid retention and hospitalization, as shown in a recent large
                                observational analysis (<a class="tab-link" href="#bib1206"
                                    data-tab="pane-pcw-references">7</a>). Increases in diuretic doses are frequently
                                required early after discharge even in patients on all other currently recommended
                                therapies for HFrEF (<a class="tab-link" href="#bib1207"
                                    data-tab="pane-pcw-references">8</a>). It is unknown how increased penetration of
                                therapy with ARNi and SGLT2i will, in the future, affect the dosing of diuretics after
                                discharge with HFrEF.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6415">Titration of diuretics has been described in multiple recent trials of
                                patients hospitalized with HF, often initiated with at least 2 times the daily home
                                diuretic dose (mg to mg) administered intravenously (<a class="tab-link" href="#bib1200"
                                    data-tab="pane-pcw-references">1</a>). Escalating attempts to achieve net diuresis
                                include serial doubling of intravenous loop diuretic doses, which can be done by bolus
                                or infusion, and sequential nephron blockade with addition of a thiazide diuretic, as
                                detailed specifically in the protocol for the diuretic arms of the CARRESS and ROSE
                                trials (<a class="tab-link" href="#bib1202" data-tab="pane-pcw-references">3</a>,<a
                                    class="tab-link" href="#bib1208" data-tab="pane-pcw-references">9</a>). In the DOSE
                                (Diuretic Optimization Strategies Evaluation) trial, there were no significant
                                differences in patients’ global assessment of symptoms or in the change in renal
                                function when diuretic therapy was administered by bolus, compared with continuous
                                infusion or at a high dose compared with a low dose. Patients in the low-dose group were
                                more likely to require a 50% increase in the dose at 48 hours than were those in the
                                high-dose group, and all treatment groups had higher doses of diuretics compared with
                                baseline preadmission doses, underlining the necessity to intensify and individualize
                                diuretic regimen (<a class="tab-link" href="#bib1200"
                                    data-tab="pane-pcw-references">1</a>). MRAs have mild diuretics properties and
                                addition of MRAs can help with diuresis in addition to significant cardiovascular
                                benefits in patients with HF. Addition of low-dose dopamine to diuretic therapy in the
                                setting of reduced eGFR did not improve outcomes in a study that included patients with
                                all EFs, but a subset analysis showed increased urine output and weight loss in patients
                                with LVEF &lt;0.40 (<a class="tab-link" href="#bib1208"
                                    data-tab="pane-pcw-references">9</a>), with significant interaction of effect with
                                LVEF. Bedside ultrafiltration initiated early after admission increased fluid loss, with
                                decreased rehospitalizations in some studies when compared with use of diuretics without
                                systematic escalation (<a class="tab-link" href="#bib1214"
                                    data-tab="pane-pcw-references">15</a>,<a class="tab-link" href="#bib1215"
                                    data-tab="pane-pcw-references">16</a>) and was also associated with adverse events
                                related to the intravenous catheters required (<a class="tab-link" href="#bib1202"
                                    data-tab="pane-pcw-references">3</a>). Many aspects of ultrafiltration including
                                patient selection, fluid removal rates, venous access, prevention of therapy-related
                                complications, and cost require further investigation.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec13" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec13">
                <div id="acsectitle0445" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0445">9.4a Parenteral Vasodilation Therapy in Patients
                Hospitalized With HF</h3>
            <div id="undtbl44" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl44">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0765">Recommendation for Parenteral Vasodilation Therapy in Patients
                                Hospitalized With HF</p>
                            <p id="tspara0770">Referenced studies that support the recommendation are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0825" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1825"><strong>In patients who are admitted with decompensated
                                                        HF, in the absence of systemic hypotension, intravenous
                                                        nitroglycerin or nitroprusside may be considered as an adjuvant
                                                        to diuretic therapy for relief of dyspnea (</strong><a
                                                        class="tab-link" href="#bib1216"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1217"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6425"><strong>Synopsis</strong></p>
            <p id="p6430">Vasodilators can be used in acute HF to acutely relieve symptoms of pulmonary congestion in
                selected patients. Although they may mitigate dyspnea and relieve pulmonary congestion, their benefits
                have not been shown to have durable effects for either rehospitalization or mortality benefit. In select
                patients who present with signs of hypoperfusion such as worsening renal function, even in the absence
                of hypotension, other escalation of care may need to be considered (see <a class="ref sec"
                    id="crosref7920" href="#sec12.3">Section 8.3</a>, “Inotropic Support,” and <a class="ref sec"
                    id="crosref7925" href="#sec13.5">Section 9.5</a>, “Evaluation and Management of Cardiogenic Shock”).
            </p>
            <p id="p6435"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1365" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6440">The role for directed vasodilators in acute decompensated HF remains
                                uncertain. Part of the rationale for their use is targeting pulmonary congestion, while
                                trying to avoid some potential adverse consequences of loop diuretics. Patients with
                                hypertension, coronary ischemia, or significant MR may be suitable candidates for the
                                use of intravenous nitroglycerin. However, tachyphylaxis may develop within 24 hours,
                                and up to 20% of those with HF may develop resistance to even high doses (<a
                                    class="tab-link" href="#bib1218" data-tab="pane-pcw-references">3</a>,<a
                                    class="tab-link" href="#bib1219" data-tab="pane-pcw-references">4</a>). Because of
                                sodium nitroprusside’s potential for producing marked hypotension, invasive hemodynamic
                                blood pressure monitoring (e.g., an arterial line) is typically required, and
                                nitroprusside is usually used in the intensive care setting; longer infusions of the
                                drug have been associated, albeit rarely, with thiocyanate and cyanide toxicity,
                                particularly in the setting of renal insufficiency and significant hepatic disease.
                                Nitroprusside is potentially of value in severely congested patients with hypertension
                                or severe MV regurgitation complicating LV dysfunction (<a class="tab-link"
                                    href="#bib1220" data-tab="pane-pcw-references">5</a>). Overall, there are no data
                                that suggest that intravenous vasodilators improve outcomes in the patient hospitalized
                                with HF; as such, use of intravenous vasodilators is limited to the relief of dyspnea in
                                the hospitalized HF patient with intact or high blood pressure (<a class="tab-link"
                                    href="#bib1221" data-tab="pane-pcw-references">6</a>,<a class="tab-link"
                                    href="#bib1222" data-tab="pane-pcw-references">7</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec13" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec13">
                <div id="acsectitle0450" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0450">9.4b VTE Prophylaxis in Hospitalized Patients</h3>
            <div id="undtbl45" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl45">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0775">Recommendation for VTE Prophylaxis in Hospitalized Patients</p>
                            <p id="tspara0780">Referenced studies that support the recommendation are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0830" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1830"><strong>In patients hospitalized with HF, prophylaxis for
                                                        VTE is recommended to prevent venous thromboembolic
                                                        disease</strong> (<a class="tab-link" href="#bib1223"
                                                        data-tab="pane-pcw-references">1-3</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6450"><strong>Synopsis</strong></p>
            <p id="p6455">HF has long been recognized as affording additional risk for venous thromboembolic disease.
                When patients are hospitalized for decompensated HF, or when patients with chronic stable HF are
                hospitalized for other reasons, they are at increased risk for venous thromboembolic disease. The risk
                may be associated with higher HF symptom burden (<a class="tab-link" href="#bib1226"
                    data-tab="pane-pcw-references">4</a>). This risk may extend for up to 2 years after hospitalization
                but is greatest in the first 30 days (<a class="tab-link" href="#bib1227"
                    data-tab="pane-pcw-references">5</a>,<a class="tab-link" href="#bib1228"
                    data-tab="pane-pcw-references">6</a>). The use of anticoagulation with subcutaneous
                low-molecular-weight heparin, unfractionated heparin, fondaparinux, or approved DOAC are used for the
                prevention of clinically symptomatic deep vein thrombosis and pulmonary embolism (<a class="tab-link"
                    href="#bib1229" data-tab="pane-pcw-references">7</a>,<a class="tab-link" href="#bib1230"
                    data-tab="pane-pcw-references">8</a>).</p>
            <p id="p6460"><strong>Recommendation-Specific</strong> <strong>Supporting</strong> <strong>Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1370" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6465">Trials using available antithrombotic drugs often were not limited to patients
                                with HF but included patients with acute illnesses, severe respiratory diseases, or
                                simply a broad spectrum of hospitalized medical patients (<a class="tab-link"
                                    href="#bib1231" data-tab="pane-pcw-references">9-12</a>). All included trials
                                excluded patients perceived to have an elevated risk of bleeding complications or of
                                toxicity from the specific agent tested (e.g., enoxaparin in patients with compromised
                                renal function). In some trials, aspirin was allowed but not controlled for as a
                                confounding variable. Despite the increased risk for the development of VTE in the 30
                                days after hospitalization, the data for extending prophylaxis to the immediate
                                post-hospital period have shown decreased development of VTE but were associated with
                                increased bleeding events and overall do not appear to provide additional benefit (<a
                                    class="tab-link" href="#bib1224" data-tab="pane-pcw-references">2</a>,<a
                                    class="tab-link" href="#bib1225" data-tab="pane-pcw-references">3</a>,<a
                                    class="tab-link" href="#bib1233" data-tab="pane-pcw-references">11</a>). For
                                patients admitted specifically for decompensated HF and with adequate renal function
                                (creatinine clearance, &gt;30 mL/min), randomized trials suggest that enoxaparin 40 mg
                                subcutaneously once daily (<a class="tab-link" href="#bib1223"
                                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib1235"
                                    data-tab="pane-pcw-references">13</a>), unfractionated heparin 5000 units
                                subcutaneously every 8 or 12 hours (<a class="tab-link" href="#bib1236"
                                    data-tab="pane-pcw-references">14-17</a>), or rivaroxaban 10 mg once daily (<a
                                    class="tab-link" href="#bib1233" data-tab="pane-pcw-references">11</a>) will
                                radiographically reduce demonstrable venous thrombosis. Effects on mortality or
                                clinically significant pulmonary embolism rates are unclear. For obese patients, a
                                higher dose of enoxaparin 60 mg once daily achieved target range of thromboprophylaxis
                                without increased bleeding (<a class="tab-link" href="#bib1234"
                                    data-tab="pane-pcw-references">12</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec13" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec13">
                <div id="acsectitle0455" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0455">9.5 Evaluation and Management of Cardiogenic Shock
            </h3>
            <div id="undtbl46" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl46">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0785">Recommendations for Evaluation and Management of Cardiogenic Shock</p>
                            <p id="tspara0790">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1"><strong>Recommendations</strong></th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0835" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1835"><strong>In patients with cardiogenic shock, intravenous
                                                        inotropic support should be used to maintain systemic perfusion
                                                        and preserve end-organ performance</strong> (<a class="tab-link"
                                                        href="#bib1240"
                                                        data-tab="pane-pcw-references">1-8</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0840" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1840"><strong>In patients with cardiogenic shock, temporary MCS
                                                        is reasonable when end-organ function cannot be maintained by
                                                        pharmacologic means to support cardiac function</strong> (<a
                                                        class="tab-link" href="#bib1248"
                                                        data-tab="pane-pcw-references">9-17</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0845" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1845"><strong>In patients with cardiogenic shock, management by
                                                        a multidisciplinary team experienced in shock is
                                                        reasonable</strong> (<a class="tab-link" href="#bib1256"
                                                        data-tab="pane-pcw-references">17-22</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0850" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1850"><strong>In patients presenting with cardiogenic shock,
                                                        placement of a PA line may be considered to define hemodynamic
                                                        subsets and appropriate management strategies</strong> (<a
                                                        class="tab-link" href="#bib1262"
                                                        data-tab="pane-pcw-references">23-27</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0855" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1855"><strong>For patients who are not rapidly responding to
                                                        initial shock measures, triage to centers that can provide
                                                        temporary MCS may be considered to optimize management</strong>
                                                    (<a class="tab-link" href="#bib1256"
                                                        data-tab="pane-pcw-references">17-22</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6475"><strong>Synopsis</strong></p>
            <p id="p6480">Cardiogenic shock is a commonly encountered clinical challenge with a high mortality and is
                characterized by a critical reduction in cardiac output manifest by end-organ dysfunction (<a
                    class="tab-link" href="#bib1267" data-tab="pane-pcw-references">28</a>). Hypotension (e.g., SBP
                &lt;90 mm Hg) is the primary clinical manifestation of shock but is not sufficient for the diagnosis.
                Additionally, end-organ hypoperfusion should be present as a consequence of cardiac dysfunction (<a
                    class="ref showTableEvent" data-id="tbl22" href="#tbl22">Tables 22</a>, <a
                    class="ref showTableEvent" data-id="tbl23" href="#tbl23">23</a>, <a class="ref showTableEvent"
                    data-id="tbl24" href="#tbl24">24</a>) (<a class="tab-link" href="#bib1268"
                    data-tab="pane-pcw-references">29</a>). Causes can be broadly separated into acute decompensations
                of chronic HF, acute myocardial dysfunction without precedent HF, and survivors of cardiac arrest. In
                the case of acute MI, urgent revascularization is paramount. The approach to cardiogenic shock should
                include its early recognition, invasive hemodynamic assessment when there is insufficient clinical
                improvement to initial measures and providing appropriate pharmacological and MCS to optimize end-organ
                perfusion and prevent metabolic complications. The evidence that supports the use of specific
                pharmacologic therapies and the nature of temporary MCS is primarily gleaned from observational
                retrospective datasets. Only a few randomized trials have been conducted to assess the most appropriate
                circulatory support device, and they have been limited by small sample size, the inherent open-label
                study design, short follow-up, and surrogate endpoints.</p>
            <div id="tbl22" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl22">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0250"><span class="captionLabel">Table 22</span> Suggested Shock Clinical
                                Criteria<a class="ref table-fn" id="tbl22fnlowast"
                                    href="javascript:popRef('tbl22fnlowast')"><sup>∗</sup></a> (<a class="tab-link"
                                    href="#bib1268" data-tab="pane-pcw-references">29</a>)</p>
                        </strong></caption>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>SBP &lt;90 mm Hg for &gt;30 min:</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0030" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">a.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0300">Or mean BP &lt;60 mm Hg for &gt;30 min</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0035" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">b.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0305">Or requirement of vasopressors to maintain systolic BP ≥90
                                                    mm Hg or mean BP ≥60 mm Hg</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Hypoperfusion defined by:</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0040" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">c.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0310">Decreased mentation</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0045" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">d.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0315">Cold extremities, livedo reticularis</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0050" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">e.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0320">Urine output &lt;30 mL/h</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0055" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">f.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0325">Lactate &gt;2 mmol/L</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0255">BP indicates blood pressure; and SBP, systolic blood pressure.</p>
                        </fn>
                        <fn id="tbl22fnlowast">
                            <p id="ntpara0045">∗ Systolic BP and hypoperfusion criteria need to be met for the shock
                                diagnosis.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="tbl23" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl23">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0260"><span class="captionLabel">Table 23</span> Suggested Shock Hemodynamic
                                Criteria<a class="ref table-fn" id="tbl23fnlowast"
                                    href="javascript:popRef('tbl23fnlowast')"><sup>∗</sup></a> (<a class="tab-link"
                                    href="#bib1268" data-tab="pane-pcw-references">29</a>)</p>
                        </strong></caption>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0060" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0330"><strong>SBP &lt;90 mm Hg or mean BP &lt;60 mm Hg</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0065" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0335"><strong>Cardiac index &lt;2.2
                                                        L/min/m</strong><sup><strong>2</strong></sup></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0070" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0340"><strong>Pulmonary capillary wedge pressure &gt;15 mm
                                                        Hg</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0075" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0345"><strong>Other hemodynamic considerations</strong></p>
                                                <table class="listgroup" border="0" width="95%" id="olist0080"
                                                    list-type="simple">
                                                    <tbody>
                                                        <tr class="li1">
                                                            <td valign="top">a.</td>
                                                            <td colspan="5" valign="top" class="paragraph">
                                                                <p id="p0350">Cardiac power output ([CO x MAP]/451)
                                                                    &lt;0.6 W</p>
                                                            </td>
                                                        </tr>
                                                        <tr class="li1">
                                                            <td valign="top">b.</td>
                                                            <td colspan="5" valign="top" class="paragraph">
                                                                <p id="p0355">Shock index (HR/systolic BP) &gt;1.0</p>
                                                            </td>
                                                        </tr>
                                                        <tr class="li1">
                                                            <td valign="top">c.</td>
                                                            <td colspan="5" valign="top" class="paragraph">
                                                                <p id="p0360">RV shock</p>
                                                                <table class="listgroup" border="0" width="95%"
                                                                    id="olist0085" list-type="simple">
                                                                    <tbody>
                                                                        <tr class="li1">
                                                                            <td valign="top">i.</td>
                                                                            <td colspan="5" valign="top"
                                                                                class="paragraph">
                                                                                <p id="p0365">Pulmonary artery pulse
                                                                                    index [(PASP-PADP)/CVP] &lt;1.0</p>
                                                                            </td>
                                                                        </tr>
                                                                        <tr class="li1">
                                                                            <td valign="top">ii.</td>
                                                                            <td colspan="5" valign="top"
                                                                                class="paragraph">
                                                                                <p id="p0370">CVP &gt;15 mm Hg</p>
                                                                            </td>
                                                                        </tr>
                                                                        <tr class="li1">
                                                                            <td valign="top">iii.</td>
                                                                            <td colspan="5" valign="top"
                                                                                class="paragraph">
                                                                                <p id="p0375">CVP-PCW &gt;0.6</p>
                                                                            </td>
                                                                        </tr>
                                                                    </tbody>
                                                                </table>
                                                                <p></p>
                                                            </td>
                                                        </tr>
                                                    </tbody>
                                                </table>
                                                <p></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0265">BP indicates blood pressure; CO, cardiac output; CVP, central venous
                                pressure; HR, heart rate; MAP, mean arterial pressure; PADP, pulmonary artery diastolic
                                pressure; PASP, pulmonary artery systolic pressure; PCW, pulmonary capillary wedge; RV,
                                right ventricular; and SBP, systolic blood pressure.</p>
                        </fn>
                        <fn id="tbl23fnlowast">
                            <p id="ntpara0050">∗ Diagnosis of shock requires ≥1 criteria to be present along with
                                cardiac index &lt;2.0 L/min/m<sup>2</sup> and SBP &lt;90 mm Hg.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="tbl24" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl24">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0270"><span class="captionLabel">Table 24</span> Society for Cardiovascular
                                Angiography and Interventions (SCAI) Cardiogenic Shock Criteria (<a class="tab-link"
                                    href="#bib1268" data-tab="pane-pcw-references">29</a>)</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Stage</th>
                            <th colspan="1" rowspan="1">Bedside Findings</th>
                            <th colspan="1" rowspan="1">Selected Laboratory Markers</th>
                            <th colspan="1" rowspan="1">Hemodynamics</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>A: At risk</strong>
                                <table class="listgroup" border="0" width="95%" id="ulist0220" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0380">Normotensive</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0385">Normal perfusion</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0390">Cause for risk for shock such as large myocardial
                                                    infarction or HF</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0225" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0395">Normal venous pressure</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0400">Clear lungs</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0405">Warm extremities</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0410">Strong palpable pulses</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0415">Normal mentation</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0230" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0420">Normal renal function</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0425">Normal lactate</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0235" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0430">SBP &gt;100 mm Hg</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0435">Hemodynamics: Normal</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>B: Beginning shock (“pre-shock”)</strong>
                                <table class="listgroup" border="0" width="95%" id="ulist0240" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0440">Hypotension</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0445">Normal perfusion</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0245" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0450">Elevated venous pressure</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0455">Rales present</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0460">Warm extremities</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0465">Strong pulses</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0470">Normal mentation</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0250" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0475">Preserved renal function</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0480">Normal lactate</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0485">Elevated BNP</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0255" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0490">SBP &lt;90 mm Hg, MAP &lt;60 mm Hg, or &gt;30 mm Hg
                                                    decrease from baseline SBP</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0495">HR &gt;100 bpm</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0500">Hemodynamics: CI ≥2.2 L/min/m<sup>2</sup></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>C: Classic cardiogenic shock</strong>
                                <table class="listgroup" border="0" width="95%" id="ulist0260" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0505">Hypotension</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0510">Hypoperfusion</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0265" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0515">Elevated venous pressure</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0520">Rales present</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0525">Cold, ashen, livedo</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0530">Weak or nonpalpable pulses</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0535">Altered mentation</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0540">Decreased urine output</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0545">Respiratory distress</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0270" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0550">Impaired renal function</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0555">Increased lactate</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0560">Elevated BNP</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0565">Increased LFTs</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0570">Acidosis</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0275" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0575">SBP &lt;90 mm Hg; MAP &lt;60 mm Hg; &gt;30 mm Hg from
                                                    baseline SBP despite drugs and temporary MCS</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0580">HR &gt;100 bpm</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0585">Hemodynamics: CI ≤2.2 L/min/m<sup>2</sup>; PCW &gt;15 mm
                                                    Hg; CPO &lt;0.6 W; PAPi &lt;2.0; CVP-PCW &gt;1.0</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>D: Deteriorating</strong>
                                <table class="listgroup" border="0" width="95%" id="ulist0280" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0590">Worsening hypotension</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0595">Worsening hypoperfusion</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0285" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0600">Same as stage C</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0290" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0605">Persistent or worsening values of stage C</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0295" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0610">Escalating use of pressors or MCS to maintain SBP and
                                                    end-organ perfusion in setting of stage C hemodynamics</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>E: Extremis</strong>
                                <table class="listgroup" border="0" width="95%" id="ulist0300" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0615">Refractory hypotension</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0620">Refractory hypoperfusion</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0305" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0625">Cardiac arrest</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0630">CPR</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0310" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0635">Worsening values of stage C laboratories</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0315" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0640">SBP only with resuscitation</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0645">PEA</p>
                                            </td>
                                        </tr>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0650">Recurrent VT/VF</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0275">BNP indicates brain natriuretic peptide; CI, cardiac index; CPO, cardiac
                                power output; CPR, cardiopulmonary resuscitation; CVP, central venous pressure; HR,
                                heart rate; LFT, liver function test; MAP, mean arterial blood pressure; MCS, mechanical
                                circulatory support; PAPi, pulmonary artery pulsatility index; PCW, pulmonary capillary
                                wedge pressures; PEA, pulseless electrical activity; SBP, systolic blood pressure; VF,
                                ventricular fibrillation; and VT, ventricular tachycardia.</p>
                            <p id="tspara0280">Adapted from Baran D (<a class="tab-link" href="#bib1268"
                                    data-tab="pane-pcw-references">29</a>), with permission from Wiley Periodicals, Inc.
                            </p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p6485"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1375" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6490">Intravenous inotropic support can increase cardiac output and improve
                                hemodynamics in patients presenting with cardiogenic shock. Despite their ubiquitous use
                                for initial management of cardiogenic shock, there are few prospective data and a
                                paucity of randomized trials to guide their use (<a class="tab-link" href="#bib1240"
                                    data-tab="pane-pcw-references">1-8</a>). However, their broad availability, ease of
                                administration, and clinician familiarity favor such agents as the first therapeutic
                                consideration when signs of organ hypoperfusion persist despite empiric volume
                                replacement and vasopressors. There is a lack of robust evidence to suggest the clear
                                benefit of one inotropic agent over another in cardiogenic shock (<a class="tab-link"
                                    href="#bib1269" data-tab="pane-pcw-references">30</a>). In general, the choice of a
                                specific inotropic agent is guided by blood pressure, concurrent arrhythmias, and
                                availability of drug.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6495">Despite the lack of direct comparative data, the use of short-term MCS has
                                dramatically increased (<a class="tab-link" href="#bib1248"
                                    data-tab="pane-pcw-references">9-16</a>,<a class="tab-link" href="#bib1270"
                                    data-tab="pane-pcw-references">31</a>,<a class="tab-link" href="#bib1271"
                                    data-tab="pane-pcw-references">32</a>). The hemodynamic benefits of the specific
                                devices vary, and few head-to-head randomized comparisons exist (<a class="tab-link"
                                    href="#bib1272" data-tab="pane-pcw-references">33-39</a>). Randomized clinical
                                trials are underway that will address the risks and benefits of one modality over
                                another. Vascular, bleeding, and neurologic complications are common to MCS devices, and
                                the risk of such complications should generally be considered in the calculation to
                                proceed with such support (<a class="tab-link" href="#bib1279"
                                    data-tab="pane-pcw-references">40</a>). As much as possible, an understanding of a
                                patient’s wishes, overall prognosis and trajectory, and assessment of therapeutic risk
                                should precede the use of invasive temporary MCS.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6500">Team-based cardiogenic shock management provides the opportunity for various
                                clinicians to provide their perspective and input to the patient’s management (<a
                                    class="tab-link" href="#bib1256" data-tab="pane-pcw-references">17-22</a>). The
                                escalation of either pharmacological and mechanical therapies should be considered in
                                the context of multidisciplinary teams of HF and critical care specialists,
                                interventional cardiologists, and cardiac surgeons. Such teams should also be capable of
                                providing appropriate palliative care. Most documented experiences have suggested
                                outcomes improve after shock teams are instituted (<a class="tab-link" href="#bib1256"
                                    data-tab="pane-pcw-references">17-22</a>). In 1 such experience, the use of a shock
                                team was associated with improved 30-day all-cause mortality (HR, 0.61; 95% CI,
                                0.41–0.93) and reduced in-hospital mortality (61.0% vs. 47.9%; <i>P</i>=0.041) (<a
                                    class="tab-link" href="#bib1258" data-tab="pane-pcw-references">19</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6505">If time allows, escalation to MCS should be guided by invasively obtained
                                hemodynamic data (e.g., PA catheterization). Several observational experiences have
                                associated PA catheterization use with improved outcomes, particularly in conjunction
                                with short-term MCS (<a class="tab-link" href="#bib1262"
                                    data-tab="pane-pcw-references">23-27</a>,<a class="tab-link" href="#bib1280"
                                    data-tab="pane-pcw-references">41</a>). PA catheterization may also be useful when
                                there is diagnostic uncertainty as to the cause of hypotension or end-organ dysfunction,
                                particularly when a patient in shock is not responding to empiric initial shock measures
                                (<a class="tab-link" href="#bib1281" data-tab="pane-pcw-references">42</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6510">Transfer to centers capable of providing such support should be considered
                                early in the assessment of a patient with cardiogenic shock and a trajectory of
                                worsening end-organ malperfusion (<a class="tab-link" href="#bib1256"
                                    data-tab="pane-pcw-references">17-22</a>,<a class="tab-link" href="#bib1282"
                                    data-tab="pane-pcw-references">43</a>). The treatment of shock should be recognized
                                as a temporizing strategy to support end-organ perfusion and blood pressure until the
                                cause of the cardiac failure has either been treated (e.g., revascularization in
                                ST-elevation MI) or recovery (e.g., myocarditis) or a definitive solution to the cardiac
                                failure can be accomplished (e.g., durable LVAD or transplant). In many cases,
                                pharmacological or MCS can provide sufficient time to address the appropriateness of
                                more definitive therapies (e.g., bridge-to-decision) with the patient, family, and the
                                multidisciplinary shock team.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec13" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec13">
                <div id="acsectitle0460" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0460">9.6 Integration of Care: Transitions and Team-Based
                Approaches</h3>
            <div id="undtbl47" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl47">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0795">Recommendations for Integration of Care: Transitions and Team-Based
                                Approaches</p>
                            <p id="tspara0800">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0860" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1860"><strong>In patients with high-risk HF, particularly those
                                                        with recurrent hospitalizations for HFrEF, referral to
                                                        multidisciplinary HF disease management programs is recommended
                                                        to reduce the risk of hospitalization</strong> (<a
                                                        class="tab-link" href="#bib1283"
                                                        data-tab="pane-pcw-references">1-4</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0865" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1865"><strong>In patients hospitalized with worsening HF,
                                                        patient-centered discharge instructions with a clear plan for
                                                        transitional care should be provided before hospital discharge
                                                        (</strong><a class="tab-link" href="#bib1287"
                                                        data-tab="pane-pcw-references"><strong>5</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1288"
                                                        data-tab="pane-pcw-references"><strong>6</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0870" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1870"><strong>In patients hospitalized with worsening HF,
                                                        participation in systems that allow benchmarking to performance
                                                        measures is reasonable to increase use of evidence-based
                                                        therapy, and to improve quality of care</strong> (<a
                                                        class="tab-link" href="#bib1289"
                                                        data-tab="pane-pcw-references">7-10</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0875" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1875"><strong>In patients being discharged after hospitalization
                                                        for worsening HF, an early follow-up, generally within 7 days of
                                                        hospital discharge, is reasonable to optimize care and reduce
                                                        rehospitalization (</strong><a class="tab-link" href="#bib1293"
                                                        data-tab="pane-pcw-references"><strong>11</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1294"
                                                        data-tab="pane-pcw-references"><strong>12</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6525"><strong>Synopsis</strong></p>
            <p id="p6530">For patients with HF, the transition from inpatient to outpatient care can be an especially
                vulnerable period because of the progressive nature of the disease state, complex medical regimens, the
                large number of comorbid conditions, and the multiple clinicians who may be involved. Patients are at
                highest risk for decompensation requiring readmission in the days and weeks post-hospital discharge (<a
                    class="tab-link" href="#bib1295" data-tab="pane-pcw-references">13</a>). Optimal transitions of care
                can decrease avoidable readmissions and improve patient satisfaction (<a class="tab-link"
                    href="#bib1296" data-tab="pane-pcw-references">14</a>). Multidisciplinary systems of care that
                promote improved communication between health care professionals, systematic use and monitoring of GDMT,
                medication reconciliation, and consistent documentation are examples of patient safety standards that
                should be ensured for all patients with HF transitioning out of the hospital.</p>
            <p id="p6535"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1380" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6540">HF disease management programs can help to organize the patient’s care across
                                settings. Potential team members may include cardiologists, primary care clinicians, HF
                                nurses, pharmacists, dieticians, social workers, and community health workers. A
                                Cochrane systematic review of 47 RCTs of disease management interventions after hospital
                                discharge found that interventions that use case management (case manager or nurse
                                coordinates care for high-risk patients) or multidisciplinary approach may decrease
                                all-cause mortality and rehospitalization (<a class="tab-link" href="#bib1285"
                                    data-tab="pane-pcw-references">3</a>). Disease management programs may comprise
                                education, self-management, medication optimization, device management, weight
                                monitoring, exercise and dietary advice, facilitated access to care during episodes of
                                decompensation, and social and psychological support (<a class="tab-link"
                                    href="#bib1296" data-tab="pane-pcw-references">14</a>). Disease management programs
                                coordinated by HF specialists, including HF nurses, may be best suited for patients with
                                HFrEF; however, there are far fewer data on the effectiveness of disease management
                                programs in patients with HFpEF (<a class="tab-link" href="#bib1284"
                                    data-tab="pane-pcw-references">2</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6545">Although hospitalizations for worsening HF are often characterized by rapid
                                changes in medical, surgical, and device therapy to optimize a patient’s clinical
                                status, the patient’s journey with achieving optimal HF care continues beyond hospital
                                discharge. Written discharge instructions or educational material given to the patient,
                                family members, or caregiver during the hospital stay or at discharge to home should
                                address all of these: activity level, diet, discharge medications, follow-up
                                appointment, weight monitoring, cardiac rehabilitation, and what to do if symptoms
                                worsen (<a class="tab-link" href="#bib1296" data-tab="pane-pcw-references">14</a>).
                                Thorough discharge planning that includes special emphasis on ensuring adherence to an
                                evidence-based medication regimen is associated with improved patient outcomes (<a
                                    class="tab-link" href="#bib1297" data-tab="pane-pcw-references">15</a>,<a
                                    class="tab-link" href="#bib1298" data-tab="pane-pcw-references">16</a>). Details of
                                the hospital course and the transitional plan of care, with special attention to changes
                                in medications and new medical diagnoses, must be transmitted in a timely and clearly
                                understandable form to all of the patient’s clinicians who will be delivering follow-up
                                care (<a class="ref showTableEvent" data-id="tbl25" href="#tbl25">Table 25</a>). Any
                                changes in prognosis that will require appropriate care coordination and follow-up
                                postdischarge should be noted.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6550">Systems of care designed to support patients with HF as they move through the
                                continuum of care can improve outcomes (<a class="tab-link" href="#bib1289"
                                    data-tab="pane-pcw-references">7</a>,<a class="tab-link" href="#bib1296"
                                    data-tab="pane-pcw-references">14</a>,<a class="tab-link" href="#bib1299"
                                    data-tab="pane-pcw-references">17</a>,<a class="tab-link" href="#bib1300"
                                    data-tab="pane-pcw-references">18</a>). Real-time feedback on performance measure
                                benchmarks can improve use of evidence-based therapy and quality of care (<a
                                    class="tab-link" href="#bib1290" data-tab="pane-pcw-references">8</a>). Quality
                                improvement programs designed to increase the prescription of appropriate discharge
                                medications can increase GDMT prescription at discharge and decrease readmissions and
                                mortality (<a class="tab-link" href="#bib1291" data-tab="pane-pcw-references">9</a>).
                                Electronic point-of-care reminders to prescribe GDMT in patients with HFrEF can improve
                                use (<a class="tab-link" href="#bib1292" data-tab="pane-pcw-references">10</a>,<a
                                    class="tab-link" href="#bib1301" data-tab="pane-pcw-references">19</a>). Leveraging
                                transparent health care analytics platforms for benchmarking and performance improvement
                                may be helpful. There are ongoing studies to determine the most effective strategies to
                                improve evidence-based care (<a class="tab-link" href="#bib1302"
                                    data-tab="pane-pcw-references">20</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6555">Early outpatient follow-up, a central element of transitional care, varies
                                significantly across U.S. hospitals (<a class="tab-link" href="#bib1293"
                                    data-tab="pane-pcw-references">11</a>). Early postdischarge follow-up may help
                                minimize gaps in understanding of changes to the care plan or knowledge of test results
                                and has been associated with a lower risk of subsequent rehospitalization (<a
                                    class="tab-link" href="#bib1293" data-tab="pane-pcw-references">11</a>,<a
                                    class="tab-link" href="#bib1294" data-tab="pane-pcw-references">12</a>). Transition
                                of care interventions have often bundled timely clinical follow-up with other
                                interventions, making it challenging to isolate any unique intervention effects (<a
                                    class="tab-link" href="#bib1303" data-tab="pane-pcw-references">21</a>). A
                                structured contact with the patient within 7 days of hospital discharge is a desired
                                goal. Although historically this has been an in-person visit, telemedicine is being
                                increasingly used for chronic management. A pragmatic randomized trial found that an
                                initial telephone visit with a nurse or pharmacist to guide follow-up may reduce the
                                need for in-person visits if they are constrained (<a class="tab-link" href="#bib1304"
                                    data-tab="pane-pcw-references">22</a>). Overall, the timing and method of delivery
                                (in-person clinic versus virtual visit by video or telephone) should be individualized
                                based on patient risk and available care delivery options. Clinical risk prediction
                                tools may help to identify patients at highest risk of postdischarge adverse outcomes
                                (<a class="tab-link" href="#bib1305" data-tab="pane-pcw-references">23-25</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="tbl25" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl25">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0285"><span class="captionLabel">Table 25</span> Important Components of a
                                Transitional Care Plan</p>
                        </strong></caption>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">A transitional care plan, communicated with the patient and
                                their outpatient clinicians before hospital discharge, should clearly outline plans for:
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0320" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0655">Addressing any precipitating causes of worsening HF
                                                    identified in the hospital;</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0325" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0660">Adjusting diuretics based on volume status (including
                                                    weight) and electrolytes;</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0330" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0665">Coordination of safety laboratory checks (e.g.,
                                                    electrolytes after initiation or intensification of GDMT);</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0335" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0670">Further changes to optimize GDMT, including:</p>
                                                <table class="listgroup" border="0" width="95%" id="ulist0340"
                                                    list-type="simple">
                                                    <tbody>
                                                        <tr class="li1">
                                                            <td valign="top">▪</td>
                                                            <td colspan="5" valign="top" class="paragraph">
                                                                <p id="p0675">Plans for resuming medications held in the
                                                                    hospital;</p>
                                                            </td>
                                                        </tr>
                                                        <tr class="li1">
                                                            <td valign="top">▪</td>
                                                            <td colspan="5" valign="top" class="paragraph">
                                                                <p id="p0680">Plans for initiating new medications;</p>
                                                            </td>
                                                        </tr>
                                                        <tr class="li1">
                                                            <td valign="top">▪</td>
                                                            <td colspan="5" valign="top" class="paragraph">
                                                                <p id="p0685">Plans for titration of GDMT to goal doses
                                                                    as tolerated;</p>
                                                            </td>
                                                        </tr>
                                                    </tbody>
                                                </table>
                                                <p></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0345" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0690">Reinforcing HF education and assessing compliance with
                                                    medical therapy and lifestyle modifications, including dietary
                                                    restrictions and physical activity;</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0350" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0695">Addressing high-risk characteristics that may be
                                                    associated with poor postdischarge clinical outcomes, such as:</p>
                                                <table class="listgroup" border="0" width="95%" id="ulist0355"
                                                    list-type="simple">
                                                    <tbody>
                                                        <tr class="li1">
                                                            <td valign="top">▪</td>
                                                            <td colspan="5" valign="top" class="paragraph">
                                                                <p id="p0700">Comorbid conditions (e.g., renal
                                                                    dysfunction, pulmonary disease, diabetes, mental
                                                                    health, and substance use disorders);</p>
                                                            </td>
                                                        </tr>
                                                        <tr class="li1">
                                                            <td valign="top">▪</td>
                                                            <td colspan="5" valign="top" class="paragraph">
                                                                <p id="p0705">Limitations in psychosocial support;</p>
                                                            </td>
                                                        </tr>
                                                        <tr class="li1">
                                                            <td valign="top">▪</td>
                                                            <td colspan="5" valign="top" class="paragraph">
                                                                <p id="p0710">Impaired health literacy, cognitive
                                                                    impairment;</p>
                                                            </td>
                                                        </tr>
                                                    </tbody>
                                                </table>
                                                <p></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0360" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0715">Additional surgical or device therapy, referral to cardiac
                                                    rehabilitation in the future, where appropriate;</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="ulist0365" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">▪</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p0720">Referral to palliative care specialists and/or enrollment
                                                    in hospice in selected patients.</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0290">GDMT indicates guideline-directed medical therapy; and HF, heart failure.
                            </p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="acd247731e13861" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e13861">
                <div id="acsectitle0465" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0465">10 Comorbidities in Patients With HF
            </h2>
            <div id="acsec14" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec14">
                <div id="acsectitle0470" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0470">10.1 Management of Comorbidities in Patients With HF
            </h3>
            <div id="undtbl48" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl48">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0805">Recommendations for the Management of Comorbidities in Patients With HF
                            </p>
                            <p id="tspara0810">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="3" rowspan="1"><strong>Management of Anemia or Iron Deficiency</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0880" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1880"><strong>In patients with HFrEF and iron deficiency with or
                                                        without anemia, intravenous iron replacement is reasonable to
                                                        improve functional status and QOL</strong> (<a class="tab-link"
                                                        href="#bib1308"
                                                        data-tab="pane-pcw-references">1-4</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0885" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1885"><strong>In patients with HF and anemia,
                                                        erythropoietin-stimulating agents should not be used to improve
                                                        morbidity and mortality (</strong><a class="tab-link"
                                                        href="#bib1312"
                                                        data-tab="pane-pcw-references"><strong>5</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1313"
                                                        data-tab="pane-pcw-references"><strong>6</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="2" rowspan="1"><strong>Management of Hypertension</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0890" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1890"><strong>In patients with HFrEF and hypertension,
                                                        uptitration of GDMT to the maximally tolerated target dose is
                                                        recommended (</strong><a class="tab-link" href="#bib1314"
                                                        data-tab="pane-pcw-references"><strong>7</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1315"
                                                        data-tab="pane-pcw-references"><strong>8</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="3" rowspan="1"><strong>Management of Sleep Disorders</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0895" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1895"><strong>In patients with HF and suspicion of
                                                        sleep-disordered breathing, a formal sleep assessment is
                                                        reasonable to confirm the diagnosis and differentiate between
                                                        obstructive and central sleep apnea (</strong><a
                                                        class="tab-link" href="#bib1316"
                                                        data-tab="pane-pcw-references"><strong>9</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1317"
                                                        data-tab="pane-pcw-references"><strong>10</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0900" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1900"><strong>In patients with HF and obstructive sleep apnea,
                                                        continuous positive airway pressure may be reasonable to improve
                                                        sleep quality and decrease daytime sleepiness (</strong><a
                                                        class="tab-link" href="#bib1316"
                                                        data-tab="pane-pcw-references"><strong>9</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1318"
                                                        data-tab="pane-pcw-references"><strong>11-13</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0905" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">6.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1905"><strong>In patients with NYHA class II to IV HFrEF and
                                                        central sleep apnea, adaptive servo-ventilation causes harm
                                                        (</strong><a class="tab-link" href="#bib1318"
                                                        data-tab="pane-pcw-references"><strong>11</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1319"
                                                        data-tab="pane-pcw-references"><strong>12</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="3" rowspan="1"><strong>Management of Diabetes</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0910" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">7.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1910"><strong>In patients with HF and type 2 diabetes, the use
                                                        of SGLT2i is recommended for the management of hyperglycemia and
                                                        to reduce HF-related morbidity and mortality</strong> (<a
                                                        class="tab-link" href="#bib1321"
                                                        data-tab="pane-pcw-references">14-17</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6570"><strong>Synopsis</strong></p>
            <p id="p6575">Multimorbidity is common in patients with HF, with &gt;85% of patients having ≥2 additional
                chronic conditions (<a class="tab-link" href="#bib1325" data-tab="pane-pcw-references">18</a>,<a
                    class="tab-link" href="#bib1326" data-tab="pane-pcw-references">19</a>). Hypertension, ischemic
                heart disease, diabetes, anemia, CKD, morbid obesity, frailty, and malnutrition are among the most
                common comorbid conditions in patients with HF (<a class="ref showTableEvent" data-id="tbl26"
                    href="#tbl26">Table 26</a>). These chronic conditions complicate the management of HF and have a
                significant impact on its prognosis. How to generate specific recommendations addressing many of these
                conditions in the setting of HF is challenging given the current state of the evidence. For example,
                although depression is common in patients with HF and strongly impacts QOL and mortality, conventional
                therapies such as antidepressants have not been effective in improving outcomes (<a class="tab-link"
                    href="#bib1327" data-tab="pane-pcw-references">20-22</a>). CKD and HF are closely intertwined in
                pathophysiology and have a complex and bidirectional relationship (<a class="tab-link" href="#bib1330"
                    data-tab="pane-pcw-references">23</a>). Renal dysfunction increases the risk of toxicities of HF
                therapies and impairs response to diuretics (<a class="tab-link" href="#bib1330"
                    data-tab="pane-pcw-references">23</a>). The effectiveness of GDMT in patients with HF and
                concomitant kidney disease is uncertain, because data for treatment outcomes in this patient population
                are sparse (<a class="tab-link" href="#bib1331" data-tab="pane-pcw-references">24</a>). Recommendations
                surrounding the management of anemia, hypertension, diabetes, and sleep disorders that are attributable
                to the presence of evolving evidence for specific treatment strategies in HF are discussed next. Other
                comorbidities not addressed in the recommendations are, of course, also important and warrant attention
                but, because of lack of large-scale trial data, are not addressed as specific recommendations. <a
                    data-tab="pane-pcw-Figures" href="#fig14" id="fig14R" class="">Figure 14</a> summarizes COR 1 and 2a
                for management of select HF comorbidities.</p>
            <div id="tbl26" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl26">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0295"><span class="captionLabel">Table 26</span> Most Common Co-Occurring
                                Chronic Conditions Among Medicare Beneficiaries With HF (N=4,947,918), 2011</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="3" rowspan="1">Beneficiaries Age ≥65 y (n=4,376,150)<a class="ref table-fn"
                                    id="tbl26fnlowast" href="javascript:popRef('tbl26fnlowast')"><sup>∗</sup></a></th>
                            <th colspan="3" rowspan="1">Beneficiaries Age &lt;65 y (n=571,768)<a class="ref table-fn"
                                    id="tbl26fndagger" href="javascript:popRef('tbl26fndagger')"><sup>†</sup></a></th>
                        </tr>
                        <tr valign="top">
                            <th colspan="1" rowspan="1"></th>
                            <th colspan="1" rowspan="1">n</th>
                            <th colspan="1" rowspan="1">%</th>
                            <th colspan="1" rowspan="1"></th>
                            <th colspan="1" rowspan="1">n</th>
                            <th colspan="1" rowspan="1">%</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Hypertension</td>
                            <td align="char" char="." colspan="1" rowspan="1">3,685,373</td>
                            <td align="char" char="." colspan="1" rowspan="1">84.2</td>
                            <td colspan="1" rowspan="1">Hypertension</td>
                            <td align="char" char="." colspan="1" rowspan="1">461,235</td>
                            <td align="char" char="." colspan="1" rowspan="1">80.7</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Ischemic heart disease</td>
                            <td align="char" char="." colspan="1" rowspan="1">3,145,718</td>
                            <td align="char" char="." colspan="1" rowspan="1">71.9</td>
                            <td colspan="1" rowspan="1">Ischemic heart disease</td>
                            <td align="char" char="." colspan="1" rowspan="1">365,889</td>
                            <td align="char" char="." colspan="1" rowspan="1">64.0</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Hyperlipidemia</td>
                            <td align="char" char="." colspan="1" rowspan="1">2,623,601</td>
                            <td align="char" char="." colspan="1" rowspan="1">60.0</td>
                            <td colspan="1" rowspan="1">Diabetes</td>
                            <td align="char" char="." colspan="1" rowspan="1">338,687</td>
                            <td align="char" char="." colspan="1" rowspan="1">59.2</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Anemia</td>
                            <td align="char" char="." colspan="1" rowspan="1">2,200,674</td>
                            <td align="char" char="." colspan="1" rowspan="1">50.3</td>
                            <td colspan="1" rowspan="1">Hyperlipidemia</td>
                            <td align="char" char="." colspan="1" rowspan="1">325,498</td>
                            <td align="char" char="." colspan="1" rowspan="1">56.9</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Diabetes</td>
                            <td align="char" char="." colspan="1" rowspan="1">2,027,875</td>
                            <td align="char" char="." colspan="1" rowspan="1">46.3</td>
                            <td colspan="1" rowspan="1">Anemia</td>
                            <td align="char" char="." colspan="1" rowspan="1">284,102</td>
                            <td align="char" char="." colspan="1" rowspan="1">49.7</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Arthritis</td>
                            <td align="char" char="." colspan="1" rowspan="1">1,901,447</td>
                            <td align="char" char="." colspan="1" rowspan="1">43.5</td>
                            <td colspan="1" rowspan="1">CKD</td>
                            <td align="char" char="." colspan="1" rowspan="1">257,015</td>
                            <td align="char" char="." colspan="1" rowspan="1">45.0</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CKD</td>
                            <td align="char" char="." colspan="1" rowspan="1">1,851,812</td>
                            <td align="char" char="." colspan="1" rowspan="1">42.3</td>
                            <td colspan="1" rowspan="1">Depression</td>
                            <td align="char" char="." colspan="1" rowspan="1">207,082</td>
                            <td align="char" char="." colspan="1" rowspan="1">36.2</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">COPD</td>
                            <td align="char" char="." colspan="1" rowspan="1">1,311,118</td>
                            <td align="char" char="." colspan="1" rowspan="1">30.0</td>
                            <td colspan="1" rowspan="1">Arthritis</td>
                            <td align="char" char="." colspan="1" rowspan="1">201,964</td>
                            <td align="char" char="." colspan="1" rowspan="1">35.3</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">AF</td>
                            <td align="char" char="." colspan="1" rowspan="1">1,247,748</td>
                            <td align="char" char="." colspan="1" rowspan="1">28.5</td>
                            <td colspan="1" rowspan="1">COPD</td>
                            <td align="char" char="." colspan="1" rowspan="1">191,016</td>
                            <td align="char" char="." colspan="1" rowspan="1">33.4</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Alzheimer’s disease or dementia</td>
                            <td align="char" char="." colspan="1" rowspan="1">1,207,704</td>
                            <td align="char" char="." colspan="1" rowspan="1">27.6</td>
                            <td colspan="1" rowspan="1">Asthma</td>
                            <td align="char" char="." colspan="1" rowspan="1">88,816</td>
                            <td align="char" char="." colspan="1" rowspan="1">15.5</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0300">Data source: Centers for Medicare &amp; Medicaid Services administrative
                                claims data, January 2011 to December 2011, from the Chronic Condition Warehouse (CCW),
                                <a target="_blank" class="references__uri" href="http://ccwdata.org">ccwdata.org</a> (<a
                                    class="tab-link" href="#bib1357" data-tab="pane-pcw-references">50</a>).</p>
                            <p id="tspara0305">AF indicates atrial fibrillation; CKD, chronic kidney disease; COPD,
                                chronic obstructive pulmonary disease; and HF, heart failure.</p>
                        </fn>
                        <fn id="tbl26fnlowast">
                            <p id="ntpara0055">∗ Mean No. of conditions is 6.1; median is 6.</p>
                        </fn>
                        <fn id="tbl26fndagger">
                            <p id="ntpara0060">† Mean No. of conditions is 5.5; median is 5.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <section class="article-section__inline-figure">
                <figure id="fig14" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/e7b368ce-b9ba-4698-8f2d-cdba1eee3f1b/gr14.jpg"
                        data-lg-src="/cms/asset/693cac9f-1d76-4a76-b1b7-ef715597cfb8/gr14.jpg" alt="Figure 14">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/693cac9f-1d76-4a76-b1b7-ef715597cfb8/gr14.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig14&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 14</span></strong>
                        <p>Recommendations for Treatment of Patients With HF and Selected Comorbidities</p>
                        <p><strong>Colors correspond to COR in</strong> <a class="ref showTableEvent" data-id="tbl2"
                                href="#tbl2"><strong>Table 2</strong></a><strong>.</strong> Recommendations for
                            treatment of patients with HF and select comorbidities are displayed. ACEi indicates
                            angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor
                            blocker; AV, atrioventricular; CHA<sub>2</sub>DS<sub>2</sub>-VASc, congestive heart failure,
                            hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack [TIA],
                            vascular disease, age 65 to 74 years, sex category; CPAP, continuous positive airway
                            pressure; CRT, cardiac resynchronization therapy; EF, ejection fraction; GDMT,
                            guideline-directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced
                            ejection fraction; IV, intravenous; LVEF, left ventricular ejection fraction; NYHA, New York
                            Heart Association; SGLT2i, sodium-glucose cotransporter-2 inhibitor; and VHD, valvular heart
                            disease. ∗Patients with chronic HF with permanent-persistent-paroxysmal AF and a
                            CHA<sub>2</sub>DS<sub>2</sub>-VASc score of ≥2 (for men) and ≥3 (for women).</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p6580"><strong>Recommendation-Specific Supportive Text</strong></p>
            <p id="p6585"><strong>Anemia</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1385" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6590">Routine baseline assessment of all patients with HF includes an evaluation for
                                anemia. Anemia is independently associated with HF disease severity and mortality (<a
                                    class="tab-link" href="#bib1332" data-tab="pane-pcw-references">25</a>), and iron
                                deficiency appears to be uniquely associated with reduced exercise capacity (<a
                                    class="tab-link" href="#bib1333" data-tab="pane-pcw-references">26</a>). Iron
                                deficiency is usually defined as ferritin level &lt;100 μg /L or 100 to 300 μg/L, if the
                                transferrin saturation is &lt;20%. Intravenous repletion of iron has been shown to
                                improve exercise capacity and QOL (<a class="tab-link" href="#bib1308"
                                    data-tab="pane-pcw-references">1-3</a>,<a class="tab-link" href="#bib1334"
                                    data-tab="pane-pcw-references">27</a>). The FAIR-HF (Ferric Carboxymaltose
                                Assessment in Patients With Iron Deficiency and Chronic Heart Failure) trial showed
                                significant improvement in NYHA classification, the 6-minute walk test, and QOL of 459
                                outpatients with chronic HF who received weekly intravenous ferric carboxymaltose until
                                iron repletion (<a class="tab-link" href="#bib1308"
                                    data-tab="pane-pcw-references">1</a>). The improvement was independent of the
                                presence of anemia. These findings were confirmed in 2 more recent trials (<a
                                    class="tab-link" href="#bib1309" data-tab="pane-pcw-references">2</a>,<a
                                    class="tab-link" href="#bib1310" data-tab="pane-pcw-references">3</a>). The IRONOUT
                                HF (Iron Repletion Effects on Oxygen Uptake in Heart Failure) trial, however, showed no
                                such improvement with oral iron supplementation (<a class="tab-link" href="#bib1335"
                                    data-tab="pane-pcw-references">28</a>). This is attributed to the poor absorption of
                                oral iron and inadequacy of oral iron to replete the iron stores in patients with HF.
                                Therefore, oral iron is not adequate to treat iron deficiency anemia in patients with
                                HF. Although these trials were underpowered to detect reductions in hard clinical
                                endpoints, 2 meta-analyses have suggested intravenous iron is associated with a
                                reduction in cardiovascular death and hospitalizations (<a class="tab-link"
                                    href="#bib1334" data-tab="pane-pcw-references">27</a>,<a class="tab-link"
                                    href="#bib1336" data-tab="pane-pcw-references">29</a>). Most recently, the
                                AFFIRM-AHF multicenter trial, which included 1132 patients with EF &lt;50% hospitalized
                                for HF, showed a decrease in hospitalization for HF with intravenous ferric
                                carboxymaltose compared to placebo (RR, 0.74; 95% CI, 0.58–0.94) but no reduction in
                                cardiovascular death (<a class="tab-link" href="#bib1311"
                                    data-tab="pane-pcw-references">4</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6595">Anemia in patients with HF is associated with impaired erythropoietin
                                production, with low levels found to be associated with worse long-term outcomes (<a
                                    class="tab-link" href="#bib1337" data-tab="pane-pcw-references">30</a>,<a
                                    class="tab-link" href="#bib1338" data-tab="pane-pcw-references">31</a>). Although
                                small studies examining the use of erythropoietin-stimulating agents for the treatment
                                of anemia in patients with HF have suggested a trend toward improvement in functional
                                capacity and reduction in hospitalization, a high-quality randomized trial of
                                darbepoetin alpha in 2278 patients showed no benefit and an increase in thrombotic
                                events, including stroke (<a class="tab-link" href="#bib1312"
                                    data-tab="pane-pcw-references">5</a>,<a class="tab-link" href="#bib1313"
                                    data-tab="pane-pcw-references">6</a>,<a class="tab-link" href="#bib1339"
                                    data-tab="pane-pcw-references">32</a>). A meta-analysis of 13 trials supports these
                                findings (<a class="tab-link" href="#bib1313" data-tab="pane-pcw-references">6</a>).
                                Accordingly, erythropoietin-stimulating agent therapy is not recommended for the
                                treatment of anemia in patients with HF.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <p id="p6600"><strong>Hypertension</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1390" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6605">Clinical trials assessing the impact of goal blood pressure reduction on
                                outcomes in patients with HFrEF and concomitant hypertension are lacking. The optimal
                                blood pressure goal and antihypertensive regimen are not known. Antihypertensive therapy
                                is associated with a decrease in the risk of incident HF in the general population (<a
                                    class="tab-link" href="#bib1340" data-tab="pane-pcw-references">33</a>,<a
                                    class="tab-link" href="#bib1341" data-tab="pane-pcw-references">34</a>), notably
                                with the more stringent SBP target &lt;120 mm Hg (<a class="tab-link" href="#bib1342"
                                    data-tab="pane-pcw-references">35</a>). However, low blood pressure, not as a part
                                of an antihypertensive treatment, has been associated with poor outcomes in patients
                                with HFrEF (<a class="tab-link" href="#bib1314" data-tab="pane-pcw-references">7</a>,<a
                                    class="tab-link" href="#bib1315" data-tab="pane-pcw-references">8</a>). This
                                observation may reflect the association between low cardiac output and low blood
                                pressure, rather than the effects of treatment for hypertension. Nevertheless,
                                hypertension in patients with HFrEF represents an opportunity to maximize GDMT to goal
                                blood pressures defined by the ACC/AHA hypertension guidelines (<a class="tab-link"
                                    href="#bib1343" data-tab="pane-pcw-references">36</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <p id="p6610"><strong>Sleep Disorders</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1395" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6615">In patients with HF, daytime sleepiness—typically a feature of obstructive
                                sleep apnea—may not reflect the degree of underlying sleep-disordered breathing (<a
                                    class="tab-link" href="#bib1344" data-tab="pane-pcw-references">37</a>). Hence, the
                                decision to refer a patient for a sleep study should be based on clinical judgment.
                                Because the treatment of obstructive sleep apnea and central sleep apnea differ, and
                                because obstructive sleep apnea and central sleep apnea can co-occur (<a
                                    class="tab-link" href="#bib1316" data-tab="pane-pcw-references">9</a>,<a
                                    class="tab-link" href="#bib1318" data-tab="pane-pcw-references">11</a>,<a
                                    class="tab-link" href="#bib1319" data-tab="pane-pcw-references">12</a>), sleep
                                studies can inform clinical decision-making in patients with HF.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6620">In patients with HF and central sleep apnea, continuous positive airway
                                pressure is associated with better sleep quality and nocturnal oxygenation (<a
                                    class="tab-link" href="#bib1316" data-tab="pane-pcw-references">9</a>) but has not
                                been shown to affect survival (<a class="tab-link" href="#bib1345"
                                    data-tab="pane-pcw-references">38</a>). In adults with HFrEF and sleep-disordered
                                breathing, meta-analyses of RCTs have shown that positive airway pressure therapy
                                results in a moderate reduction in BNP (<a class="tab-link" href="#bib1346"
                                    data-tab="pane-pcw-references">39</a>) and improvement in blood pressure and LVEF
                                (<a class="tab-link" href="#bib1347" data-tab="pane-pcw-references">40</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">6.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6625">Adaptive servo-ventilation was associated with increased mortality in 2 RCTs
                                involving patients with HFrEF and central sleep apnea (<a class="tab-link"
                                    href="#bib1318" data-tab="pane-pcw-references">11</a>,<a class="tab-link"
                                    href="#bib1319" data-tab="pane-pcw-references">12</a>). Meta-analyses have supported
                                these results (<a class="tab-link" href="#bib1348"
                                    data-tab="pane-pcw-references">41</a>,<a class="tab-link" href="#bib1349"
                                    data-tab="pane-pcw-references">42</a>). The weight of evidence does not support the
                                use of adaptive servo-ventilation for central sleep apnea in HFrEF.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <p id="p6630"><strong>Diabetes</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1400" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">7.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6635">The American Diabetes Association guidelines recommend the use of SGLT2i as
                                first-line agent for the treatment of hyperglycemia in patients with diabetes with HF or
                                at high risk of HF (<a class="tab-link" href="#bib1350"
                                    data-tab="pane-pcw-references">43</a>). SGLT2i are the first class of
                                glucose-lowering agents to receive approval from the FDA for the treatment of HFrEF.
                                Treatment of patients with type 2 diabetes with SGLT2i, including canagliflozin,
                                dapagliflozin, empagliflozin, and sotagliflozin, is associated with a reduction in major
                                adverse cardiovascular events, including hospitalization for HF and cardiovascular death
                                (<a class="tab-link" href="#bib1351" data-tab="pane-pcw-references">44</a>). The
                                mechanisms underlying the improvement in cardiovascular outcomes attributed to SGLT2i
                                are, however, unknown but appear to be only partially related to the glucosuric effect
                                (<a class="tab-link" href="#bib1352" data-tab="pane-pcw-references">45</a>). Two RCTs
                                totaling 8474 patients with NYHA class II, III, or IV HF and EF ≤40%—DAPA-HF assessing
                                dapagliflozin and EMPEROR-Reduced assessing empagliflozin—showed significant reductions
                                in the relative risk of all-cause death (13%), cardiovascular death (14%),
                                hospitalization for HF (26%), and renal outcomes (38%) with SGLT2i treatment (<a
                                    class="tab-link" href="#bib1321" data-tab="pane-pcw-references">14-17</a>). Benefits
                                were consistent across age, sex, and in patients with or without diabetes. Whether
                                dapagliflozin or empagliflozin improves outcomes specifically in patients with HFpEF is
                                being studied (<a class="tab-link" href="#bib1353"
                                    data-tab="pane-pcw-references">46</a>,<a class="tab-link" href="#bib1354"
                                    data-tab="pane-pcw-references">47</a>). The SOLOIST-WHF trial extends the benefits
                                of SGLT2i to patients with diabetes and acutely decompensated HF (<a class="tab-link"
                                    href="#bib1355" data-tab="pane-pcw-references">48</a>). Patients on SGLT2i should be
                                closely monitored for potential risks, including severe genitourinary infections and,
                                less commonly, diabetic ketoacidosis (<a class="tab-link" href="#bib1356"
                                    data-tab="pane-pcw-references">49</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec14" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec14">
                <div id="acsectitle0475" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0475">10.2 Management of AF in HF</h3>
            <div id="undtbl49" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl49">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0815">Recommendations for Management of AF in HF</p>
                            <p id="tspara0820">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0915" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1915"><strong>Patients with chronic HF with
                                                        permanent-persistent-paroxysmal AF and a
                                                        CHA</strong><sub><strong>2</strong></sub><strong>DS</strong><sub><strong>2</strong></sub><strong>-VASc
                                                        score of ≥2 (for men) and ≥3 (for women) should receive chronic
                                                        anticoagulant therapy</strong> (<a class="tab-link"
                                                        href="#bib1358"
                                                        data-tab="pane-pcw-references">1-5</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>A</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0920" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1920"><strong>For patients with chronic HF with
                                                        permanent-persistent-paroxysmal AF, DOAC is recommended over
                                                        warfarin in eligible patients</strong> (<a class="tab-link"
                                                        href="#bib1359"
                                                        data-tab="pane-pcw-references">2-10</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0925" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1925"><strong>For patients with HF and symptoms caused by AF, AF
                                                        ablation is reasonable to improve symptoms and QOL</strong> (<a
                                                        class="tab-link" href="#bib1368"
                                                        data-tab="pane-pcw-references">11-14</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0930" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1930"><strong>For patients with AF and LVEF ≤50%, if a rhythm
                                                        control strategy fails or is not desired, and ventricular rates
                                                        remain rapid despite medical therapy, atrioventricular nodal
                                                        ablation with implantation of a CRT device is
                                                        reasonable</strong> (<a class="tab-link" href="#bib1372"
                                                        data-tab="pane-pcw-references">15-22</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0935" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1935"><strong>For patients with chronic HF and
                                                        permanent-persistent-paroxysmal AF, chronic anticoagulant
                                                        therapy is reasonable for men and women without additional risk
                                                        factors</strong> (<a class="tab-link" href="#bib1380"
                                                        data-tab="pane-pcw-references">23-26</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6655"><strong>Synopsis</strong></p>
            <p id="p6660">The interplay between AF and HF is complex. It is clear that AF may worsen HF but also that HF
                increases the risk of AF. Data from randomized trials support the use of anticoagulation among those
                with HF and AF but not in patients with HF without AF. Anticoagulation may be accomplished with DOAC or
                with warfarin when favored because of other indications, cost or drug-drug interactions (the DOAC are
                generally preferred). The choice between rate or rhythm control strategy reflects both patient symptoms
                and the likelihood of better ventricular function with sinus rhythm. RCTs of rhythm control with
                antiarrhythmic agents versus rate control have not shown a benefit of rhythm control. More recent RCTs
                with ablation show that ablation may be preferable to antiarrhythmic drugs for a rhythm control
                strategy. Patients thought to have a cardiomyopathy resulting from rapid AF despite attempts at rate
                control should be aggressively treated to maintain sinus rhythm and, if that is not successful,
                atrioventricular nodal ablation with placement of a CRT device can be considered. Patients with HF, and
                difficult to control rates, may benefit from atrioventricular node ablation and implantation of a
                permanent pacemaker if other rate and rhythm control measures fail. If their LVEF is &gt;50%, there is
                no current evidence that CRT is beneficial compared with RV pacing (<a class="tab-link" href="#bib1372"
                    data-tab="pane-pcw-references">15</a>,<a class="tab-link" href="#bib1378"
                    data-tab="pane-pcw-references">21</a>).</p>
            <p id="p6665"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1405" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6670">The efficacy of long-term warfarin for the prevention of stroke in patients
                                with AF is well established; randomized trials have shown reduced embolic rates and
                                mortality. The AHA/ACC/Heart Rhythm Society guidelines for AF recommend use of the
                                CHA<sub>2</sub>DS<sub>2</sub>-VASc score (history of hypertension, age ≥75 [doubled
                                weight], diabetes mellitus, previous stroke or transient ischemic attack or
                                thromboembolism [doubled weight], vascular disease, age 65 to 74 years, sex category) to
                                assess patient risk for adverse outcomes before initiating anticoagulation therapy (<a
                                    class="tab-link" href="#bib1358" data-tab="pane-pcw-references">1</a>,<a
                                    class="tab-link" href="#bib1384" data-tab="pane-pcw-references">27</a>,<a
                                    class="tab-link" href="#bib1385" data-tab="pane-pcw-references">28</a>). Regardless
                                of whether patients receive rhythm or rate control, anticoagulation is recommended for
                                patients with HF and AF for stroke prevention with a CHA<sub>2</sub>DS<sub>2</sub>-VASc
                                score of ≥2 (for men) and ≥3 (for women) (<a class="tab-link" href="#bib1359"
                                    data-tab="pane-pcw-references">2-5</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6675">Trials of DOAC have compared the efficacy and safety with warfarin therapy
                                rather than placebo. Several DOAC are available, including the factor Xa inhibitors
                                apixaban, rivaroxaban, edoxaban, and the direct thrombin inhibitor dabigatran (<a
                                    class="tab-link" href="#bib1359" data-tab="pane-pcw-references">2-5</a>). These
                                drugs do not need routine anticoagulation monitoring or dose adjustment. The fixed
                                dosing together with fewer interactions may simplify patient management, particularly
                                with the polypharmacy commonly seen in HF, but cost for some patients can be prohibitive
                                when not covered by insurance. These drugs have a potential for an improved benefit–risk
                                profile compared with warfarin, which may increase their use in practice, especially in
                                those at increased bleeding risk (<a class="tab-link" href="#bib1363"
                                    data-tab="pane-pcw-references">6-9</a>). In a meta-analysis of 4 trials examining
                                efficacy and safety of DOAC in patients with and without HF, DOAC more effectively
                                reduced the rate of stroke or systemic embolism, major bleeding, and intracranial
                                bleeding compared with warfarin, with no treatment heterogeneity by HF status (<a
                                    class="tab-link" href="#bib1367" data-tab="pane-pcw-references">10</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6680">The 2 largest RCTs of AF ablation in HF showed a benefit in hospitalizations
                                and mortality with ablation (<a class="tab-link" href="#bib1368"
                                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib1369"
                                    data-tab="pane-pcw-references">12</a>) although other smaller trials did not. In the
                                AATAC (Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in
                                Patients with Congestive Heart Failure and an Implanted Device) trial, 203 patients with
                                persistent AF, LVEF &lt;40%, and NYHA class II to III HF, ablation improved the
                                likelihood of maintaining normal sinus rhythm at 24 months compared with amiodarone and,
                                in addition, had a 45% decrease in hospitalization and decrease in mortality (8% vs.
                                18%) (<a class="tab-link" href="#bib1368" data-tab="pane-pcw-references">11</a>). The
                                CASTLE AF (Catheter Ablation for Atrial Fibrillation with Heart Failure) trial
                                randomized 363 patients with paroxysmal or persistent AF, LVEF &lt;35%, NYHA class II to
                                IV HF, and ICD to ablation versus standard medical care (<a class="tab-link"
                                    href="#bib1369" data-tab="pane-pcw-references">12</a>). The composite endpoint of
                                death or rehospitalization was lower in ablation (28.5%) compared with standard care
                                (44.6%). In addition, there was a lower mortality in the ablation group. In a
                                meta-analysis of 11 RCTs comparing rhythm versus rate control, patients undergoing
                                catheter ablation had improved survival (49% relative risk reduction) and reduced
                                hospitalizations (56% relative risk reduction) (<a class="tab-link" href="#bib1370"
                                    data-tab="pane-pcw-references">13</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6685">If a rhythm control strategy fails or is undesired, and ventricular rates
                                remain rapid despite medical therapy after all other options are exhausted,
                                atrioventricular nodal ablation with implantation of a CRT device can be considered as a
                                treatment option. Ablate and pace is an old strategy for difficult to rate control AF.
                                Early studies with RV pacing showed benefit (<a class="tab-link" href="#bib1372"
                                    data-tab="pane-pcw-references">15</a>,<a class="tab-link" href="#bib1373"
                                    data-tab="pane-pcw-references">16</a>). However, when RV pacing was compared with
                                cardiac resynchronization in more recent trials, especially in those with reduced LVEFs,
                                CRT generally produced more benefit than RV pacing (<a class="tab-link" href="#bib1374"
                                    data-tab="pane-pcw-references">17-21</a>). The PAVE (Left Ventricular-Based Cardiac
                                Stimulation post AV Nodal Ablation Evaluation) and the BLOCK-HF (Biventricular versus
                                Right Ventricular Pacing in Patients with AV block) trials included patients with LVEF
                                &gt;35%, with mean EF 46% (<a class="tab-link" href="#bib1379"
                                    data-tab="pane-pcw-references">22</a>) in PAVE and 40% in BLOCK-HF (enrolled ≤50%).
                                In both of these trials, patients undergoing CRT had improved outcomes.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6690">HF is a hypercoagulable state and serves as an independent risk factor for
                                stroke, systemic embolism, and mortality in the setting of AF (<a class="tab-link"
                                    href="#bib1380" data-tab="pane-pcw-references">23</a>,<a class="tab-link"
                                    href="#bib1381" data-tab="pane-pcw-references">24</a>). There are compelling data to
                                support the use of anticoagulation in most patients with HF and concomitant AF, barring
                                contraindications. In patients with HF and a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of
                                1, those with AF had a 3-fold higher risk compared with individuals without concomitant
                                AF (<a class="tab-link" href="#bib1382" data-tab="pane-pcw-references">25</a>). In a
                                post hoc analysis of 2 contemporary HF trials, paroxysmal and new onset AF were
                                associated with a greater risk for hospitalization caused by HF or stroke (<a
                                    class="tab-link" href="#bib1383" data-tab="pane-pcw-references">26</a>). In a recent
                                registry study, the risk of stroke was particularly higher in the initial period after
                                diagnosis of HF among patients with prevalent AF (<a class="tab-link" href="#bib1386"
                                    data-tab="pane-pcw-references">29</a>). Because HF is a risk factor, additional risk
                                factors may not be required to support the use of anticoagulation in patients with HF,
                                and the decision to anticoagulate can be individualized according to risk versus
                                benefit.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acd247731e14650" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e14650">
                <div id="acsectitle0480" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0480">11 Special Populations</h2>
            <div id="acsec15" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec15">
                <div id="acsectitle0485" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0485">11.1 Disparities and Vulnerable Populations<a
                    class="ref table-fn" id="dtbl4fnlowast" href="javascript:popRef('dtbl4fnlowast')"><sup>∗</sup></a>
            </h3>
            <div id="undtbl50" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl50">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0825">Recommendations for Disparities and Vulnerable Populations</p>
                            <p id="tspara0830">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0940" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1940"><strong>In vulnerable patient populations at risk for
                                                        health disparities, HF risk assessments and multidisciplinary
                                                        management strategies should target both known risks for CVD and
                                                        social determinants of health, as a means toward elimination of
                                                        disparate HF outcomes</strong> (<a class="tab-link"
                                                        href="#bib1387"
                                                        data-tab="pane-pcw-references">1-6</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0945" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1945"><strong>Evidence of health disparities should be monitored
                                                        and addressed at the clinical practice and the health care
                                                        system levels</strong> (<a class="tab-link" href="#bib1393"
                                                        data-tab="pane-pcw-references">7-13</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn id="dtbl4fnlowast">
                            <p id="ntpara0085">∗ This section crosslinks to <a class="ref sec" id="crosref2030"
                                    href="#sec11.1.1">Section 7.1.1</a>, “Stage C Nonpharmacological Interventions and
                                Self-Care Support in HF,” where screening and interventions for social determinants of
                                health are now addressed.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p6700"><strong>Synopsis</strong></p>
            <p id="p6705">There are important differences in HF incidence, risk factors, clinical care needs, and
                outcomes between specific patient populations (<a class="tab-link" href="#bib1388"
                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib1389"
                    data-tab="pane-pcw-references">3</a>,<a class="tab-link" href="#bib1400"
                    data-tab="pane-pcw-references">14</a>,<a class="tab-link" href="#bib1401"
                    data-tab="pane-pcw-references">15</a>) (<a class="ref showTableEvent" data-id="tbl27"
                    href="#tbl27">Table 27</a>). It is essential that HF clinicians be aware of the biological factors,
                social determinants of health, and implicit biases that impact the burden of disease, clinical
                decision-making, and effective delivery of GDMT (<a class="tab-link" href="#bib1395"
                    data-tab="pane-pcw-references">9</a>,<a class="tab-link" href="#bib1402"
                    data-tab="pane-pcw-references">16-18</a>). Women generally present with HF later in life, with more
                comorbidities and lower patient-reported health status than men (<a class="tab-link" href="#bib1396"
                    data-tab="pane-pcw-references">10</a>,<a class="tab-link" href="#bib1405"
                    data-tab="pane-pcw-references">19</a>). Survival for women with HF is generally more favorable (<a
                    class="tab-link" href="#bib1406" data-tab="pane-pcw-references">20</a>), although access to
                specialty care may be lower (<a class="tab-link" href="#bib1407"
                    data-tab="pane-pcw-references">21-24</a>). The highest incident of HF is consistently observed in
                self-identified Black patients (<a class="tab-link" href="#bib1411"
                    data-tab="pane-pcw-references">25</a>,<a class="tab-link" href="#bib1412"
                    data-tab="pane-pcw-references">26</a>). HF hospitalization and mortality rates for Black patients
                are also higher than for White patients, with the gap increasing over time for young men (<a
                    class="tab-link" href="#bib1388" data-tab="pane-pcw-references">2</a>,<a class="tab-link"
                    href="#bib1390" data-tab="pane-pcw-references">4</a>,<a class="tab-link" href="#bib1413"
                    data-tab="pane-pcw-references">27</a>). These differences are driven mostly by social circumstances;
                a biological premise or genetic explanation for disease or disease severity should not be inferred by
                race or ethnicity (<a class="tab-link" href="#bib1414" data-tab="pane-pcw-references">28</a>). Older
                patients with HF are especially vulnerable to polypharmacy, multimorbidity, cognitive decline, and
                frailty (<a class="tab-link" href="#bib1415" data-tab="pane-pcw-references">29</a>,<a class="tab-link"
                    href="#bib1416" data-tab="pane-pcw-references">30</a>). Important strategies to remove biases within
                health care professionals and systems impacting minority and socioeconomically disadvantaged patient
                populations include implicit bias training, recruiting a diverse workforce, and promoting broad access
                to HF care (<a class="tab-link" href="#bib1414" data-tab="pane-pcw-references">28</a>,<a
                    class="tab-link" href="#bib1417" data-tab="pane-pcw-references">31-35</a>).</p>
            <div id="tbl27" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl27">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0310"><span class="captionLabel">Table 27</span> Risk of HF and Outcomes in
                                Special Populations</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Vulnerable Population</th>
                            <th colspan="1" rowspan="1">Risk of HF</th>
                            <th colspan="1" rowspan="1">HF Outcomes</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Women</strong></td>
                            <td colspan="1" rowspan="1">The lifetime risk of HF is equivalent between sexes, but HFpEF
                                risk is higher in women—in FHS participants with new-onset HF, odds of HFpEF (EF
                                &gt;45%) are 2.8-fold higher in women than in men (<a class="tab-link" href="#bib1452"
                                    data-tab="pane-pcw-references">66</a>).<br>Sex-specific differences in the
                                predictive value of cardiac biomarkers for incident HF (<a class="tab-link"
                                    href="#bib1453" data-tab="pane-pcw-references">67</a>).<br>Nontraditional
                                cardiovascular risk factors, including anxiety, depression, caregiver stress, and low
                                household income may contribute more toward incident heart disease in women than men (<a
                                    class="tab-link" href="#bib1454" data-tab="pane-pcw-references">68</a>).</td>
                            <td colspan="1" rowspan="1">Overall, more favorable survival with HF than men. In the
                                OPTIMIZE-HF registry, women with acute HF had a lower 1-y mortality (HR, 0.93; 95% CI,
                                0.89–0.97), although women are more likely not to receive optimal GDMT (<a
                                    class="tab-link" href="#bib1406" data-tab="pane-pcw-references">20</a>,<a
                                    class="tab-link" href="#bib1455" data-tab="pane-pcw-references">69-71</a>).<br>Lower
                                patient-reported quality of life for women with HFrEF, compared with men (<a
                                    class="tab-link" href="#bib1396" data-tab="pane-pcw-references">10</a>,<a
                                    class="tab-link" href="#bib1457" data-tab="pane-pcw-references">71</a>).<br>Greater
                                transplant waitlist mortality for women but equivalent survival after heart
                                transplantation or LVAD implantation (<a class="tab-link" href="#bib1410"
                                    data-tab="pane-pcw-references">24</a>,<a class="tab-link" href="#bib1438"
                                    data-tab="pane-pcw-references">52</a>).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Older adults</strong></td>
                            <td colspan="1" rowspan="1">Per FHS, at 40 y of age, the lifetime risk of incident HF is 20%
                                for both sexes; at 80 y of age, the risk remains 20% for men and women despite the
                                shorter life expectancy (<a class="tab-link" href="#bib1458"
                                    data-tab="pane-pcw-references">72</a>).<br>LVEF is preserved in at least two-thirds
                                of older adults with the diagnosis of HF (<a class="tab-link" href="#bib1459"
                                    data-tab="pane-pcw-references">73</a>).</td>
                            <td colspan="1" rowspan="1">Among 1233 patients with HF aged ≥80 y, 40% mortality during
                                mean 27-mo follow-up; survival associated with prescription of GDMT (<a class="tab-link"
                                    href="#bib1460" data-tab="pane-pcw-references">74</a>).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Lower socioeconomic status populations</strong></td>
                            <td colspan="1" rowspan="1">Among 27,078 White and Black adults of low income (70% earned
                                &lt;$15,000/y) participating from 2002–2009 in the Southern Community Cohort Study, a 1
                                interquartile increase in neighborhood deprivation index was associated with a 12%
                                increase in risk of HF (adjusted HR, 1.12; 95% CI, 1.07–1.18) (<a class="tab-link"
                                    href="#bib1432" data-tab="pane-pcw-references">46</a>).</td>
                            <td colspan="1" rowspan="1">Age-adjusted 1999–2018 HF mortality (deaths/100,000; mean and
                                95% CI) was higher with increasing quartiles of ADI, which is based on 17 indicators of
                                employment, poverty, and education:<ul class="NLM_list-list_type-simple"
                                    style="list-style-type:none" id="ulist0370">
                                    <li id="u0625">
                                        <p class="inline">Quartile 1, 20.0 (19.4–20.5);</p>
                                    </li>
                                    <li id="u0630">
                                        <p class="inline">Quartile 2, 23.3 (22.6–24.0);</p>
                                    </li>
                                    <li id="u0635">
                                        <p class="inline">Quartile 3, 26.4 (25.5–27.3);</p>
                                    </li>
                                    <li id="u0640">
                                        <p class="inline">Quartile 4, 33.1 (31.8–34.4) (<a class="tab-link"
                                                href="#bib1392" data-tab="pane-pcw-references">6</a>).</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Black populations</strong></td>
                            <td colspan="1" rowspan="1">In MESA, patients of Black race had highest risk of incident HF
                                (4.6/1000 person-years) and highest proportion of nonischemic incident HF (<a
                                    class="tab-link" href="#bib1412" data-tab="pane-pcw-references">26</a>).<br>Higher
                                prevalence of HF risk factors including hypertension, obesity, and diabetes, compared
                                with White populations (<a class="tab-link" href="#bib1461"
                                    data-tab="pane-pcw-references">75</a>).</td>
                            <td colspan="1" rowspan="1">CDC data show race-based differences in HF mortality over time:
                                Black men had a 1.16-fold versus 1.43-fold higher age-adjusted HF-related CVD death rate
                                compared with White men in 1999 versus 2017; Black women had a 1.35-fold versus
                                1.54-fold higher age-adjusted HF-related CVD death rate compared with White women in
                                1999 versus 2017 (<a class="tab-link" href="#bib1413"
                                    data-tab="pane-pcw-references">27</a>).<br>Gap in outcomes is more pronounced among
                                younger adults (35–64 y of age) versus older adults (65–84 y of age); age-adjusted
                                HF-related CVD death rates were 2.60-fold and 2.97-fold higher in young Black versus
                                White men and women, respectively (<a class="tab-link" href="#bib1413"
                                    data-tab="pane-pcw-references">27</a>).<br>Higher rates of hospitalization (<a
                                    class="tab-link" href="#bib1389" data-tab="pane-pcw-references">3</a>) and mortality
                                among patients with HFpEF (<a class="tab-link" href="#bib1462"
                                    data-tab="pane-pcw-references">76</a>).<br>Lower 5-year survival after heart
                                transplant (<a class="tab-link" href="#bib1463"
                                    data-tab="pane-pcw-references">77-79</a>).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Hispanic populations</strong></td>
                            <td colspan="1" rowspan="1">MESA study showed higher HF incidence in Hispanic compared with
                                non-Hispanic White groups (3.5 versus 2.4 per 1000 person-years) but lower than for
                                African Americans (4.6/1000 person-years) (<a class="tab-link" href="#bib1393"
                                    data-tab="pane-pcw-references">7</a>,<a class="tab-link" href="#bib1412"
                                    data-tab="pane-pcw-references">26</a>,<a class="tab-link" href="#bib1466"
                                    data-tab="pane-pcw-references">80</a>).</td>
                            <td colspan="1" rowspan="1">Despite higher rates of hospitalization for HF compared with
                                non-Hispanic Whites, Hispanic patients with HF have shown lower short-term mortality
                                rates (<a class="tab-link" href="#bib1467" data-tab="pane-pcw-references">81</a>).<br>In
                                GWTG, Hispanic patients with HFpEF had lower mortality (OR, 0.50; 95% CI, 0.31–0.81)
                                than non-Hispanic Whites, but this was not the case for Hispanic patients with HFrEF
                                (OR, 0.94; 95% CI, 0.62–1.43) (<a class="tab-link" href="#bib1468"
                                    data-tab="pane-pcw-references">82</a>).<br>Lower risk of developing AF in the
                                setting of HF, compared with White patients (<a class="tab-link" href="#bib1469"
                                    data-tab="pane-pcw-references">83</a>).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Asian and Pacific Islander populations</strong></td>
                            <td colspan="1" rowspan="1">Limited population-specific data for Asian and Pacific Islander
                                subgroups in the United States (<a class="tab-link" href="#bib1470"
                                    data-tab="pane-pcw-references">84</a>,<a class="tab-link" href="#bib1471"
                                    data-tab="pane-pcw-references">85</a>).</td>
                            <td colspan="1" rowspan="1">High rates of preventable HF hospitalization observed in some
                                Asian and Pacific Islander populations (<a class="tab-link" href="#bib1399"
                                    data-tab="pane-pcw-references">13</a>).<br>Lower mortality rates from HF for Asian
                                subgroups when listed as the primary cause of death, compared with non-Hispanic White
                                groups (<a class="tab-link" href="#bib1472" data-tab="pane-pcw-references">86</a>).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Native American and Alaskan Native populations</strong>
                            </td>
                            <td colspan="1" rowspan="1">Limited population-specific data, with cardiovascular risk
                                factor trends best characterized by the Strong Heart Study and Strong Heart Family
                                Study, demonstrating high rates of hypertension and diabetes (<a class="tab-link"
                                    href="#bib1397" data-tab="pane-pcw-references">11</a>,<a class="tab-link"
                                    href="#bib1473" data-tab="pane-pcw-references">87</a>).</td>
                            <td colspan="1" rowspan="1">Limited data suggest HF mortality rates in American Indians and
                                Alaska Natives are similar to those in White populations (<a class="tab-link"
                                    href="#bib1474" data-tab="pane-pcw-references">88</a>).</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0315">CDC indicates Centers for Disease Control and Prevention; CVD,
                                cardiovascular disease; FHS, Framingham Heart Study; GDMT, guideline-directed medical
                                therapy; GWTG, Get With The Guidelines registry; HF, heart failure; HFpEF, heart failure
                                with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction;
                                HR, hazard ratio; LVAD, left ventricular assist device; LVEF, left ventricular ejection
                                fraction; MESA, Multi-Ethnic Study of Atherosclerosis; OPTMIZE-HF, Organized Program To
                                Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure; and OR, odds
                                ratio.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p6710"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1410" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6715">Hypertension is significantly more prevalent in Black patients, compared with
                                White patients, populations in the United States, with a younger age of onset and
                                greater attributable cardiovascular risks (<a class="tab-link" href="#bib1422"
                                    data-tab="pane-pcw-references">36</a>,<a class="tab-link" href="#bib1423"
                                    data-tab="pane-pcw-references">37</a>). An estimated 50,000 to 350,000 immigrants to
                                the United States from Mexico and Central America may have asymptomatic <i>Trypanosoma
                                    cruzi</i>, with 20% progressing to Chagas cardiomyopathy (<a class="tab-link"
                                    href="#bib1424" data-tab="pane-pcw-references">38</a>). Diabetes is highly prevalent
                                in Southeast Asian and Pacific Islander populations and more strongly associated with
                                poor HF outcomes (<a class="tab-link" href="#bib1425"
                                    data-tab="pane-pcw-references">39</a>,<a class="tab-link" href="#bib1426"
                                    data-tab="pane-pcw-references">40</a>). Among patients with established HF, social
                                and medical vulnerabilities can impede successful delivery of GDMT and are associated
                                with poorer outcomes (<a class="tab-link" href="#bib1391"
                                    data-tab="pane-pcw-references">5</a>,<a class="tab-link" href="#bib1427"
                                    data-tab="pane-pcw-references">41</a>). Among older adults, low income, social
                                isolation, and lack of caregiver support increase HF mortality and low QOL (<a
                                    class="tab-link" href="#bib1395" data-tab="pane-pcw-references">9</a>,<a
                                    class="tab-link" href="#bib1404" data-tab="pane-pcw-references">18</a>,<a
                                    class="tab-link" href="#bib1428" data-tab="pane-pcw-references">42</a>). Nursing
                                home residents, and elderly inpatients with acute HF, are at risk of inadequate GDMT
                                prescription, although interventions in nursing facilities can improve care delivery for
                                HF (<a class="tab-link" href="#bib1416" data-tab="pane-pcw-references">30</a>,<a
                                    class="tab-link" href="#bib1429" data-tab="pane-pcw-references">43-45</a>). Lower
                                socioeconomic status is associated with HF incidence and HF mortality (<a
                                    class="tab-link" href="#bib1392" data-tab="pane-pcw-references">6</a>,<a
                                    class="tab-link" href="#bib1432" data-tab="pane-pcw-references">46</a>,<a
                                    class="tab-link" href="#bib1433" data-tab="pane-pcw-references">47</a>).
                                Homelessness (<a class="tab-link" href="#bib1434"
                                    data-tab="pane-pcw-references">48</a>), substance use, food insecurity, and lack of
                                transportation each represent potential barriers to optimal disease management (<a
                                    class="tab-link" href="#bib1435" data-tab="pane-pcw-references">49</a>). Case
                                management and social work services are essential to the comprehensive multidisciplinary
                                HF team approach for coordinating complex medical, psychiatric, and social needs across
                                multiple sectors.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6720">Health care system factors are a potential source of disparate HF care
                                delivery and outcomes. Women are less likely to receive discharge instructions for HF
                                (<a class="tab-link" href="#bib1436" data-tab="pane-pcw-references">50</a>), less likely
                                to be referred to specialty care (<a class="tab-link" href="#bib1407"
                                    data-tab="pane-pcw-references">21</a>,<a class="tab-link" href="#bib1408"
                                    data-tab="pane-pcw-references">22</a>), and less likely to receive a heart
                                transplantation (<a class="tab-link" href="#bib1437"
                                    data-tab="pane-pcw-references">51-54</a>), compared with men. Patients with HF of
                                Black race have been identified as less likely to receive care from a cardiologist
                                during an ICU admission for HF (<a class="tab-link" href="#bib1441"
                                    data-tab="pane-pcw-references">55</a>), have less access to specialized inpatient HF
                                care (<a class="tab-link" href="#bib1398" data-tab="pane-pcw-references">12</a>), and
                                may be vulnerable to clinician biases during evaluation for advanced HF therapies (<a
                                    class="tab-link" href="#bib1397" data-tab="pane-pcw-references">11</a>,<a
                                    class="tab-link" href="#bib1439" data-tab="pane-pcw-references">53</a>). Hispanic
                                patients are disproportionately noninsured in the United States (<a class="tab-link"
                                    href="#bib1442" data-tab="pane-pcw-references">56</a>), may experience language
                                barriers to quality care (<a class="tab-link" href="#bib1393"
                                    data-tab="pane-pcw-references">7</a>,<a class="tab-link" href="#bib1443"
                                    data-tab="pane-pcw-references">57</a>), and also have less access to specialized
                                inpatient HF care (<a class="tab-link" href="#bib1398"
                                    data-tab="pane-pcw-references">12</a>). Native American and Alaskan Native
                                populations experience particular challenges in specialty care access because Indian
                                Health Service facilities are often small and rural (<a class="tab-link" href="#bib1397"
                                    data-tab="pane-pcw-references">11</a>). Engaging patients in medical care within
                                culturally tailored environments has proven successful (<a class="tab-link"
                                    href="#bib1444" data-tab="pane-pcw-references">58</a>,<a class="tab-link"
                                    href="#bib1445" data-tab="pane-pcw-references">59</a>). HF written educational
                                materials for patients and caregivers should be delivered at or below the sixth grade
                                reading level (<a class="tab-link" href="#bib1446"
                                    data-tab="pane-pcw-references">60</a>). Workplace interventions that improve
                                cultural competency and address implicit biases are increasingly available. Many aspects
                                of GDMT have been inadequately studied by population subgroups, largely as a result of
                                clinical trial underrepresentation (<a class="tab-link" href="#bib1447"
                                    data-tab="pane-pcw-references">61-65</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec15" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec15">
                <div id="acsectitle0490" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0490">11.2 Cardio-Oncology</h3>
            <p id="p6735"><strong>Synopsis</strong></p>
            <p id="p6740">Advances in cancer therapy and an aging population have led to a growing number of cancer
                patients with comorbid CVD receiving treatment for cancer (<a class="tab-link" href="#bib1507"
                    data-tab="pane-pcw-references">33</a>,<a class="tab-link" href="#bib1508"
                    data-tab="pane-pcw-references">34</a>). Cardiovascular complications of cancer therapy, notably
                cardiomyopathy and HF, can result in significant morbidity and interruption of treatment, impacting both
                short- and long-term survival (<a class="tab-link" href="#bib1509"
                    data-tab="pane-pcw-references">35</a>,<a class="tab-link" href="#bib1510"
                    data-tab="pane-pcw-references">36</a>). Because drug development in cancer therapeutics grows at an
                exponential pace, establishing a unified framework for the management of cancer therapy–related
                cardiomyopathy—commonly defined as a decrease in LVEF of at least 10% to &lt;50%—is necessary to
                mitigate the cardiovascular risks of established novel therapies. Cardio-oncology is the practice of
                precancer therapy cardiovascular risk stratification, prevention, early detection, and treatment of
                cardiovascular complications (<a class="tab-link" href="#bib1510"
                    data-tab="pane-pcw-references">36</a>,<a class="tab-link" href="#bib1511"
                    data-tab="pane-pcw-references">37</a>). The evidence from which guideline recommendations in
                cardio-oncology have emerged has been based on studies of anthracycline and trastuzumab-induced
                cardiomyopathy. Cancer therapy–related cardiomyopathy is, however, a heterogeneous disease, with a wide
                range of presentations—from asymptomatic LV dysfunction to cardiogenic shock—and drug-dependent
                pathophysiologic mechanisms that are often poorly understood. Until sufficient high-quality,
                drug-specific evidence and cost-effectiveness analyses for screening and monitoring are available, these
                recommendations are applicable across potentially cardiotoxic therapies (<a class="ref showTableEvent"
                    data-id="tbl28" href="#tbl28">Table 28</a>).</p>
            <div id="tbl28" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl28">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0320"><span class="captionLabel">Table 28</span> Cancer Therapies Known to Be
                                Associated With Cardiomyopathy</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="2">Class</th>
                            <th colspan="1" rowspan="2">Agent(s)</th>
                            <th colspan="2" rowspan="1">Cardiac Function Monitoring Often Performed in Clinical Practice
                            </th>
                        </tr>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Pretherapy</th>
                            <th colspan="1" rowspan="1">Serial</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Anthracyclines (<a class="tab-link" href="#bib1529"
                                    data-tab="pane-pcw-references">55-57</a>)</td>
                            <td colspan="1" rowspan="1">Doxorubicin, epirubicin</td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Alkylating agents (<a class="tab-link" href="#bib1532"
                                    data-tab="pane-pcw-references">58-60</a>)</td>
                            <td colspan="1" rowspan="1">Cyclophosphamide, ifosfamide, melphalan</td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Antimicrotubule agents (<a class="tab-link" href="#bib1535"
                                    data-tab="pane-pcw-references">61</a>,<a class="tab-link" href="#bib1536"
                                    data-tab="pane-pcw-references">62</a>)</td>
                            <td colspan="1" rowspan="1">Docetaxel</td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Antimetabolites (<a class="tab-link" href="#bib1537"
                                    data-tab="pane-pcw-references">63-72</a>)</td>
                            <td colspan="1" rowspan="1">Fluorouracil, capecitabine, fludarabine, decitabine</td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Anti-HER2 agents (<a class="tab-link" href="#bib1547"
                                    data-tab="pane-pcw-references">73-76</a>)</td>
                            <td colspan="1" rowspan="1">Trastuzumab, pertuzumab</td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Monoclonal antibodies (<a class="tab-link" href="#bib1551"
                                    data-tab="pane-pcw-references">77</a>)</td>
                            <td colspan="1" rowspan="1">Rituximab</td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Tyrosine-kinase inhibitors (<a class="tab-link" href="#bib1552"
                                    data-tab="pane-pcw-references">78-100</a>)</td>
                            <td colspan="1" rowspan="1">Dabrafenib, dasatinib, lapatinib, pazopanib, ponatinib,
                                sorafenib, trametinib, sunitinib, vandetanib, imatinib, vandetanib</td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Immune checkpoint inhibitors (<a class="tab-link"
                                    href="#bib1513" data-tab="pane-pcw-references">39</a>,<a class="tab-link"
                                    href="#bib1514" data-tab="pane-pcw-references">40</a>,<a class="tab-link"
                                    href="#bib1575" data-tab="pane-pcw-references">101</a>)</td>
                            <td colspan="1" rowspan="1">Nivolumab, ipilimumab, pembrolizumab</td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Protease inhibitors (<a class="tab-link" href="#bib1576"
                                    data-tab="pane-pcw-references">102-106</a>)</td>
                            <td colspan="1" rowspan="1">Bortezomib, carfilzomib</td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Endocrine therapy (<a class="tab-link" href="#bib1581"
                                    data-tab="pane-pcw-references">107-111</a>)</td>
                            <td colspan="1" rowspan="1">Goserelin, leuprolide, flutamide, bicalutamide, nilutamide</td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Chimeric antigen receptor T-cell therapy (<a class="tab-link"
                                    href="#bib1586" data-tab="pane-pcw-references">112</a>,<a class="tab-link"
                                    href="#bib1587" data-tab="pane-pcw-references">113</a>)</td>
                            <td colspan="1" rowspan="1">Tisagenlecleucel, axicabtagene ciloleucel</td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Hematopoietic stem cell transplantation (<a class="tab-link"
                                    href="#bib1481" data-tab="pane-pcw-references">7</a>,<a class="tab-link"
                                    href="#bib1518" data-tab="pane-pcw-references">44</a>,<a class="tab-link"
                                    href="#bib1588" data-tab="pane-pcw-references">114-119</a>)</td>
                            <td colspan="1" rowspan="1">Hematopoietic stem cell transplantation</td>
                            <td align="center" colspan="1" rowspan="1">X</td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Radiation (<a class="tab-link" href="#bib1481"
                                    data-tab="pane-pcw-references">7</a>,<a class="tab-link" href="#bib1518"
                                    data-tab="pane-pcw-references">44</a>,<a class="tab-link" href="#bib1588"
                                    data-tab="pane-pcw-references">114-119</a>)</td>
                            <td colspan="1" rowspan="1">Chest</td>
                            <td colspan="1" rowspan="1"></td>
                            <td colspan="1" rowspan="1"></td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6745"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1415" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6750">HF secondary to cancer therapy–related cardiomyopathy is associated with
                                significantly worse outcomes (<a class="tab-link" href="#bib1475"
                                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib1476"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib1512"
                                    data-tab="pane-pcw-references">38</a>). Patients who develop HF while receiving
                                potentially cardiotoxic therapies should have these therapies discontinued while a
                                diagnostic workup is undertaken to ascertain the cause of HF and initiate GDMT. The
                                complex decision to resume, modify, or permanently discontinue therapy by the primary
                                oncologist should be done in a patient-centered approach in concert with a
                                cardiovascular specialist in cardio-oncology. Factors impacting the decision include the
                                severity of cancer therapy–related cardiomyopathy and the response to neurohormonal
                                blockade, the offending agent’s specific mechanism of injury, the patient’s comorbid
                                conditions and cancer-related prognosis and, lastly, the availability of alternative
                                noncardiotoxic treatment options. However, the clinical significance of asymptomatic
                                cancer therapy–related cardiomyopathy that is identified on routine monitoring is less
                                clear. This is most apparent in patients receiving trastuzumab in whom asymptomatic
                                decreases in LVEF can occur in &gt;10% of patients yet result in a high recovery rate
                                and low rate of discontinuation of therapy (<a class="tab-link" href="#bib1475"
                                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib1476"
                                    data-tab="pane-pcw-references">2</a>). Accordingly, trastuzumab is often continued
                                in patients deemed low risk while neurohormonal blockade is initiated. Conversely,
                                patients diagnosed with immune checkpoint-related myocarditis typically have the
                                offending agents discontinued indefinitely, given the associated high mortality (<a
                                    class="tab-link" href="#bib1513" data-tab="pane-pcw-references">39</a>,<a
                                    class="tab-link" href="#bib1514" data-tab="pane-pcw-references">40</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6755">Studying the effectiveness of neurohormonal therapies specifically in patients
                                with the <i>CTRC</i> gene is challenging given the relative infrequency of events,
                                heterogeneity of offending agents, the poorly understood pathophysiology, and the
                                overlap with comorbid CVD. Available data in patients with anthracycline and
                                trastuzumab-induced cardiomyopathy suggest beta blockers and ACEi are effective in
                                improving LV dysfunction (<a class="tab-link" href="#bib1476"
                                    data-tab="pane-pcw-references">2-4</a>). Given the dearth of data specific to cancer
                                therapy–related cardiomyopathy for other GDMT, their use should align with the HFrEF
                                management guidelines. Initiation and uptitration of standard HF therapies remains the
                                mainstay of treatment in patients with cancer therapy–related cardiomyopathy or LVEF
                                &lt;50%, with close monitoring of cardiac function to guide discussions with oncology on
                                the resumption of, or choice of, subsequent cancer therapies (<a class="tab-link"
                                    href="#bib1476" data-tab="pane-pcw-references">2</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6760">Pretherapy quantification of LVEF in patients receiving potentially
                                cardiotoxic cancer therapies serves 4 purposes: 1) pretherapy risk stratification and
                                diagnosis of preexisting cardiomyopathy, 2) establish a reference baseline to which
                                reevaluations can be compared, 3) initiate cardioprotective medications before cancer
                                therapy, and 4) guide choice of cancer therapy. Echocardiography is recommended as the
                                first-line modality for LVEF assessment given its availability, safety, relatively low
                                cost, and its ability to provide structural and functional information beyond LVEF (<a
                                    class="tab-link" href="#bib1476" data-tab="pane-pcw-references">2</a>,<a
                                    class="tab-link" href="#bib1479" data-tab="pane-pcw-references">5-16</a>,<a
                                    class="tab-link" href="#bib1515" data-tab="pane-pcw-references">41-47</a>). The risk
                                of cancer therapy–related cardiomyopathy varies greatly across cancer therapies and is
                                modified by preexisting cardiovascular risk factors (<a class="ref showTableEvent"
                                    data-id="tbl29" href="#tbl29">Table 29</a>). Pretherapy LVEF is a strong predictor
                                of major adverse cardiovascular events in patients receiving potentially cardiotoxic
                                therapies (<a class="tab-link" href="#bib1476" data-tab="pane-pcw-references">2</a>,<a
                                    class="tab-link" href="#bib1479" data-tab="pane-pcw-references">5-10</a>,<a
                                    class="tab-link" href="#bib1516" data-tab="pane-pcw-references">42-47</a>). The
                                clinical use and cost-effectiveness of systematic screening in all patients, however, is
                                unclear (<a class="tab-link" href="#bib1485" data-tab="pane-pcw-references">11-16</a>).
                                Patients with cancer and preexisting cardiovascular risk factors are at significantly
                                higher risk of cancer therapy–related cardiomyopathy, representing a population in which
                                pretherapy evaluation would have a significantly higher yield (<a class="tab-link"
                                    href="#bib1476" data-tab="pane-pcw-references">2</a>,<a class="tab-link"
                                    href="#bib1479" data-tab="pane-pcw-references">5-10</a>,<a class="tab-link"
                                    href="#bib1516" data-tab="pane-pcw-references">42-47</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6765">The purpose of serial monitoring of LVEF in patients receiving potentially
                                cardiotoxic anticancer agents is to identify subclinical cardiac injury, initiate
                                cardioprotective agents, and consider temporary or permanent interruption of the
                                offending agent (<a class="tab-link" href="#bib1476"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib1478"
                                    data-tab="pane-pcw-references">4</a>,<a class="tab-link" href="#bib1480"
                                    data-tab="pane-pcw-references">6</a>,<a class="tab-link" href="#bib1482"
                                    data-tab="pane-pcw-references">8</a>,<a class="tab-link" href="#bib1522"
                                    data-tab="pane-pcw-references">48</a>). The practice of LVEF monitoring has mostly
                                been implemented in patients receiving anthracyclines, trastuzumab, or both (<a
                                    class="ref showTableEvent" data-id="tbl28" href="#tbl28">Table 28</a>). In a study
                                of 2625 patients receiving anthracyclines for breast cancer or lymphoma who underwent
                                serial LVEF monitoring, cancer therapy–related cardiomyopathy occurred in 9% of
                                patients, of whom 81% had mild symptoms (NYHA class I to II) (<a class="tab-link"
                                    href="#bib1478" data-tab="pane-pcw-references">4</a>). Beta blockers and ACEi-ARB
                                were initiated in all patients, with 86% having at least partial recovery of LVEF (<a
                                    class="tab-link" href="#bib1478" data-tab="pane-pcw-references">4</a>). Patients
                                with recovered LVEF had a lower incidence of cardiac events than those that did not (<a
                                    class="tab-link" href="#bib1478" data-tab="pane-pcw-references">4</a>). The clinical
                                significance of an asymptomatic decrease in LVEF and the optimal frequency and duration
                                of monitoring is less clear and likely depend on patient risk, the anticancer agent
                                used, and its cumulative dose. Although a one-size-fits-all approach to monitoring for
                                cancer therapy–related cardiomyopathy may be easier to implement systematically, it may
                                not be the most cost-effective. Until additional data are available, limiting the
                                monitoring to patients at higher risk of cancer therapy–related cardiomyopathy (<a
                                    class="ref showTableEvent" data-id="tbl29" href="#tbl29">Table 29</a>) is a
                                reasonable strategy.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6770">Whether the preemptive use of ACEi-ARB, spironolactone, or selected beta
                                blockers such as carvedilol and nebivolol is effective in reducing the risk of cancer
                                therapy–related cardiomyopathy has been investigated in a number of small clinic trials,
                                with conflicting findings (<a class="tab-link" href="#bib1491"
                                    data-tab="pane-pcw-references">17-27</a>,<a class="tab-link" href="#bib1523"
                                    data-tab="pane-pcw-references">49</a>). The most supportive of this practice is a
                                study that randomized 114 patients receiving high-dose chemotherapy and having a
                                posttreatment troponin rise &gt;0.07 ng/mL to enalapril or placebo (<a class="tab-link"
                                    href="#bib1494" data-tab="pane-pcw-references">20</a>). None of the patients in the
                                enalapril arm met the primary endpoint (&gt;10% decrease in LVEF to below 50%), while
                                43% of patients in the standard of care group had a significant decrease in LVEF (<a
                                    class="tab-link" href="#bib1494" data-tab="pane-pcw-references">20</a>). Although
                                other studies have shown similar findings, the magnitude of the difference in LVEF
                                between arms was often small (&lt;5%) and of questionable clinical significance (<a
                                    class="tab-link" href="#bib1493" data-tab="pane-pcw-references">19</a>,<a
                                    class="tab-link" href="#bib1496" data-tab="pane-pcw-references">22</a>). Not all
                                studies have replicated these findings (<a class="tab-link" href="#bib1492"
                                    data-tab="pane-pcw-references">18</a>,<a class="tab-link" href="#bib1495"
                                    data-tab="pane-pcw-references">21</a>,<a class="tab-link" href="#bib1498"
                                    data-tab="pane-pcw-references">24</a>,<a class="tab-link" href="#bib1500"
                                    data-tab="pane-pcw-references">26</a>). Most importantly, none of the studies have
                                assessed whether preemptive use of HF therapies in patients at risk for cancer
                                therapy–related cardiomyopathy improves clinical outcomes, such as mortality or
                                hospitalization for HF. Additional studies are needed to define the appropriate criteria
                                and patient population in whom to initiate medical therapies for the primary prevention
                                of cancer therapy–related cardiomyopathy.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">6.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6775">Cardiovascular biomarkers, notably troponin, have been studied for
                                cardiovascular risk stratification in patients undergoing potentially cardiotoxic
                                therapies (<a class="tab-link" href="#bib1503"
                                    data-tab="pane-pcw-references">29-32</a>). A study of 452 patients with breast
                                cancer showed that an elevated pretreatment level (&gt;14 ng/L) was associated with a
                                4-fold increase in the risk of cancer therapy–related cardiomyopathy (<a
                                    class="tab-link" href="#bib1506" data-tab="pane-pcw-references">32</a>). Other
                                smaller studies have found no advantage in measuring troponin or natriuretic peptides
                                pretherapy (<a class="tab-link" href="#bib1524"
                                    data-tab="pane-pcw-references">50-53</a>). Overall, these biomarker studies were
                                observational and small in sample size and number of events (<a class="tab-link"
                                    href="#bib1528" data-tab="pane-pcw-references">54</a>). Serial biomarkers may be
                                more useful in risk stratification. For example, in a study of 703 patients receiving
                                anthracyclines, an increase in troponin within 72 hours of chemotherapy and 1 month
                                after the completion of treatment course were associated with a greater risk of cancer
                                therapy–related cardiomyopathy (<a class="tab-link" href="#bib1503"
                                    data-tab="pane-pcw-references">29</a>). The clinical use of measuring biomarkers was
                                assessed in 1 trial in which 114 patients with posttreatment increase in troponin to
                                &gt;0.07 ng/mL were randomized to enalapril or standard of care (<a class="tab-link"
                                    href="#bib1494" data-tab="pane-pcw-references">20</a>). None of the patients in the
                                enalapril group had a decrease in LVEF, compared with 43% in the standard of care group
                                (<a class="tab-link" href="#bib1494" data-tab="pane-pcw-references">20</a>). Data for
                                the use of natriuretic peptides are limited. In practice, biomarkers could provide rapid
                                risk stratification in patients for which echocardiographic findings are equivocal and
                                help determine whether symptoms are cardiovascular in origin.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="tbl29" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl29">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0325"><span class="captionLabel">Table 29</span> Risk Factors for Cancer
                                Therapy–Related Cardiomyopathy</p>
                        </strong></caption>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Age ≥60 y</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Black race</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">CAD</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Hypertension</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Diabetes</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Preexisting cardiomyopathy</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Previous exposure to anthracyclines</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Previous chest radiation</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Elevated troponin pretherapy</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0330">CAD indicates coronary artery disease.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="acsec15" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec15">
                <div id="acsectitle0495" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0495">11.3 HF and Pregnancy</h3>
            <div id="undtbl52" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl52">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0845">Recommendations for HF and Pregnancy</p>
                            <p id="tspara0850">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0980" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1980"><strong>In women with a history of HF or cardiomyopathy,
                                                        including previous peripartum cardiomyopathy, patient-centered
                                                        counseling regarding contraception and the risks of
                                                        cardiovascular deterioration during pregnancy should be
                                                        provided</strong> (<a class="tab-link" href="#bib1594"
                                                        data-tab="pane-pcw-references">1-8</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2b</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0985" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1985"><strong>In women with acute HF caused by peripartum
                                                        cardiomyopathy and LVEF &lt;30%, anticoagulation may be
                                                        reasonable at diagnosis, until 6 to 8 weeks postpartum, although
                                                        the efficacy and safety are uncertain</strong> (<a
                                                        class="tab-link" href="#bib1602"
                                                        data-tab="pane-pcw-references">9-12</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>3: Harm</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0990" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1990"><strong>In women with HF or cardiomyopathy who are
                                                        pregnant or currently planning for pregnancy, ACEi, ARB, ARNi,
                                                        MRA, SGLT2i, ivabradine, and vericiguat should not be
                                                        administered because of significant risks of fetal harm</strong>
                                                    (<a class="tab-link" href="#bib1606"
                                                        data-tab="pane-pcw-references">13-15</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6790"><strong>Synopsis</strong></p>
            <p id="p6795">HF may complicate pregnancy either secondary to an existing prepregnancy cardiomyopathy, or as
                a result of peripartum cardiomyopathy (<a class="tab-link" href="#bib1609"
                    data-tab="pane-pcw-references">16-18</a>). Peripartum cardiomyopathy is defined as systolic
                dysfunction, typically LVEF &lt;45%, often with LV dilation, occurring in late pregnancy or early
                postpartum with no other identifiable cardiomyopathy cause (<a class="tab-link" href="#bib1607"
                    data-tab="pane-pcw-references">14</a>,<a class="tab-link" href="#bib1612"
                    data-tab="pane-pcw-references">19-21</a>). Peripartum cardiomyopathy occurs globally (<a
                    class="tab-link" href="#bib1615" data-tab="pane-pcw-references">22</a>,<a class="tab-link"
                    href="#bib1616" data-tab="pane-pcw-references">23</a>), with the highest incidences in Nigeria,
                Haiti, and South Africa. Incidence in the United States is 1 in 1000 to 8000 deliveries and has risen
                over time (<a class="tab-link" href="#bib1617" data-tab="pane-pcw-references">24</a>,<a class="tab-link"
                    href="#bib1618" data-tab="pane-pcw-references">25</a>). Peripartum cardiomyopathy risk factors
                include maternal age &gt;30 years, African ancestry, multiparity, multigestation,
                preeclampsia/eclampsia, anemia, diabetes, obesity, and prolonged tocolysis (<a class="tab-link"
                    href="#bib1615" data-tab="pane-pcw-references">22</a>,<a class="tab-link" href="#bib1616"
                    data-tab="pane-pcw-references">23</a>,<a class="tab-link" href="#bib1619"
                    data-tab="pane-pcw-references">26-30</a>). A genetic contribution is recognized (<a class="tab-link"
                    href="#bib1624" data-tab="pane-pcw-references">31-33</a>), particularly titan gene mutations (<a
                    class="tab-link" href="#bib1627" data-tab="pane-pcw-references">34</a>,<a class="tab-link"
                    href="#bib1628" data-tab="pane-pcw-references">35</a>). Most women present with HF within 1 month
                postpartum; cardiogenic shock, arrhythmias, or venous-arterial thromboembolism are all possible.
                Treatment includes GDMT adjusted for pregnancy or breastfeeding status and anticoagulation consideration
                (<a class="tab-link" href="#bib1609" data-tab="pane-pcw-references">16</a>); identification of a
                pathogenic 16-kDa prolactin led to trials of the dopamine-agonist bromocriptine (<a class="tab-link"
                    href="#bib1629" data-tab="pane-pcw-references">36-41</a>). Patient-centered multidisciplinary
                planning is essential, including early institution of mechanical support for shock (<a class="tab-link"
                    href="#bib1635" data-tab="pane-pcw-references">42</a>) (<a class="ref showTableEvent"
                    data-id="tbl30" href="#tbl30">Table 30</a>). Prognosis is related to initial LVEF, LV thrombosis, RV
                involvement, preeclampsia, geographic region, and race (<a class="tab-link" href="#bib1600"
                    data-tab="pane-pcw-references">7</a>,<a class="tab-link" href="#bib1636"
                    data-tab="pane-pcw-references">43-48</a>). LV recovery and survival is generally favorable in
                developed countries (<a class="tab-link" href="#bib1604" data-tab="pane-pcw-references">11</a>,<a
                    class="tab-link" href="#bib1618" data-tab="pane-pcw-references">25</a>,<a class="tab-link"
                    href="#bib1642" data-tab="pane-pcw-references">49</a>); a 100-patient U.S. registry showed 93%
                transplant/LVAD-free 1-year survival (<a class="tab-link" href="#bib1639"
                    data-tab="pane-pcw-references">46</a>).</p>
            <div id="tbl30" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl30">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0335"><span class="captionLabel">Table 30</span> HF Management Strategies
                                Across the Pregnancy Continuum</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1"></th>
                            <th colspan="1" rowspan="1">Preconception</th>
                            <th colspan="1" rowspan="1">During Pregnancy</th>
                            <th colspan="1" rowspan="1">Postpartum</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Nonpharmacological strategies</td>
                            <td colspan="1" rowspan="1">Preconception genetic counseling and testing for potentially
                                heritable cardiac conditions.<br>Use of pregnancy cardiovascular risk tools (<a
                                    class="tab-link" href="#bib1644" data-tab="pane-pcw-references">51</a>,<a
                                    class="tab-link" href="#bib1649" data-tab="pane-pcw-references">56-58</a>), and
                                echocardiography for myocardial structure and function assessment, to provide
                                information that facilitates informed counseling.<br>For women planning a pregnancy,
                                provide personalized counseling that promotes the autonomy and goals of the patient (and
                                her partner, as applicable), the patient’s ability for self-care and risk awareness, and
                                ensures adequate psychosocial support for decision-making (<a class="tab-link"
                                    href="#bib1596" data-tab="pane-pcw-references">3</a>).<br>For women not currently
                                planning a pregnancy but who might conceive, discuss HF-specific considerations
                                regarding pregnancy and refer to gynecology or primary care for contraceptive
                                counseling.</td>
                            <td colspan="1" rowspan="1">Close maternal monitoring for HF signs or symptoms or other
                                cardiovascular instability by cardiology and obstetric and maternal-fetal medicine
                                teams; close fetal monitoring by the obstetric and maternal-fetal medicine
                                teams.<br>Consideration of routine echocardiographic screening in the third trimester
                                for reassessment of myocardial structure and function before labor; echocardiography for
                                any significant changes in HF symptoms or signs during pregnancy, or if HF medications
                                are reduced or discontinued (<a class="tab-link" href="#bib1611"
                                    data-tab="pane-pcw-references">18</a>).<br>BNP or NT-proBNP monitoring during
                                pregnancy may have some value for prediction of cardiovascular events (<a
                                    class="tab-link" href="#bib1666" data-tab="pane-pcw-references">73</a>,<a
                                    class="tab-link" href="#bib1667" data-tab="pane-pcw-references">74</a>).<br>Close
                                maternal monitoring by obstetrics and maternal-fetal medicine teams for preeclampsia,
                                which has shared risk factors and pathogenesis with PPCM (<a class="tab-link"
                                    href="#bib1640" data-tab="pane-pcw-references">47</a>,<a class="tab-link"
                                    href="#bib1668" data-tab="pane-pcw-references">75</a>).<br>For women presenting with
                                decompensated HF or cardiogenic shock, hemodynamic monitoring and MCS, as appropriate,
                                within a multidisciplinary collaborative approach that supports prompt decision-making
                                about the timing and mechanism of delivery.</td>
                            <td colspan="1" rowspan="1">Multidisciplinary recommendations from obstetrics and
                                neonatology and pediatrics teams and shared decision-making regarding the maternal and
                                neonatal risks and benefits of breastfeeding.<br>For women presenting with decompensated
                                HF or cardiogenic shock, HF management should include hemodynamic monitoring and
                                mechanical circulatory support as appropriate</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Pharmacological strategies</td>
                            <td colspan="1" rowspan="1">Review of all current medications.<br>For women planning
                                pregnancy imminently, modification of HF pharmacotherapy including. discontinuation of
                                any ACEi, ARB, ARNi, MRA, or SGLT2i or ivabradine medications; within a construct of
                                multidisciplinary shared decision-making, continuation of a beta blocker (most commonly
                                metoprolol), hydralazine, and nitrates; adjustment of diuretic dosing to minimize the
                                risk of placental hypoperfusion (<a class="tab-link" href="#bib1606"
                                    data-tab="pane-pcw-references">13-15</a>).<br>Ideally, repeat echocardiography
                                approximately 3 mo after preconception HF medication adjustments to ensure stability of
                                myocardial structure and function before conception.</td>
                            <td colspan="1" rowspan="1">Close monitoring of maternal blood pressure, heart rate, and
                                volume status, with adjustment of the modified HF regimen as appropriate to avoid
                                hypotension (systemic vasodilation peaks in the second trimester) and placental
                                hypoperfusion.<br>For women with HF or cardiomyopathy presenting during pregnancy
                                without preconception counseling and assessment, urgent discontinuation of any GDMT
                                pharmacotherapies with fetal toxicities; within a construct of multidisciplinary shared
                                decision-making, continuation of a beta blocker (most commonly metoprolol succinate),
                                hydralazine, and nitrates; adjustment of diuretic dosing to minimize the risk of
                                placental hypoperfusion.</td>
                            <td colspan="1" rowspan="1">For women with acute HF caused by PPCM and LVEF &lt;30%,
                                consideration of anticoagulation until 6–8 wk postpartum, although the efficacy and
                                safety remain uncertain at this time.<br>For postpartum women with severe acute HF
                                caused by PPCM and LVEF &lt;35%, in GDMT pharmacotherapy and prophylactic
                                anticoagulation, to improve LVEF recovery (<a class="tab-link" href="#bib1599"
                                    data-tab="pane-pcw-references">6</a>,<a class="tab-link" href="#bib1624"
                                    data-tab="pane-pcw-references">31</a>,<a class="tab-link" href="#bib1629"
                                    data-tab="pane-pcw-references">36-41</a>,<a class="tab-link" href="#bib1669"
                                    data-tab="pane-pcw-references">76</a>); the efficacy and safety of bromocriptine for
                                acute PPCM treatment remains uncertain at this time, particularly in the setting of
                                contemporary HF GDMT and cardiogenic shock management.<a class="ref table-fn"
                                    id="tbl30fnlowast" href="javascript:popRef('tbl30fnlowast')"><sup>∗</sup></a><br>For
                                women who choose to breastfeed, review medications with neonatology and pediatrics teams
                                for neonatal safety during lactation, ideally with pharmacist consultation if
                                available.<br>Within a construct of multidisciplinary shared decision-making,
                                medications that may be appropriate during breastfeeding include ACEi (enalapril or
                                captopril preferred, monitor neonatal weight), beta blockers (metoprolol preferred,
                                monitor neonatal heart rate) (<a class="tab-link" href="#bib1608"
                                    data-tab="pane-pcw-references">15</a>).<br>Diuretics can suppress lactation, but
                                with neonatal follow-up the use of furosemide may be appropriate (<a class="tab-link"
                                    href="#bib1608" data-tab="pane-pcw-references">15</a>).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Multidisciplinary care beyond the cardiology team</td>
                            <td colspan="1" rowspan="1">Consultation with genetics, gynecology, and maternal-fetal
                                medicine teams, as appropriate to the outcome of shared decision-making.</td>
                            <td colspan="1" rowspan="1">Multidisciplinary management with obstetrics and maternal-fetal
                                medicine teams during pregnancy.<br>For women with decompensated HF or evidence of
                                hemodynamic instability antepartum, delivery planning will include obstetrics and
                                maternal-fetal medicine, anesthesia, and neonatology teams.</td>
                            <td colspan="1" rowspan="1">Multidisciplinary management with obstetrics, maternal-fetal
                                medicine, neonatology, and pediatrics teams, especially for multidisciplinary
                                recommendations regarding lactation.<br>Consultation with gynecology team for ongoing
                                contraceptive planning.</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0340">ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin
                                receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; BNP, B-natriuretic
                                peptide; GDMT, guideline-directed medical therapy; HF, heart failure; LVEF, left
                                ventricular ejection fraction; MCS, mechanical circulatory support; MRA,
                                mineralocorticoid receptor antagonist; NT-proBNP, N-terminal prohormone of brain
                                natriuretic peptide; PPCM, peripartum cardiomyopathy; RCT, randomized controlled trial;
                                RV, right ventricular; and SGLT2i, sodium-glucose cotransporter-2 inhibitor.</p>
                        </fn>
                        <fn id="tbl30fnlowast">
                            <p id="ntpara0065">∗ An initial open-label pilot RCT in South Africa suggested addition of
                                bromocriptine to GDMT was associated with greater LVEF improvement and a lower rate of
                                the composite endpoint at 6 mo (<a class="tab-link" href="#bib1630"
                                    data-tab="pane-pcw-references">37</a>). Among 96 women with acute PPCM in a Burkina
                                Faso RCT, 4 wk of bromocriptine was associated with LVEF recovery and lower mortality
                                (16.6% versus 29.1%; <i>P</i>&lt;0.001) (<a class="tab-link" href="#bib1632"
                                    data-tab="pane-pcw-references">39</a>). A multicenter German study randomized 63
                                patients to 1 versus 8 wk of bromocriptine (no placebo, as deemed unethical) (<a
                                    class="tab-link" href="#bib1631" data-tab="pane-pcw-references">38</a>), with LVEF
                                recovery ≥50% in 52% and 68% of the 1- and 8-wk groups, respectively, and no deaths. A
                                substudy also showed high rates of RV recovery (<a class="tab-link" href="#bib1634"
                                    data-tab="pane-pcw-references">41</a>). Two retrospective cohorts (Germany, Canada)
                                and a multicenter cohort of subsequent pregnancies also suggested greater LVEF recovery
                                with bromocriptine (<a class="tab-link" href="#bib1624"
                                    data-tab="pane-pcw-references">31</a>,<a class="tab-link" href="#bib1631"
                                    data-tab="pane-pcw-references">38</a>,<a class="tab-link" href="#bib1633"
                                    data-tab="pane-pcw-references">40</a>). Bromocriptine may currently be most
                                justified in women with LVEF &lt;25% or cardiogenic shock. The downsides of prohibiting
                                breastfeeding should be considered. Bromocriptine should be accompanied by at least
                                prophylactic-dosed anticoagulation, because of potential hypercoagulability (<a
                                    class="tab-link" href="#bib1631" data-tab="pane-pcw-references">38</a>). The
                                European Society of Cardiology endorses “BOARD” (Bromocriptine, Oral HF therapy,
                                Anticoagulation, vasoRelaxing agents, Diuretics) for acute PPCM management (<a
                                    class="tab-link" href="#bib1606" data-tab="pane-pcw-references">13</a>,<a
                                    class="tab-link" href="#bib1607" data-tab="pane-pcw-references">14</a>).</p>
                        </fn>
                    </div>
                </div>
            </div>
            <p id="p6800"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1420" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6805">Pregnancy is generally well-tolerated in women with cardiomyopathy and NYHA
                                class I prepregnancy. However, clinical deterioration can occur, so prepregnancy
                                counseling and shared decision-making are essential (<a class="tab-link" href="#bib1594"
                                    data-tab="pane-pcw-references">1</a>,<a class="tab-link" href="#bib1596"
                                    data-tab="pane-pcw-references">3</a>,<a class="tab-link" href="#bib1643"
                                    data-tab="pane-pcw-references">50</a>). Among women with non–peripartum
                                cardiomyopathy, major cardiovascular events occurred in 39% (United States) and 35%
                                (Canada) of pregnancies, with 1% and 7% mortality, respectively (<a class="tab-link"
                                    href="#bib1644" data-tab="pane-pcw-references">51</a>,<a class="tab-link"
                                    href="#bib1645" data-tab="pane-pcw-references">52</a>). Previous cardiac events,
                                NYHA class III to IV, or LVEF &lt;40% markedly increased maternal and fetal risks (<a
                                    class="tab-link" href="#bib1644" data-tab="pane-pcw-references">51-55</a>). The
                                ROPAC (Registry of Pregnancy and Cardiac disease) study describes pregnancy outcomes for
                                1321 women with structural heart disease: Women with prepregnancy or peripartum
                                cardiomyopathy had the highest mortality rate (2.4%) (<a class="tab-link"
                                    href="#bib1595" data-tab="pane-pcw-references">2</a>,<a class="tab-link"
                                    href="#bib1615" data-tab="pane-pcw-references">22</a>). ROPAC was used to validate
                                the modified WHO risk classification (<a class="tab-link" href="#bib1649"
                                    data-tab="pane-pcw-references">56</a>); the ZAHARA I (Zwangerschap bij Aangeboren
                                Hartafwijkingen I) and CARPREG II (CARdiac disease in PREGnancy) scores also support
                                shared decision-making (<a class="tab-link" href="#bib1644"
                                    data-tab="pane-pcw-references">51</a>,<a class="tab-link" href="#bib1650"
                                    data-tab="pane-pcw-references">57</a>,<a class="tab-link" href="#bib1651"
                                    data-tab="pane-pcw-references">58</a>). Subsequent pregnancies for women with
                                previous peripartum cardiomyopathy have been associated with further decreases in LV
                                function, maternal death, and adverse fetal outcomes (<a class="tab-link"
                                    href="#bib1636" data-tab="pane-pcw-references">43</a>,<a class="tab-link"
                                    href="#bib1651" data-tab="pane-pcw-references">58</a>). The strongest prognostic
                                determinant is LVEF &lt;50% before a subsequent pregnancy (<a class="tab-link"
                                    href="#bib1599" data-tab="pane-pcw-references">6-8</a>). An international systematic
                                review that included 93 subsequent pregnancies with persistent LV dysfunction reported
                                48% further LVEF deterioration, 49% HF symptoms, and 16% mortality, whereas among 98
                                with recovered LV function presubsequent pregnancy, these rates were 27%, 32%, and 0%,
                                respectively (<a class="tab-link" href="#bib1598" data-tab="pane-pcw-references">5</a>).
                            </p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6810">Pregnancy is a hypercoagulable state even in the absence of cardiovascular
                                complications. In the setting of acute HF, particularly when there is LV blood stasis
                                because of severely reduced systolic function, the risk of intracardiac thrombus
                                formation is significant. The incidence of intracardiac thrombi during acute HF caused
                                by peripartum cardiomyopathy has been reported to be around 16% to 17% (<a
                                    class="tab-link" href="#bib9" data-tab="pane-pcw-references">9</a>,<a
                                    class="tab-link" href="#bib10" data-tab="pane-pcw-references">10</a>), with 9%
                                thromboembolic events in 2 separate cohorts (<a class="tab-link" href="#bib1604"
                                    data-tab="pane-pcw-references">11</a>,<a class="tab-link" href="#bib1605"
                                    data-tab="pane-pcw-references">12</a>). Women with an intracardiac thrombus or a
                                thromboembolic event receive anticoagulation as per standard of care. Women with
                                severely depressed LVEF (&lt;30%) in the setting of acute HF caused by peripartum
                                cardiomyopathy can be considered for anticoagulation, especially in the first 6 to 8
                                weeks postpartum, when hypercoagulability is most pronounced. If bromocriptine is used
                                for postpartum women with severe acute HF caused by peripartum cardiomyopathy and LVEF
                                &lt;35%, it should be accompanied by at least prophylactic-dosed anticoagulation,
                                because of the potential association with thromboembolic events (<a class="tab-link"
                                    href="#bib1599" data-tab="pane-pcw-references">6</a>). However, the efficacy and
                                safety of bromocriptine for acute peripartum cardiomyopathy treatment currently remains
                                uncertain, and further randomized placebo-controlled trials are required to define the
                                role of this therapy, particularly in the setting of contemporary HF GDMT and
                                cardiogenic shock management.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6815">In 2015, the FDA adopted the Pregnancy and Lactation Labeling Rule, which
                                retired the previous pregnancy risk categories A through X and, instead, assigned a
                                descriptive risk summary to aid medication counseling for pregnant and breastfeeding
                                women. ACEi and ARB are associated with second- and third-trimester renal and tubular
                                dysplasia, oligohydramnios, fetal growth restriction, ossification disorders of the
                                skull, lung hypoplasia, contractures, large joints, anemia, and intrauterine fetal death
                                and are, therefore, strictly contraindicated (<a class="tab-link" href="#bib1652"
                                    data-tab="pane-pcw-references">59-61</a>). There are no specific data for ARNi or
                                ivabradine. For spironolactone, there is sufficient information regarding dose-dependent
                                feminization of male rabbit and rat offspring to raise concern (<a class="tab-link"
                                    href="#bib1655" data-tab="pane-pcw-references">62</a>); data are limited for
                                eplerenone. HFrEF medications considered acceptable during pregnancy (<a
                                    class="tab-link" href="#bib1608" data-tab="pane-pcw-references">15</a>), within a
                                construct of multidisciplinary shared decision-making regarding benefits and potential
                                risks, are furosemide, beta blockers (most commonly metoprolol) (<a class="tab-link"
                                    href="#bib1656" data-tab="pane-pcw-references">63-65</a>), hydralazine, and nitrates
                                (<a class="tab-link" href="#bib1606" data-tab="pane-pcw-references">13</a>,<a
                                    class="tab-link" href="#bib1607" data-tab="pane-pcw-references">14</a>,<a
                                    class="tab-link" href="#bib1612" data-tab="pane-pcw-references">19</a>). Women with
                                peripartum cardiomyopathy were historically counseled against breastfeeding because of
                                metabolic demands and prolactin stimulation, but breastfeeding may even be associated
                                with LV recovery (<a class="tab-link" href="#bib1659"
                                    data-tab="pane-pcw-references">66-70</a>). Postpartum women who breastfeed can start
                                ACEi (enalapril or captopril preferred), and metoprolol remains the preferred beta
                                blocker (<a class="tab-link" href="#bib1659" data-tab="pane-pcw-references">66</a>,<a
                                    class="tab-link" href="#bib1664" data-tab="pane-pcw-references">71</a>). The
                                National Library of Medicine hosts LactMed ( <a target="_blank" class="references__uri"
                                    href="https://www.ncbi.nlm.nih.gov/books/NBK501922/">https://www.ncbi.nlm.nih.gov/books/NBK501922/</a>)
                                (<a class="tab-link" href="#bib1665" data-tab="pane-pcw-references">72</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acd247731e15983" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e15983">
                <div id="acsectitle0500" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0500">12 Quality Metrics and Reporting</h2>
            <div id="acsec16" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec16">
                <div id="acsectitle0505" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0505">12.1 Performance Measurement</h3>
            <div id="undtbl53" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl53">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0855">Recommendations for Performance Measurement</p>
                            <p id="tspara0860">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist0995" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p1995"><strong>Performance measures based on professionally
                                                        developed clinical practice guidelines should be used with the
                                                        goal of improving quality of care for patients with HF</strong>
                                                    (<a class="tab-link" href="#bib1670"
                                                        data-tab="pane-pcw-references">1-7</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-NR</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist1000" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p2000"><strong>Participation in quality improvement programs,
                                                        including patient registries that provide benchmark feedback on
                                                        nationally endorsed, clinical practice guideline–based quality
                                                        and performance measures can be beneficial in improving the
                                                        quality of care for patients with HF (</strong><a
                                                        class="tab-link" href="#bib1670"
                                                        data-tab="pane-pcw-references"><strong>1</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1671"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1674"
                                                        data-tab="pane-pcw-references"><strong>5</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1675"
                                                        data-tab="pane-pcw-references"><strong>6</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6830"><strong>Synopsis</strong></p>
            <p id="p6835">The ACC/AHA Task Force on Performance Measures (Task Force) distinguishes quality measures
                from performance measures. Performance measures are selected from the most important ACC/AHA clinical
                practice guideline recommendations with the strongest evidence. These measures are suitable for public
                reporting or pay for performance. Quality measures are those metrics that may be useful for local
                quality improvement but do not reach the performance measure standard. Performance measures of the
                ACC/AHA focus on process of care measures that measure the quality of care by the clinician, facility,
                and health system. Patient registries that track such measures can provide feedback to participants,
                which may help with improvement in quality.</p>
            <p id="p6840"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1425" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6845">The current ACC/AHA performance and quality measures (based on the 2013
                                ACC/AHA HF guideline and the 2017 ACC/AHA/HFSA guideline supplement) are displayed in <a
                                    class="ref showTableEvent" data-id="tbl31" href="#tbl31">Table 31</a> (<a
                                    class="tab-link" href="#bib1677" data-tab="pane-pcw-references">8</a>). The
                                performance measures are derived from the most definitive guideline recommendations
                                (i.e., NYHA class I and class III recommendations). Observational data suggest that
                                hospitals that receive feedback on their HF care improve over time (<a class="tab-link"
                                    href="#bib1670" data-tab="pane-pcw-references">1-7</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6850">Hospitals that perform well on medication-related performance measures have
                                better HF mortality rates than hospitals with poorer performance (<a class="tab-link"
                                    href="#bib1672" data-tab="pane-pcw-references">3</a>,<a class="tab-link"
                                    href="#bib1673" data-tab="pane-pcw-references">4</a>). Other observational data
                                suggest that hospitals that participate in registries have better process of care and
                                outcomes compared with hospitals that do not participate (<a class="tab-link"
                                    href="#bib1674" data-tab="pane-pcw-references">5</a>,<a class="tab-link"
                                    href="#bib1675" data-tab="pane-pcw-references">6</a>). Randomized studies of audit
                                and feedback of performance, in many different patient groups, have, in general, showed
                                improvement in care (<a class="tab-link" href="#bib1676"
                                    data-tab="pane-pcw-references">7</a>). However, public reporting of HF measures in
                                Ontario, Canada, did not clearly improve care during a randomized trial (<a
                                    class="tab-link" href="#bib1678" data-tab="pane-pcw-references">9</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="tbl31" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl31">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0345"><span class="captionLabel">Table 31</span> ACC/AHA 2020 HF Clinical
                                Performance, Quality, and Structural Measures (<a class="tab-link" href="#bib1677"
                                    data-tab="pane-pcw-references">8</a>)</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Measure No.</th>
                            <th colspan="1" rowspan="1">Measure Title</th>
                            <th colspan="1" rowspan="1">Care Setting</th>
                            <th colspan="1" rowspan="1">Attribution</th>
                            <th colspan="1" rowspan="1">Measure Domain</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-1</td>
                            <td colspan="1" rowspan="1">LVEF assessment</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Diagnostic</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-2</td>
                            <td colspan="1" rowspan="1">Symptom and activity assessment</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Monitoring</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-3</td>
                            <td colspan="1" rowspan="1">Symptom management</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Treatment</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-4</td>
                            <td colspan="1" rowspan="1">Beta-blocker therapy for HFrEF</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient<br>Inpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Treatment</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-5</td>
                            <td colspan="1" rowspan="1">ACEi, ARB, or ARNi therapy for HFrEF</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient<br>Inpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Treatment</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-6</td>
                            <td colspan="1" rowspan="1">ARNi therapy for HFrEF</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient<br>Inpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Treatment</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-7</td>
                            <td colspan="1" rowspan="1">Dose of beta blocker therapy for HFrEF</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Treatment</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-8</td>
                            <td colspan="1" rowspan="1">Dose of ACEi, ARB, or ARNi therapy for HFrEF</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Treatment</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-9</td>
                            <td colspan="1" rowspan="1">MRA therapy for HFrEF</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient<br>Inpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Treatment</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-10</td>
                            <td colspan="1" rowspan="1">Laboratory monitoring in new MRA therapy</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient<br>Inpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Monitoring</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-11</td>
                            <td colspan="1" rowspan="1">Hydralazine and isosorbide dinitrate therapy for HFrEF in those
                                patients self-identified as Black or African American</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient<br>Inpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Treatment</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-12</td>
                            <td colspan="1" rowspan="1">Counseling regarding ICD placement for patients with HFrEF on
                                GDMT</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Treatment</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">PM-13</td>
                            <td colspan="1" rowspan="1">CRT implantation for patients with HFrEF on GDMT</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Treatment</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">QM-1</td>
                            <td colspan="1" rowspan="1">Patient self-care education</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Self-care</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">QM-2</td>
                            <td colspan="1" rowspan="1">Measurement of patient-reported outcome-health status</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Monitoring</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">QM-3</td>
                            <td colspan="1" rowspan="1">Sustained or improved health status in HF</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Outcome</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">QM-4</td>
                            <td colspan="1" rowspan="1">Post-discharge appointment for patients with HF</td>
                            <td align="center" colspan="1" rowspan="1">Inpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner, facility</td>
                            <td align="center" colspan="1" rowspan="1">Treatment</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">SM-1</td>
                            <td colspan="1" rowspan="1">HF registry participation</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient<br>Inpatient</td>
                            <td colspan="1" rowspan="1">Facility</td>
                            <td align="center" colspan="1" rowspan="1">Structure</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="5" rowspan="1">Rehabilitation PMs Related to HF (From the 2018 ACC/AHA
                                performance measures for cardiac rehabilitation (<a class="tab-link" href="#bib1679"
                                    data-tab="pane-pcw-references">10</a>))</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Rehab PM-2</td>
                            <td colspan="1" rowspan="1">Exercise training referral for HF from inpatient setting</td>
                            <td align="center" colspan="1" rowspan="1">Inpatient</td>
                            <td colspan="1" rowspan="1">Facility</td>
                            <td align="center" colspan="1" rowspan="1">Process</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Rehab PM-4</td>
                            <td colspan="1" rowspan="1">Exercise training referral for HF from outpatient setting</td>
                            <td align="center" colspan="1" rowspan="1">Outpatient</td>
                            <td colspan="1" rowspan="1">Individual practitioner<br>Facility</td>
                            <td align="center" colspan="1" rowspan="1">Process</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0350">ACEi indicates angiotensin-converting enzyme inhibitor; ACC, American
                                College of Cardiology; AHA, American Heart Association; ARB, angiotensin receptor
                                blocker; ARNi, angiotensin receptor-neprilysin inhibitor; CRT, cardiac resynchronization
                                therapy; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF, heart
                                failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator;
                                LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist;
                                PM, performance measure; QM, quality measure; and SM, structural measure.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="acd247731e16395" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e16395">
                <div id="acsectitle0510" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0510">13 Goals of Care</h2>
            <div id="acsec17" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec17">
                <div id="acsectitle0515" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0515">13.1 Palliative and Supportive Care, Shared
                Decision-Making, and End-of-Life</h3>
            <div id="undtbl54" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl54">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0865">Recommendations for Palliative and Supportive Care, Shared
                                Decision-Making, and End-of-Life</p>
                            <p id="tspara0870">Referenced studies that support the recommendations are summarized in the
                                <a class="ref" href="#mmc2">Online Data Supplements</a>.</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendations</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist1005" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p2005"><strong>For all patients with HF, palliative and
                                                        supportive care—including high-quality communication, conveyance
                                                        of prognosis, clarifying goals of care, shared decision-making,
                                                        symptom management, and caregiver support—should be provided to
                                                        improve QOL and relieve suffering</strong> (<a class="tab-link"
                                                        href="#bib1680"
                                                        data-tab="pane-pcw-references">1</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>1</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist1010" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">2.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p2010"><strong>For patients with HF being considered for, or
                                                        treated with, life-extending therapies, the option for
                                                        discontinuation should be anticipated and discussed through the
                                                        continuum of care, including at the time of initiation, and
                                                        reassessed with changing medical conditions and shifting goals
                                                        of care (</strong><a class="tab-link" href="#bib1681"
                                                        data-tab="pane-pcw-references"><strong>2</strong></a><strong>,</strong><a
                                                        class="tab-link" href="#bib1682"
                                                        data-tab="pane-pcw-references"><strong>3</strong></a><strong>).</strong>
                                                </p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>B-R</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist1020" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">3.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p2020"><strong>For patients with HF—particularly stage D HF
                                                        patients being evaluated for advanced therapies, patients
                                                        requiring inotropic support or temporary mechanical support,
                                                        patients experiencing uncontrolled symptoms, major medical
                                                        decisions, or multimorbidity, frailty, and cognitive
                                                        impairment—specialist palliative care consultation can be useful
                                                        to improve QOL and relieve suffering</strong> (<a
                                                        class="tab-link" href="#bib1683"
                                                        data-tab="pane-pcw-references">4-6</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist1015" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">4.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p2015"><strong>For patients with HF, execution of advance care
                                                        directives can be useful to improve documentation of treatment
                                                        preferences, delivery of patient-centered care, and dying in
                                                        preferred place</strong> (<a class="tab-link" href="#bib1686"
                                                        data-tab="pane-pcw-references">7</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist1025" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">5.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p2025"><strong>In patients with advanced HF with expected
                                                        survival &lt;6 months, timely referral to hospice can be useful
                                                        to improve QOL</strong> (<a class="tab-link" href="#bib1687"
                                                        data-tab="pane-pcw-references">8</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6865"><strong>Synopsis</strong></p>
            <p id="p6870">Palliative care—defined as patient- and family-centered care that optimizes health-related QOL
                by anticipating, preventing, and treating suffering—should be integrated into the care of all patients
                with HF (<a class="tab-link" href="#bib1688" data-tab="pane-pcw-references">9</a>). Palliative care
                includes high-quality communication, estimation of prognosis, anticipatory guidance, addressing
                uncertainty; shared decision-making about medically reasonable treatment options; advance care planning;
                attention to physical, emotional, spiritual, and psychological distress; relief of suffering; and
                inclusion of family caregivers in patient care and attention to their needs during bereavement (<a
                    class="tab-link" href="#bib1689" data-tab="pane-pcw-references">10</a>). Other supportive needs
                include home and case management assistance, transportation, and care coordination (<a class="tab-link"
                    href="#bib1690" data-tab="pane-pcw-references">11</a>). Palliative and supportive care has a role
                across the stages of HF, starting early in the course of illness, intensifying in end-stage disease, and
                extending into caregiver bereavement (<a data-tab="pane-pcw-Figures" href="#fig15" id="fig15R"
                    class="">Figure 15</a>) (<a class="tab-link" href="#bib1691" data-tab="pane-pcw-references">12</a>).
                Many palliative care needs can and should be addressed by the patient’s interdisciplinary care team
                (primary palliative care), including clarifying their core values, health outcome goals, and therapeutic
                preferences (<a class="tab-link" href="#bib1680" data-tab="pane-pcw-references">1</a>). Specialty
                palliative care clinicians (secondary palliative care) may be consulted to collaboratively care for
                patients and their families with more challenging needs (<a class="tab-link" href="#bib1686"
                    data-tab="pane-pcw-references">7</a>). Barriers to the receipt of palliative care include reluctance
                of health care professionals to address death and dying and a propensity for patients and caregivers to
                equate palliation and hospice as hastening death (<a class="tab-link" href="#bib1692"
                    data-tab="pane-pcw-references">15</a>).</p>
            <section class="article-section__inline-figure">
                <figure id="fig15" class="article__inlineFigure figure"><img class="figure__image"
                        src="/specs/ux3/releasedAssets/images/loader.gif"
                        data-src="/cms/asset/37a35b0c-ea73-424a-9931-ed7a432c3a74/gr15.jpg"
                        data-lg-src="/cms/asset/ec3182d5-b132-4871-a2c3-3e2c74de9607/gr15.jpg" alt="Figure 15">
                    <figcaption class="figure__caption">
                        <div class="figure-link"><a
                                href="/cms/asset/ec3182d5-b132-4871-a2c3-3e2c74de9607/gr15.jpg?download"
                                class="btn figure__download__btn" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download Figure</span></a><a
                                href="/action/downloadFigures?id=fig15&amp;doi=10.1016%2Fj.jacc.2021.12.012"
                                class="btn figure__download__btn ppt-figure-link" download=""><i aria-hidden="true"
                                    class="icon-download"></i><span>Download PowerPoint</span></a></div><strong><span
                                class="captionLabel">Figure 15</span></strong>
                        <p>A Depiction of the Clinical Course of HF With Associated Types and Intensities of Available
                            Therapies Over Time (<a class="tab-link" href="#bib1691"
                                data-tab="pane-pcw-references">12</a>)</p>
                        <p>CHF indicates congestive heart failure; HF, heart failure; and MCS, mechanical circulatory
                            support. Adapted with permission of the American Thoracic Society. Copyright © 2021 American
                            Thoracic Society. All rights reserved. The American Journal of Respiratory and Critical Care
                            Medicine is an official journal of the American Thoracic Society (<a class="tab-link"
                                href="#bib1705" data-tab="pane-pcw-references">13</a>). Readers are encouraged to read
                            the entire article for the correct context at <a target="_blank" class="references__uri"
                                href="https://www.atsjournals.org/doi/abs/10.1164/rccm.200605-587ST">https://www.atsjournals.org/doi/abs/10.1164/rccm.200605-587ST</a>.
                            The authors, editors, and The American Thoracic Society are not responsible for errors or
                            omissions in adaptations. Adapted with permission from the World Health Organization (<a
                                class="tab-link" href="#bib1705" data-tab="pane-pcw-references">14</a>). Copyright ©
                            1990 World Health Organization.</p>
                    </figcaption>
                </figure>
            </section>
            <p id="p6875"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1430" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6880">Palliative and supportive approaches to the care of patients with HF is
                                inherent to their overall care and should be incorporated throughout the course of
                                illness by all health care professionals (<a class="tab-link" href="#bib1688"
                                    data-tab="pane-pcw-references">9</a>). The application of the principles embraced
                                have been shown to improve various processes of care and patient outcomes (<a
                                    class="ref showTableEvent" data-id="tbl32" href="#tbl32">Table 32</a>). Palliative
                                and supportive care discussions do not imply that a formal palliative care consultation
                                is needed for each patient but that team members should integrate palliative and
                                supportive considerations into routine care.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">2.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6885">As overall illness progresses, major decisions are increasingly made regarding
                                the initiation, continued use, and discontinuation of potentially life-sustaining
                                therapies, including intravenous inotropes, ICDs, MCS, and renal replacement therapy.
                                Dependence on, and deactivation of, potentially life-sustaining therapies should be
                                anticipated and discussed at the time of initiation and reconsidered serially with
                                changing medical realities and evolving goals of care (<a class="tab-link"
                                    href="#bib1691" data-tab="pane-pcw-references">12</a>). Patients have a right to
                                decline or withdraw care at any time, consistent with the principle of respect for
                                autonomy (<a class="tab-link" href="#bib1693" data-tab="pane-pcw-references">19</a>).
                                Failure to proactively address topics such as deactivation of ICD and LVAD therapies can
                                lead to suffering at the end of life (<a class="tab-link" href="#bib1681"
                                    data-tab="pane-pcw-references">2</a>,<a class="tab-link" href="#bib1682"
                                    data-tab="pane-pcw-references">3</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">3.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6895">Although a range of clinicians caring for patients with HF are able to manage
                                many palliative care needs, formal palliative care consultation may be particularly
                                helpful for patients with these: 1) refractory symptoms; 2) major medical decisions
                                (e.g., in the United States, inclusion of a palliative care specialist on the team is
                                mandatory for payment from Medicare for LVAD implantation); and 3) multimorbidity,
                                frailty, or cognitive impairment (multiple validated frailty and cognitive measures are
                                available). A growing body of evidence supports the inclusion of specialty palliative
                                care into the management of patients diagnosed with a range of advanced diseases (<a
                                    class="tab-link" href="#bib1696" data-tab="pane-pcw-references">20</a>), including
                                HF. An interdisciplinary palliative care intervention in patients with advanced HF
                                showed greater benefits in QOL, anxiety, depression, and spiritual well-being compared
                                with usual care alone (PAL-HF [Palliative Care in Heart Failure]) (<a class="tab-link"
                                    href="#bib1683" data-tab="pane-pcw-references">4</a>). However, other trials have
                                been mixed (<a class="tab-link" href="#bib1684" data-tab="pane-pcw-references">5</a>,<a
                                    class="tab-link" href="#bib1685" data-tab="pane-pcw-references">6</a>), and many
                                negative (<a class="tab-link" href="#bib1697" data-tab="pane-pcw-references">21-23</a>),
                                such that formal palliative care interventions should be tailored to patient and
                                caregiver wants and needs.</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">4.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6890">Advance care planning is a process that supports understanding and sharing of
                                patients’ personal values, life goals, and preferences regarding future medical care.
                                Key domains include discussing patients’ values, documenting plans for medical
                                treatments, designating a surrogate decision maker, and revisiting this process over
                                time (<a class="tab-link" href="#bib1694" data-tab="pane-pcw-references">24</a>).
                                Familiarity with local and state laws is needed relating to advance care planning,
                                decisions regarding life-sustaining treatments, and evolving treatments with legal
                                ramifications, especially when caring for vulnerable populations (<a class="tab-link"
                                    href="#bib1693" data-tab="pane-pcw-references">19</a>). Few patients with HF have
                                formally defined their care goals and designated a surrogate decision maker (<a
                                    class="tab-link" href="#bib1695" data-tab="pane-pcw-references">25</a>).</p>
                        </td>
                    </tr>
                    <tr class="li1">
                        <td valign="top">5.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6900">Hospice is a specific model of subspecialty palliative care that is offered to
                                patients with a terminal disease who are at the end of life when curative or
                                life-prolonging therapy is no longer the focus of treatment (<a class="tab-link"
                                    href="#bib1689" data-tab="pane-pcw-references">10</a>). Historically, hospice use
                                has been low among patients dying with HF and, among those engaging in hospice, the
                                duration of time in hospice was short, suggesting late referral. Low hospice referral
                                rates and high-intensity care at end of life often reflects health care professional
                                biases and limitations in models of care rather than patient values (<a class="tab-link"
                                    href="#bib1700" data-tab="pane-pcw-references">26</a>). This appears to be changing
                                in the United States, where CDC data from 2003 to 2017 on U.S. site of death show that
                                the proportion of cardiovascular deaths related to HF occurring in hospice facilities
                                rose from 0.2% to 8.2% and deaths at home rose from 20.6% to 30.7% (<a class="tab-link"
                                    href="#bib1701" data-tab="pane-pcw-references">27</a>).</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="tbl32" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl32">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0355"><span class="captionLabel">Table 32</span> Palliative and Supportive Care
                                Domains to Improve Processes of Care and Patient Outcomes</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">Palliative and Supportive Domains of Care</th>
                            <th colspan="1" rowspan="1">What Palliative Care Adds to Overall HF Management</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">High-quality communication</td>
                            <td colspan="1" rowspan="1">Central to palliative care approaches are communication and
                                patient-caregiver engagement techniques (<a class="tab-link" href="#bib1702"
                                    data-tab="pane-pcw-references">16</a>).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Conveyance of prognosis</td>
                            <td colspan="1" rowspan="1">Palliative care specifically addresses patient and caregiver
                                understanding of disease, treatment, and prognosis. Research suggests that patients tend
                                to overestimate their survival (<a class="tab-link" href="#bib1703"
                                    data-tab="pane-pcw-references">17</a>) and overestimate the potential benefits of
                                treatment (<a class="tab-link" href="#bib1704" data-tab="pane-pcw-references">18</a>).
                                Objective risk models can calibrate expectations, but discussion of uncertainty should
                                accompany prognostic conversations, often summarized as “hope for the best, plan for the
                                worst.”</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Clarifying goals of care</td>
                            <td colspan="1" rowspan="1">Management of patients with HF as their disease becomes
                                end-stage and death seems near includes decisions about when to discontinue treatments
                                designed primarily to prolong life (e.g., ICD, hospitalization, tube feeding), decisions
                                on when to initiate treatments to reduce pain and suffering that may hasten death (e.g.,
                                narcotics), and decisions about the location of death, home services, and hospice care.
                                Exploring patients’ expressed preferences, values, needs, concerns, means and desires
                                through clinician-led discussion can clarify values-treatment concordance and improve
                                medical decision-making (<a class="tab-link" href="#bib1691"
                                    data-tab="pane-pcw-references">12</a>).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Shared decision-making</td>
                            <td colspan="1" rowspan="1">Shared decision-making is a process by which patients and
                                clinicians work together to make optimal health care decisions from medically reasonable
                                options that align with what matters most to patients. Shared decision-making requires:
                                unbiased medical evidence about the risks, benefits, and burdens of each alternative,
                                including no intervention; clinician expertise in communication and tailoring that
                                evidence for individual patients; and patient goals and informed preferences (<a
                                    class="tab-link" href="#bib1691" data-tab="pane-pcw-references">12</a>).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Symptom management</td>
                            <td colspan="1" rowspan="1">Dyspnea, fatigue, pain, nausea, depression, anxiety, and other
                                symptoms of HF refractory to cardiovascular therapies can be partially remediated
                                through palliative and supportive approaches in addition to GDMT (<a class="tab-link"
                                    href="#bib1684" data-tab="pane-pcw-references">5</a>).</td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">Caregiver support</td>
                            <td colspan="1" rowspan="1">Care of the patient with heart failure should extend to their
                                loved ones, including beyond their death, to offer support to families and help them
                                cope with loss.</td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0360">GDMT indicates guideline-directed medical therapy; HF, heart failure; and
                                ICD, implantable cardioverter-defibrillator.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="acd247731e16696" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e16696">
                <div id="acsectitle0520" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0520">14 Recommendation for Patient-Reported
                Outcomes and Evidence Gaps and Future Research Directions</h2>
            <div id="acsec18" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec18">
                <div id="acsectitle0525" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0525">14.1 Patient-Reported Outcomes</h3>
            <div id="undtbl55" class="anchor-spacer"></div>
            <div class="article-table-content" id="undtbl55">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0875">Recommendation for Patient-Reported Outcomes</p>
                        </strong></caption>
                    <thead>
                        <tr valign="top">
                            <th colspan="1" rowspan="1">COR</th>
                            <th colspan="1" rowspan="1">LOE</th>
                            <th colspan="1" rowspan="1">Recommendation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>2a</strong></td>
                            <td colspan="1" rowspan="1"><strong>C-LD</strong></td>
                            <td colspan="1" rowspan="1">
                                <table class="listgroup" border="0" width="95%" id="olist1030" list-type="simple">
                                    <tbody>
                                        <tr class="li1">
                                            <td valign="top">1.</td>
                                            <td colspan="5" valign="top" class="paragraph">
                                                <p id="p2030"><strong>In patients with HF, standardized assessment of
                                                        patient-reported health status using a validated questionnaire
                                                        can be useful to provide incremental information for patient
                                                        functional status, symptom burden, and prognosis</strong> (<a
                                                        class="tab-link" href="#bib1706"
                                                        data-tab="pane-pcw-references">1-19</a>)<strong>.</strong></p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <p id="p6920"><strong>Synopsis</strong></p>
            <p id="p6925">Health status encapsulates symptoms, functional status, and health-related QOL. Understanding
                health status is important for treatment decisions and counseling. Clinicians traditionally evaluate
                health status based on the clinical interview and exam, summarizing it as the NYHA functional
                classification. Additionally, patient-reported health status can be ascertained using standardized
                questionnaires, such as the Kansas City Cardiomyopathy Questionnaire or the Minnesota Living with Heart
                Failure Questionnaire. Previous studies found discordance between patient-reported health status and
                clinician assessment using NYHA classification (<a class="tab-link" href="#bib1725"
                    data-tab="pane-pcw-references">20</a>,<a class="tab-link" href="#bib1726"
                    data-tab="pane-pcw-references">21</a>). Patient-reported health status may have higher reliability
                and better sensitivity for clinical changes than NYHA classification and is moderately correlated with
                CPET and the 6-minute walk test (<a class="tab-link" href="#bib1706"
                    data-tab="pane-pcw-references">1-8</a>). Patient-reported health status is an independent predictor
                of hospitalization and mortality (<a class="tab-link" href="#bib1714"
                    data-tab="pane-pcw-references">9-19</a>). There are minimal data regarding the effect of
                incorporating patient-reported health status assessment into routine care. However, these assessments
                provide valuable incremental information beyond the standard evaluation. Increasing the patient’s voice
                in clinical assessment and decision-making is important in its own right. Additionally, there is
                substantial variation in risk-adjusted health status across practices (<a class="tab-link"
                    href="#bib1727" data-tab="pane-pcw-references">22</a>). Future efforts should focus on expanding the
                use of patient-reported health status in routine care while researching its implementation and impact.
            </p>
            <p id="p6930"><strong>Recommendation-Specific Supportive Text</strong></p>
            <table class="listgroup" border="0" width="95%" id="olist1435" list-type="simple">
                <tbody>
                    <tr class="li1">
                        <td valign="top">1.</td>
                        <td colspan="5" valign="top" class="paragraph">
                            <p id="p6935">Standardized patient-reported health status questionnaires provide reliable
                                measures of health status correlated to other functional status measures (<a
                                    class="tab-link" href="#bib1706" data-tab="pane-pcw-references">1-8</a>) and
                                independently associated with clinical outcomes (<a class="tab-link" href="#bib1714"
                                    data-tab="pane-pcw-references">9-19</a>). HF-specific health status assessments
                                (e.g., Kansas City Cardiomyopathy Questionnaire, Minnesota Living with Heart Failure
                                Questionnaire, PROMIS-Plus-HF [Patient-Reported Outcomes Measurement Information
                                System-Plus-Heart Failure]) are preferable because they are more sensitive to changes in
                                disease status and more responsive to HF therapy than generic health status measures (<a
                                    class="tab-link" href="#bib1706" data-tab="pane-pcw-references">1</a>). Although
                                select clinics have successfully implemented patient-reported health status in clinical
                                practice (<a class="tab-link" href="#bib1728" data-tab="pane-pcw-references">23</a>),
                                there are minimal data regarding the impact of such efforts. However, there are
                                potential advantages to routine assessment. First, better understanding of symptom
                                burden and prognosis may improve the quality of treatment decisions and, subsequently,
                                QOL. Health status can be improved via guideline-recommended therapies (<a
                                    class="tab-link" href="#bib1729" data-tab="pane-pcw-references">24-31</a>). Although
                                some therapies are recommended for mortality benefit, symptom assessment can identify
                                patients needing additional interventions (e.g., diuretic escalation). Second, routine
                                assessment can facilitate population health management by identifying high-risk patients
                                needing closer monitoring or referral to specialized centers. Third, patient-reported
                                health status assessment increases the patient’s role, which can motivate initiation and
                                uptitration of medical therapy. However, routine assessment of patient-reported status
                                increases the burden of data collection for patients and health systems and underscores
                                the need for future studies evaluating the impact of assessment.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p></p>
            <div id="acsec18" class="anchor-spacer"></div>
            <h2 class="article-section__title section__title" id="sec18">
                <div id="acsectitle0530" class="anchor-spacer"></div>
            </h2>
            <h3 class="article-section__subtitle" id="sectitle0530">14.2 Evidence Gaps and Future Research Directions
            </h3>
            <p id="p6940">Significant gaps exist despite evolving evidence and treatment strategies in patients with HF.
                <a class="ref showTableEvent" data-id="tbl33" href="#tbl33">Table 33</a> provides selected, common
                issues that should be addressed in future clinical research.</p>
            <div id="tbl33" class="anchor-spacer"></div>
            <div class="article-table-content" id="tbl33">
                <table class="table article-section__table">
                    <caption><strong>
                            <p id="tspara0365"><span class="captionLabel">Table 33</span> Evidence Gaps and Future
                                Research Directions</p>
                        </strong></caption>
                    <tbody>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Definition</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0375">
                                    <li id="u0645">
                                        <p class="inline"> Consensus on specific classifications of HFrEF, HFpEF,
                                            HFmrEF, and HFimpEF or whether a 2-category definition of HFrEF and HF with
                                            normal EF, or an additional category of HFimpEF is needed separately for
                                            HFpEF; and whether these approaches can be uniformly applied to clinical
                                            trials and practice.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0380">
                                    <li id="u0650">
                                        <p class="inline"> Definitions, detection, and management of myocarditis and
                                            myocardial injury, especially in the context of rapidly evolving concepts,
                                            such as COVID-19 infection and cardiotoxicity.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0385">
                                    <li id="u0655">
                                        <p class="inline"> Definition and classification of cardiomyopathies.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Screening</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0390">
                                    <li id="u0660">
                                        <p class="inline"> Cost-effectiveness of different strategies to screen for HF.
                                        </p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0395">
                                    <li id="u0665">
                                        <p class="inline"> Prediction of higher risk for HF among patients with
                                            traditional risk factors (e.g., which patients with diabetes would be at a
                                            higher risk HF, warranting preventive treatment for HF).</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Diagnostics and Monitoring</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0400">
                                    <li id="u0670">
                                        <p class="inline"> Individualized treatment targeting specific causes.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0405">
                                    <li id="u0675">
                                        <p class="inline"> Advanced role of precision medicine with incorporation of
                                            genetic, personalized, and individualized factors in medical management of
                                            HF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0410">
                                    <li id="u0680">
                                        <p class="inline"> High-value methods to use biomarkers in the optimization of
                                            medical therapy.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0415">
                                    <li id="u0685">
                                        <p class="inline"> Ability to use integrated systems biology models, including
                                            biomarkers, molecular markers, omics, diagnostic modalities, and genetic
                                            variables for diagnosis, prognosis, and targeting therapies.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0420">
                                    <li id="u0690">
                                        <p class="inline"> Ability to monitor and adjust therapy to individual changes
                                            over time.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Nonmedical Strategies</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0425">
                                    <li id="u0695">
                                        <p class="inline"> Efficacy and safety of specific dietary interventions, sodium
                                            restriction, and fluid restriction to prevent and treat HF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0430">
                                    <li id="u0700">
                                        <p class="inline"> Efficacy and safety of cardiac rehabilitation in patients
                                            with HFpEF and HFmrEF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Medical Therapies</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0435">
                                    <li id="u0705">
                                        <p class="inline"> Effective management strategies for patients with HFpEF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0440">
                                    <li id="u0710">
                                        <p class="inline"> Evidence for specific treatment strategies for HFmrEF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0445">
                                    <li id="u0715">
                                        <p class="inline"> Research on causes and targeted therapies for
                                            cardiomyopathies such as peripartum cardiomyopathy.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0450">
                                    <li id="u0720">
                                        <p class="inline"> Treatment of asymptomatic LV dysfunction to prevent
                                            transition to symptomatic HF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0455">
                                    <li id="u0725">
                                        <p class="inline"> Therapies targeting different phenotypes of HF; patients with
                                            advanced HF, persistent congestion, patients with profiles excluded from
                                            clinical trials such as those with advanced kidney failure or hypotension.
                                        </p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0460">
                                    <li id="u0730">
                                        <p class="inline"> Studies on targets for optimal decongestion; treatment and
                                            prevention of cardiorenal syndrome and diuretic resistance.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0465">
                                    <li id="u0735">
                                        <p class="inline"> Diagnostic and management strategies of RV failure.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0470">
                                    <li id="u0740">
                                        <p class="inline"> Efficacy and safety of hydralazine isosorbide in non–African
                                            American patients with HF and also in African American patients on GDMT
                                            including SGLT2i and ARNi.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0475">
                                    <li id="u0745">
                                        <p class="inline"> Efficacy and safety of vericiguat in patients with HFrEF and
                                            markedly elevated natriuretic peptide levels.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0480">
                                    <li id="u0750">
                                        <p class="inline"> Efficacy and safety of omecamtiv mecarbil in patients with
                                            stage D (advanced HF) HFrEF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0485">
                                    <li id="u0755">
                                        <p class="inline"> Additional efficacy and safety of SGLT2i therapies in
                                            patients with HFpEF or patients with HFmrEF, efficacy and safety of combined
                                            SGLT2i and SGLT1i in HFrEF, HFmrEF, or HFpEF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0490">
                                    <li id="u0760">
                                        <p class="inline"> Additional efficacy and safety of SGLT2i studies in
                                            hospitalized patients with acute decompensated HF with and without diabetes.
                                        </p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0495">
                                    <li id="u0765">
                                        <p class="inline"> Efficacy and safety of nonsteroidal, selective MRA in
                                            patients with HF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0500">
                                    <li id="u0770">
                                        <p class="inline"> Efficacy and safety of ARNi in pre-HF stage (stage B).</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0505">
                                    <li id="u0775">
                                        <p class="inline"> Effective management strategies for combined post- and
                                            precapillary pulmonary hypertension.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0510">
                                    <li id="u0780">
                                        <p class="inline"> Novel treatments for ATTR cardiomyopathy.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0515">
                                    <li id="u0785">
                                        <p class="inline"> Treatment strategies targeting downstream processes such as
                                            fibrosis, cardiac metabolism or contractile performance in dilated
                                            cardiomyopathies and HFpEF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0520">
                                    <li id="u0790">
                                        <p class="inline"> Comparative effectiveness and safety of different initiation
                                            and titration of GDMT at the same time or in different sequences, optimal
                                            strategies for sequencing and titration of therapies for HFrEF and HFpEF.
                                        </p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0525">
                                    <li id="u0795">
                                        <p class="inline"> Studies on prediction of patient response; studies on how to
                                            incorporate patient preferences.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0530">
                                    <li id="u0800">
                                        <p class="inline"> Efficacy and safety of optimal BP target in patients with
                                            established HF and hypertension.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0535">
                                    <li id="u0805">
                                        <p class="inline"> Optimal BP target while optimizing GDMT in patients with
                                            HFrEF and HFpEF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0540">
                                    <li id="u0810">
                                        <p class="inline"> Appropriate management of electrolyte abnormalities in HF
                                            (e.g., hyperkalemia or hypokalemia).</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0545">
                                    <li id="u0815">
                                        <p class="inline"> Role of potassium binders in optimization of GDMT and
                                            clinical outcomes in patients with HF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0550">
                                    <li id="u0820">
                                        <p class="inline"> Efficacy and safety of pirfenidone and other targeted
                                            treatment strategies for maladaptive fibrosis in patients with HFpEF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0555">
                                    <li id="u0825">
                                        <p class="inline"> AF risk in patients treated with PUFA for patients at risk
                                            for HF or with HF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Device Management and Advanced Therapies</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0560">
                                    <li id="u0830">
                                        <p class="inline"> Optimal and timely selection of candidates for percutaneous
                                            interventions, MCS, or cardiac transplantation.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0565">
                                    <li id="u0835">
                                        <p class="inline"> Interventional approaches to recurrent, life-threatening
                                            ventricular tachyarrhythmias.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0570">
                                    <li id="u0840">
                                        <p class="inline"> Comparative effectiveness of His-bundle pacing or multisite
                                            pacing to prevent progression of HF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0575">
                                    <li id="u0845">
                                        <p class="inline"> Safety and efficacy of cardiac contractility modulation,
                                            vagal nerve stimulation, autonomic modulation, and renal denervation in
                                            patients with HF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0580">
                                    <li id="u0850">
                                        <p class="inline"> Safety and efficacy of splanchnic nerve ablation splanchnic
                                            nerve ablation to reduce splanchnic vasoconstriction and volume
                                            redistribution in HF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0585">
                                    <li id="u0855">
                                        <p class="inline"> Safety and efficacy of interatrial shunt, pericardiectomy,
                                            baroreceptor and neuromodulation, and renal denervation in HFpEF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0590">
                                    <li id="u0860">
                                        <p class="inline"> Safety and efficacy of percutaneous or surgical interventions
                                            for tricuspid regurgitation.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Clinical Outcomes</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0595">
                                    <li id="u0865">
                                        <p class="inline"> Impact of therapies in patient-reported outcomes, including
                                            symptoms and QOL.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0600">
                                    <li id="u0870">
                                        <p class="inline"> Studies addressing patient goals about care and care
                                            intensity as it intersects with disease trajectory.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0605">
                                    <li id="u0875">
                                        <p class="inline"> Real-world evidence data to characterize generalization of
                                            therapies in HF populations who may not have been represented in trials.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Systems of Care and Social Determinants of
                                    Health</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0610">
                                    <li id="u0880">
                                        <p class="inline"> Implementation studies on how to develop a structured
                                            approach to patient participation in informed decision-making and goal
                                            setting through the continuum of HF care.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0615">
                                    <li id="u0885">
                                        <p class="inline"> Implementation science for adoption and optimization of GDMT
                                            by clinicians on how to initiate multiple or sequenced GDMT, how to
                                            integrate these into learning health systems and networks, and how to
                                            increase patient education and adherence.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0620">
                                    <li id="u0890">
                                        <p class="inline"> Pragmatic studies on multidisciplinary new care models (e.g.,
                                            cardiac teams for structural and valve management, shock teams,
                                            cardiometabolic clinics, telemedicine, digital health, cardiac
                                            rehabilitation at home or postdischarge, and palliative care).</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0625">
                                    <li id="u0895">
                                        <p class="inline"> Studies on strategies to eliminate structural racism,
                                            disparities, and health inequities in HF care.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0630">
                                    <li id="u0900">
                                        <p class="inline"> Studies addressing evidence gaps in women, racial, and ethnic
                                            populations.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0635">
                                    <li id="u0905">
                                        <p class="inline"> Management strategies for palliative care.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0640">
                                    <li id="u0910">
                                        <p class="inline"> Identification of factors that lead to unwarranted variations
                                            in HF care.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0645">
                                    <li id="u0915">
                                        <p class="inline"> Identify characteristics of systems of care (e.g.,
                                            disciplines and staffing, electronic health records, and models of care)
                                            that optimize GDMT before and after the discharge of hospitalized patients.
                                        </p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Comorbidities</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0650">
                                    <li id="u0920">
                                        <p class="inline"> Further studies on rhythm control versus ablation in AF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0655">
                                    <li id="u0925">
                                        <p class="inline"> Appropriate patient selection in evolving percutaneous
                                            approaches in VHD (e.g., timing and appropriate patient selection for TAVI,
                                            Mitraclip, tricuspid valve interventions).</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0660">
                                    <li id="u0930">
                                        <p class="inline"> Effective and safe treatment options in CKD, sleep-disordered
                                            breathing, chronic lung disease, diabetes, depression, cognitive disorders,
                                            and iron deficiency.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0665">
                                    <li id="u0935">
                                        <p class="inline"> Efficacy and safety of transvenous stimulation of the phrenic
                                            nerve or role of nocturnal supplemental oxygen for treatment of central
                                            sleep apnea in patients with HF.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0670">
                                    <li id="u0940">
                                        <p class="inline"> Efficacy and safety of weight loss management and treatment
                                            strategies in patients with HF and obesity.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0675">
                                    <li id="u0945">
                                        <p class="inline"> Efficacy and safety of nutritional and food supplementation
                                            in patients with HF and frailty and malnutrition.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0680">
                                    <li id="u0950">
                                        <p class="inline"> Efficacy and safety of GDMT in end-stage renal disease or in
                                            patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup>.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1"><strong>Future/Novel Strategies</strong></td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0685">
                                    <li id="u0955">
                                        <p class="inline"> Pharmacological therapies targeting novel pathways and
                                            endophenotypes.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0690">
                                    <li id="u0960">
                                        <p class="inline"> New device therapies, including percutaneous and durable
                                            mechanical support devices.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0695">
                                    <li id="u0965">
                                        <p class="inline"> Invasive (e.g., pulmonary artery pressure monitoring
                                            catheter) or noninvasive remote monitoring.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0700">
                                    <li id="u0970">
                                        <p class="inline"> Studies on telehealth, digital health, apps, wearables
                                            technology, and artificial intelligence.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0705">
                                    <li id="u0975">
                                        <p class="inline"> Role of enrichment trials, adaptive trials, umbrella trials,
                                            basket trials, and machine learning–based trials.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0710">
                                    <li id="u0980">
                                        <p class="inline"> Therapies targeting multiple cardiovascular, cardiometabolic,
                                            renovascular, and pathobiological mechanisms.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                        <tr valign="top">
                            <td colspan="1" rowspan="1">
                                <ul class="NLM_list-list_type-simple" style="list-style-type:none" id="ulist0715">
                                    <li id="u0985">
                                        <p class="inline"> Novel dissemination and implementation techniques to identify
                                            patients with HF (e.g., natural language processing of electronic health
                                            records and automated analysis of cardiac imaging data) and to test and
                                            monitor proven interventions.</p>
                                    </li>
                                </ul>
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="tableFooter">
                    <div class="fn-group">
                        <fn>
                            <p id="tspara0370">AF indicates atrial fibrillation; ARNi, angiotensin receptor-neprilysin
                                inhibitor; ATTR, transthyretin amyloidosis; BP, blood pressure; CKD, chronic kidney
                                disease; COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate;
                                GDMT, guideline-directed medical therapy; HF, heart failure; HFimpEF, heart failure with
                                improved ejection fraction; HFmrEF, heart failure with mildly reduced ejection fraction;
                                HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced
                                ejection fraction; LV, left ventricular; MCS, mechanical circulatory support; MRA,
                                mineralocorticoid receptor antagonist; PUFA, polyunsaturated fatty acid; QOL, quality of
                                life; RV, right ventricular; SGLT1i, sodium-glucose cotransporter-1 inhibitors; SGLT2i,
                                sodium-glucose cotransporter-2 inhibitors; TAVI, transcatheter aortic valve
                                implantation; and VHD, valvular heart disease.</p>
                        </fn>
                    </div>
                </div>
            </div>
            <div id="acd247731e17250" class="anchor-spacer"></div>
            <h1 class="article-section__title section__title" id="d247731e17250">
                <div id="acsectitle0535" class="anchor-spacer"></div>
            </h1>
            <h2 class="article-section__title section__title" id="sectitle0535">Presidents and Staff</h2>
            <p id="p6950"><strong><i>American College of Cardiology</i></strong></p>
            <p id="p6955">Dipti N. Itchhaporia, MD, FACC, President</p>
            <p id="p6960">Cathleen C. Gates, Chief Executive Officer</p>
            <p id="p6965">MaryAnne Elma, MPH, Senior Director, Enterprise Content and Digital Strategy</p>
            <p id="p6970">Grace D. Ronan, Team Leader, Clinical Policy Publications</p>
            <p id="p6975">Timothy W. Schutt, MA, Clinical Practice Guidelines Analyst</p>
            <p id="p6980"><strong><i>American College of Cardiology/American Heart Association</i></strong></p>
            <p id="p6985">Thomas S.D. Getchius, Director, Guideline Strategy and Operations</p>
            <p id="p6990">Abdul R. Abdullah, MD, Director, Guideline Science and Methodology</p>
            <p id="p6995"><strong><i>American Heart Association</i></strong></p>
            <p id="p7000">Donald M. Lloyd-Jones, MD, ScM, FAHA, President</p>
            <p id="p7005">Nancy Brown, Chief Executive Officer</p>
            <p id="p7010">Mariell Jessup, MD, FAHA, Chief Science and Medical Officer</p>
            <p id="p7015">Radhika Rajgopal Singh, PhD, Senior Vice President, Office of Science and Medicine</p>
            <p id="p7020">Paul St. Laurent, DNP, RN, Senior Science and Medicine Advisor, Office of Science, Medicine
                and Health</p>
            <p id="p7025">Jody Hundley, Production and Operations Manager, Scientific Publications, Office of Science
                Operations</p>
            <div class="NLM_app-group">
                <div class="NLM_app" id="appsec1">
                    <div id="acsectitle0540" class="anchor-spacer"></div>
                    <h2 class="article-section__title section__title" id="sectitle0540">Appendix</h2><a
                        href="/doi/suppl/10.1016/j.jacc.2021.12.012/suppl_file/mmc1.pdf" target="_blank" id="mmc1">HFGL
                        Supplemental Appendix</a><a href="/doi/suppl/10.1016/j.jacc.2021.12.012/suppl_file/mmc2.pdf"
                        target="_blank" id="mmc2">HFGL Online Data Supplement</a>
                </div>
                <div class="NLM_app" id="appsec2">Appendix 1<div id="acsectitle0545" class="anchor-spacer"></div>
                    <h2 class="article-section__title section__title" id="sectitle0545">Author Relationships With
                        Industry and Other Entities (Relevant)—2022 AHA/ACC/HFSA Guideline for the Management of Heart
                        Failure</h2>
                    <div id="undtbl56" class="anchor-spacer"></div>
                    <div class="article-table-content" id="undtbl56">
                        <table class="table article-section__table">
                            <thead>
                                <tr valign="top">
                                    <th colspan="1" rowspan="1">Committee Member</th>
                                    <th colspan="1" rowspan="1">Employment</th>
                                    <th colspan="1" rowspan="1">Consultant</th>
                                    <th colspan="1" rowspan="1">Speakers Bureau</th>
                                    <th colspan="1" rowspan="1">Ownership/ Partnership/ Principal</th>
                                    <th colspan="1" rowspan="1">Personal Research</th>
                                    <th colspan="1" rowspan="1">Institutional, Organizational, or Other Financial
                                        Benefit</th>
                                    <th colspan="1" rowspan="1">Expert Witness</th>
                                    <th colspan="1" rowspan="1">Salary</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Paul A. Heidenreich <i>(Chair)</i></td>
                                    <td align="center" colspan="1" rowspan="1">Stanford University School of
                                        Medicine—Professor and Vice-Chair for Quality, Department of Medicine</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Biykem Bozkurt <i>(Vice Chair)</i></td>
                                    <td align="center" colspan="1" rowspan="1">Baylor College of Medicine and DeBakey VA
                                        Medical Center Cardiology Department—Mary and Gordon Cain Chair; W.A. “Tex” and
                                        Deborah Moncrief, Jr., Chair; Professor of Medicine Medical Care Line Executive,
                                        DeBakey VA Medical Center; Director, Winters Center for Heart Failure Research;
                                        Associate Director, Cardiovascular Research Institute; Vice-Chair of Medicine,
                                        Baylor College of Medicine</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0720"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2035">Abbott<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2040">Amgen</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2045">Baxter</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2050">Bristol-Myers Squibb<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2055">E.R. Squibb &amp; Sons, L.L.C.<a
                                                                class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2060">Relypsa</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2065">Sanofi-aventis<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2070">scPharmaceuticals</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2075">Vifor</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0725"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2080">Abbott<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2085">Amgen</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2090">Relypsa</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2095">Respicardia</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2100">Sanofi-Aventis<a class="ref table-fn"
                                                                id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2105">Past President, HFSA (2019-2020)</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">David Aguilar</td>
                                    <td align="center" colspan="1" rowspan="1">University of Kentucky—Professor of
                                        Medicine, Department of Medicine, Division of Cardiovascular Medicine</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Larry A. Allen</td>
                                    <td align="center" colspan="1" rowspan="1">University of Colorado School of
                                        Medicine, Anschutz Medical Campus—Professor of Medicine, Department of Medicine,
                                        Division of Cardiology</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0730"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2110">Abbott</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2115">ACI Clinical<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2120">Amgen<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2125">Boston Scientific<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2130">Cytokinetics</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2135">Novartis</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0735"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2140">Abbott<a class="ref table-fn" id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2145">Amgen</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2150">Boston Scientific<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                            <a class="ref table-fn" id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2155">Janssen Pharmaceuticals</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2160">Medtronic Vascular Inc.</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2165">Novartis<a class="ref table-fn"
                                                                id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Joni J. Byun</td>
                                    <td align="center" colspan="1" rowspan="1">Penultimate PR—President</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Monica M. Colvin</td>
                                    <td align="center" colspan="1" rowspan="1">University of Michigan—Professor of
                                        Medicine, Department of Medicine, Cardiovascular Division;<br>Associate
                                        Director, Heart Transplant Program, Advanced Heart Failure, Transplant, and MCS
                                        Natera</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0740"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2170">CareDX</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0745"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2175">Abbott<a class="ref table-fn" id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Anita Deswal</td>
                                    <td align="center" colspan="1" rowspan="1">UT MD Anderson Cancer Center—Ting Tsung
                                        and Wei Fong Chao Distinguished Chair,<br>Professor of Medicine, and Chair of
                                        Cardiology</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Mark H. Drazner</td>
                                    <td align="center" colspan="1" rowspan="1">UT Southwestern Medical Center—Professor
                                        and Clinical Chief of Cardiology, Department of Internal Medicine, Cardiology
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Shannon M. Dunlay</td>
                                    <td align="center" colspan="1" rowspan="1">Mayo Clinic—Professor of Health Services
                                        Research and Medicine, Department of Cardiovascular Medicine</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Linda R. Evers</td>
                                    <td align="center" colspan="1" rowspan="1">Stevens &amp; Lee—Shareholder and Chair
                                        of Stevens &amp; Lee’s Energy, Communications and Public Utility Group</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">James C. Fang</td>
                                    <td align="center" colspan="1" rowspan="1">University of Utah—Professor of Medicine,
                                        Division of Cardiovascular Medicine</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0750"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2180">Boston Scientific<a class="ref table-fn"
                                                                id="dtbl5fndagger"
                                                                href="javascript:popRef('dtbl5fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0755"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2185">ACI Clinical (Adjudication Committee)<a
                                                                class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2190">Amgen (Steering Committee)</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2195">AstraZeneca (Steering Committee)</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2200">Boston Scientific<a class="ref table-fn"
                                                                id="dtbl5fndagger"
                                                                href="javascript:popRef('dtbl5fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2205">Novartis (Executive Committee)</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Savitri E. Fedson</td>
                                    <td align="center" colspan="1" rowspan="1">Michael E. DeBakey Medical
                                        Center—Professor, Medical Director, Advanced Heart Failure and Transplantation,
                                        Section of Cardiology</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Gregg C. Fonarow</td>
                                    <td align="center" colspan="1" rowspan="1">Geffen School of Medicine at
                                        UCLA—Professor of Cardiovascular Medicine, Chief, UCLA Division of Cardiology,
                                        Department of Medicine</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0760"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2210">Abbott<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2215">Amgen</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2220">AstraZeneca</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2225">CHF Solutions</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2230">Cytokinetics</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2235">Edwards Lifesciences<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2240">Janssen Pharmaceuticals</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2245">Medtronic</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2250">Merck<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2255">Novartis<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2260">Regeneron</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0765"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2265">Boston Scientific</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2270">Novartis<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2275">Medtronic</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Salim S. Hayek</td>
                                    <td align="center" colspan="1" rowspan="1">University of Michigan in Ann
                                        Arbor—Assistant Professor, Department of Medicine, Division of Cardiology</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Adrian F. Hernandez</td>
                                    <td align="center" colspan="1" rowspan="1">Duke University School of Medicine—Vice
                                        Dean of Clinical Research</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0770"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2280">Amgen</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2285">AstraZeneca</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2290">Bayer</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2295">BioFourmis</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2300">Boehringer Ingelheim<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2305">Boston Scientific<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2310">Cytokinetics</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2315">Eli Lilly</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2320">Merck<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2325">Myokardia</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2330">Novartis<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2335">Pfizer</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2340">Relypsa</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2345">Sanofi-aventis<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0775"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2350">American Regent</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2355">Amgen</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2360">Boston Scientific</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2365">AstraZeneca<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2370">Boehringer Ingelheim</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2375">Daiichi Sankyo</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2380">Genentech</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2385">GlaxoSmithKline<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2390">Janssen Pharmaceuticals<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2395">Merck<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2400">Novartis<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2405">Verily<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Prateeti Khazanie</td>
                                    <td align="center" colspan="1" rowspan="1">University of Colorado—Assistant
                                        Professor of Medicine, Department of Medicine, Division of Cardiology</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Michelle M. Kittleson</td>
                                    <td align="center" colspan="1" rowspan="1">Smidt Heart Institute
                                        Cedars-Sinai—Professor of Medicine, Cardiology</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Christopher S. Lee</td>
                                    <td align="center" colspan="1" rowspan="1">Boston College, William F. Connell School
                                        of Nursing—Professor and Associate Dean for Research</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Mark S. Link</td>
                                    <td align="center" colspan="1" rowspan="1">UT Southwestern Medical Center,
                                        Dallas—Professor of Medicine and Director, Cardiac Electrophysiology; Laurence
                                        and Susan Hirsch/Centex Distinguished Chair in Heart Disease, Department of
                                        Internal Medicine, Division of Cardiology</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Carmelo A. Milano</td>
                                    <td align="center" colspan="1" rowspan="1">Duke University Medical Center—Professor
                                        of Surgery, Surgery Department</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0780"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2410">Abbott<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0785"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2415">Abbott<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2420">Medtronic<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2425">NuPulse<a class="ref table-fn" id="dtbl5fndagger"
                                                                href="javascript:popRef('dtbl5fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0790"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2430">Abbott<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2435">AbioMed<a class="ref table-fn" id="dtbl5fndagger"
                                                                href="javascript:popRef('dtbl5fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2440">Allergan<a class="ref table-fn" id="dtbl5fndagger"
                                                                href="javascript:popRef('dtbl5fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2445">CryoLife<a class="ref table-fn" id="dtbl5fndagger"
                                                                href="javascript:popRef('dtbl5fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2450">Ethicon<a class="ref table-fn" id="dtbl5fndagger"
                                                                href="javascript:popRef('dtbl5fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2455">LivaNova<a class="ref table-fn" id="dtbl5fndagger"
                                                                href="javascript:popRef('dtbl5fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Lorraine C. Nnacheta<a class="ref table-fn"
                                            id="dtbl5fnsect" href="javascript:popRef('dtbl5fnsect')"><sup>§</sup></a>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">American Heart Association/American
                                        College of Cardiology—Guideline Advisor</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0795"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2460">AHA/ACC salaried employee</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Alexander T. Sandhu</td>
                                    <td align="center" colspan="1" rowspan="1">Stanford University—Instructor of
                                        Medicine, Division of Cardiology, Department of Medicine</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Lynne Warner Stevenson</td>
                                    <td align="center" colspan="1" rowspan="1">Vanderbilt University Medical Center,
                                        Vanderbilt Heart and Vascular Institute—Director of Cardiomyopathy and Lisa M.
                                        Jacobson Professor of Cardiovascular Medicine</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0800"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2465">Novartis</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0805"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2470">Abbott<a class="ref table-fn" id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2475">Biotronik</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2480">Boston Scientific</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2485">Bristol-Myers Squibb<a class="ref table-fn"
                                                                id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2490">Endotronic<a class="ref table-fn"
                                                                id="dtbl5fndagger"
                                                                href="javascript:popRef('dtbl5fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2495">Gore Medical<a class="ref table-fn"
                                                                id="dtbl5fndagger"
                                                                href="javascript:popRef('dtbl5fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2500">Johnson &amp; Johnson</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Orly Vardeny</td>
                                    <td align="center" colspan="1" rowspan="1">Minneapolis VA Health Care System and
                                        University of Minnesota—Associate Professor of Medicine, Department of Medicine
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0810"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2505">Amgen</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2510">Novartis</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2515">Sanofi-Pasteur</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0815"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2520">AstraZeneca<a class="ref table-fn"
                                                                id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2525">Bayer<a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0820"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2530">AstraZeneca<a class="ref table-fn"
                                                                id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Amanda R. Vest</td>
                                    <td align="center" colspan="1" rowspan="1">Tufts Medical Center, Cardiovascular
                                        Center—Assistant Professor of Medicine</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0825"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2535">Boehringer Ingelheim<a class="ref table-fn"
                                                                id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                            <a class="ref table-fn" id="dtbl5fnlowast"
                                                                href="javascript:popRef('dtbl5fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2540">CareDx<a class="ref table-fn" id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2545">Corvia<a class="ref table-fn" id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2550">Transmedics<a class="ref table-fn"
                                                                id="dtbl5fnddagger"
                                                                href="javascript:popRef('dtbl5fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Clyde W. Yancy</td>
                                    <td align="center" colspan="1" rowspan="1">Northwestern University, Feinberg School
                                        of Medicine; Northwestern Memorial Hospital—Professor of Medicine (Cardiology);
                                        Professor of Medical Social Sciences; Chief of Cardiology; Vice-Dean, Diversity
                                        &amp; Inclusion; Associate Director Cardiovascular Institute Internal
                                        Medicine/Cardiology &amp; Medical Social Sciences</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0830"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2555">Abbott<a class="ref table-fn" id="dtbl5fndagger"
                                                                href="javascript:popRef('dtbl5fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2560"><i>JAMA Cardiology</i>, Deputy Editor</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                            </tbody>
                        </table>
                        <div class="tableFooter">
                            <div class="fn-group">
                                <fn>
                                    <p id="tspara0880">This table represents the relationships of committee members with
                                        industry and other entities that were determined to be relevant to this
                                        document. These relationships were reviewed and updated in conjunction with all
                                        meetings and/or conference calls of the writing committee during the document
                                        development process. The table does not necessarily reflect relationships with
                                        industry at the time of publication. A person is deemed to have a significant
                                        interest in a business if the interest represents ownership of ≥5% of the voting
                                        stock or share of the business entity, or ownership of ≥$5000 of the fair market
                                        value of the business entity; or if funds received by the person from the
                                        business entity exceed 5% of the person’s gross income for the previous year.
                                        Relationships that exist with no financial benefit are also included for the
                                        purpose of transparency. Relationships in this table are modest unless otherwise
                                        noted.</p>
                                    <p id="tspara0885">According to the ACC/AHA, a person has a <i>relevant</i>
                                        relationship IF: a) the <i>relationship or interest</i> relates to the same or
                                        similar subject matter, intellectual property or asset, topic, or issue
                                        addressed in the <i>document;</i> or b) the <i>company/entity</i> (with whom the
                                        relationship exists) makes a drug, drug class, or device addressed in the
                                        <i>document</i> or makes a competing drug or device addressed in the
                                        <i>document</i>; or c) the <i>person or a member of the person’s household</i>,
                                        has a reasonable potential for financial, professional or other personal gain or
                                        loss as a result of the issues/content addressed in the <i>document</i>. Writing
                                        committee members are required to recuse themselves from voting on sections to
                                        which their specific relationships with industry and other entities may apply.
                                    </p>
                                    <p id="tspara0890">ACC indicates American College of Cardiology; ACCF, American
                                        College of Cardiology Foundation; AHA, American Heart Association; HFSA, Heart
                                        Failure Society of America; RWI, relationships with industry and other entities;
                                        UCLA, University of California, Los Angeles; UT, University of Texas; and VA,
                                        Veterans Affairs.</p>
                                </fn>
                                <fn id="dtbl5fnlowast">
                                    <p id="ntpara0090">∗ Significant relationship.</p>
                                </fn>
                                <fn id="dtbl5fndagger">
                                    <p id="ntpara0095">† No financial benefit.</p>
                                </fn>
                                <fn id="dtbl5fnddagger">
                                    <p id="ntpara0100">‡ This disclosure was entered under the Clinical Trial Enroller
                                        category in the ACC’s disclosure system. To appear in this category, the author
                                        acknowledges that there is no <i>direct</i> or <i>institutional</i> relationship
                                        with the trial sponsor as defined in the (ACCF or AHA/ACC) Disclosure Policy for
                                        Writing Committees.</p>
                                </fn>
                                <fn id="dtbl5fnsect">
                                    <p id="ntpara0105">§ Lorraine Nnacheta is an AHA/ACC joint staff member and acts as
                                        the guideline advisor for the “2022 AHA/ACC/HFSA Guideline for the Management of
                                        Heart Failure.” No relevant relationships to report. Non-voting author on
                                        recommendations and not included/counted in the RWI balance for this committee.
                                    </p>
                                </fn>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="NLM_app" id="appsec3">Appendix 2<div id="acsectitle0550" class="anchor-spacer"></div>
                    <h2 class="article-section__title section__title" id="sectitle0550">Reviewer Relationships With
                        Industry and Other Entities (Comprehensive)—2022 AHA/ACC/HFSA Guideline for the Management of
                        Heart Failure (June 2021)</h2>
                    <div id="undtbl57" class="anchor-spacer"></div>
                    <div class="article-table-content" id="undtbl57">
                        <table class="table article-section__table">
                            <thead>
                                <tr valign="top">
                                    <th colspan="1" rowspan="1">Reviewer</th>
                                    <th colspan="1" rowspan="1">Representation</th>
                                    <th colspan="1" rowspan="1">Employment</th>
                                    <th colspan="1" rowspan="1">Consultant</th>
                                    <th colspan="1" rowspan="1">Speakers Bureau</th>
                                    <th colspan="1" rowspan="1">Ownership/ Partnership/ Principal</th>
                                    <th colspan="1" rowspan="1">Personal Research</th>
                                    <th colspan="1" rowspan="1">Institutional, Organizational, or Other Financial
                                        Benefit</th>
                                    <th colspan="1" rowspan="1">Expert Witness</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Anastasia Armbruster</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">University of Health Sciences &amp;
                                        Pharmacy in St. Louis</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0835"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2565">AstraZeneca Pharmaceuticals</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Alison Bailey</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—ACC</td>
                                    <td align="center" colspan="1" rowspan="1">Centennial Heart at Parkridge</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0840"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2570">American Society of Preventive Cardiology<a
                                                                class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2575">OptumRx</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Joshua A. Beckman</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Vanderbilt University</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0845"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2580">Amgen</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2585">JanOne</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2590">Janssen Pharmaceuticals<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0850"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2595">EMX<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2600">JanaCare<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0855"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2605">Bayer (DSMB)</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2610">Novartis</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0860"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2615">Vascular Interventional Advances<a
                                                                class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2620">NovoNordisk<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Claudio Bravo</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA</td>
                                    <td align="center" colspan="1" rowspan="1">University of Washington</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Patricia Chang</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA/ACC</td>
                                    <td align="center" colspan="1" rowspan="1">University of North Carolina</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Richard Cheng</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA</td>
                                    <td align="center" colspan="1" rowspan="1">University of Washington</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist088765"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p26925">Eidos</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p26930">Ionis</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Lisa de las Fuentes</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Washington University in St. Louis</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0870"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2645">Acceleron</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2650">Aerovate</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2655">Altavant</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2660">Arena</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2665">Bayer</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2670">Complexa<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2675">Express Scripts</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2680">Gossamer</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2685">Johnson&amp;Johnson</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2690">Phase Bio</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2695">Sommetrics</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2700">V-wave</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2705">Vaderis</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2710">WebMD<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0875"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2715">Simply Speaking<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0880"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2720">Acceleron<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2725">Bayer</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2730">Complexa<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2735">Johnson&amp;Johnson<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2740">Liquidia<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2745">Medtronic<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2750">NIH<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2755">Trio Analytics</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2760">United Therapeutics<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2765">University of Kentucky (DSMB)<a
                                                                class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2770">University of Toronto (DSMB)<a
                                                                class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0885"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2775">ACC<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2780">AHA<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2785"><i>Circulation</i> Journals</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2790">Foundation for the NIH<a class="ref table-fn"
                                                                id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2795">Pulmonary Hypertension Association<a
                                                                class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Akshay Desai</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA/ACC</td>
                                    <td align="center" colspan="1" rowspan="1">Brigham and Women’s Hospital</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0890"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2800">Abbott Laboratories<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2805">Alnylam<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2810">Amgen<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2815">AstraZeneca Pharmaceuticals<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2820">Biofourmis<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2825">Boehringer Ingelheim</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2830">Boston Scientific<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2835">Corvidia Therapeutics<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2840">Cytokinetics</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2845">Dalcor Pharma<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2850">Lupin Pharma</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2855">Merck</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2860">Novartis<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2865">Regeneron<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2870">Relypsa<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2875">Sun Pharma</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0895"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2880">Alnylam<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2885">AstraZeneca Pharmaceuticals<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2890">Bayer<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2895">Myokardia<a class="ref table-fn"
                                                                id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2900">Novartis<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0900"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2905">Baim Clinical Research Institute<a
                                                                class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2910">TIMI Study Group<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Howard Eisen</td>
                                    <td align="center" colspan="1" rowspan="1">Official Reviewer—AHA</td>
                                    <td align="center" colspan="1" rowspan="1">Penn State Health</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Mona Fiuzat</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA/ACC</td>
                                    <td align="center" colspan="1" rowspan="1">Duke University</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0905"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2915">Fire1</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0910"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2920">Roche<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Bulent Gorenek</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Eskisehir Osmangazi University</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0915"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2925">AstraZeneca Pharmaceuticals</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2930">Bayer</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2935">Daiichi Sankyo</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2940">Roche</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2945">Sandoz</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2950">Sanofi</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">José A. Joglar</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">UT Southwestern Medical Center</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">W. Schuyler Jones</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Duke University</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0920"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2955">Bayer<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2960">Janssen Pharmaceuticals</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0925"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2965">Boehringer Ingelheim</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2970">Bristol Myers Squibb</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2975">PCORI</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Daniel Judge</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA/ACC</td>
                                    <td align="center" colspan="1" rowspan="1">The Medical University of South Carolina
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0930"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2980">ADRx</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2985">Cytokinetics</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2990">Pfizer</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p2995">Tenaya Therapeutics</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0935"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3000">Capricor (DSMB)</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3005">TRiNDS (DSMB)</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0940"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3010">Array Biopharma<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3015">Eidos Therapeutics<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3020">Myokardia<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Kimberly Ketter</td>
                                    <td align="center" colspan="1" rowspan="1">Lay Reviewer</td>
                                    <td align="center" colspan="1" rowspan="1">Morris Cardiovascular &amp; Risk
                                        Reduction Center</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0945"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3025">Verilogue</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Dharam Kumbhani</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA/ACC</td>
                                    <td align="center" colspan="1" rowspan="1">UT Southwestern Medical Center</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0950"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3030">ACC<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0955"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3035"><i>Circulation</i>, Associate Editor<a
                                                                class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Daniel Mark</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Duke University</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0960"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3040">Novartis</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0965"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3045">Elsevier<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3050">Heartflow<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3055">Merck<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3060">NIH<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Paul Mather</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA/ACC</td>
                                    <td align="center" colspan="1" rowspan="1">University of Pennsylvania</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0970"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3065">Novartis<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Shweta Motiwala</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA/ACC</td>
                                    <td align="center" colspan="1" rowspan="1">Harvard University</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0975"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3070">Baim Institute for Clinical Research<a
                                                                class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3075">Eli Lilly</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3080">Relay Therapeutics<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0980"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3085">Relay Therapeutics<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0985"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3090">Puma Biotechnology<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3095">Relypsa<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0990"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3100">American Regent<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3105">Boehringer Ingelheim<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3110">Edwards Lifesciences<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3115">NuPulse CV<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Debabrata Mukherjee</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Texas Tech University</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist0995"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3120">ACC<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Patrick T. O’Gara</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Brigham and Women’s Hospital</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1000"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3125">Edwards Lifesciences<a class="ref table-fn"
                                                                id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3130">Medtronic<a class="ref table-fn"
                                                                id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3135"><i>JAMA</i><a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3140">NIH<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Francis D. Pagani</td>
                                    <td align="center" colspan="1" rowspan="1">Official Reviewer—AHA</td>
                                    <td align="center" colspan="1" rowspan="1">University of Michigan</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Gurusher Panjrath</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—ACC</td>
                                    <td align="center" colspan="1" rowspan="1">George Washington University</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1005"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3145">CVRx</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1010"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3150">Pfizer<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1015"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3155">Abbott Laboratories<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Mariann Piano</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Vanderbilt University</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Sean Pinney</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA/ACC</td>
                                    <td align="center" colspan="1" rowspan="1">University of Chicago</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1020"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3160">Abbott Laboratories</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3165">CareDX, Inc.</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3170">Medtronic</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3175">NuPulse</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3180">Procyrion</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3185">Transmedics</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Bunny Pozehl</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA/ACC</td>
                                    <td align="center" colspan="1" rowspan="1">University of Nebraska</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Tanveer Rab</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Emory University</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1025"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3190">ABIM</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3195">ACC<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3200">American Bifurcation Club<a class="ref table-fn"
                                                                id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Nosheen Reza</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—ACC</td>
                                    <td align="center" colspan="1" rowspan="1">University of Pennsylvania</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Jo E. Rodgers</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA</td>
                                    <td align="center" colspan="1" rowspan="1">University of North Carolina</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1030"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3205">Novartis<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1035"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3210">Duke Clinical Research Institute<a
                                                                class="ref table-fn" id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3215">GlaxoSmithKline</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Chris Salerno</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—ACC</td>
                                    <td align="center" colspan="1" rowspan="1">St. Vincent Hospital</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1040"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3220">Abbott</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1045"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3225">Medtronic</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1050"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3230">Abbott<a class="ref table-fn" id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3235">Medtronic<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Sanjiv Shah</td>
                                    <td align="center" colspan="1" rowspan="1">Official Reviewer—HFSA</td>
                                    <td align="center" colspan="1" rowspan="1">Northwestern University</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1055"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3240">Abbott</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3245">ABIM</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3250">Amgen</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3255">Aria</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3260">AstraZeneca Pharmaceuticals<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3265">Axon</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3270">Bayer</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3275">Boehringer Ingelheim</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3280">Boston Scientific</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3285">Bristol Myers Squibb</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3290">Cardiora</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3295">CVRx</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3300">Cyclerion</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3305">Cytokinetics</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3310">Eisai</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3315">Ekoi.ai</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3320">GlaxoSmithKline</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3325">Imara</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3330">Ionis</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3335">Ironwood</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3340">Janssen Pharmaceuticals</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3345">Keyto</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3350">Eli Lilly</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3355">Merck</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3360">Myokardia</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3365">Novartis<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3370">NovoNordisk</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3375">Pfizer</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3380">Prothena</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3385">Regeneron</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3390">Sanofi</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3395">Shifamed</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3400">Tenax</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3405">United Therapeutics</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1060"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3410">Pulmonary Hypertension Association</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1065"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3415">Actelion<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3420">AHA<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3425">Covia<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3430">NIH<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Erica S. Spatz</td>
                                    <td align="center" colspan="1" rowspan="1">Official Reviewer, Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Yale University</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1070"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3435">Centers for Medicare &amp; Medicaid Services<a
                                                                class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3440">U.S. Food and Drug Administration<a
                                                                class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Nancy Sweitzer</td>
                                    <td align="center" colspan="1" rowspan="1">Official Reviewer—HFSA</td>
                                    <td align="center" colspan="1" rowspan="1">University of Arizona</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1075"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3445">Medscape<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3450">Myokardia</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1080"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3455">NIH<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3460">Merck</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3465">Novartis<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1085"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3470">AHA<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3475">Amgen<a class="ref table-fn" id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3480">Array BioPharma<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3485">Cellular Logistics<a class="ref table-fn"
                                                                id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3490">Corvia Medical<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3495">CVRx<a class="ref table-fn" id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3500">NIH<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3505">University of Arizona<a class="ref table-fn"
                                                                id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Jacqueline E. Tamis-Holland</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Mount Sinai</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1090"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3510">Gaffney Events Educational Trust</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1095"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3515">AHA<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3520">Bronx Lebanon Hospital, Cardiology Fellowship
                                                            Program Director<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3525">NYS<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3530">The NGS Predict Study<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Jennifer Thibodeau</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA</td>
                                    <td align="center" colspan="1" rowspan="1">UT Southwestern Medical Center</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1100"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3535">CareDX<a class="ref table-fn" id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3540">Cytokinetics<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3545">Eidos Therapeutics<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3550">NIH<a class="ref table-fn" id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Sanjeev Trehan</td>
                                    <td align="center" colspan="1" rowspan="1">Official Reviewer—ACC (Board of
                                        Governors)</td>
                                    <td align="center" colspan="1" rowspan="1">Saint Francis Health System</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Mary Norine Walsh</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—AHA/ACC</td>
                                    <td align="center" colspan="1" rowspan="1">Ascension Medical Group</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1105"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3555">Amgen<a class="ref table-fn" id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3560">EBR Systems</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3565">PCORI<a class="ref table-fn" id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3570">Thoratec<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3575">Uppsala University<a class="ref table-fn"
                                                                id="dtbl6fnddagger"
                                                                href="javascript:popRef('dtbl6fnddagger')"><sup>‡</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Barbara Wiggins</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—ACC</td>
                                    <td align="center" colspan="1" rowspan="1">Medical University of South Carolina</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1110"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3580">Lexicomp</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1115"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3585">ACC<a class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3590"><i>American Journal of Cardiovascular</i> Drugs<a
                                                                class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3595">PERT Consortium Clinical Protocols<a
                                                                class="ref table-fn" id="dtbl6fndagger"
                                                                href="javascript:popRef('dtbl6fndagger')"><sup>†</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1">Y. Joseph Woo</td>
                                    <td align="center" colspan="1" rowspan="1">Content Reviewer—Joint Committee on
                                        Clinical Practice Guidelines</td>
                                    <td align="center" colspan="1" rowspan="1">Stanford University School of Medicine
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                    <td align="center" colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1120"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3600">Associate Editor, <i>Journal of Thoracic and
                                                                Cardiovascular Disease</i></p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3605">NIH<a class="ref table-fn" id="dtbl6fnlowast"
                                                                href="javascript:popRef('dtbl6fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                    <td align="center" colspan="1" rowspan="1">None</td>
                                </tr>
                            </tbody>
                        </table>
                        <div class="tableFooter">
                            <div class="fn-group">
                                <fn>
                                    <p id="tspara0895">This table represents all relationships of reviewers with
                                        industry and other entities that were reported at the time of peer review,
                                        including those not deemed to be relevant to this document, at the time this
                                        document was under review. The table does not necessarily reflect relationships
                                        with industry at the time of publication. A person is deemed to have a
                                        significant interest in a business if the interest represents ownership of ≥5%
                                        of the voting stock or share of the business entity, or ownership of ≥$5000 of
                                        the fair market value of the business entity; or if funds received by the person
                                        from the business entity exceed 5% of the person’s gross income for the previous
                                        year. Relationships that exist with no financial benefit are also included for
                                        the purpose of transparency. Relationships in this table are modest unless
                                        otherwise noted. Names are listed in alphabetical order within each category of
                                        review. Please refer to <a target="_blank" class="references__uri"
                                            href="https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy</a>
                                        for definitions of disclosure categories or additional information about the
                                        ACC/AHA Disclosure Policy for Writing Committees.</p>
                                    <p id="tspara0900">ABIM indicates American Board of Internal Medicine; ACC, American
                                        College of Cardiology; ACCF, American College of Cardiology Foundation; AHA,
                                        American Heart Association; DSMB, Data and Safety Monitoring Board; JAMA,
                                        Journal of the American Medical Association; NGS, Next-generation sequencing;
                                        NIH, National Institutes of Health; NYS, New York State; PCORI, Patient-Centered
                                        Outcomes Research Institute; PERT, Pulmonary Embolism Response Team; TIMI,
                                        Thrombolysis in Myocardial Infarction; and UT, University of Texas.</p>
                                </fn>
                                <fn id="dtbl6fnlowast">
                                    <p id="ntpara0110">∗ Significant relationship.</p>
                                </fn>
                                <fn id="dtbl6fndagger">
                                    <p id="ntpara0115">† No financial benefit.</p>
                                </fn>
                                <fn id="dtbl6fnddagger">
                                    <p id="ntpara0120">‡ This disclosure was entered under the Clinical Trial Enroller
                                        category in the ACC’s disclosure system. To appear in this category, the author
                                        acknowledges that there is no direct or institutional relationship with the
                                        trial sponsor as defined in the (ACCF or AHA/ACC) Disclosure Policy for Writing
                                        Committees.</p>
                                </fn>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="NLM_app" id="appsec4">Appendix 3<div id="acsectitle0555" class="anchor-spacer"></div>
                    <h2 class="article-section__title section__title" id="sectitle0555">Appendix for <a
                            class="ref showTableEvent" data-id="tbl3" href="#tbl3">Tables 3</a> and <a
                            class="ref showTableEvent" data-id="tbl4" href="#tbl4">4</a>: Suggested Thresholds for
                        Structural Heart Disease and Evidence of Increased Filling Pressures</h2>
                    <div id="undtbl58" class="anchor-spacer"></div>
                    <div class="article-table-content" id="undtbl58">
                        <table class="table article-section__table">
                            <tbody>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1"><strong>Morphology</strong></td>
                                    <td colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1125"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3610">LAVI ≥29 mL/m<sup>2</sup></p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3615">LVMI &gt;116/95 g/m<sup>2</sup></p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3620">RWT &gt;0.42</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3625">LV wall thickness ≥12 mm</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1"><strong>Ventricular systolic function</strong></td>
                                    <td colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1130"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3630">LVEF &lt;50%</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3635">GLS &lt;16%</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1"><strong>Ventricular diastolic function</strong></td>
                                    <td colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1135"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3640">Average E/e′ ≥15 for increased filling pressures
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3645">Septal e′ &lt;7 cm/s</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3650">Lateral e′ &lt;10 cm/s</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3655">TR velocity &gt;2.8 m/s</p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3660">Estimated PA systolic pressure &gt;35 mm Hg</p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                </tr>
                                <tr valign="top">
                                    <td colspan="1" rowspan="1"><strong>Biomarker</strong></td>
                                    <td colspan="1" rowspan="1">
                                        <table class="listgroup" border="0" width="95%" id="ulist1140"
                                            list-type="simple">
                                            <tbody>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3665">BNP ≥35 pg/mL<a class="ref table-fn"
                                                                id="dtbl7fnlowast"
                                                                href="javascript:popRef('dtbl7fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                                <tr class="li1">
                                                    <td valign="top">▪</td>
                                                    <td colspan="5" valign="top" class="paragraph">
                                                        <p id="p3670">NT-proBNP ≥125 pg/mL<a class="ref table-fn"
                                                                id="dtbl7fnlowast"
                                                                href="javascript:popRef('dtbl7fnlowast')"><sup>∗</sup></a>
                                                        </p>
                                                    </td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </td>
                                </tr>
                            </tbody>
                        </table>
                        <div class="tableFooter">
                            <div class="fn-group">
                                <fn>
                                    <p id="tspara0905">AF indicates atrial fibrillation; BNP, brain natriuretic peptide;
                                        CKD, chronic kidney disease; GLS, global longitudinal strain; HF, heart failure;
                                        LAVI, left atrial volume index; LV, left ventricular; LVEF, left ventricular
                                        ejection fraction; LVMI, left ventricular mass index; NT-proBNP, natriuretic
                                        peptide tests; PA, pulmonary artery; RWT, relative wall thickness; and TR,
                                        tricuspid regurgitation.</p>
                                </fn>
                                <fn id="dtbl7fnlowast">
                                    <p id="ntpara0125">∗ Cutoffs provided for natriuretic peptide levels may have lower
                                        specificity, especially in older patients or in patients with AF or CKD.
                                        Usually, higher cutoff values are recommended for the diagnosis of HF in these
                                        patients. Natriuretic peptide cutoffs selected for population screening for
                                        pre-HF (stage B HF) may be &lt;99% reference limits and need to be defined
                                        according to the population at risk.</p>
                                </fn>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <h2 class="article-section__title section__title" id="d247731e414">
                Footnotes
            </h2>
            <fn>
                <p id="ntpara0185">Writing committee members are required to recuse themselves from voting on sections
                    to which their specific relationships with industry may apply; see <a class="ref"
                        href="#appsec1">Appendix 1</a> for detailed information.</p>
            </fn>
            <fn>
                <p id="ntpara0130">This document was approved by the American College of Cardiology Clinical Policy
                    Approval Committee, the American Heart Association Science Advisory and Coordinating Committee, the
                    American College of Cardiology Science and Quality Committee, and the Heart Failure Society of
                    America Executive Committee in December 2021 and the American Heart Association Executive Committee
                    in January 2022.</p>
            </fn>
            <fn>
                <p id="ntpara0135">The American College of Cardiology requests that this document be cited as follows:
                    Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM,
                    Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS,
                    Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022
                    AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of
                    Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll
                        Cardiol.</i> 2022;79:e263–e421.</p>
            </fn>
            <fn>
                <p id="ntpara0140">This article has been copublished in <i>Circulation</i> and the <i>Journal of Cardiac
                        Failure</i>.</p>
            </fn>
            <fn>
                <p id="ntpara0145">Copies: This document is available on the websites of the American College of
                    Cardiology ( <a target="_blank" class="references__uri" href="http://www.acc.org">www.acc.org</a>),
                    the American Heart Association ( <a target="_blank" class="references__uri"
                        href="http://professional.heart.org">professional.heart.org</a>), and the Heart Failure Society
                    of America ( <a target="_blank" class="references__uri"
                        href="http://www.hfsa.org">www.hfsa.org</a>). For copies of this document, please contact the
                    Elsevier Inc. Reprint Department via fax (212-633-3820) or (E-mail: <a target="_blank"
                        class="references__email" href="mailto:reprints@elsevier.com"><span
                            class="nobrWithWbr">reprints@elsevier.<wbr>com</span></a>).</p>
            </fn>
            <fn>
                <p id="ntpara0150">Permissions: Multiple copies, modification, alteration, enhancement, and/or
                    distribution of this document are not permitted without the express permission of the American
                    College of Cardiology. Requests may be completed online via the Elsevier website at <a
                        target="_blank" class="references__uri"
                        href="https://www.elsevier.com/about/policies/author-agreement/obtaining-permission">https://www.elsevier.com/about/policies/author-agreement/obtaining-permission</a>.
                </p>
            </fn>
        </div>
    </section><!--/fulltext content-->
    <div class="response">
        <div class="sub-article-title"></div>
    </div>
</div>